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2Abstract 
The negative individual and social impacts of alcohol consumption raise a considerable policy 
interest surrounding alcohol treatment.  Economic evaluations help on the allocation of scarce 
health care resources, but these have been inadequately conducted in the alcohol field.  
This thesis builds up a taxonomy of alcohol-related consequences that should be included in 
economic evaluations of alcohol treatment and uses this taxonomy to critically review the published 
evidence around the cost effectiveness of alcohol treatments.  The review provides a set of 
recommendations and most of them are pursued throughout the thesis.   
An economic model for the cost effectiveness of alcohol treatments is developed.  The framework 
provides the means to conduct economic evaluation while bearing the complexity and challenges of 
decision making in the field of human behaviour.  A link between drinking patterns, health 
consequences and alcohol treatment effectiveness and cost effectiveness is created.  This is a 
probabilistic lifetime model that uses the cohort simulation approach.  The model can be applied to 
any setting and this is exemplified for a UK-scenario.  The methods and data for the generation of 
UK-specific model inputs are described and used in two model applications.  A first application of 
the model extrapolates the results of a short term randomized controlled trial and provides the 
expected lifetime costs and outcomes of the treatments compared, by age and gender.  A second 
application compares two alcohol treatments delivered in different countries and to populations very 
different at baseline.  Both case-studies show the importance of time and that only a long-term 
analysis can capture both short-term alcohol consequences, such as injuries, and long-term 
consequences, such as most forms of alcohol-related chronic diseases.   
Assumptions and implications of the methods and analyses are discussed and recommendations for 
future research are presented. 
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Chapter 1. Introduction 
1.1 Background 
Alcohol consumption contributes substantially to the global burden of disease (4% of total mortality 
and between 4% and 5% of disability adjusted life years) and is of the world’s largest avoidable risk 
factors (Rehm et al., 2009).  Europe has a high level of alcohol consumption and the resulting 
alcohol-related disabilities are the highest in the world (WHO, 2009).  A recent analysis of the 
burden of disease in the European region in 2002 showed that alcohol consumption was causally 
related to 6.1% of all deaths, 12.3% of all Years of Life Lost (YLL) and 10.7% of all Disability 
Adjusted Life Years (DALYs) (Rehm et al., 2006c).  It is estimated that 23 million Europeans (5% 
of men, 1% of women) are dependent on alcohol (WHO, 2004).  In addition to being a drug of 
dependence, alcohol is a cause of some 60 different diseases and conditions with short and long 
term health consequences (Room et al., 2005).  A one litre reduction of pure alcohol drunk per adult 
each year could decrease total mortality in men by 1% in southern and central Europe, and 3% in 
northern Europe (Anderson and Baumberg, 2006).  Alcohol consumption increases the risk of social 
harms, ranging from social nuisances such as public disorder through to more serious consequences 
such as marital harm, child abuse, drink-driving accidents, loss of work productivity, serious pre-
natal conditions, crime, violence and homicide (Babor et al., 2003).   
The physical, psychological and social harms of excessive alcohol use represent an important public 
health problem and are associated with considerable social costs.  These have been estimated for the 
European Union, United States and Canada to be around €270bn (2003 prices) (Anderson and 
Baumberg, 2006), USA$185bn (1998 prices) (WHO, 2004), and CAN$14.6bn (2002 prices) (Rehm 
et al., 2006a), respectively.   
Alcohol treatment has the potential to reduce the incidence, progression, and costs of individual 
health and social complications.  There is considerable evidence base on the effectiveness of 
different alcohol treatments based on short-term drinking and health outcomes (Raistrick et al., 
2006; Miller WR and Wilbourne PL, 2002; Heather et al., 2006).  Several studies have attempted to 
summarize this evidence in systematic reviews and/ or meta-analysis of the effectiveness of Brief 
Interventions (BI) (Kaner et al., 2007; McQueen et al., 2009) and of other psychosocial alcohol 
treatments, such as Motivational Interviewing (MI) (Burke et al., 2003; Lundahl and Burke, 2009).  
More intense alcohol approaches have also shown evidence of effect for reducing alcohol-related 
harm, such as behavioural training for problem drinkers (Walters, 2000) and pharmacological  
therapies (Mann et al., 2004; Srisurapanont and Jarusuraisin, 2005).  However, there are limitations 
17 
in evidence synthesis due to the wide range of alcohol treatment outcomes and the lack of 
standardization when reporting treatment effects (French, 2000).  The effects measured have 
generally related to short-term changes (French, 2000).  In addition, evidence synthesis is 
challenged by the large range of alcohol treatments (Howard, 1993).   
While there is evidence on the effectiveness of alcohol treatments there is far less evidence on the 
cost effectiveness of alcohol treatment (Anderson and Baumberg, 2006; Anderson et al., 2009; 
Babor et al., 2003; Slattery et al., 2003; Ludbrook, 2004; French, 2000; Godfrey, 1994) and of 
substance abuse treatment in general (Cartwright, 2000; Godfrey and Parrott, 2000).  Decision 
makers have increased the use of cost effectiveness analysis to inform decisions as to which 
interventions should be reimbursed from collective funding (Taylor et al., 2004).  Research suggests 
that funding for alcohol treatments has been lacking across many countries (Meara and Frank, 2005).  
Better quality and weight of evidence about the cost effectiveness as well as the effectiveness of 
alcohol interventions could be an important aid to those attempting to assess the allocation of scarce 
health care funds across and within conditions. 
The discipline of health economics highlights that health care resources are limited and the health 
care system is subject to a budget constraint.  Economic evaluation techniques provide a valuable 
framework to allocate resources to the most effective alcohol treatment alternatives.  Full economic 
evaluations are evaluations where the costs and consequences of at least two alternatives are 
compared.  Such evaluations can help decisions on which strategy represents better value for money 
(Gold et al., 1996b; Drummond et al., 2005c).  While there has been a considerable expansion of 
the quality and quantity of health economic evaluations in many clinical areas, this has not occurred 
for alcohol treatment and indeed, as reviewed in this thesis, many existing studies lack 
methodological rigour.  The overall aim of this thesis is to explore and develop economic evaluation 
techniques relevant to alcohol treatment.   
1.2 What are economic evaluations? 
Full economic evaluations can be classified as Cost Effectiveness Analysis (CEA), Cost Benefit 
Analysis (CBA) or Cost Utility Analysis (CUA).  The three analytical approaches are distinguished 
based on the way health benefits associated with alternative interventions under comparison are 
measured and valued (Drummond et al., 2005b; Tsuchiya and Williams, 2001).  In a CEA, costs are 
related to a single, common effect that may differ in magnitude between the alternative programmes, 
for example drinks consumed per day.  However, natural units pose numerous problems related to 
standardization and comparability.  This is because different studies may report different units and 
the same units can also have different interpretations.  Furthermore, interventions may have several 
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health outcomes that are not all captured in a single natural unit of effect.  Many studies use 
abstinence as the outcome of the analysis.  However, do abstinence-based measures capture all the 
health effects of alcohol treatment?  Would a reduction in alcohol consumption have no value?  
Previous reviews showed that most of the economic studies in the addiction field report natural 
effectiveness estimates as the outcome measure of treatment (French, 2000; Homer et al., 2008; 
Popovici et al., 2008).  The problem is that to make decisions on the allocation of scarce resources 
between competing treatments outcomes should be comparable and a single outcome measure 
should be used.  This single outcome measure can be obtained with the other two types of economic 
evaluation: CBA and CUA. 
CBA requires the monetary valuation of health benefits and reports a net monetary gain (or loss) or 
a cost/benefit ratio.  It overcomes the problem of different outcome measures or comparing 
programmes with multiple outcomes as everything is measured in monetary terms (Godfrey, 1994).  
Even though several evaluations of alcohol treatment have claimed to be a CBA (French, 2000), in 
fact few would be classified as such because they have not attempted to value health benefits in 
monetary terms presenting ratios of the costs of programmes to non-health outcomes (for example, 
future health care costs).  The philosophical foundation of CBA lays in principles of welfare 
economics where the relevant source of values are individual consumers (Drummond et al., 2005c).  
Using techniques of Willingness to Pay (WTP) the CBA framework can quantify a wide range of 
effects.  CBA is broader in scope and so it can inform resource allocation decisions both within and 
between sectors of the economy.  However, this does not come without problems (Drummond and 
Stoddart, 1995). 
A CUA uses measures that reflect the value individuals put on their health, called utilities.  Quality 
Adjusted Life Years (QALYs) are a widely used measure of health benefits used in CUA that 
incorporates mortality and morbidity estimates in a single index.  Generic measures of Health-
Related Quality of Life (HRQoL), such as QALYs, are extremely useful for a decision maker 
because the outcome measure is comparable across conditions and interventions.   
Cost per QALY estimates allow a comparison between different health care interventions that 
compete for the same pool of funding.  However, generic instruments measure a subject’s overall 
HRQoL and might not capture specific individual impacts of alcohol treatment. 
While the type of study defines how the individual outcomes of treatment are considered, which 
other costs and consequences are included in an economic evaluation depend upon the perspective 
the analyst takes.  Two main perspectives can be distinguished, the welfarist perspective and the 
decision maker perspective.  In the welfarist approach individuals are considered to be the best 
judges of their own welfare (consumer sovereignty) (Drummond et al., 2005c) and this perspective 
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is more in line with a CBA.  The decision maker or “extra-welfarist” perspective considers how best 
to allocate an exiting budget and is more in line with CEA and CUA.  Whilst a welfarist perspective 
has the potential to be wider in terms of the costs and consequences included, the decision maker 
perspective tends to be much narrower.   
1.3 Challenges to economic evaluations of alcohol treatment 
The first section of this chapter emphasized the paucity of economic evaluations of alcohol 
treatment.  Why is there a lack of economic evaluations of alcohol treatment?  Why is their quality 
poor? 
The apparent lack of development of methodology behind the economic evaluation of alcohol 
treatments might be related to particular features of research in the alcohol field.  The variety of 
treatment approaches is related to several factors such as, focus on different types of drinkers (less 
or more severe), delivery in different settings (e.g., hospital, primary care, community, prison), 
delivery by different types of health personnel (e.g., nurses, family doctors, psychiatrists, 
psychologists), different treatment intensities (number of contacts, treatment duration, etc.), and 
different definitions (e.g., what is considered a brief intervention in one study is an extended 
intervention in another (Drummond et al., 2009)).  In addition, alcohol treatment is usually 
accompanied by other types of health interventions (e.g., psychosocial treatment in addition to a 
pharmacological treatment) and ancillary services (housing, childcare, etc.).  
From an economic perspective many existing studies are not full economic evaluations.  Partial 
economic evaluations are of limited help to decision makers because these do not identify the 
interventions where investment produces the greatest increase in benefit at least cost (Maynard and 
Godfrey, 1994).  Indeed, many economic studies in the alcohol field are cost-of-illness studies that 
are concerned with the social costs of alcohol consumption.  Cost-offset studies, examining the 
effect of a specific intervention, are limited to whether the costs of the intervention are offset by 
health care savings (Holder, 1987; Holder et al., 2000; Reutzel et al., 1987; Holder and Blose, 
1992).  An intriguing feature of many of these studies is that the individual benefits of treatment are 
disregarded.  The impact of alcohol treatment on quantity and quality of life of the individual 
drinker is not valued and only the impact on the health care sector and/ or other sectors of economy 
is valued, therefore assuming that health benefits to patients have a zero value to society.   
This is consistent with the rational addiction model (Becker and Murphy, 1988), which assumes 
individuals have taken the potential future health harms into account in their consumption decisions.  
Such a model, if this assumption about behaviour is valid, would also be in line with the welfarist 
perspective explained above.  However, alcohol drinkers, particularly dependent drinkers, might not 
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be able to make the best decisions about their own welfare and need help through treatment.  In this 
case, the benefits of alcohol treatment upon the individual drinker should be taken into account, 
which is the case in other health treatment and economic evaluations where the prime focus is 
individual outcomes.  This assumption about individual behaviour is consistent with the “extra-
welfarist” perspective where the objective is to maximize health gains subject to a budget 
constraint.   
The health gains from alcohol treatment encompass physical and psychological individual outcomes 
which have been taken into account in different ways in previous studies.  There is no agreement on 
a common measure of effect of treatment.  For example, studies report different measures of alcohol 
consumption, such as abstinence and grams per day, or the scores of different questionnaires 
specific to alcohol problems.  This poses a clear problem of comparability between the effects of 
different treatments and is one of the main challenges in economic evaluations of alcohol treatment.  
There is also no apparent consensus about the terminology used for definitions in the field.  For 
example, the international literature uses different definitions for “binge drinking” and for “brief 
interventions”.  The lack of consistency and standardization in methods in studies of substance 
abuse interventions has also been described in French (2000) and Popovici et al. (2008). 
Alcohol treatments are associated with a wide range of consequences outside the health sector and 
capturing these in the evaluation of treatment is not easy and has been poorly done in previous 
studies (French, 2000; Godfrey, 1994).  Homer et al. (2008) and French (2000) have noted the 
importance of taking into account the social impact of alcohol through a broad societal perspective 
in economic studies.  The consequences that fall on society are various, for example criminal 
activity, road traffic accidents, workplace losses, health care use, and so on.  With such a wide 
range of alcohol-related consequences there is a danger that studies overlap categories of 
consequences and end up double counting.  For example, double counting occurs if health care 
costs related with a criminal act are taken into account both under criminal activity costs and health 
care costs.   
In a review of the economic benefits of addiction interventions McCollister and French (2003) 
mentioned that despite the relatively small contribution of changes in health services utilization, in 
comparison with reduced criminal activity, this outcome domain was the most used in studies that 
evaluated the social impact of treatment.  The authors also pointed out the importance of including 
criminal activity in economic evaluations as it represented the greatest economic benefit of 
addiction interventions.   
The quality of the research conducted in the field is also compromised by the paucity of economic 
data collected together with clinical outcomes in studies of high quality, such as Randomized 
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Controlled Trials (RCT).  For this reason costs have been collected retrospectively from various 
sources.  Furthermore, effectiveness estimates of alcohol treatment are based on studies with a short 
time horizon.  This raises another feature in the field which is the temporal relationship between 
drinking and effects of consumption, particularly an unsafe consumption.  Alcohol-related 
consequences happen in different time periods.  While some of the consequences are acute, for 
example, most forms of injury, other consequences are chronic since most of alcohol-related 
diseases are the effect of long-term consumption.  Alcohol consequences may also be difficult to 
measure in a prospective study due to an insufficient follow-up time.  The extent of these 
consequences is determined not solely by the amount of alcohol consumed but also by its 
consumption pattern, i.e. the frequency and setting of drinking over time (Rehm et al., 2009).  
French (2000), Homer et al. (2008) and Popovici et al. (2008) recognized that alcohol treatment has 
long-term health and social benefits and mentioned the need for long-term data and modelling 
techniques.   
1.4 Objectives 
The discussion above invites a series of objectives for the remainder of this thesis.  Economic 
evaluations of alcohol treatments need to follow more rigorous principles in order to guide policy 
decisions with confidence and help inform decisions with respect to the allocation of scarce 
resources.  The current literature, reviewed in Chapter 3, contains many inconsistencies in the 
methods used for the identification, measurement and valuation of costs and consequences relevant 
to alcohol treatment.   
The general objectives of this thesis are: 
1) To discuss issues and provide guidance which could increase the rigour employed in 
economic evaluations of alcohol treatment 
2) To explore methods to ensure more consistency in future studies in order to build up the 
economic evidence base 
3) To explore both short and long term drinking outcomes in economic evaluations of alcohol 
treatment 
1.5 Structure of the thesis 
The research for this thesis is pursued in three main areas.  The first part explores criteria to take 
forward economic evaluations and looks at the current state of research according to those criteria.  
The review shows that current research has focused on abstinence-based measures and has 
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disregarded the long-term effects of alcohol treatments.  The second part of the thesis develops an 
economic evaluation model that studies health consequences, not confined to abstinence, over a 
long-term horizon.  The third part applies the model in one country setting and tests it with two 
empirical examples.  The breakdown of each chapter is as follows. 
Chapter 2 explores all alcohol-related consequences that could be identified in an economic analysis 
of alcohol treatments.  A taxonomy of the alcohol-related societal and individual-level 
consequences is developed.  This taxonomy is designed to promote consistency and uniformity in 
economic evaluations of alcohol treatment and provides a quality assurance guide to previous 
studies by helping on the clarification of the alcohol-related consequences that have been included 
and omitted.  The taxonomy developed in this chapter is the foundation for the extraction of the 
methodology in Chapter 3.   
In Chapter 3 the existing literature on economic evaluations of alcohol treatment is identified.  The 
methods used for the identification, measurement and valuation of society-level outcomes, 
individual-level outcomes and input costs are reviewed and appraised.  This literature is used to 
provide a set of recommendations on the conduct of cost effectiveness analyses, most of these 
recommendations are followed in the remaining of the thesis.   
Chapter 4 uses the evidence of Chapters 2 and 3 to inform the design of a decision analytical model 
that simulates the drinking patterns of a cohort over lifetime.  Determining the cost effectiveness 
and predicting the outcomes of different alcohol treatments requires modelling of the long term 
consequences of changing drinking patterns.  The model of drinking behaviour establishes a link 
between drinking patterns, health consequences and alcohol treatment effectiveness and cost 
effectiveness.  This is an important contribution to the techniques usually applied where only short 
term costs and outcomes are analysed. 
Chapter 5 explores the generation of country-specific model inputs, with an example of the 
application of the methods to the UK.  These are the inputs required to populate the model that are 
specific to the setting where the economic evaluation is drawn but independent of the alcohol 
treatments evaluated.  Therefore, the values generated in this chapter can be used for a range of 
alcohol treatments assessed in the UK.   
Chapters 6 and 7 consist of two applications of the Markov model of drinking behaviour developed 
in Chapter 4.  Both case-studies are presented for a UK setting and use the country-specific model 
inputs calculated in Chapter 5.   
Chapter 6 applies the Markov model to the UKATT trial (UKATT Research Team, 2005b, a).  The 
UKATT trial consisted of a cost effectiveness analysis alongside a pragmatic multicentre 
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randomized trial aimed at comparing the cost effectiveness of Social Behaviour and Network 
Therapy (SBNT), a new treatment for alcohol problems, with that of the proved Motivational 
Enhancement Therapy (MET), under real world conditions.  The short term trial showed no strong 
evidence about the effectiveness and cost effectiveness of the two treatments.  The Markov model 
of drinking behaviour assesses the incremental costs, survival and QALYs for MET vs. SBNT over 
the long term.   
Chapter 7 presents a cost effectiveness analysis of a new pharmacological alcohol treatment 
compared to the current standard of care for the management of problematic drinkers using the 
model developed in Chapter 4.  This second case-study presents important distinguishing features 
from the first one.  Along with the model application and the generation of cost effectiveness results, 
some analyses are conducted before carrying out the economic evaluation.  These analyses involve 
matching patients’ baseline characteristics and allow the comparison of treatment effects taken from 
two independent RCTs conducted in different countries, with different follow-up periods and with 
patients significantly different in terms of baseline characteristics.   
Both case-studies show the importance of assessing the long-term consequences when examining 
the cost effectiveness of alcohol treatments.  There is a considerable change in the cost effectiveness 
results as the short-term analysis progresses to a long-term horizon, which provides evidence for the 
cost effectiveness of alcohol treatments and the need to measure costs and outcomes over a lifetime 
horizon.   
The final chapter, Chapter 8, presents an overview and discussion of the previous chapters. The 
principal achievements with each of the chapters are summarized and issues arising from this thesis 
are formed into an agenda for future research. 
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Chapter 2. Taxonomy of societal and individual alcohol 
consequences in the Economic Evaluation of Alcohol Treatments 
2.1 Rationale for a taxonomy of alcohol consequences 
There is considerable methodological heterogeneity in economic evaluations of alcohol treatment.  
The lack of harmonization in methods and terminology, the variety of alcohol treatment approaches 
and the complexity and multiplicity of treatment outcomes may have contributed to the slow 
development of economic analyses of alcohol treatment. A major issue is the identification of 
alcohol treatment consequences. This task is complex because of the multiple consequences that can 
be identified and the temporal lag between receiving alcohol treatment and observing changes in 
alcohol-related consequences.  In addition, measuring and valuing consequences such as the impact 
that alcohol drinking has on friends, victims and families’ utility is a challenging endeavour.  There 
is no general agreement in which consequences should be identified, measured and valued in 
economic evaluations of alcohol treatment (Babor et al., 2003; Ensor and Godfrey, 1993; Lehto, 
1997).  A recent review of studies that evaluated the economic benefits of interventions noted that 
several outcome domains have been excluded from previous studies and called for more rigorous 
methods for performing economic evaluations of addiction interventions (McCollister and French, 
2003).   
This chapter identifies the consequences of alcohol consumption that should be accounted for in an 
economic evaluation of psychosocial or pharmacological alcohol treatments and how these 
consequences can be measured and valued.  Economic evaluations also identify the resources used 
or inputs of the programme evaluated.  This does not pose an additional challenge when compared 
to other health interventions and is not explored further in this chapter.  The main objective is to 
stratify all alcohol-related social and individual consequences into domains and categories.  This 
stratification is built throughout the chapter resulting in a taxonomy of alcohol-consequences.  
Identification, measurement and valuation methods are presented as these help with the 
stratification and provide information for the following chapters.  The taxonomy built throughout 
this chapter will be used in Chapter 3 as a framework for the extraction of the methodology that has 
been used in economic evaluations of alcohol treatment.  In addition, the development of this 
taxonomy will inform the structure of an economic framework for the model developed in Chapter 
4.   
In economic terms, social consequences are the sum of private and external consequences that can 
represent a cost or a benefit.  Private alcohol consequences are the consequences accruing to the 
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individuals engaged in the drinking activity while external consequences are consequences of an 
action by drinker(s) that fall on others.  Within alcohol-related consequences this thesis defines 
society-level consequences as the consequences that arise from individuals’ drinking behaviour 
which affect society, including alcohol-related victims and drinkers’ families.  Individual-level 
consequences are defined as the consequences felt by the drinkers themselves.  In this chapter, it is 
argued that the consequences taken into account in economic evaluations of alcohol treatment 
depend on two interrelated factors: 1) the theory of consumer behaviour and, 2) the perspective 
under which these are evaluated. 
The taxonomy is designed to be used in economic evaluations of alcohol treatment and therefore the 
consequences identified are those that represent a cost at the societal and individual-level and that 
can be reduced by alcohol treatment.  By focusing on alcohol treatments this thesis disregards social 
or individual benefits related with low risk alcohol consumption.  Several social benefits of alcohol 
consumption have been described such as social enhancement and pleasure (Peele and Brodsky, 
2000), reduction of the burden in the health care system due to a reduction in Coronary Heart 
Disease (CHD) and reduction in absence with productivity gains to society due to better physical 
health and psychosocial adjustment for the individual (Vasse et al., 1998).  Individual benefits of 
moderate alcohol consumption include higher wages (Barrett, 2002; French and Zarkin, 1995; 
Slater et al., 1999), and individual health benefits due to a reduction in stress levels and lower 
incidence of CHD (Boffetta and Garfinkel, 1990; Doll et al., 1994; English et al., 1995; Peele and 
Brodsky, 2000).  These benefits are related to a level of consumption that would not require 
treatment.  Alcohol misusers that accept to be treated recognize that their alcohol-related problems 
supersede the potential benefits of alcohol consumption.  In contrast, other policies directed at all 
drinkers whether having problems or not and involving some coercion, for example, taxation, could 
be thought of having different individual impacts.  For example, the evaluation of population-level 
interventions, such as prevention and legislation, would need to take into account the impact on the 
benefits of low risk alcohol consumption. 
The social costs of alcohol have been widely described and many studies provide a framework for 
the identification, measurement and valuation of these costs (Leontaridi, 2003).  However, the 
framework provided has been embedded in cost-of-illness or public finance studies and is not 
directly extrapolated to cost effectiveness analyses of two or more interventions.  Cost-of-illness 
studies can demonstrate the scale of health problems, but they are limited in determining how 
resources are to be allocated because they do not measure the individual benefits or compare 
interventions in terms of their costs and outcomes (Byford et al., 2000; Drummond, 1992; Currie et 
al., 2000).  The taxonomy of alcohol consequences for cost effectiveness analysis of alcohol 
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treatment combines: 1) the theoretical framework described for social cost studies, as these studies 
can provide a framework for the cost estimation in economic evaluations (Luce et al., 1996; Rice, 
2000), with 2) the framework used in economic evaluations.  The stratification developed here 
prevents double counting as categories that could erroneously be allocated to more than one domain 
are allocated to a single domain, based on identification, measurement and valuation methods.   
The taxonomy of alcohol consequences is designed in two separate steps.  In a first step, all alcohol-
related consequences are divided between society-level and individual-level and in a second step, 
within these two groups, consequences are stratified into domains.  For each domain, the categories 
that should be identified in an economic evaluation of alcohol treatment are gradually accumulated.  
Firstly, in section 2.2 the society-level consequences of alcohol treatment are explored.  Secondly, 
in section 2.3 the individual-level consequences of a treatment-seeking population are depicted.  
Section 2.4 presents an overview of the factors that determine the extent of consequences that are 
included in the economic evaluation of alcohol treatments.  Finally, section 2.5 presents the 
taxonomy of alcohol-related consequences in full. 
2.2 Society-level consequences 
As previously noted, this document classifies society-level consequences as the consequences that 
arise from individuals’ drinking behaviour that affect society, including alcohol-related victims and 
drinkers’ families.  It could be questioned whether the consequences imposed by the drinkers upon 
other members of their own family constitute private consequences at an individual or at a societal 
level.  On the one hand, the drinker might take into account the effects on other family members in 
deciding his or her extent of substance abuse and then these consequences would be treated under 
the individual-drinker level consequences domain.  On the other hand, the consequences of alcohol 
misuse upon other people who have had no part in the initial decision should be treated at a societal 
level.  The chosen approach in this thesis is to include consequences to the drinker’s family in this 
section.   
Alcohol drinking above safe levels imposes a cost to different spheres of society.  Society-level 
consequences are stratified into the following seven domains, according to where and to whom in 
society they fall: 1) criminal activity, 2) road traffic accidents, 3) workplace and productivity losses, 
4) health-related quality of life, 5) general health care, 6) other specific alcohol treatment and, 7) 
social services and non-statutory care.  Providing treatment for alcohol problems has the potential to 
reduce these social costs.  Therefore, when evaluating the cost effectiveness of alcohol treatments, 
ideally, all the aforementioned consequences should be analysed.  These seven domains are 
explained in the seven subsections below and at the end of each subsection a summary table is 
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presented.  The summary tables describing each society-level consequence domain are added up at 
the end to constitute a single table with the full taxonomy of alcohol consequences. 
2.2.1 Criminal activity
This subsection outlines the main issues involved with identifying, measuring, and valuing alcohol-
related crime consequences. 
Identification- Acute alcohol intoxication contributes to crime.  The time span between drinking 
and offences to the criminal justice is short and treatment interventions have the potential to reduce 
criminal activity in a not too distant period of time.  Crime and disorder data in many countries are 
far from perfect and this contributes to the difficulties researchers may face in identifying and 
measuring these consequences.  Crime data are largely derived from subjective judgements about 
alcohol’s role in affecting behaviour, and it is difficult to be sure that the event would not have 
occurred, or would have less serious consequences, if the offender had not been drinking.  Alcohol 
can be implicated as a causal factor in crime in two ways: high alcohol intake represents a risk 
factor in becoming a victim and alcohol is also a potential causal factor in committing a crime 
(WHO, 2000). 
Ensor and Godfrey (1993) argued that while some crimes are drink-specific, such as underage 
drinking, drunk and incapable, and drink driving, others are linked to alcohol misuse such as 
property damage, arson, aggression, acquisitive crime and sexual offences.  The unequivocal 
influence of alcohol on offending behaviour can only be determined in those cases for which 
alcohol consumption is inherent to the offence definition (e.g., drink and disorderly) or, further, if 
an offender is tested against some objective legal standard (e.g., drink driving) (Tierney and Hobbs, 
2003).   
There is a great deal of research examining the link between alcohol consumption and various types 
of crime and disorder.  In a Home Office research study (Bennett, 2000) it was shown that a 
significant proportion of people arrested by the police for a range of offences had been drinking 
prior to their arrest.  Another study found that violent offenders were more likely to be heavy 
drinkers than demographically matched samples of the population in general (Welte and Miller, 
1987).  In addition, a high proportion of violent crimes and public order offences are committed by 
people who have been drinking (Graham and West, 2001).   
Measurement- Establishing the link between alcohol consumption and crime activities is not easy 
and measuring the problems that alcohol drinking rises is not any easier than identifying these 
problems.  There is a significant and positive association between alcohol consumption and rates of 
violence (Home Office, 2002).  However, a causality relation is not as well defined because alcohol 
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misuse is, to some degree, one of the causes of criminal activity but not the only one.  Even when 
drinking immediately precedes a criminal act, the attribution of alcohol as a casual factor in the 
crime is not at all clear.   
The measurement of the extent of crime usually relies on crime reports or other sources of crime 
statistics (crime surveys, data from police departments, Closed-Circuit Television (CCTV), incident 
log databases, etc.), depending on the country and current practices.  The allocation of offences to 
alcohol can be done through a direct approach or an indirect approach (WHO, 2000).  For the 
specific case of alcohol-related crime, the direct approach is used when a connection between 
alcohol consumption and an offence, offender or victim is established.  This approach, due to the 
subjective judgements behind it, is subject to many uncertainties (WHO, 2000).  Using alcohol test 
data may overestimate the cost findings as those found to have drunk prior to committing an offence 
may not necessarily commit that offence because of alcohol misuse.  Another possibility is using 
police officers records of whether alcohol was a factor in the arrest which can sometimes be used as 
an indicator of alcohol-related crime.  One can argue that this is a rather “crude” and subjective 
measure and with lack of reliability as not all offences end up in arrestment.  Notifiable offences 
recorded by the police might not be the best source as they are greatly influenced by the level of 
enforcement.  Additionally, police can only record those crimes that come to their attention and 
hence the number of recorded offences can be an underestimate of the actual number of offences 
committed (WHO, 2000).  For this reason victim and population surveys are also important to find 
better estimates. The indirect approach involves making correlations between spatial, temporal and 
contextual indicators of alcohol consumption and crime and disorder (Tierney and Hobbs, 2003).   
According to data availability, two processes for measuring the effect of alcohol treatment on 
criminal activity within an economic evaluation are suggested: 1) use of patient-level criminal data 
to compare data before and after the delivery of treatment or, 2) use of national estimates of overall 
criminal activity and apply Alcohol Attribution Factors (AAFs) for levels of consumption before 
and after treatment.  The former is applicable to economic evaluations conducted alongside a 
clinical trial with questionnaires addressing crime issues.  The latter involves the use of AAFs for 
the role of alcohol in criminal behaviour which have been presented in some studies, for different 
levels of alcohol consumption (English et al., 1995; Babor et al., 2003).  AAFs are defined as the 
proportion of all outcomes from a cause, which can be attributable to alcohol, after controlling for 
the confounding effects of demographic variables and other risk factors (Gordis, 2009).  For 
example, Rehm et al. (2003c) presented global AAFs for injury mortality and morbidity with a 
specific World Health Organization (WHO) code for violence (W 158).  One of the problems with 
the use of national estimates is that crime data is country-specific and the methods used to record it 
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vary both between and within countries.  Applying attribution factors to estimates of overall 
criminal activity is not an easy task as the attribution factors are generated for crimes which do not 
always have the same exact specification as the estimates of overall criminal activity to which they 
are applied. 
Valuation- Estimation of the social costs of crime is an arduous task as costs of a different nature 
have to be accounted for.  In a methodological study, Rajkumar and French (1997) demonstrated a 
method to estimate all the benefits of avoided crime.  The societal costs from criminal acts have 
also been estimated by other authors (Cohen, 2000; Miller et al., 1996).  These valuations include 
victim costs (medical care, productivity loss, damaged property, quality of life) and also the 
opportunity costs of engaging in a criminal career, i.e. the costs of following a criminal career 
instead of the next best alternative path.   
In an extensive American report (Miller et al., 1996) criminal acts were taken from patient reports, 
police reports, department of justice reports, department of transportation records or questionnaires 
delivered to the victims.  The Miller et al. (1996) report also presented monetary conversions 
(monetary value per unit change in outcome) for identified offences.   
In order to facilitate the valuation of criminal activity actions for the taxonomy, the types of 
consequences are divided into those actions taken in anticipation of crime, actions taken as a 
consequence of crime and actions taken as a response to crime (Leontaridi, 2003).  The valuation 
process is specific to each one of these consequences as presented below. 
2.2.1.1 Actions taken in anticipation of crime 
This category includes measures that reduce the probability or risk of potential victims becoming 
one.  This involves the acquisition of security products such as alarms, security lights, security for 
vehicles, special doors and gates, contract with a security agency, and precautionary behaviour 
such as taxis instead of public transport, staying at home after dark and avoidance of dangerous 
areas (Leontaridi, 2003).  Individuals also purchase insurance policies to avoid the financial 
uncertainty from the risk of becoming victims of crime.  Insurance consists of a financial transfer 
from potential victims with insurance to actual victims with insurance and does not alter the 
resources available to the society.  However, resources used in insurance administration represent 
an opportunity cost to the economy as they could be used to provide other activities and should be 
accounted for.  For almost all of these actions a monetary valuation can be obtained due to the 
existence of market prices.  Brand and Price (2000) estimated the costs of acquisition of security 
products and the costs of insurance administration associated with the anticipation of crime.  
However, the authors did not estimate costs that result from precautionary behaviour. 
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Actions of precautionary behaviour, might lead to a reduction in the consumption of goods and 
services by the general population which causes a loss of revenue to local businesses.  This 
component of precautionary behaviour can be valued with the market price of commodities.   
Actions taken in anticipation of crime are more broadly the result of fear of crime, which has a 
psychological component that is not captured on the action per se. The fear of crime will have an 
impact on the quality of life of the general population and this health component is better valued 
under the health-related quality of life losses domain.  For example, a person that lives in a 
dangerous neighbourhood might not go out at night for leisure, which eventually translates into a 
lower quality of life than that of a person that lives in secure area.  Dolan and Peasgood (2007) 
developed a methodology to provide estimates of the costs arising from the anticipation of possible 
victimisation.  They called these costs the costs of fear of crime. The authors focused on measuring 
and valuing health losses arising from fear of crime and recognized crime as an important factor 
affecting quality of life. Therefore, according to measurement and valuation methods, the health 
component of fear of crime is categorized under the health-related quality of life domain below.   
The costs discussed are arguably a small subset of the total costs of fear of crime, since they do not 
include the non-health costs of changes in behaviour and changes in views about society (Dolan and 
Peasgood, 2007).  These latter components have never been measured and are a matter for further 
research. 
2.2.1.2 Actions taken as a consequence of crime 
The consequences of crime are various and encompass different domains.  Before going into the 
detail of this subsection, it should be noted that some of the consequences of crime are allocated to 
a different domain.  This enables a more comprehensive stratification of the domains and avoids 
double counting. 
Crime has consequences to other individuals (including drinker’s family, households and businesses) 
and the economy in general.  Crime victims may need victim support. The psychological and 
physical impacts of crime on victims and victim’s families and friends involve recovery from 
injuries and shock directly affecting their quality of life.  These costs can far outweigh any financial 
cost.  This is further explored under the domain “health-related quality of life” below (subsection 
2.2.4).   
Other society-level consequences of crime include the loss on productive output and absenteeism of 
the victim due to injuries, or participation in the criminal justice process.  This loss on productive 
output is related to the time lost by the victim and could have otherwise been spent as work or 
leisure.  There is also a loss on productive output due to victim’s premature mortality from 
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homicide.  These consequences will be further explained in the appropriate domain “workplace and 
productivity losses” below (subsection 2.2.3).  
Crime can also induce an increase in the demand of health services by the victims.  This impact on 
health services is further explained in the domain “general health care utilization” below (subsection 
2.2.5). 
Crime victims may have their property damaged or stolen. Stolen property represents an unwanted 
transfer of resources.  The costs of stolen property can be shifted from victims to society by means 
of insurance coverage and government-sponsored reparation programmes.  Damaged property 
involves an opportunity cost of using resources for repairs that could be used somewhere else.  The 
costs involved in the administration process in order to compensate victims from stolen property or 
for the resources used in damaged items can be used as a monetary value to estimate these losses. 
2.2.1.3 Actions taken in response to crime and tackling criminal activities 
This category of consequences covers actions taken by the police, prosecution and defence services,
courts1, and prison and probation services. A monetary value of these actions can be retrieved 
from government sources, for example the publications from the Home Office (1998) and from HM 
Treasury (2000) in the UK.   
A summary table for the domain of criminal activity depicting all the categories identified above 
and correspondent variables is presented below (Table 1).  When evaluating alcohol treatments, 
ideally all the presented variables should be identified, measured and valued.  It should be stressed 
again that, in order to avoid double counting, some categories related to criminal activity are 
allocated to another domain, according to their valuation method.  For example, even though 
victims suffer an impact in their health-related quality of life due to criminal activity, such 
consequences are accounted for in the domain of “health-related quality of life”. 
 
1 In England, criminal offences are split into three categories: i) triable only on indictment- these are the most 
serious and always tried in Crown Court; ii) triable-either-way- these offences may be tried either at the 
Crown or magistrates’ court; iii) summary- these offences are triable only at a magistrates’ court. 
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Table 1- Society-level consequences: criminal activity 
Building a taxonomy of Alcohol Consequences 
Society Level Consequences 
Anticipation of crime 
Acquisition of security products 
Precautionary behaviour 
Insurance administration 
Consequence of crime Damaged/ stolen property Criminal 
activity 
Response to crime 
Prosecution service 
Courts 
Defence  
Prison and probation services 
2.2.2 Road traffic accidents
Identification- Driving over the legal limit of alcohol is considered an offence and is strongly 
associated with road accidents and road deaths to motor vehicle occupants and to pedestrians.  
These accidents result in property damage, victims’ loss of quality of life, medical care costs, police 
enforcement, and lost work.  The time span between acute alcohol ingestion and drink-driving 
accidents is short and treatment interventions have the potential to reduce alcohol-related road 
traffic accidents in a not too distant period of time.  A previous review demonstrated the existence 
of a causal relationship between alcohol and road fatalities and injuries (English et al., 1995).  
Rehm et al. (2003b) included traffic accidents in the unintentional injury category and presented 
global AAFs for injury mortality and morbidity due to motor vehicle accidents. 
Most European Union countries have a maximum Blood Alcohol Concentration (BAC) allowed for 
drink-driving, which varies between 0.0 g/L and 0.8 g/L (Anderson and Baumberg, 2006).  The 
current maximum BAC for a driver is 0.8 g/ L in the UK.   
Measurement- Road crash data can be used to estimate the number of alcohol-related crashes.  
Road crash reports may be based on BAC, breathalyser, motor skills test, or just observation.  The 
WHO International Guide for Measuring Alcohol Consumption and Harm (2000) presented a 
number of different measurement possibilities such as: 1) fatal crashes with positive BAC; 2) 
alcohol-related crashes based on police reports; 3) night-time crashes; 4) single-vehicle night-time 
crashes; 6) fatal crashes; 7) roadside surveys and; 8) arrests for driving under the influence.  
Alternatively, AAFs can be used together with global estimates of road accident data. 
Valuation- Drink driving consequences have an impact on the criminal justice system, on lost 
output due to premature deaths or a serious causality and on the physical and psychological health 
of accident victims.  In order to avoid double counting, the valuation of each one of these 
consequences is explained under the appropriate domain subsection.  Under the criminal justice 
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system there are costs related to drink driving offences that fall on courts and on prison (see sub 
section 2.2.1.3 above).  This offence also has an impact on the loss of victims productivity due to 
drink driving premature deaths or absenteeism (see subsection 2.2.3 below) and on the health 
system through the use of medical care and ambulances (see subsection 2.2.5 below).  The health-
related quality of life losses involved are the health and emotional impact on accident victims (see 
subsection 2.2.4 below). 
The costs of road traffic accidents that should be identified in an economic evaluation of alcohol 
treatment are summarized in Table 2 below and these are twofold: the legal costs of dealing with 
drink driving offences within the criminal justice system and the costs related to property damage 
from drink and driving accidents.  The same argument with respect to the avoidance of double 
counting, as presented in the above section, prevails.  Therefore, for example, the impact these 
accidents have on victims’ productivity is accounted for in the domain of “workplace and 
productivity losses”. 
Table 2- Society-level consequences: road traffic accidents 
Building a taxonomy for the costs of Alcohol Consequences 
Society Level Consequences 
Road traffic 
accidents 
Legal costs of drink driving offences 
Property damage from drink and driving accidents 
2.2.3 Workplace and productivity losses
Identification- Productivity losses are related to the impact that alcohol misuse has on the 
workplace and the wider economy.  Studies of the relationship between alcohol use or misuse and 
labour market outcomes suffer from the uncertainty about the causal path between them (Leontaridi, 
2003).  Alcohol misuse may affect productivity, wages and labour opportunities but problems at 
work may, in turn, induce heavier drinking.   
Measurement and valuation- The methods used for the measurement and valuation of this domain 
are controversial and have been extensively discussed in the literature, but no consensus has been 
reached (Drummond et al., 2005c; Gold et al., 1996b; Drummond and McGuire, 2001).  Three 
different mutually exclusive approaches have been suggested for measuring and valuing workplace 
and productivity losses: the traditional human capital method (Rice and Cooper, 1967), the friction 
cost method (Koopmanschap et al., 1995) and the incorporation of these costs in quality of life 
measurements (Gold et al., 1996a).  The first is widely used and wages are assumed to be equivalent 
to the value of an individual’s productive worth and used as a monetary conversion.  This method 
usually does not take into account those who are not in the workforce, such as homemakers, retired, 
students and children.  Despite this, a value can be placed on some activities by estimating the cost 
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of hiring a market replacement for each individual function.  In the second, friction cost method, 
only the time to replace and train a replacement worker is costed and loss of earnings are not valued.  
This second approach assumes that in an efficiently functioning labour market, there would be no 
reason for overall levels of employment to change and the social costs of productivity losses would 
only be the sunk costs of any training required.  In flexible, efficiently functioning labour markets 
there would be a wage at which all those who would like a job would be able to get it.  So, one 
could expect those job places freed by the problematic drinker to be occupied by someone else.  
However, in reality a net decrease or increase in the number of jobs in the economy cannot be 
determined a priori.  It depends on factors such as labour intensity (concentration of labour versus 
capital) and the flexibility of alternative use of resources such as employee retraining (Drummond 
and McGuire, 2001).  The third approach is the most controversial in that it is assumed that in 
valuing their utility loss on normal activities individuals implicitly include their earnings and 
productivity losses.  Overall, there is no economic agreement regarding the methods for inclusion of 
productivity costs in an economic evaluation.  There is some concern relating to double counting 
when productivity costs are valued in monetary terms, which has to be controlled for when 
valuation of HRQoL is incorporated in the same analysis.  Therefore, when estimating the value of 
health, individuals should ignore income effects (Drummond et al., 2005c) if one of the two first 
approaches described above is used for measuring and valuing productivity losses.   
For a more clear description of the effects of alcohol misuse in productivity losses these are divided 
in the following three categories: 1) productivity losses due to morbidity; 2) productivity losses due 
to mortality; and 3) productivity losses due to criminal careers.  There are many inconsistencies in 
the literature regarding the effect of alcohol in these losses and a review of the evidence is provided 
below.   
2.2.3.1 Productivity losses due to morbidity 
The evidence of the relationship between alcohol consumption and productivity losses due to 
morbidity is mixed.  Productivity losses due to morbidity can be the result of absenteeism, reduced 
employee efficiency, reduced employment and workplace accidents (Leontaridi, 2003).  The extent 
to which alcohol is related to each one of these variables is discussed in the following text. 
 Absenteeism 
There is some evidence that alcohol misuse encourages drinkers’ short and long-term absenteeism 
(Gill, 1994).  The relationship between alcohol misuse and individual drinkers’ absenteeism is not 
clearly established yet.  However, the risk of absence attributable to injury has been shown to be 
related to the amount of alcohol consumed (Head et al., 2002).  For this case, there is no time gap 
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between alcohol drinking and consequences as injuries are usually the result of acute drinking.  
Several types of alcohol-related unintentional injuries can be identified and these are: falls, 
drowning, burns, poisonings, motor vehicle accidents (already mentioned in sub section 2.2.2), 
workplace accidents (covered below), and others.  The reviews conducted by Rehm et al. (2003b; 
2004) and English et al. (1995) calculated AAFs for these injuries morbidity (and also mortality).  
Absenteeism is also increased for victims of alcohol-related crime or victims of road accidents and 
family and close friends of the problem drinker. 
Chronic drinking may also affect absenteeism.  Many long term diseases are associated with alcohol 
misuse, some with an AAF of 100%, leading to sickness absence.  Sickness absence is reflected in 
reduced productivity and diverted resources away from their efficient use.   
The costs due to absenteeism can be calculated using the human capital method by measuring the 
number of working days lost due to alcohol misuse/ victimization (usually from the company or 
workplace reports) and valuing them using the average costs of an employee, after taking into 
account employer’s costs (national insurance contributions, pension contributions, etc.).  This 
method usually assumes that the rates of absenteeism are the same among full and part-time 
employees.  Alternatively, the friction cost method could be used where only the costs during the 
replacement period are taken into account. 
Sickness absence should not be confounded with the time lost due to health care use.  This time lost 
is costed in an economic evaluation of alcohol treatment under individual-level consequences.   
 Reduced employee efficiency 
Reduced efficiency at the workplace may be the result of a hangover, of health problems associated 
with alcohol misuse or may be the direct effect of employees being under the influence of alcohol 
while at work.  The productivity of co-workers and managers is affected as well as the morale in the 
workplace (Ames et al., 1997). 
It is extremely difficult to measure the proportion of reduced efficiency due to alcohol misuse and 
the extent of its effect on society (Gill, 1994).  A relationship between alcohol consumption and 
wage appears to exist but the magnitude of this relationship is not always reported in a consistent 
way.  If a wage reduction is a result of problem alcohol-drinking behaviour of the individual worker, 
then this reduction would translate to how much society loses in terms of reduced efficiency, and 
therefore the measurement and valuation problems would be solved.  However, this assumes a 
perfect economy where workers productivity would be assessed and wages regulated accordingly to 
workers’ performance.  It is extremely difficult to cost the impact alcohol consumption has on a 
36 
reduction in employee efficiency but this is not a reason for not attempting to do so in the economic 
evaluation of alcohol treatments. 
 Reduced employment 
There is strong evidence of a negative relationship between problematic alcohol consumption and 
employment.  Mullahy and Sindelar (1996) found that problem drinking reduces employment and 
increases unemployment.  The same results were observed in a more recent study (Terza, 2002).  
Lower employment probability was also found in a recent study conducted in Finland for an alcohol 
dependent population (Johansson et al., 2007).  The authors of the Finnish study also showed that 
abstaining does not decrease employment probability and that the underperformance of abstainers in 
a labour market is due to the fact that some abstainers are ex-drinkers (Johansson et al., 2006).  A 
study conducted in England, using data from the Health Survey England, showed that problem 
drinking is negatively associated with employment (MacDonald and Shields, 2004).  In contrast, the 
study conducted by Feng et al. (2001) found a positive, albeit insignificant, association between 
problem drinking and employment.   
One possible explanation for problem drinking reducing employment is that dependent workers 
may find it difficult to cope with demanding tasks.  MacDonald and Shields (2004) argued that 
alcohol misuse may lower performance among heavy and dependent drinkers through a 
“discouraged worker effect” as it may lead to a lower chance of finding employment and hence to a 
greater chance of discouragement in the labour market. 
Even though the relationship between alcohol drinking and reduced employment is somehow 
controversial, measuring this relationship and how alcohol treatment impacts it should be attempted 
in an economic evaluation.  The measurement of reduced employment can be done by a cross-
sectional or observational study where a probability of working can be retrieved for this specific 
population.  Then the valuation can be done by using the average costs of an employee from the last 
job she or he had, after taking into account employer’s costs (national insurance contributions, 
pension contributions, etc.). 
 Productivity losses due to workplace accidents 
Workplace accidents lead to loss of productivity due to absenteeism and also reduced efficiency.  
While there appears to be clear evidence concerning the relationship between alcohol use and injury 
in the general population, there are major gaps in knowledge on the relationship between alcohol 
use and workplace injury.  Epidemiological studies in the workplace have not provided conclusive 
evidence that a strong causal link exists between alcohol use and workplace injuries/accidents 
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(MacDonald, 1997).  There is more information about fatal injuries in the workplace than there is 
for non-fatal ones.   
Cherpitel (1993) conducted a review of hospital Emergency Department (ED) studies and identified 
only one study that focused on workplace injuries.  The identified case-control study showed that 
only 4% of work-related injuries were associated with alcohol use (Lings et al., 1984).  Another 
study conducted at an ED also concluded that few work injuries (5%) were alcohol-related (Trent, 
1991).  In contrast, Orozco et al (2005) conducted a study at an ED and found a relatively high 
number of alcohol-related injuries at workplaces.  It might be the case that alcohol-related work 
injuries are underrepresented due to the study design, where the focus is not specifically on injuries 
that occur in the workplace. 
Most of the other studies are cross-sectional surveys and, in general, they indicate a weak 
association between alcohol use and non-fatal workplace injuries.  Veazie and Smith (2000) found 
that alcohol dependent workers were not at a higher risk of injury.  The same findings were reported 
in a study conducted by Spicer et al. (2003).  In contrast, Dawson (1994) found that the odds of 
occupational injury increased with the frequency of heavy drinking.  It might be that the 
inconsistency between findings is related to a failure in controlling adequately for occupational 
differences as some jobs have a much higher risk of accident than others (Holcom et al., 1993). 
Despite the different arguments presented in the literature, when evaluating an alcohol treatment the 
potential for a reduction in workplace injuries should be accounted for.  Work injury data can 
usually be obtained from medical reports.  Unit costs can be used to value the health care costs 
(allocated to “general healthcare” subsection 2.2.5) and productivity losses due to workplace injury 
can be valued through the human capital approach. 
2.2.3.2 Productivity losses due to mortality 
The category of productivity loses due to mortality can be informed by two variables: premature 
death and workplace fatalities. 
 Premature death 
Alcohol misuse can result in deaths directly related to alcohol or where alcohol is an attribution 
factor.  Productivity losses due to premature deaths are those of the alcohol drinkers and of the 
victims of alcohol-related offences and drink-driving accidents. 
Premature deaths represent a loss of productive output in the economy and should be included in the 
economic evaluation of alcohol treatment.  However, measuring the effect alcohol treatment has in 
reducing premature mortality is not straightforward due to the lag in time between alcohol drinking 
38 
and alcohol-related diseases mortality.  This lag in time is not a problem for premature deaths from 
alcohol-related injury.  If the economic evaluation of the specific alcohol treatments evaluated is not 
informed by a long follow-up study, then alcohol-related mortality from chronic diseases cannot be 
captured.  In addition, a study with a small sample size does not capture all mortality from alcohol-
related injuries.  Those situations can be overcome by adopting a modelling approach.  In a 
modelling approach, productivity losses due to premature mortality that are avoided by alcohol 
treatment can be estimated using population data of alcohol-related mortality together with the 
effect of treatment in alcohol behaviour.  The number of alcohol-related deaths can be taken from 
country-specific mortality statistics.  For the cases where alcohol misuse is an attribution factor, 
attribution factors should be used (Britton and McPherson, 2001).   
Productivity losses due to premature deaths can be valued in terms of the discounted present value 
of the sum of employment earnings over the estimated life years, through the human capital 
approach (Mushkin, 1978).  This approach undervalues life since it does not take a value of life over 
and above earnings lost (see sub section 2.2.4 below for “health-related quality of life 
consequences”).  To avoid death or sickness, people would be willing to pay much more than 
simply their lost future earnings.  A WTP approach would certainly produce higher estimates for 
productivity losses due to mortality.  Just as the human capital approach, the WTP is a method 
broadly used to assign money values to health outcomes.  This method involves asking respondents 
about the contingency of an actual market existing for a programme or health benefit and to reveal 
the maximum they would be willing to pay for such programme or benefit (Drummond et al., 
2005c).   
The need to value life has arisen in other public sectors such as transport and environment.  
Methods of WTP have their foundation in transport cost benefit analysis (Drummond et al., 2005c)  
For example, the money value of a statistical life, i.e. the value of life in uncertain conditions, has 
been calculated by Jones-Lee et al. (1985) in the context of road safety.  In Great Britain, the 
Department of Transport uses the Value of Preventing a Fatality (VPF) for the estimation of the 
values of road causalities and accidents prevention.  It uses the WTP approach for valuing human 
costs and also includes lost output, and medical and ambulance costs.  The value of prevention of a 
fatality has been put between £750,000 to £1,250,000 in 1997 prices (Department of Transport, 
2007).  The Health and Safety Executive stated: “VPF is often understood to mean that a value is 
being placed on a life. This is not the case. It is simply another way of saying what people are 
prepared to pay to secure a certain averaged risk reduction” (Health and Safety Executive, 2001; p 
65). 
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However, WTP methods do not value only productivity losses.  The human capital approach is 
more suitable for this domain as the focus is on the productivity losses due to premature mortality.  
 Workplace fatalities 
Alcohol use can also contribute to work-related accidents that cause premature mortality.  Some 
studies that examined the role of alcohol in fatal workplace injuries concluded that alcohol 
contributes to workplace fatalities, such as the Hollo et al. (1993) study and the Driscoll (2003) 
study.  However, just as for workplace morbidity, there is some controversy on the contribution of 
alcohol to workplace mortality.  Measurement and valuation principles follow the same arguments 
as in “premature death” above. 
2.2.3.3 Productivity losses due to criminal careers 
The productivity losses incurred due to criminal careers are based on the value of foregone 
production by persons that follow a criminal life, for example illegal production of alcohol.  
However, estimating the proportion of drinkers that actually follow a criminal career as a 
consequence of their consumption is not an easy exercise.  Nevertheless, ideally, an attempt to cost 
this category should be made in an economic evaluation of alcohol treatment. 
The categories that should be identified under the domain of workplace and productivity losses, 
when conducting an economic evaluation of alcohol treatments, are summarized in Table 3. 
Table 3- Society-level consequences: workplace and productivity losses 
Building a taxonomy for the costs of Alcohol Consequences 
Society Level Consequences 
Due to morbidity 
Absenteeism 
Reduced efficiency 
Reduced employment 
Workplace accidents 
Due to mortality Premature death Workplace fatalities 
Workplace 
and 
productivity 
losses 
Due to criminal career 
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2.2.4 Health-related quality of life
Identification- Alcohol misuse may cause losses in health-related quality of life2 and utility at a 
societal level.  HRQoL losses may impact different groups of society and are broken down into the 
following categories: 1) loss in HRQoL to family and friends due to death or illness of the alcohol 
misuser or of his/ her victims; 2) loss in HRQoL to the victims of crime or drink-driving accidents; 
3) loss in HRQoL to the general population due to fear of crime. 
These losses impose a cost to society, in the form of non-physical resources, i.e. they impose costs 
where the valuation process is different from other costs in terms of the methodology used.  Past 
and also some current studies call these costs “intangible costs”.  Intangible costs are costs that 
when reduced do not release production or consumption resources for other uses making it 
extremely difficult to place a value upon them.  So, when HRQoL is reduced or eliminated, it does 
not yield resources available for other uses, and vice versa.  In contrast, tangible costs are the costs, 
which when reduced, yield resources which are then available to the community for consumption or 
investment purposes (Single et al., 2001).  However, Drummond et al. (2005c) argued that these 
HRQoL consequences are not “costs” (that is, resources denied to others) and are not strictly 
intangible as they are measured and valued, through utility or WTP approaches, as explained below.  
The same point of view is undertaken by Culyer (2005, p. 177) who stated that there are in fact 
“many quantifying measures of pain, disutility and so on”.  For these latter reasons, the term 
“intangible costs” is substituted by “non-physical resources” henceforth in this thesis.   
The utility and willingness to pay approaches for measuring and valuing non-physical resources are 
the ones advocated for an economic evaluation of alcohol treatment.   
Measurement- The effect of alcohol misuse on society’s physical, mental and social dimensions of 
well being can be represented by measures of HRQoL.  Examples of HRQoL measures are generic 
preference-based measures and general health profiles (Drummond et al., 2005).   
 
2 WHO (2002) defines Quality of Life as a multidimensional concept incorporating individuals’ perspective 
of their position in life after accounting for their cultural settings and with regard to their goals, expectations, 
standards and concerns. 
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Generic preference-based measures of health have two components, one is a system for describing 
health or its impact on quality of life using a standardized descriptive system, and the second is an 
algorithm for assigning values to each state described by the system.  The focus here is on 
measurement, i.e. the first component of generic preference-based measures.  The individual is 
usually asked to report their own health by using the descriptive system.   
Generic preference-based measures include: the Quality of Well-Being (QWB) scale (Kaplan et al., 
1995), Rosser Classification of illness states, Index of Health-Related Quality of life, Health Utility 
Index (HUI) marks one, two and three (HUI1, HUI2 and HUI3) (Torrance et al., 1995), EuroQol 5 
Dimensions (EQ-5D) (Williams, 1990), Short Form 6 Dimensions (SF-6D) (Brazier et al., 2002; 
Brazier et al., 2004)- a derivative of the SF-36 (Ware and Sherbourne, 1992) and the Assessment of 
Quality of Life (AQoL) (Hawthorne et al., 1999).  The EQ-5D (Williams, 1990; Brooks, 1996) is a 
self-rated descriptive system that comprises 5 dimensions of health (mobility, self-care, usual 
activities, pain/ discomfort, anxiety/depression) and a five-digit number describing the five-
dimensional health status.  Each dimension has three possible levels of severity (i.e. no problems, 
moderate, extreme problems). In total, 243, (35), health states can be defined.   
Briefly, the methods to measure preference under certainty include the Time Trade-Off (TTO), the 
Paired Comparison and the Person Trade-Off (PTO) methods.  Measuring preference under 
uncertainty is done through the widely known Standard Gamble (SG) method.  Scaling methods 
such as rating scale, category scaling, visual analogue scale and ratio scale are not choice-based 
methods (Drummond et al., 2005c) 
General health profiles also measure HRQoL and can be applied across different patient populations 
and in different disease areas.  However, usually the scoring for these instruments is not based on 
preferences of individuals for the various possible outcomes (Drummond et al., 2005c). A well-
know general health profile is the SF-36 (Ware and Sherbourne, 1992).  The SF-36 health survey is 
a standardized questionnaire used to assess patient health across eight dimensions.  This instrument 
does not produce a single quality of life score, but rather produces a profile of scores across the 
different domains of the instrument.  So, improvement in different dimensions cannot be compared, 
neither can different programmes that produce outcomes of different types.  However, methods 
exist to convert the SF-36 score into a single utility index (Brazier et al., 2002). 
Another approach is attaching money values to these HRQoL consequences.  The methods used for 
measurement under these circumstances usually include questionnaires or surveys.  These 
techniques are explained in the valuation stage below.   
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Valuation- Regarding the second component of generic preference-based measures of health, i.e. 
the valuation process, the scoring of each state is provided by an algorithm based on valuations 
obtained from a sample of, usually, the general population and using one of the measurement 
techniques described.  These instruments generate preference-based single index scores for each 
state of health on the scale required to construct QALYs.  A QALY represents a common health 
output measure that captures both changes in morbidity and mortality.  QALYs are a measure of 
health utility with in-built equity criteria in that one QALY is of equal worth for everybody.  
Quality adjustment factors, used to determine QALYs, are weights usually ranging from 0 to 1.  
These weights are called utilities and reflect the relative desirability of each health state. 
For example, the EQ5D can be scored in a number of ways depending on the method of valuation 
and source country, but the most widely used to date is the UK York TTO Tariff, which is based on 
a UK population valuation (Brazier et al., 2007; Kind et al., 1999).  The EQ-5D index represents 
societal preference values for the 243 health states with the state of “perfect health” (11111) being 
assigned a value of 1 and the state of “death” being assigned a value of 0.  Negative values 
represent states worse than death.  Dolan (1995) obtained an index for the UK population by using a 
large population sample (n = 2997).  He used the TTO in the valuation of 42 EQ-5D health states 
and derived an algorithm for societal preference values of all possible EQ-5D health states 
Several alternatives to QALYs have been suggested as Healthy-Years Equivalents (HYEs), Saved-
young-life equivalents (SAVEs), and Disability Adjusted Life Years (DALYs).  HYEs measure the 
preferences over the entire path of health states through which the individual would pass, rather 
than for each state alone.  In addition, it measures preferences using a two-stage standard gamble 
(Mehrez and Gafni, 1993, 1991).  The SAVEs approach uses the PTO method in its determination 
of preferences.  In the SAVEs approach each member of society is asked what kinds of trade-offs 
they would like for others.  In contrast, in the QALY approach, people are asked about trade-off 
they would like for themselves (Drummond et al., 2005c).  DALYs are the selected unit used by the 
WHO.  Unlike QALYs, DALYs use age weights that give the highest values to years lived in young 
adulthood and by doing so the measure adopts a stronger equity position.  The disability weight is 
estimated by a panel of public health experts (Arnesen and Kapiriri, 2004).   
Another approach to value these consequences is to attach monetary values to health outcomes and 
three techniques can be used for doing so: 1) the human capital approach, 2) revealed preferences, 
and 3) stated preferences of WTP or contingent valuation (Drummond et al., 2005c).  There is no 
internationally agreed method for putting a monetary value on human life.   
The human capital approach can be used in two ways: 1) as the sole basis for valuing all aspects of 
health improvements, and 2) as a method of valuing part of the benefits of health care interventions, 
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valuing productivity changes only (Drummond et al., 2005c).  The loss of productive output has 
already been taken into account in subsection 2.2.3.  The loss of the non-physical value of life is not 
valued when the human capital approach is used.  In addition, the lives of those who are not in the 
workforce, such as homemakers and the retired are not usually valued with this method.  However, 
there will be a loss of unpaid work as well as the loss of life incurred by these people.   
The revealed preference approach is a wage-risk approach based on actual consumer choices.  
However, estimations are job specific and vary with context.  This approach is rather difficult to 
implement regarding health outcomes valuation.  The stated preferences of WTP approach or 
contingent valuation uses survey methods.  In this context, respondents reveal the maximum they 
would be willing to pay for a reduction in the psychological disturbance that others’ alcohol misuse 
is imposing on them or for a change that reduced the probability of illness or death.  The estimates 
with this method usually overwhelm the estimates by the human capital approach.  Lifetime 
earnings, as calculated by the human capital approach, can be seen as a lower bound to a person’s 
willingness to pay for a decreased risk of death.  The WTP approach is extremely important, 
otherwise premature deaths of those out of the workforce would end up being beneficial to 
community as this population is consuming more than producing.  It also allows taking into account 
the non-physical consequences of alcohol consumption. 
Special attention should be taken in order to avoid double counting.  As mentioned above, if 
productivity losses are measured in monetary terms the analyst should ensure that individuals 
ignore income effects when asked about their quality of life. 
Most of the literature to date has solely included HRQoL of victims.  Despite evidence of both 
stress-related psychological and physical symptoms experienced by family members of substance 
misusers (Copello et al., 2009), the HRQoL of family and friends of the alcohol misuser has rarely 
been measured.  The HRQoL impact of fear of crime has also not been extensively valued in the 
literature (Dubourg et al., 2005).  Dolan and Peasgood (2007) recommended the use of QALYs to 
estimate the health losses associated with the fear of crime.  This same approach was also used to 
value the costs of crime to victims in Dolan et al. (2005). 
A summary table of health-related quality of life consequences due to alcohol misuse is presented in 
Table 4.  When performing an economic evaluation of alcohol treatment, an attempt should be made 
to cost all the categories identified under this domain. 
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Table 4- Society-level consequences: health-related quality of life 
Building a taxonomy for the costs of Alcohol Consequences 
Society Level Consequences 
Health-Related 
Quality of Life 
(HRQoL) 
HRQoL of family and friends of the alcohol misuser 
HRQoL of victims of crime and drink-driving accidents 
HRQoL of the general population: fear of crime 
2.2.5 General health care
Alcohol misuse is related to a range of health effects which may result in an excess use of 
healthcare resources compared to the rest of the population (Leontaridi, 2003).  In publicly funded 
health care systems, this presents a considerable societal burden as a significant quantity of medical 
resources is diverted from other purposes to alcohol-related problems, whilst in private insurance 
systems such costs could fall on other contributors.  There is considerable research into the potential 
for treatment to reduce future healthcare costs (Holder, 1987; Holder et al., 2000; Holder and Blose, 
1992; Parthasarathy et al., 2001; Potamianos et al., 1986; UKATT Research Team, 2005a).  
Therefore, this should be accounted for in an economic evaluation of alcohol treatment.  
Identification- There is strong evidence that the consumption of alcohol is related to a variety of 
health consequences to the individual drinker and members of society affected by drinking 
behaviour.  These consequences may be attributable to a long-term use of alcohol, as is the case of 
drinkers’ chronic diseases or they can be a short-term effect of drinking alcohol, as is the case of 
intentional and unintentional injuries.  Other consequences are due to both patterns as is the case of 
suicide and strokes.  The strength and, in some cases, the direction of this association (e.g. CHD) 
varies with the level of consumption and with the drinking pattern, by age and gender (Rehm et al., 
2001a). 
Some health consequences would not exist if alcohol was not present, i.e. they are totally 
attributable to alcohol drinking.  Examples of these conditions are: alcoholic psychosis, alcohol 
dependence, alcohol abuse, alcoholic polyneuropathy, alcoholic cardiomyopathy, alcoholic gastritis, 
alcoholic liver cirrhosis, ethanol toxicity, methanol toxicity and other alcohol poisoning.  Other 
health consequences are partly attributable to alcohol abuse, such as: lip cancer, oral cancer, 
pharyngeal cancer, oesophageal cancer, colon cancer, rectal cancer, hepatic cancer, pancreatic 
cancer, laryngeal cancer, breast cancer, pellagra, hypertension, ischemic heart disease, cardiac 
dyrshythmias, heart failure, stroke, oesophageal varices, gastro-oesophageal haem, cholelithisasis, 
acute pancreatitis, low birth weight, intentional and unintentional injuries (Single et al., 2001).  The 
WHO (2002) identifies alcohol-related unintentional injuries as: motor vehicle accidents (W150), 
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poisonings (W151), falls (W152), fires (W153), drownings (W154), and other unintentional injuries 
(W155), and alcohol-related intentional injuries as: self-inflicted injuries (W157), violence (W158), 
war (W159) and other intentional injuries (W160).  The epidemiological contribution of alcohol on 
injuries and chronic diseases has been reported in widely know studies (Ezzati et al., 2004; Corrao 
et al., 1999; Corrao et al., 2000). 
The previously described domains of alcohol-related crime (section 2.2.1), road traffic accidents 
(section 2.2.2), workplace accidents (section 2.2.3) and health-related quality of life (section 2.2.4) 
encompass consequences that lead to an increase in health care utilization. 
Measurement- Measuring the events identified above in order to cost general health care utilization 
due to alcohol consumption is difficult for the same reasons presented above for measuring 
productivity losses due to mortality.  However, the focus here is on morbidity and associated health 
care costs.  In a short-term study those events might not be captured due to the time lag between 
alcohol drinking and chronic diseases morbidity.  In addition, if the sample size is small the 
probability of capturing the effects of acute exposition to alcohol, as is the case of the injuries 
described above, is low.  Therefore, a modelling approach will help in overcoming some of these 
problems and the burden on the health care system can be quantified.  Within this approach 
population risk estimates can be applied to individuals’ levels of consumption observed before and 
after alcohol treatment (see Chapter 4).  However, obtaining population estimates of the relationship 
between alcohol drinking and the events that may in turn represent a burden in general health care, 
is not straightforward.   
The probability and severity of adverse health effects of alcohol are strongly related to level of 
intake, often in a non-linear fashion and situation-dependent.  The attributable fractions of alcohol-
related morbidity can be determined with a fair degree of confidence from large-scale population-
based epidemiological studies establishing the risk of disorders at different levels of consumption 
(WHO, 2000).  Risk functions allow for alcohol diseases risks to be estimated at any level of 
consumption (Corrao et al., 1999; Corrao et al., 2004; Corrao et al., 2000).  However, the 
determination of AAFs is complicated for those disorders that might relate to consumption in a 
curvilinear fashion as for coronary heart disease.   
The relationship between alcohol consumption and CHD is complex.  On the one hand, alcohol 
consumption at high levels is associated with hypertension, which is a strong risk factor for stroke.  
On the other hand, at low levels of consumption, alcohol may have a protective effect for stroke, 
due to its effect on High Density Lipoprotein (HDL) cholesterol, platelet stickiness and other 
thrombogenic factors.  The review conducted by English et al. (1995) showed a J shape for risk of 
stroke and level of alcohol consumption and this is supported by other studies (Boffetta and 
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Garfinkel, 1990; Corrao et al., 2000; Doll et al., 1994).  However, Rhem et al. (2001a) and Puddey 
et al. (1999) showed that patterns of drinking influence CHD and so this J relationship is not always 
verified.  In addition, the J-shaped relationship is solely observed in established market economies 
for age groups (men and women) older than 45 where benefits of light to moderate consumptions on 
CHD and other ischemic disease categories apply (Rehm et al., 2001b).  It should be noted that the 
population with which this thesis is concerned and to whom alcohol treatment is delivered is 
drinking at high level and would, therefore, be at the end part of a J-shaped curve where the effects 
of alcohol are solely detrimental. 
There is also some uncertainty about the causal relationship between mental disorders and alcohol 
misuse.  It is not straightforward to develop AAFs for mental disorders and determine which 
fraction of alcohol health service resources for mental disorder is caused by alcohol abuse.   
On the basis of accepted, standard epidemiological criteria (Rothman et al., 2008), alcohol 
consumption is causally associated with both intentional and unintentional injury.  Both the risk of 
injury and the severity of injury follow a dose-response relation with the amount of alcohol present 
in the body at the time of injury (Rehm et al., 2003a).  AAFs have been calculated for intentional 
and unintentional injuries (Ezzati et al., 2004; English et al., 1995; Rehm et al., 2003b; Rehm et al., 
2003c) and this can be used in order to calculate the costs to the health service due to alcohol-
related injuries.  A recent study developed a lifetime mortality risk function for alcohol injuries 
where both the amount of alcohol consumed and patterns of drinking were included (Taylor et al., 
2008).  Injury morbidity AAFs can be derived by multiplying the mortality AAFs by two thirds for 
motor vehicle accidents and by four ninths for all other types of injuries (Ezzati et al., 2004). 
When costing these consequences in an economic evaluation of alcohol treatment the AAFs can be 
applied to the number of cases in the country of interest.  For a hospital perspective, the number of 
cases of each alcohol-related problem can be retrieved from data on the main case of hospital 
admission, according to the coding system used in the country of the study, for example the 
International Classification of Disease 10th edition (ICD-10) from the WHO (1992) or the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) from the American Psychiatric 
Association (1994).  Secondary or contributory diagnoses are inconsistently recorded, so the WHO 
international guide recommends the analyst to focus only on principal diagnoses (WHO, 2000).   
Valuation- General health services use may include the following: accident and emergency services; 
hospital out-patient, inpatient and day patient visits; practice nurse consultations; General Practice 
(GP) surgery visits; home visits by GP or nurse; occupational therapist contact; individual 
psychotherapy visit; ambulance services; laboratory services; non-dependency drugs, etc.  These 
services are just an example as they vary between and within countries depending on a range of 
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factors, such as: current practice, institutional arrangements, setting, legislation, and health system 
organization, among other factors. 
A monetary valuation of alcohol-related consequences on the health care system uses gross or 
micro- costing methods, depending on the detail of the data available, as explained in Drummond et 
al. (2005c) and further explored in Chapter 3.  Several sources are available to provide, for example, 
the cost estimates for a unit of health care, such as the cost of a day of inpatient treatment or the cost 
of a visit to the emergency department.  When micro-costing is conducted, data on the type and 
frequency of medical and psychiatric services consumed can be matched with unit cost estimates to 
determine health care costs.  Unit costs are available in several countries, for example in England 
the Personal Social Services Research Unit (PSSRU) (Curtis, 2007) can be used.  A gross approach 
is facilitated by the existence of a coding system, like the ICD in the UK, so the level of services 
can be related to particular health problems.  In this case, average costs such as the reference costs 
provided by the Department of Health in the UK (Department of Health, 2006) with conditions 
coded in Healthcare Resource Groups (HRG) (The NHS Information Centre, 2007a) can be applied 
after matching ICD codes to HRG codes.  Then, morbidity rates for the specific country can be 
applied to these health care expenditures in order to get a weighted cost (this is explored further in 
Chapter 5).  A summary table with examples of the general health care costs that can be included in 
an economic evaluation of alcohol treatment is presented below (Table 5). 
Table 5- Society-level consequences: general health care 
Building a taxonomy for the costs of Alcohol Consequences 
Society Level Consequences 
General 
health care 
General Health care is specific to setting, current practice and other conditions. The health 
care resources presented here are other than those related to the inputs of the alcohol 
treatment under analysis. Examples: accident and emergency services; hospital out-
patient, inpatient and day patient visits; practice nurse consultations; GP surgery visits; 
home visits by GP or nurse; occupational therapist contact; individual psychotherapy visit; 
ambulance services; laboratory services and; non-dependency drugs. 
2.2.6 Other specific alcohol treatment
Identification- This domain relates to specific alcohol treatments uptake, other than the alcohol 
interventions to which the economic evaluation is drawn.  As explained for the domain of general 
health care utilization, the taxonomy intends to be fully comprehensive, even though the 
identification of specific alcohol treatments in the analysis will depend on the type of health care 
financing and other country-specific factors.  Some countries have publicly supported clinics that 
are dedicated to the treatment of alcohol and other substances abuse.  In the UK, many of the 
alcohol treatment services are provided in the voluntary sector and the National Health Service 
(NHS) provides a very wide range of services being the dominant funder of alcohol services. 
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Measurement- Many health care systems collect data about the health problems for which patients 
sought and received treatment.  A treatment episode or service received from a health provider can 
be linked to an alcohol-related diagnosis and attributed to alcohol abuse. The services covered in 
this domain are specifically delivered to patients with alcohol problems, so the use of AAFs is not 
required (AAF=1).   
Valuation- The valuation process of these health care consequences is the same as the one 
presented in subsection 2.2.5 above.  A monetary valuation of these health care costs is calculated 
by estimating the specific health expenditure related to the alcohol problem. 
A summary table with examples of the specific alcohol treatment costs that can be included in an 
economic evaluation of alcohol treatment is presented below (Table 6).  The provision of alcohol 
treatment might reduce the uptake of other specific alcohol treatment and for this reason this 
domain should be considered in the cost effectiveness analysis of alcohol treatments. 
Table 6- Society-level consequences: other specific alcohol treatment 
Building a taxonomy for the costs of Alcohol Consequences 
Society Level Consequences 
Other 
specific 
alcohol 
treatment  
Alcohol treatment is specific to the setting, current practice and other conditions.  The 
specific alcohol treatment uptake is other than the alcohol treatment under analysis. 
Examples: therapeutic community, hospital detoxification, detoxification in primary 
care, short and long-term residential treatment, referral to other agencies after treatment, 
dependency drugs, hospital inpatient for alcohol problems, specialist alcohol clinic 
advice or counselling.  
2.2.7 Social services and non-statutory care
Identification- The societal cost burden due to alcohol consumption expands to an increase in the 
uptake of social services and non-statutory care.  The effect of treatment in this domain depends on 
the availability of these services in the country where the economic evaluation is being undertaken.  
Alcohol misuse and its related problems may have an impact on the use of the following services: 
advisor regarding state benefits and housing issues, social workers interventions, occupational 
therapists, citizens’ advice services, advisors on legal or debt issues, homeless persons’ agencies, 
employment advisors and fire services.  These services are examples as their exact definitions vary 
between and within countries. 
Measurement- The use of these services can be measured in the form of number of contacts per 
cause, which can usually be found in the services’ records. 
Valuation- In England, for example, there are national sources that provide estimates of the costs 
for social services, such as the PSSRU (Curtis, 2007).  The number of alcohol-related contacts is 
multiplied by the unit costs in order to get a monetary value for these consequences.   
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Welfare benefits as a result of alcohol-related sickness represent a financial transfer from, for 
example, taxpayers to the sick person, and should not be included.  However, administration costs 
involved in these procedures should be taken into account as they could be used to provide other 
activities. 
Alcohol treatment has the potential to reduce alcohol misuse which can have a beneficial impact on 
the utilization of social services.  A summary table with examples of the variables that can be 
identified under this domain is presented below (Table 7). 
Table 7- Society-level consequences: social services and non-statutory care 
Building a taxonomy for the costs of Alcohol Consequences 
Society Level Consequences 
Social services 
and non-
statutory care 
Social services and non-statutory care are specific to the setting and other conditions. 
Examples of possible identified variables: advisor regarding state benefits and housing 
issues, social workers interventions, occupational therapists, citizens’ advice services, 
advisors on legal or debt issues, homeless persons’ agencies, employment advisors and 
fire services, and related administration costs. 
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Table 8 presents the stratification of all society-level consequences, with the identified domains and 
correspondent categories and variables.   
Table 8- Society-level consequences in the economic evaluation of alcohol treatments 
A- Society Level Consequences 
1.1 Anticipation 
of crime 
1.1.1 Acquisition of security products 
1.1.2 Precautionary behaviour 
1.1.3 Insurance administration 
Health impact of fear of crime: included in 4.3 
1.2 Consequence 
of crime 
1.2.1 Damaged/ stolen property 
Productivity losses due to injury: included in 3.1.1 and 3.1.2 
Productivity losses due to premature death: included in 3.2.1 
Psychological impact on family and friends: included in 4.1 
Psychological impact on victims: included in 4.2 
Health services uptake: included in 5 
1- Criminal 
activity 
1.3 Response to 
crime 
1.3.1 Prosecution service 
1.3.2 Courts 
1.3.3 Defence 
1.3.4 Prison and probation services 
2- Road traffic 
accidents 
2.1 Drink driving offences 
2.2 Property damage 
Productivity losses due to injury: included in 3.1.1 and 3.1.2 
Productivity losses due to premature death: included in 3.2.1 
Psychological impact on family and friends: included in 4.1 
Psychological impact on victims: included in 4.2 
Health services uptake: included in 5 
3.1 Due to 
morbidity 
3.1.1 Absenteeism 
3.1.2 Reduced efficiency 
3.1.3 Reduced employment 
3.1.4 Workplace accidents 
3.2 Due to 
mortality 
3.2.1 Premature death 
3.2.2 Workplace fatalities 
3- Workplace 
and productivity 
losses 
3.3 Due to criminal career 
4- Health-
Related Quality 
of Life (HRQoL) 
4.1 HRQoL of family and friends of the alcohol misuser 
4.2 HRQoL of victims of crime and drink-driving accidents 
4.3 HRQoL of the general population: fear of crime 
5- General health 
care utilization 
General Health care is specific to setting, current practice and other conditions.  
The health care resources here identified are other than those related to the inputs of 
the alcohol treatments under analysis. 
6-Other specific 
alcohol 
treatment 
utilization  
Specific alcohol treatment is specific to setting, current practice and other 
conditions.  The specific alcohol treatment uptake is other than the alcohol 
treatment under analysis. 
7- Social services 
and non-
statutory care 
Social services and non-statutory care are specific to setting, and other conditions.  
51 
2.3 Individual-level consequences 
Individual-level consequences are the consequences accruing to the individuals engaged in the 
drinking activity.  Alcohol treatment has the potential to reduce these consequences and the costs 
associated, hence, these should be identified, measured and valued in any economic evaluation of 
alcohol treatment.   
The individual-level effects are part of the effectiveness component of the economic evaluation.  
The process of valuing individual-level health consequences classifies the type of economic 
evaluation as CEA, CUA and CBA.  Clinicians are generally more interested in measures with 
clinical relevance, such as a change in alcohol consumption, and therefore may prefer a CEA design.  
In contrast, health financiers and health policy decision makers are interested in common or general 
health measures that allow a comparison between different health interventions, favouring the 
conduct of CBA and CUA. 
The following text stratifies the consequences that impose a cost to the individual drinker, with the 
purpose of designing a taxonomy to be used when evaluating the cost effectiveness of alcohol 
treatments.  The impact of alcohol consumption on the individual drinker is stratified in the 
following two domains: health consequences, and patients’ expenditure.
2.3.1 Health consequences
The societal and individual-level consequences are conceptually different and, while for the society 
consequences all categories could be included in the study, for individual-level health consequences 
in practice only one category should be included.  The type of health consequence included defines 
the type of economic evaluation. For example, if the study uses QALYs as the outcome measure, 
then it is classified as a CUA.  If the health measure is valued in monetary terms, the evaluation is a 
CBA.  CEA uses natural health measures such as alcohol drinks per day.  For a matter of 
presentation all individual-level consequences are presented below and gathered in the taxonomy, 
even though just one health consequence is generally included depending on the economic study 
design. 
Health consequences are divided for the taxonomy into clinical consequences and HRQoL.   
2.3.1.1 Clinical consequences 
The category of clinical consequences is divided into alcohol consumption, alcohol-related 
problems, and life expectancy.  The commonly used instruments specifically used for classifying 
clinical consequences do not present the facets of HRQoL instruments 
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Alcohol consumption is measured by the quantity and/ or frequency of consumption.  Different 
instruments can be used, for example, the Alcohol Problems Questionnaire (APQ) (Drummond, 
1990) and the Alcohol Use Disorders Identification Test (AUDIT) questionnaire (Babor et al., 2001) 
are widely used.  Changes in alcohol consumption are frequently used as an outcome measure in 
cost effectiveness analysis of alcohol treatment.   
Specific terminology is used when referring to the level of alcohol consumption.  Given that some 
of these terms will be used in this thesis it is worth providing a description of the different terms 
and definitions at this point.  There is a lack of consensus regarding the definition of, for example, a 
standard drink, a binge drinking episode, low risk alcohol consumption, hazardous alcohol drinking 
and harmful alcohol drinking.  The concept of “standard drink” differs from country to country and 
changes over time.  In the UK one unit or one standard drink equals 10 millilitres (ml) or 
approximately 8 grams (g) of pure alcohol (Anderson and Baumberg, 2006), while in the US one 
standard drink equals 13.6g of ethanol.  Conversions between standard drinks are possible as one ml 
of alcohol contains 0.785g of alcohol (ethanol).  According to the WHO (1992), the commonly used 
term “binge drinking”, which means the same as “episodic heavy drinking”, reflects a drinking 
occasion where at least 60g of alcohol are consumed.  Three other terms are often used: “low risk”, 
“hazardous” and “harmful” alcohol consumption.  Hazardous consumption is defined as a level of 
consumption or pattern of drinking that increases the risk of developing alcohol-related harm 
(Babor et al., 2003).  Harmful drinking is defined as a pattern of drinking that causes damage to 
health, either physical or mental, and is introduced in the ICD-10 classification of mental and 
behavioural disorders as a diagnostic term (WHO, 1992).  Low risk alcohol consumption is a level 
of consumption that carries no risk to health.  According to the WHO (1992) definition, 
“abstinence” is when zero grams of alcohol per day are consumed.  Whereas, “relapse” is the 
opposite of abstinence, meaning any alcohol consumption (Anderson and Baumberg, 2006).  
Alcohol dependence is a term used when the use of alcohol takes a much higher priority for 
individuals than other behaviours that once had a greater value.  Alcohol dependence is included as 
a diagnostic entity in the ICD-10 (WHO, 1992).   
General consequences of alcohol misuse are captured by the alcohol-related problems variable.  
Alcohol-related problems to the individual drinker can be measured by instruments such as the 
Severity of Alcohol Dependence Questionnaire (SADQ) (Stockwell et al., 1983), AUDIT (Babor et 
al., 2001), Leeds Dependence Questionnaire (LDQ) (Raistrick et al., 1994), the APQ (Drummond, 
1990), or the Alcohol Dependence Scale (ADS) (Skinner and Allen, 1982).  Several studies use 
these questionnaires as a measure of effectiveness of the intervention, where a change in the 
questionnaire score is monitored.   
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Life expectancy or life years gained with alcohol treatment is another effectiveness measure that an 
economic evaluation might adopt.  According to the level and pattern of consumption alcohol 
decreases life expectancy to a higher or lower extent and therefore, treatment can result in Life 
Years Gained (LYG).  Because of the lag in time between treatment and capturing alcohol-specific 
mortality for alcohol-related diseases or the sample size not being big enough to capture mortality 
due to injuries, the cost effectiveness analysis needs to adopt modelling techniques.  When 
measures of health-related quality of life are used, life years and morbidity are captured in the 
domain of “health-related quality of life”, below.  The use of QALYs and DALYs instead of life 
years lost means that the assessment includes a valuation of the deterioration in the quality of life.   
2.3.1.2 Health-related quality of life 
The risk of the most commonly experienced negative social consequences of alcohol such as: 
getting into a fight, harming home life, work, studies, friendships or social life, increases 
proportionally to the amount of alcohol consumed (Anderson and Baumberg, 2006).  There is also 
evidence that marriages where there are alcohol problems are more likely to breakdown and to end 
in divorce (Leonard and Rothbard, 1999; Fu and Goldman, 2000).  All these consequences, together 
with alcohol-related health problems, cause a loss of quality of life to the alcohol misuser that 
should be included when conducting an economic evaluation of alcohol treatment.  By reducing the 
extent of these consequences, alcohol treatment has the potential to improve drinker’s quality of life. 
The effect of alcohol misuse on drinkers’ physical, mental and social dimensions of well being can 
be represented by measures of HRQoL that might capture life years and morbidity.  This domain is 
separated in three categories based on HRQoL measures: 1) utility approach, 2) monetary approach 
and 3) health profile approach. 
In the utility approach, instruments such as the QWB scale (Kaplan et al., 1995) and EQ-5D 
(Williams, 1990) generate preference-based single index scores for each state of health.  When 
expressed as a numerical weight on a preference scale, health state preference values can be 
combined with length of life to calculate preference-based measures such as QALYs.  As mentioned, 
QALY is a generic measure of HRQoL that accounts for both the quantity and quality of life (a 
more extensive explanation of measurement and valuation in the utility approach has been provided 
in section 2.2.4).  In order to avoid double counting, when participants are asked about health state 
preferences they should not take into account productivity losses.  QALYs have been established as 
a popular measure of health benefits (Richardson and Manca, 2004).  However, the preference-
based instruments available to measure HRQoL do not include facets of quality of life related to 
alcohol consumption making quality of life valuations for individuals with alcohol problems 
difficult to determine and deriving utility measures might turn to be rather difficult in this field.  
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Gunther et al. (2007) examined whether the EQ-5D could be used as a valid measure for describing 
and valuing HRQoL in alcohol dependent individuals.  The EQ-5D was compared against a quality 
of life measure, a utility scale, measures of psychopathology and measures of social functioning.  
The similarity with some of the measures favoured EQ-5D’s validity, however the instrument 
showed a moderate ceiling effect (Gunther et al., 2007).  The authors noted that, despite EQ-5D’s 
validity, more research would be needed in order to conclude on the suitability of this instrument to 
an alcohol-dependent population.  Their results showed that the EQ-5D may not discriminate very 
well between health states in individuals with alcohol dependence.  Nevertheless, two bodies that 
have issued guidance on the conduct of economic evaluations, the UK National Institute for Health 
and Clinical Excellence (NICE, 2008) and the US Public Health Service Panel on Cost 
Effectiveness in Health and Medicine (Gold et al., 1996b), recommend the use of generic QALYs 
based on a health state classification system with preference weights assigned by the public coupled 
with a generic preference-based instrument such a the EQ-5D.   
The monetary approach attaches money values to HRQoL consequences.  Three techniques can be 
used for a monetary valuation: 1) the human capital approach, 2) revealed preferences, and 3) stated 
preferences of WTP or contingent valuation (Drummond et al., 2005c).  Measurement and valuation 
methods using these techniques are explained in section 2.2.4 above.  When using this approach for 
valuing health consequences, participants should be asked not to take into account productivity 
losses otherwise there would be a risk of double counting.   
The health profile approach uses generic instruments that do not produce a single quality of life 
score, but rather produce a profile of scores.  An example is the widely known SF-36 health survey 
(Ware and Sherbourne, 1992).  Some studies assessing HRQoL in individuals with alcohol use 
disorders have used generic instruments designed to measure a subject’s overall HRQoL.  A review 
conducted by Foster et al. (1999) concluded that the HRQoL of alcohol-dependent subjects was 
very poor when compared to normative populations.  Accordingly, other studies reported that the 
HRQoL of subjects with alcohol use disorders was poor compared to that of a reference population 
(Foster et al., 1998; McKenna et al., 1996; Romeis et al., 1999; Volk et al., 1997).  Foster et al. 
(2000) reported differences between gender, with women presenting lower HRQoL.  . 
Foster et al. (2000) also showed that a HRQoL instrument originally designed for cancer patients, 
the Rotterdam Symptoms Taxonomy (Dehaes et al., 1990), was a useful HRQoL assessment tool in 
alcohol dependent subjects.  Recently, a specific instrument derived from the SF-36 generic scale 
was developed in order to measure the HRQoL of alcohol-dependent individuals, the AlQoL 9 
(Malet et al., 2006).  However, these are condition-specific and not generic measures of HRQoL.  
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They do not provide a comprehensive measure of quality of life and, therefore, cannot be used to 
compare the cost-effectiveness of programs in different disease areas (Drummond et al., 2005c). 
2.3.2 Patients’ expenditure
Patients’ expenditures related to their alcohol misuse can also be affected by alcohol treatment.  
These include out of pocket health care costs (other than the treatment specifically analysed in the 
economic evaluation), expenditure on alcohol, travel and time costs due to other health care use 
(other than treatment under analysis), higher health insurance premiums and criminal justice related 
costs (e.g. lawyers fees, penalties and so on).  Depending on the perspective of the study these 
expenditures can be valued or not.  Including expenditure on alcohol assumes that any utility from 
alcohol consumption is null and that, by reducing alcohol consumption as an effect of treatment, 
drinkers have the opportunity to reallocate their budget to other goods and services that increase 
their utility.  This should be the case for very high levels of consumption or dependence and 
assumes a dynamic utility function.  McCollister and French (2003) stated that from a societal 
perspective expenditures on alcohol are simply an income transfer from one individual in society to 
another and therefore do not represent a net benefit or loss.  Nevertheless, these expenditures 
represent a lost opportunity to purchase other goods and for this reason some studies might choose 
to include them in an economic evaluation (McCollister and French, 2003). 
There is strong evidence of a relationship between problem drinking or dependence and loss of 
earnings (Mullahy and Sindelar, 1996; Mullahy and Sindelar, 1991, 1993; French and Zarkin, 1995; 
MacDonald and Shields, 2004; Terza, 2002).  In order to avoid double counting, loss of earnings to 
the alcohol misuser are considered under society-level consequences (workplace and productivity 
losses domain). 
Alcohol treatment has the potential to reduce alcohol misuse which can have a beneficial impact on 
the individual-level consequences presented above.  A summary table with the individual-level 
domains that can be accounted for in an economic evaluation of alcohol treatment is presented 
below (Table 9).  It is emphasized that, usually, only one primary outcome from the health 
consequences domain is considered in an economic analysis.  The individual health measure chosen 
and how it is valued in the analysis classifies the type of economic evaluation as cost effectiveness 
analysis, cost benefit analysis or cost utility analysis.   
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Table 9- Individual-level consequences domains 
Building a taxonomy for the costs of Alcohol Consequences 
Individual Level Consequences 
1.1- Clinical consequences 
1.1.1 Alcohol consumption* 
1.1.2 Alcohol-related problems* 
1.1.3 Life expectancy* 1- Health 
consequences†
1.2- HRQoL 
1.2.1 Utility approach** 
1.2.2 Monetary approach***  
1.2.3 Health profile approach* 
2- Patients’ 
expenditure 
2.1 Out of pocket health care costs†† 
2.2 Expenditure on alcohol 
2.3 Travel and time costs†† 
2.4 Higher health insurance premium 
2.5 Criminal justice related costs  
Loss of earnings: included in society- level consequences 
*Used in cost effectiveness analysis or in cost benefit analysis if a monetary valuation is attached; **Used in 
cost utility analysis or in cost benefit analysis if a monetary valuation is attached; ***Used in cost benefit 
analysis; †Only one outcome is usually used; ††Other than the treatments compared in the economic evaluation. 
2.4 The level of consequences in Economic Evaluations 
This section discusses the extent to which the identified consequences are accounted for when 
conducting an economic evaluation of alcohol treatments.  It argues that the consequences that are 
taken into account in economic evaluations of alcohol treatment depend on two interrelated factors: 
1) the theory of consumer behaviour and, 2) the perspective under which these are evaluated. 
2.4.1 Level of consequences and theory of consumer behaviour
The extent to which individual-level consequences are accounted for is embedded in consumer 
theory.  Three models of addiction are briefly presented: rational addiction, myopic addiction and 
imperfectly rational addiction models.   
Within the theory of consumer rationality, drinking alcohol and incurring its present and future 
negative consequences is a rational decision as the drinker has full knowledge of the effect of the 
contemplated addiction (Becker and Murphy, 1988).  Under the theory of rational addiction 
consumers value their own consumption rationally and seek to maximize the value of their 
consumption subject to various limitations such as income and borrowing power.  The rational 
addiction model asserts that, alcohol use, like other behaviour, forms part of a solution to a global 
expected lifetime-utility maximisation (Becker and Murphy, 1988).  Therefore, the costs incurred 
by the individual (e.g. private medical treatment, loss of quality and quantity of life, wages loss, 
drinkers’ spending on alcohol, lawyers’ fees and defence costs and penalties) are assumed to be 
offset by the benefits that the consumer obtains from alcohol use, namely pleasure.  Under this 
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model of addiction, alcohol consumption enhances welfare and externalities can be dealt with by 
suitable government action.  The theory of consumer rationality is aligned with a perspective where 
the individual-level effects are not considered in economic evaluations of alcohol treatment, also 
called a “welfarist” perspective as explained in the next section.   
On the other hand, addictive behaviour seems to violate the assumption of rational consumer 
behaviour, which is consistent with the models of myopic addiction (Liang et al., 2003).  When 
there are market failures, for example if the consumer has limited information on the adverse effects 
of consumption or the nature of their alcohol problem, they cannot make rational choices (Godfrey, 
2006).  Therefore, consumers may not be fully informed or may be misinformed about the 
consequences their actions will impose on themselves.  In this case, the misinformed consumer 
sustains unperceived costs and this has an effect on the potential range of consequences that are 
considered.  Single et al. (2001) argue that if alcohol problems do not involve rational decisions and 
in fact the consumer is willing to stop consuming in order to avoid the negative consequences 
alcohol imposes on him or herself, then all individual negative consequences should be accounted 
for as these have not been knowingly incurred.   
Even if the negative consequences of alcohol have been knowingly incurred, short-run utility 
maximization does not necessarily imply long-term positive overall benefits from alcohol misuse, 
which is consistent with an imperfectly rational addiction model (Schelling, 1978) and with a 
decision-maker perspective.  The alcohol demand model presented by Cook and Moore (2000) was 
specified in the rational-addiction form.  However, the authors noted that it would be reasonable 
that some consumers moderate their drinking in response to expectations concerning effects on 
employment, family, health status and future schooling (Cook and Moore, 2000).  A standard 
rational addiction model appears inappropriate for the economic evaluation of alcohol treatments 
where individuals require treatment in order to reduce alcohol drinking and associated problems.   
The imperfectly rational addiction model is the approach that better aligns with economic 
evaluations of alcohol treatment for a treatment-seeking population or a population accepting 
treatment given that the knowledge of the effect of the contemplated behaviour drives these 
problematic drinkers to treatment.  This is a population that is willing to stop or moderate 
consumption in order to avoid the negative consequences alcohol imposes on him or herself and 
needs help for doing so.  There are also coercive alcohol treatments such as those related to drink-
driving offences.  In this case it can be assumed that the alcohol misuser has full knowledge of the 
associated consequences and a rational addict model might be a better fit.  Even though the 
theoretical predictions of the rational addiction model of Becker and Murphy (1988) have been 
confirmed empirically (Ferguson, 2000) this has not been tested for a treated population.  There is 
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no right or wrong answer for the best theory to be used in an economic evaluation framework.  
Overall, if the consequences of alcohol misuse to the drinkers were to be classified as private and 
not taken into account in economic evaluations, then it must be assumed that drinkers are fully 
informed, they accept to bear the internal and external costs of consumption and they make rational 
consumption decisions in light of all the information available to them.  In contrast, full information 
may not be available as to the consequences that alcohol abuse imposes on the drinker, the drinker 
may not make a rational decision and there may be no mechanism by which the costs that alcohol 
misuse imposes on the rest of community can be converted into internal costs to be borne by the 
drinker (Single et al., 2001).  A compromise between the rational and myopic addiction models is 
found under an imperfectly rational addiction model, where alcohol drinkers are willing to reduce or 
cut their consumption.   
There is no consensus in the model of addiction that should be used in economic evaluations of 
alcohol treatment.  It is extremely important that researchers state the theory followed in their 
analyses as the application of a specific theory depends on the question addressed and who is 
addressing it and where.  This will ultimately determine the costs and consequences included in an 
economic evaluation.  A rational addiction model might be a better fit for private health care 
systems than public ones.  As the following section shows, this is consistent with the general use of 
a welfarist and decision maker perspectives, for private and public health care systems, respectively. 
2.4.2 Level of consequences and perspective of the analysis
The perspective of the analysis influences the types of consequences included in an economic 
evaluation.  A societal perspective is one where all costs and consequences, no matter on whom or 
where they fall, are included.  However, different economic theories suggest modifications to a 
societal perspective and three different analytical perspectives can be distinguished: 1) the 
“welfarist” perspective, 2) the “extra-welfarist” perspective and 3) the “decision making approach” 
(Drummond et al., 2005c).   
Welfare economics is concerned with social welfare being comprised of the utilities of each 
member of society where individuals are the best judges of their own welfare (consumer 
sovereignty).  A Welfarist approach is a conceptually broader perspective based on WTP valuations 
and potentially includes a wider range of costs and consequences to inform resource allocation 
decisions both within and between sectors of economy.  However, this approach involves a number 
of assumptions about the rationality and information knowledge of alcohol misusers which may 
exclude some other effects such as individual-level effects.  Welfarists argue that the social 
consequences of alcohol abuse should only be estimated as net social consequences given that 
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drinkers’ private consequences and their associated costs and benefits are irrelevant to the interests 
of the community as a whole.  Under such approach, individuals are assumed to take into account 
both the private benefits and costs of an activity when they decide to undertake such activity.  The 
foundation of CBA is in principles of welfare economics where the relevant source of monetary 
values for programme outcomes are the individual consumers (Drummond et al., 2005c). 
The “extrawelfarist” approach aligns the economic evaluation framework with the decision maker.  
The decision maker or extra-welfarist approaches have a narrower view of the consequences that 
should be included in the analysis.  Decision makers make choices within a constrained budget and 
the objective of the economic evaluation is different according to different sectors, which 
determines the consequences that are identified, measured and valued.  For example, for a public 
health care decision maker the main objective is to maximise individual HRQoL constrained by the 
health care budget.  If a study is performed from a health insurer’s perspective, this will lead to the 
exclusion of all costs outside the healthcare sector, and of all costs within the healthcare sector that 
are not reimbursed by the health insurer (e.g. co-payments) (Oostenbrink et al., 2002).  A different 
approach is used in other areas of public policy.  For example, for a criminal justice perspective, 
individual-level consequences might not be considered.  When evaluating criminal justice 
interventions, the decision maker may only include the impact on criminal justice expenditures, the 
number of offences, and fear of crime.   
Decision makers across the world set different frameworks for the conduct of economic evaluations 
of health care interventions.  Different countries adopt different perspectives (Claxton et al., 2010).  
In the Netherlands, for example, it is recommended that economic evaluations take a societal 
perspective and measure health benefits in terms of QALYs (Ziekenfondsraad, 1999), with 
preferences stated by the general population.  The Dutch pharmacoeconomic guidelines stated that 
“given the social perspective, a representative random sample from the population is the most 
suitable source of data for the evaluation of the quality of life in utilities” (Ziekenfondsraad, 1999,p 
19).   
In England and Wales, NICE represents national policy decisions on whether appraised health 
technologies should or should not be funded by the tax-funded NHS.  NICE advocates the use of 
economic evaluations to make real decisions in health care.  It uses the concept of a reference case, 
which was introduced by the Washington Panel (Gold et al., 1996b), in order to define the methods 
that should be used in a particular analysis.  Under this reference case NICE’s perspective on costs 
is that of the NHS and Personal Social Services and the perspective on outcomes takes into account 
all health effects on individuals.  It also establishes QALYs as the preferred measure of health 
benefit, elicited through a choice-based method and using a validated generic measure with 
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population values to describe health states (NICE, 2008).  The choice of population values is 
consistent with the extrawelfarist approach, where priority choices are made within a publicly-
funded rather than a free market health care system based on willingness to pay (Godfrey, 2006).   
The health service perspective is widely used to assess the relative efficiency of alternative 
healthcare interventions. However, there has been some criticism to the health system perspective.  
An economic evaluation with a health system perspective can determine the mix of interventions 
that maximize health outcomes within a limited health budget.  Yet, this does not necessarily 
maximize the welfare of society (Johannesson, 1995).  Byford and Raftery (1998) pointed out two 
main reasons for the use of a societal perspective instead of a health system one.  First, only a 
societal perspective can detect cost shifting between sectors as the costs and benefits that result 
from health interventions may be incurred by sectors other than the health service.  Second, a 
narrow perspective does not take into account alternative uses for resources outside the healthcare 
sector (Byford and Raftery, 1998).   
Studies that adopt narrow perspectives may lead to resource allocation decisions that are not 
optimal and because different perspectives have different objectives there is a potential to allocative 
inefficiency.  However, it should be recognized that it is very difficult to measure all the range of 
both inputs and consequences of different interventions across all sectors of the economy and a 
general equilibrium might be not be achieved.  This has been observed in a report on the appropriate 
perspective for health care decisions by Claxton et al. (2010).  The authors questioned the 
application of a societal perspective, especially when a NHS budget fixed by the government needs 
to be followed and, therefore, the financial transfers between different sectors are beyond the remit 
of NICE.  An extension of NICE’s perspective could provide an incentive to price technologies to 
the point at which the overall benefits, to the NHS and the wider economy, are null, and external 
benefits would be turned into higher internal NHS costs (Claxton et al., 2010).  Nevertheless, wider 
effects can be considered under NICE’s perspective in exceptional circumstances identified by the 
Department of Health (NICE, 2008).  It has been recognized that the simplification of constraints 
and objectives when analyses are limited to health care technologies may not be appropriate from a 
wider view (Claxton et al., 2007).  With this respect, NICE has issued guidance on public health 
interventions and national policies (NICE, 2009).  Public health interventions are directed at 
populations or communities rather than specific individuals, as for example a prevention strategy of 
alcohol abuse targeting the general population.  The broad nature of costs and benefits of public 
health interventions suggests that an intersectoral approach is required in order to identify them 
(Weatherly et al., 2009).  This thesis focuses on alcohol treatment and not on alcohol public health 
interventions.  However, the wider impact of treatment on society makes alcohol treatments a 
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special health technology that might justify the exceptional account of broader consequences by 
bodies such as NICE. 
The key point is that economic evaluations are explicit about the perspective adopted and are put 
into the context of the defined goals.  The exclusion of items must be made explicit and the impact 
of their exclusion on the final results should be discussed.  The implications of the decision and the 
generalisability of the results to other jurisdictions also need to be assessed.   
The final section gathers the information presented in all sections into a summary taxonomy. 
2.5 Taxonomy of alcohol consequences 
Sections 2.2 and 2.3 above provide a stratification of societal and individual-level consequences of 
alcohol consumption into domains and corresponding categories.  Section 2.4 shows that the 
consequences included depend on the theory of consumer behaviour followed and on the 
perspective of the analysis.   
The final taxonomy is built by adding up the tables presented at the end of each domain of the first 
two sections of this chapter.  The stratification presented prevents double counting in a transparent 
and theoretically consistent way.  The perspective of the analysis is also one item that needs to be 
filled in the taxonomy.  The two main components of the final taxonomy are the society-level 
consequences and the individual-level consequences.  All domains and variables can be identified in 
the analysis, with an exception for the health consequences domain under individual-level 
consequences.  In the health consequences domain only one health measure should be included and 
this defines the type of economic evaluation.  The resulting stratification is presented in Table 10.  
A number of factors will influence the set of items of the taxonomy that are included in an 
economic evaluation.  Depending on the perspective of the analysis, some alcohol treatments may 
not affect all alcohol-related society-level consequences.  In a public health care system perspective, 
for example, any increase in health problems will impose costs that fall in the general population 
through social insurance schemes or taxes.  In this case the domains of “General Health Care” and 
“Other specific alcohol treatment” are included in the economic evaluation.  A societal perspective, 
where all costs and consequences are included, may be appropriate for broad based policy 
decisions.  For example, those decisions where a shift between different sector budgets must be 
taken into account.  
The taxonomy can be used as a layout for the consequences that should be identified, measured and 
valued in the economic evaluation of alcohol treatments and a new taxonomy can be completed 
after the analysis is conducted, in order to appraise the consequences actually included.  Data 
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availability might condition the feasibility of taking into account all the consequences identified at 
the beginning of the evaluation.  The reason for the exclusion of some consequences should be 
explained in the analysis and the failure to include some of the consequences may encourage further 
research.  The taxonomy enlightens the appraisal of the methods used for the identification, 
measurement and valuation of society-level and individual-level consequences in economic 
evaluations of alcohol treatments.  Therefore, by detecting the gaps in the inclusion of consequences, 
the need for better studies with respect to the methods for estimating alcohol-related consequences 
can be justified.   
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Table 10- Taxonomy of alcohol consequences in the economic evaluation of alcohol treatments 
Alcohol Consequences in an Economic Evaluation of alcohol treatments 
Study/ project ID-  Perspective-  
Domains Type of economic evaluation:
A- Society Level Consequences 
Anticipation of crime 
Acquisition of security products 
Precautionary behaviour 
Insurance administration 
Consequence of crime Damaged/ stolen property 1- Criminal activity 
Response to crime 
Prosecution service 
Courts 
Defence 
Prison and probation services 
Drink driving offences 2- Road traffic accidents Property damage 
Due to morbidity 
Absenteeism 
Reduced efficiency 
Reduced employment 
Workplace accidents 
Due to mortality Premature death Workplace fatalities 
3- Workplace and 
productivity losses 
Due to criminal career  
4- Health-Related Quality of 
Life (HRQoL) 
HRQoL of family and friends of the alcohol misuser 
HRQoL of victims of crime and drink-driving accidents 
HRQoL of the general population: fear of crime 
5- General health care General Health care is specific to setting, current practice and other conditions†† 
6-Other specific alcohol 
treatment 
Specific alcohol treatment is specific to setting, current practice and 
other conditions†† 
7- Social services and non-
statutory care 
Social services and non-statutory care are specific to setting, and other 
conditions 
B- Individual Level Consequences 
Clinical consequences 
Alcohol consumption* 
Alcohol-related problems* 
Life expectancy* 1- Health consequences†
HRQoL  
Utility approach** 
Monetary approach***  
Health profile approach* 
2- Patients’ expenditure  
Out of pocket health care cost†† 
Expenditure on alcohol 
Travel and time costs†† 
Higher health insurance premium 
Criminal justice related costs 
*Used in cost effectiveness analysis or in cost benefit analysis if a monetary valuation is applied; **Used in 
cost utility analysis or in cost benefit analysis if a monetary valuation is applied; ***Used in cost benefit 
analysis; †Only one outcome is usually used ††Other than the treatments compared in the economic evaluation. 
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2.6 Conclusion 
This chapter stratifies the alcohol-related consequences that should be addressed in the economic 
evaluation of psychosocial or pharmacological alcohol treatments.  It is an attempt to resolve the 
inconsistencies in the methodology and reporting of alcohol consequences.   
Three main points can be concluded.  First, all theoretical considerations behind an economic 
evaluation should be stated.  There is no correct or incorrect theory of consumer behaviour that 
should be followed nor is there a single perspective.  The important issue for the economic 
evaluation taxonomy is that any assumption is made explicit rather than implicit and researchers 
must attempt to justify their assumptions and the effect of these assumptions on the evaluation 
results.  Second, many of the aspects stated in the previous point are related with the country of the 
analysis, and organization of health care services.  The concept of opportunity cost, which is 
extremely important in health economics, depends on the perspective of the analysis.  For a health 
system perspective, the opportunity cost of investing in a healthcare intervention is the health 
benefits that could have been achieved had the investment occurred for the next best health care 
alternative. Whilst, for a societal perspective, the opportunity cost of investing in a healthcare 
intervention is the benefits forgone had the investment occurred for the next best alternative for 
society.  Third, even when a societal perspective is attempted there are problems related to data 
availability. If consequences are excluded because of the lack of data this might prevent an efficient 
allocation of resources. 
The broad range of alcohol consequences included in the taxonomy can be embedded in a public 
health concept where treatment will improve the health of the individual drinker and of the 
population.  This guidance will help in the presentation of cost effectiveness evidence to those who 
need it and treatment integration into the overall policy response to alcohol.  The stratification can 
be used across boundaries.  However, a common taxonomy of alcohol-related consequences does 
not mean that the results of a cost effectiveness analysis can be generalized across settings and 
countries and such comparisons are only accurate if other factors, such as the setting and population 
characteristics, remain constant.   
To conclude, this chapter brings together the framework applied in social cost studies of alcohol 
with the theory underlying economic evaluations of health care interventions.  This allowed the 
development of a comprehensive alcohol-related consequences taxonomy which enlightens the 
harmonization of methods in the alcohol research field.  The taxonomy enables the critical appraisal 
of economic evaluations of alcohol treatments and stimulates development and refinement of 
economic evaluations in the alcohol field.  It will be used in the following chapter where the 
methods applied in previous full economic evaluations of alcohol treatment are reviewed. 
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Chapter 3. Review of Economic Evaluations of alcohol treatments 
3.1 Objectives of the review 
The aim of this chapter is to review the methodology used in published full economic evaluations 
retrieved through a systematic search of the literature, and offer research recommendations with a 
view to enhancing the rigour, consistency and harmonization of economic evaluations in the alcohol 
field.  This chapter aims at comparing the studies in terms of the methods used to assess the society-
level consequences and the methods used to carry out the analysis of individual-level consequences 
and costs of the intervention.  Accordingly, it is not the review’s aim to present any summary 
measure or provide a qualitative description of the results of the different studies.  This 
methodological review is used to inform the development of an economic model for alcohol 
treatment in the following chapter.  The taxonomy of society and individual-level consequences 
built in Chapter 2 is used as a framework for the extraction of the methodology used in the studies. 
Within health economics only full economic evaluations can help on resource allocation and 
decision making on which strategy is good value for money (Drummond et al., 2005c; Gold et al., 
1996b).  A considerable amount of the economic literature of alcohol interventions consists of 
partial economic evaluations and, even though cost studies provide useful information for a full 
economic evaluation (Popovici et al., 2008), they do not help in setting priorities in the health care 
system and are not reviewed here.  This methodological review focuses on full economic 
evaluations as a quality control strategy.  The objective is to critically appraise the methods adopted 
in the best designed economic evaluations of alcohol treatment to date and also use this information 
for the remainder of the thesis. 
This review focuses on: 
1. The identification of society and individual-level consequences affected by different types 
of alcohol treatment 
2. The different methods for measurement of the two groups of consequences and their 
advantages and disadvantages  
3. The different methods for valuation of the two groups of consequences and their advantages 
and disadvantages 
4. Identification, measurement and valuation methods used for costing the treatments 
Even though costing treatments does not present a challenge in economic evaluations of alcohol 
treatment these methods are also reviewed here.  This is done for a matter of consistency, so that all 
66 
items that make part of an economic evaluation are analysed.  It also provides information, for the 
model developed in the upcoming chapter.   
The next section presents the methods used for the systematic search, where the selection criteria 
and search strategy are reported.  This is followed by the methods used for the methodology 
extraction of the selected studies.  The following two sections report the results of the systematic 
search and the results of the methodology extraction.  The limitations of the methodological review 
are then considered. The last section presents a critique of the methodology used in the studies 
reviewed and suggests recommendations for future practice. 
Methods 
The following two sections present the methods for the systematic search and for the methodology 
extraction, respectively. 
3.2 Methods for the systematic search  
The first step is scoping the primary literature (Appendix 1- Scoping strategy).  The literature 
scoping confirms that no similar comprehensive methodological review has been conducted and 
endorses the need for a methodological review of full economic evaluations of alcohol treatment.   
3.2.1 Selection criteria 
Selection criteria, both inclusion and exclusion criteria, are derived from the prime aim which is to 
review and extract the methodology that has been adopted in economic evaluations of alcohol 
treatment.  These criteria are defined in terms of type of study, type of participants, types of 
interventions, and types of costs and consequences.  
Decisions about the inclusion or exclusion of studies are made according to inclusion and exclusion 
criteria.  This reduces the risk of study selection based on researchers’ preferences, practices or 
products (Higgins and Green, 2006; Khan et al., 2001).  Only studies that meet all of the inclusion 
criteria and none of the exclusion criteria are included in the review.  Inclusion and exclusion 
criteria are summarized in Table 11.  The text below the table provides an explanation for the 
defined criteria. 
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Table 11- Study exclusion and inclusion criteria 
Criteria Inclusion Criteria Exclusion criteria 
Type of study 
Full economic evaluations 
(CEA, CUA, CBA)*. 
Studies that report both costs 
and consequences of 
alternatives (cost consequence 
analysis, cost minimization 
analysis). 
Partial economic evaluations (cost-
offset analysis, cost-outcome 
description, cost description, 
efficacy/ effectiveness evaluations 
and outcome descriptions). 
Methodological studies. 
Review studies. 
Participants 
Individual patients to which 
alcohol treatment is directed, 
which include: harmful, 
hazardous or dependent. 
General population with no 
confirmation of problem drinking. 
Intervention 
Treatment of alcohol abuse, 
problem drinking or alcohol 
dependence (pharmacological 
or/ and psychosocial), 
including relapse prevention 
programmes and screening 
followed by brief interventions.  
Alcohol interventions at a population 
level: 1) alcohol policy and 
legislative interventions; 2) 
enforcement measures of legislation; 
3) prevention of alcohol misuse; and 
4) screening and detection studies. 
Technologies that attenuate or treat 
health problems caused or 
aggravated by alcohol consumption. 
Mixed drug/ tobacco and alcohol 
interventions. 
Costs and consequences 
Clear description of 
identification, measurement 
and valuation methods. 
Studies with no description of the 
methods for identification, 
measurement and valuation; studies 
representing extensions of previous 
ones. 
*CEA, Cost Effectiveness Analysis; CUA, Cost Utility Analysis; CBA, Cost Benefit Analysis. 
Types of studies- Only full economic evaluations are included.  Included studies are classified as 
CEA, CUA and CBA, as described in Chapter 1.  Thus, for any study to be included health and 
economic consequences, as well as costs, have to be described for each alternative and so partial 
economic evaluations are not included.  Partial economic evaluations include studies such as: cost-
offset analysis; cost-outcome description; cost description; efficacy or effectiveness evaluations; 
and outcome descriptions.  Cost-offset studies in the alcohol literature are concerned with the 
valuation of the resources used to deliver an alcohol intervention.  These studies focus on whether 
treatment costs are offset by savings in future alcohol-related medical care and set a higher hurdle 
for alcohol treatments when compared to other health care treatments, since a number of important 
avoided alcohol consequences are excluded (Ludbrook, 2004).  Also excluded are systematic 
reviews and methodological studies, since they are not full economic evaluations studies.   
Types of participants- Studies are included if they focus on harmful, hazardous and/ or dependent 
drinkers that are the target of a specific alcohol treatment.  Studies are excluded if the population of 
68 
interest is not classified as having alcohol problems and is not the target of a specific alcohol 
treatment.  
Types of interventions- Included interventions are alcohol interventions, more specifically alcohol 
treatments delivered at the individual-level consisting of psychosocial and/ or pharmacological 
approaches.  Interventions that consist of screening followed by counselling are also included.  
Although some authors classify such studies as prevention it is assumed that the objective of 
counselling is to improve an individual’s condition and when counselling is delivered to problem 
drinkers, these studies are classified here as treatment studies.   
Excluded studies are those that do not focus on alcohol treatment, and evaluate interventions 
delivered at a population level, such as: 1) alcohol policy and legislative interventions (alcohol 
taxes, drink driving controls, licensing provisions and alcohol advertising policy); 2) enforcement 
measures of legislation; 3) prevention of alcohol misuse (school-based interventions and mass 
media campaigns); and 4) screening and detection studies (screening instruments for the detection 
of problem drinking, alcohol abuse and dependence and the laboratory tests that confirm results or 
monitor abstinence).  In addition, studies that evaluate technologies that attenuate or treat health 
problems caused or aggravated by alcohol consumption are excluded as they do not focus on 
alcohol treatment per se. Studies where it is not possible to disaggregate alcohol interventions from 
other addiction interventions are not included.  Therefore, mixed alcohol and drug or tobacco 
interventions are excluded due to the difficulty of disentangling identification, measurement and 
valuation procedures for the different treatments or population types. 
Types of costs and consequences- Economic evaluations that allow an assessment of the 
identification, measurement and valuation of outcomes and cost domains are included. Studies that 
are a methodological extension of another one are excluded and only the published study with a 
more complete description of the methodology applied is selected.  
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3.2.2 Search strategy for identification of studies
Searches are undertaken of the following sources:  
1) Electronic databases- NHS Economic Evaluation Database (EED) and MEDLINE (1996 to 
present).  NHS EED identifies potential economic evaluations by searching the following databases: 
MEDLINE (from 1995 to present), EMBASE (from 2002 to present), PsychINFO (from 2006 to 
present) and CINAHL (from 1995 to present). The search run in MEDLINE is restricted to records 
added in the previous (2008) and current year (2009) of the search run in the NHS EED, in case 
there are relevant records not yet reviewed and added to the NHS EED. 
2) Handsearching of key journals: Journal of Studies on Alcohol, Alcoholism: Clinical and 
Experimental Research and the British Journal of General Practice. 
3) Reference lists and citation tracking: bibliographic search for reference lists of retrieved studies 
and citation tracking of key papers using Science Citation Index and Google Scholar. 
The search terms are presented in Appendix 2- Search terms for the methodological review.  
Searches of electronic databases use free-text terms and keywords (and where appropriate MESH 
headings) for economic evaluations.  As suggested by Counsell (1998) the search terms for 
searching electronic databases break down the research question into participants, type of 
intervention, type of costs/ consequences and study design.  This breakdown is followed for the 
MEDLINE search.  The search on the NHSEED database only uses population terms.  This is 
because the study design terms are embedded in the NHSEED database, so these do not have to be 
specified.  Also, narrowing the search down by using intervention terms does not retrieve all 
important full economic evaluations of alcohol treatment.   
Each search terms are combined by using Boolean operators.  The assessed references are managed 
by using Endnote X1, a bibliographic software package.  The selection criteria are first applied to 
all citations generated from the electronic searching to decide whether full copies of potentially 
relevant references should be obtained.  Once these copies are obtained the inclusion/ exclusion 
criteria are thoroughly applied to all collated literature and decisions of inclusion are made. 
3.3 Methods for the methodology extraction 
First, studies are classified into two groups: primary and modelling studies.  In addition, studies are 
classified as CEA, CBA and/ or CUA.  The different study design has an impact on how the costs 
and consequences are identified and subsequently measured and valued.  The first group includes 
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studies based mainly on primary data collection.  These studies usually measure costs and effects 
over a maximum period of 12 months.  Primary studies can be economic evaluations conducted 
alongside a RCT (e.g., UKATT Research Team, 2005a; Fleming et al., 2002; Shakeshaft et al., 
2002) or simply use effectiveness data from a previous trial (e.g., Barrett et al., 2006).  Modelling 
studies usually use various sources of data and mathematical techniques.  They allow long-term 
health and economic assessments in the absence of empirical data based on the extrapolation of 
known data (e.g., Palmer et al., 2000). Drummond et al. (2005c; p 277) explained that economic 
evaluation for decision making usually needs to draw on evidence from a range of sources and that 
decision analytical models provide a means of bringing evidence together.   
Second, the methodology used in each selected study is extracted for society-level consequences, 
individual-level consequences and treatment costs according to identification, measurement and 
valuation methods.  Identification consists of listing likely variables of the intervention.  The 
decision of excluding or including these variables is related with the perspective of the study, as 
explored in Chapter 2.  Measurement refers to measuring the identified variables and the changes as 
result of treatment.  The valuation process consists of putting a value on the identified variables. 
According to the definitions presented in Chapter 2, society-level consequences are the 
consequences that arise from individuals’ drinking behaviour that affect society, including alcohol-
related victims and drinkers’ families, while individual-level consequences are the consequences 
felt by the drinkers themselves.  Therefore, for the purpose of this review, societal treatment 
outcomes are the consequences that fall on society as a whole and not on the individual or target 
population (e.g. change in health services use, and utility and productivity losses to victims).  
Accordingly, individual treatment outcomes are the consequences that come as a result of the 
intervention falling on the target population for which the intervention is designed and to whom it is 
delivered.  Finally, input costs are the costs directly related to the intervention that the study is 
assessing.  The alcohol-consequences taxonomy presented in the previous chapter is used as a 
framework to stratify the identified domains and categories for the two levels of consequences 
identified in the selected studies.   
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Results 
The following two sections present the results of the systematic search and of the methodology 
extraction, respectively. 
3.4 Results of the systematic search 
The study selection process is presented in Figure 1 below, where the number of studies retrieved is 
indicated.  
Figure 1- Flow chart of retrieved studies 
 
The following four stages detail the individual steps of the selection process:  
Stage 1- The search identifies 416 potential full economic evaluations, where 292 are from NHS 
EED, 110 from MEDLINE and 14 are identified through hand search.  These studies are screened 
for retrieval.  At this stage, studies are excluded according to the type of studies as defined in the 
selection criteria.  Most of the studies excluded are cost-offset and cost-outcomes analysis.  
Duplicates of NHSEED and Medline searches are identified.  A total of 162 studies are retrieved for 
further evaluation. 
Stage 2- At this stage, 162 full economic evaluations are analysed (NHSEED n= 145, MEDLINE 
n= 4, Hand search n= 13).  Studies are excluded according to intervention and participants selection 
criteria.  The studies excluded are economic evaluations of various substance abuse treatments and/ 
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or analyse prevention programmes delivered to the general population.  This results in 29 studies 
that make it through to stage 3. 
Stage 3- At this stage there are 29 economic evaluations of alcohol treatment (NHS EED n= 22, 
MEDLINE n= 2, Hand search n= 5).  According to the types of cost and consequences selection 
criteria, two studies identified through hand search are excluded (O'Farrell et al., 1996a; Rychlik et 
al., 2001) as the methodology presented is similar to another study published by the same authors 
(O'Farrell et al., 1996b; Rychlik et al., 2003) 
Stage 4- A total of 27 economic evaluations are included in the methodological review, from which 
methods for identification, measurement and valuation of outcomes and costs are retrieved. 
3.5 Results of the methodology extraction 
3.5.1 Classification of the studies
This section classifies the studies reviewed into modelling vs. primary and as CEA, CBA and CUA.  
It also provides a general view of these studies.  After a short presentation of the 27 studies, the 
taxonomy of alcohol consequences presented in Chapter 2 is followed and the identification, 
measurement and valuation of society-level and individual-level consequences are presented.   
Table 12 divides the selected studies (27 economic evaluations) into modelling and primary studies.  
In addition, the classification of the studies as CEA, CBA and CUA, is provided.   
Table 12- Classification of 27 peer-reviewed economic evaluations of alcohol treatment 
 Studies references N 
CEA 
Alwyn et al. (2004); Babor et al. (2006); Barrett et al. (2006); Bischof et 
al. (2008); Fals-Stewart et al. (2005); Fleming et al. (2002)*; Humphreys 
and Moos (1996); Kunz et al. (2004); Lock et al. (2006); Long et al. 
(1998); Nalpas et al. (2003); O'Farrell et al. (1996b); Parrott et al. 
(2006)*; Pettinati et al. (1999); Rychlik et al. (2003); Shakeshaft et al. 
(2002); Sobell et al. (2002); Zarkin et al. (2008). 
18 
CUA Parrott et al. (2006)*; UKATT Research Team (2005a). 2 
Primary 
CBA Fleming et al. (2002)*. 1 
CEA Doran et al. (2004); Gentilello et al. (2005); Lindholm (1998); Palmer et al. (2000); Schadlich and Brecht (1998); Wutzke et al. (2001). 6
CUA Corry et al. (2004); Mortimer and Segal (2005). 2 Modelling 
CBA ------ 0 
CEA, Cost Effectiveness Analysis; CBA, Cost Benefit Analysis; CUA, Cost Utility Analysis. *The Fleming 
et al. (2002) and Parrott et al. (2006) studies fall in two classifications and therefore, the total number of 
studies does not add to the original 27 economic evaluations. 
The majority of published economic evaluations of alcohol treatment do not use modelling 
techniques (19 studies) and perform a cost effectiveness analysis (18 studies).  Within the eight 
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modelling studies identified, most of these are cost effectiveness analysis (6 studies).  Two primary 
studies perform a cost utility analysis, where one of the studies (Parrott et al., 2006) performs both a 
cost utility and a cost effectiveness analysis.  Only one full economic evaluation, without modelling 
techniques, is classified as a cost benefit analysis.  This study (Fleming et al., 2002) also performs a 
cost effectiveness analysis.  Two modelling studies are cost utility analysis and there is no 
modelling study that can be classified as cost benefit analysis.  A summary table of the objectives, 
population and setting, type of treatment, perspective, study design and primary outcome measure is 
presented in Appendix 3- Characteristics of the studies reviewed.   
Cost effectiveness analyses of brief alcohol interventions (Barrett et al., 2006; Doran et al., 2004; 
Fleming et al., 2002; Gentilello et al., 2005; Lindholm, 1998; Shakeshaft et al., 2002; Wutzke et al., 
2001; Babor et al., 2006; Kunz et al., 2004; Lock et al., 2006; Zarkin et al., 2008) use different 
endpoints, various settings and different types of health professionals delivering the interventions.  
Two other CEA look at couples-based therapy (Fals-Stewart et al., 2005; O'Farrell et al., 1996b).  
Two modelling studies perform a CEA of acamprosate treatment.  Schadlich and Brecht (1998) 
model the proportion of abstinent alcoholics, while Palmer et al. (2000) model life expectancy for 
abstinent and non-abstinent patients.  Rychlik et al. (2003) also perform a CEA of relapse 
prevention with acamprosate but without using modelling techniques.  The three studies that 
evaluate relapse prevention with acamprosate focus on an alcohol-dependent population recently 
detoxified.  Four other CEA evaluate the cost effectiveness of different detoxification programmes 
for alcohol dependent patients (Long et al., 1998; Nalpas et al., 2003; Parrott et al., 2006; Alwyn et 
al., 2004).  Sobell et al. (2002) perform a cost effectiveness analysis of advice strategies delivered 
using a public health approach to problematic drinkers, while Pettinati et al. (1999) assess the cost 
effectiveness of inpatient versus outpatient therapy based on the 12-step programme of Alcoholic 
Anonymous (AA), and Humphreys and Moos (1996) assess the cost effectiveness of using AA 
versus professional outpatient treatment. 
Four recent economic evaluations are cost utility analyses valuing quality of life improvements.  
Two of the studies are economic evaluations of alcohol treatment where no modelling is involved 
(Parrott et al., 2006; UKATT Research Team, 2005a), where the Parrott et al. (2006) is classified as 
both CUA and CEA.  These last two studies focus on patients seeking treatment and have QALYs 
as the clinical endpoint of the evaluation.  In another CUA the authors model the QALYs gained 
(Mortimer and Segal, 2005) from interventions for prevention and treatment of problem drinking 
and alcohol dependence.  The fourth CUA retrieved is the Corry et al. (2004) study where the 
authors conduct a cost effectiveness analysis of treatments for alcohol dependency and harmful use, 
modelling the number of years lived with disability. 
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Only one study values health consequences in monetary terms and is classified as a cost benefit 
analysis (Fleming et al., 2002).  This study, when using a societal perspective, performs a CBA 
where no value is given to the individual outcomes of the drinker and only the health consequences 
to the victims are considered.   
The following subsections are broken down as follows: firstly, all society-level consequences 
variables are presented under their respective domain.  Secondly, individual-level consequences 
variables are presented, together with a quality appraisal for the selection of the outcome(s) in each 
study.  This is followed by a section with a description of the methods used for costing the specific 
alcohol treatments analysed in the economic evaluations.  A general picture of the variables 
identified in the different studies is presented.  For more information regarding each study see 
Appendix 4- Methods for identification, measurement and valuation of individual consequences, 
societal consequences and treatment under evaluation costs, where a non-aggregated description of 
identification, measurement and valuation methods is provided. 
3.5.2 Society-level consequences 
Using the taxonomy of alcohol consequences presented in Chapter 2, society-level consequences 
are stratified into seven domains, namely: 1) criminal activity, 2) road traffic accidents, 3) 
workplace and productivity losses, 4) health-related quality of life, 5) general health care, 6) other 
specific alcohol treatment and, 7) social services and non-statutory care.  Different variables are 
identified in the studies reviewed and these, along with a reference to the studies that include each 
variable, are presented for each domain.  The variables identified, generally, depend on the setting 
of the analysis, the health/ judicial system on vigour, the perspective of the study and also the type 
of treatment under evaluation.  Measurement and valuation processes depend on available data, 
whether the data is national or local for example, the setting and also the country where the study 
takes place.   
3.5.2.1 Criminal activity 
Alcohol-related crime consequences are included in five studies (Barrett et al., 2006; Fleming et al., 
2002; O'Farrell et al., 1996b; Parrott et al., 2006; UKATT Research Team, 2005a).  Table 13 below 
presents the variables of alcohol-related crime identified in the selected studies.  Two categories are 
identified under the criminal activity domain: consequences of crime to victims and actions taken in 
response to crime. 
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Table 13- Criminal activity variables 
Offences  Study reference 
Consequences of crime to victims 
Property loss or damage Fleming et al., 2002 
Actions taken in response to crime 
Courts Parrott et al., 2006; UKATT Research Team, 2005a; Barrett et al., 2006 
Defence costs Barrett et al., 2006; Fleming et al., 2002 
Prison and probation services Parrott et al., 2006; O’Farrell et al., 1996b; Barrett et al., 2006 
Measurement in all studies is based on the number of events reported in criminal justice records 
during follow-up.  The Fleming et al. (2002) study valuation process is based on a research report 
for the US Department of Justice (Miller et al., 1996) which identified, measured and valued 
victims costs and consequences.  Miller et al. (1996) focused on quantifying the costs incurred 
directly by or on behalf of the crime victim.  This report costed the following variables: property 
damage, medical care, mental health care, initial police response and fire services, victim services, 
victim’s productivity losses, and victim’s loss of quality of life.  For this domain, police response 
and property damage are the variables of interest.  The costs of operating the criminal justice system 
in Fleming et al. (2002) are not reported separately from other criminal justice-related costs such as 
medical care, and mental health services costs.  Therefore, for this study, it is not possible to 
disentangle the costs falling on criminal justice from other crime-related costs.   
The other four studies value criminal activity using UK government reports (Harries, 1999; HM 
Treasury, 2000; Home Office, 1998; Field, 1997) or US state-specific judicial data, such as that 
from the Massachusetts Department of Corrections used in O’Farrell et al (1996b).  None of the 
studies identify actions taken in anticipation of crime, which would include measures that reduce 
the probability or risk of potential victims becoming one. 
3.5.2.2 Road traffic accidents 
Road traffic accidents costs are included in one reviewed study (Fleming et al., 2002) and derived 
from the US-based research report already described (Miller et al., 1996).  In order to avoid double 
counting, the variables measured and valued under this domain should be drink driving offences 
and property damage due to road accidents.  However, the estimates related to road traffic accidents 
in Fleming et al. (2002) are calculated for health care costs, productivity losses and quality of life 
losses and these are allocated to their corresponding domain in the taxonomy. 
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3.5.2.3 Workplace and productivity losses 
Productivity losses related to the impact of alcohol misuse are included in four studies (Barrett et al., 
2006; Fleming et al., 2002; Nalpas et al., 2003; Lock et al., 2006) and estimated for losses due to 
morbidity, more specifically due to absenteeism.  The estimates of the Fleming et al. (2002) study 
are derived from Miller et al. (1996), and include victims’ of crime and motor vehicle accidents 
reduced productivity due to absenteeism, calculated through the Human Capital Approach (HCA).  
The UK-based study (Barrett et al., 2006) also uses the HCA and production losses are valued based 
on the individual gross daily salary in order to reflect society’s loss of work output due to drinkers’ 
abstinence.  Nalpas et al. (2003) value the work time loss due to alcohol problems according to the 
socioprofessional category and the corresponding salary of governmental employees.  Lock et al. 
(2006), despite identifying absences from work, do not provide information regarding methods and 
valuation.  Only productivity losses due to morbidity, and more specifically absenteeism, are 
included in the studies.  Reduced efficiency, reduced employment and workplace accidents, are not 
taken into account in any study.  Similarly, workplace and productivity losses due to mortality such 
as premature death and workplace fatalities are not included in the economic evaluations of alcohol 
treatment reviewed. 
3.5.2.4 Health-related quality of life 
Health-related quality of life losses to the victims of crime and drink-driving accidents are only 
taken into account in one study (Fleming et al., 2002).  These estimates are taken from the Miller et 
al. (1996) report where HRQoL valuation was based on jury awards to victims.  HRQoL losses to 
friends and family and due to fear of crime are not included in any of the reviewed studies. 
3.5.2.5 General health care and other specific alcohol treatment 
Alcohol consumption generates ill health which increases the use of general health care and alcohol 
treatment other than the intervention under analysis.  In addition, victims of criminal activity or 
road accidents also cause an increase in the use of general health care services.  All the studies that 
include society-level consequences identify at least one variable from these two domains.  Table 14 
and Table 15 below depict general health care and other specific alcohol treatment variables 
identified in the economic evaluations reviewed, respectively.  
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Table 14- General health care variables 
Health services used Study reference 
Accident and emergency hospital  
Parrott et al., 2006; UKATT Research Team, 2005a; 
Fleming et al., 2002; Barrett et al., 2006; Gentilello et al., 
2005; Lock et al.,2006 
Hospital out-patient Parrott et al., 2006; UKATT Research Team, 2005a; Barrett et al., 2006; Lock et al.,2006 
Hospital inpatient  
Parrott et al., 2006; UKATT Research Team, 2005a; 
Fleming et al., 2002; Barrett et al., 2006; Rychlick et al., 
2003; Gentilello et al., 2005; Lock et al.,2006 
Hospital day patient visit UKATT Research Team 2005a; Barrett et al., 2006 
Practice nurse consultations UKATT Research Team, 2005a; Barrett et al., 2006; Lock et al.,2006 
General Practice (GP) surgery Parrott et al., 2006; UKATT Research Team, 2005a; Barrett et al., 2006; Lock et al.,2006 
Home visits by GP Parrott et al., 2006; UKATT Research Team, 2005a 
Home visit by practice nurse UKATT Research Team, 2005a; Barrett et al., 2006 
Occupational therapist Barrett et al., 2006 
Individual psychotherapy visit Barrett et al., 2006 
Out-patient psychological visit Barrett et al., 2006 
In-patient psychological days Barrett et al., 2006 
Ambulance services  Barrett et al., 2006 
Other (no dependency) prescribed drugs  UKATT Research Team 2005a 
Health care costs- not specified Lindholm et al., 1998 
Alcohol-related interventions and 
complications Palmer at al., 2000; Schadlich and Brecht, 1998 
Table 15- Other specific alcohol treatment variables 
Alcohol-specific treatment services Study reference 
Therapeutic community alcohol 
treatment 
UKATT Research Team, 2005a; O’Farrell et al., 1996b; 
Barrett et al., 2006; Bischof et al., 2008; Humphreys 
and Moos, 1996 
Hospital detoxification or detoxification 
in primary care 
O’Farrell et al., 1996b; Barrett et al., 2006; UKATT 
Research Team, 2005a; Bischof et al., 2008; 
Humphreys and Moos, 1996  
Residential treatment UKATT Research Team 2005a; Barrett et al., 2006; Humphreys and Moos, 1996 
Hospital inpatient treatment  O’Farrell et al., 1996b; Humphreys and Moos, 1996 
Specific counselling or advice Barrett et al., 2006; Bischof et al., 2008; Humphreys and Moos, 1996 
The increased use of general health care from individual’s alcohol consumption and/or victims is 
identified in ten of the selected full economic evaluations (Barrett et al., 2006; Fleming et al., 2002; 
Gentilello et al., 2005; Lindholm, 1998; Lock et al., 2006; Parrott et al., 2006; Rychlik et al., 2003; 
78 
UKATT Research Team, 2005a; Palmer et al., 2000; Schadlich and Brecht, 1998).  Other specific 
alcohol treatment utilization variables are identified in five studies (Barrett et al., 2006; Bischof et 
al., 2008; Humphreys and Moos, 1996; O'Farrell et al., 1996b; UKATT Research Team, 2005a).   
Costs are estimated by multiplying resource quantities by a monetary valuation of the resources 
identified.  Resource quantities for general health care and other specific alcohol treatment domains 
are measured with different levels of precision.  In general, primary studies use the more detailed 
“micro-costing” methods while modelling studies usually use “gross-costing” methods.  When a 
study is performed using micro-costing, information on resource use on a very detailed level is 
required.  This bottom up collection of data tends to be costly and runs the risk of being context 
specific.  For gross-costing, the intervention is broken down into larger intermediate products for 
which resource use is determined.  This top down costing allocates a total budget to specific 
services which may lack sensitivity (Raftery, 2000). 
In modelling studies (Gentilello et al., 2005; Lindholm, 1998; Palmer et al., 2000; Schadlich and 
Brecht, 1998), resource use information is modelled using secondary analysis of epidemiological 
information and/or assumptions.  Costs are calculated by allocating expenditures to the major 
diagnostic categories.  Monetary valuations are taken from national average estimates such as the 
federal statistical office in Germany (Palmer et al., 2000), the Marketscan® database in the US 
(Gentilello et al., 2005) and, the Swedish council on technology assessment in health care in 
Sweden (Lindholm, 1998).   
For most of the primary economic evaluations, quantities of health services used are recorded from 
patient questionnaires at different follow-up times or patient diaries, this being the most informative 
and reliable method.  If only secondary data is available, then medical records are used or, where 
data is inexistent, assumptions are made.  Monetary valuations are taken from national sources of 
unit costs such as the UK PSSRU (Netten and Curtis, 2002) or alcohol treatment literature (Slattery 
et al., 2003) used in the UKATT Research Team (2005a) study. 
3.5.2.6 Social services and non-statutory care 
Social services and non-statutory care are included in three of the 27 studies (Barrett et al., 2006; 
Parrott et al., 2006; UKATT Research Team, 2005a).  The services identified are presented in Table 
16.  Quantities of social services and non-statutory care used are, generally, recorded from patient 
questionnaires or retrieved from services records.  Average unit costs are then applied to the volume 
of resource use in order to get a monetary valuation for the identified variables. 
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Table 16- Social services and non-statutory care variables 
Services used Study reference 
Advisor regarding sate benefits or housing issues Parrott et al., 2006; Barrett et al., 2006 
Social worker  Parrott et al., 2006; Barrett et al., 2006 
Citizens advice Parrott et al., 2006 
Advisor on legal or debt issues  Parrott et al., 2006; Barrett et al., 2006 
Homeless persons agency Barrett et al., 2006 
Social services in general UKATT Research Team, 2005a 
Fire Service (call out) Barrett et al., 2006 
3.5.2.7 Summary of society-level consequences 
From the 27 reviewed studies, 12 studies exclude society-level consequences from their analysis 
(Alwyn et al., 2004; Babor et al., 2006; Corry et al., 2004; Doran et al., 2004; Kunz et al., 2004; 
Long et al., 1998; Mortimer and Segal, 2005; Shakeshaft et al., 2002; Sobell et al., 2002; Wutzke et 
al., 2001; Zarkin et al., 2008; Fals-Stewart et al., 2005).  Most of these studies rightly claim an 
agency or health system perspective.  The studies by Mortimer and Segal (2005) and Fals-Stewart et 
al. (2005) state a societal perspective, although this is not the perspective actually undertaken in the 
analysis.  The society-level consequences identified in O’Farrell et al. (1996b) are not taken into 
account in the ratio of costs to effects.  The study presents results according to two perspectives.  
For the Veteran Affairs Medical Centre (VAMC) perspective, the study conducts a CEA where the 
ratio of treatment costs (without any economic consequences) to effects is presented.  For the health 
system and criminal justice system perspectives, albeit the study claims that a CBA is conducted, in 
fact a cost analysis is presented where the benefits are restricted to reductions in health care and 
legal costs.  Nevertheless, the society-level consequences identified in the cost analysis are included 
here. 
A summary of the society-level consequences domains included in the studies is presented in Table 
17. 
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Table 17- Summary of society-level consequences included in the reviewed studies 
Domain  N Study reference 
Anticipation of 
crime -
Consequence of 
crime 1 (Fleming et al., 2002) 1- Criminal activity 
Response to crime 5 
(Barrett et al., 2006; Fleming et al., 2002; 
O'Farrell et al., 1996b; Parrott et al., 2006; 
UKATT Research Team, 2005a) 
Drink driving 
offences -2- Road traffic accidents Property damage -  
Due to morbidity:   
Absenteeism 4 (Barrett et al., 2006; Fleming et al., 2002; Nalpas et al., 2003; Lock et al., 2006) 
Reduced efficiency -  
Reduced 
employment -
Workplace 
accidents -
Due to mortality:   
Premature death -  
Workplace fatalities -  
3- Workplace and 
productivity Losses 
Due to criminal 
careers -
HRQoL of family 
and friends -
HRQoL of victims 1 (Fleming et al., 2002) 4- Health-Related Quality of Life  
HRQoL population -  
5- General health 
care utilization 
Accident and 
emergency services, 
hospital out-patient, 
inpatient and day 
patient visits, etc. 
10 
(Barrett et al., 2006; Fleming et al., 2002; 
Gentilello et al., 2005; Lindholm, 1998; Lock et 
al., 2006; Parrott et al., 2006; Rychlik et al., 
2003; UKATT Research Team, 2005a; Palmer et 
al., 2000; Schadlich and Brecht, 1998) 
6- Other specific 
alcohol treatment 
utilization  
Detoxification, 
inpatient, outpatient 
and residential 
treatment, self-help 
groups, etc. 
5
(Barrett et al., 2006; Bischof et al., 2008; 
Humphreys and Moos, 1996; O'Farrell et al., 
1996b; UKATT Research Team, 2005a) 
7- Social services 
and non-statutory 
care 
Advisor regarding 
state benefits and 
housing issues, etc. 
3 (Barrett et al., 2006; Parrott et al., 2006; UKATT Research Team, 2005a) 
Note: not all reviewed studies include society-level consequences; N, number of studies. 
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3.5.3 Individual-level consequences
According to the taxonomy of alcohol-related consequences developed in Chapter 2, individual 
outcomes are divided into the following two domains: 1) health consequences (clinical 
consequences and health-related quality of life), and 2) patients’ expenditure.   
The following subsections depict all variables identified along with the instruments used to measure 
them.  The health consequence variables presented are the endpoint of the economic analysis and 
are pooled from all studies into the correspondent domain, so that the range of individual outcomes 
included in previous economic evaluations can be explored.  
First, the variables included in all studies are presented alongside the instruments used for their 
measurement.  Variables are also classified as discrete numeric or continuous according to how they 
are measured in each study because statistical techniques differ according to the type of variable.  
Discrete numeric variables can only take a finite number of values while continuous variables can 
take any value within the limits of the variable (Anderson et al., 2005).  Second, all the outcomes of 
the economic evaluations reviewed are gathered in a summary table.  The degree of quality in terms 
of how the studies define the endpoint of the economic evaluation is discussed for each study 
individually. 
3.5.3.1 Health consequences: Clinical consequences 
Within the category of clinical consequences, variables can be related to alcohol consumption 
(Table 18), and alcohol-related problems and life expectancy (Table 19).   
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Table 18- Clinical consequences: alcohol consumption 
Variables 
identified in the 
studies 
N Type of variable (continuous or discrete)  Example of measurement instruments used 
Drinks/ drinking 
day 8
Continuous- mean number of drinks in a 
drinking day 
Total grams 
consumed in X 
time 
3
Continuous- mean grams consumed 
Discrete numeric- proportion drinking either 
side of a specified threshold 
Drinks/ X time 7
Continuous- mean number of drinks consumed 
Discrete numeric- proportion at-risk, where at 
risk is defined according to number of drinks 
Drinking days/ X 
time 1
Continuous- mean drinking days 
Discrete numeric- proportion drinking above 
certain number of days 
Binge drinking 
episodes/ heavy 
drinking 
8
Continuous - mean number of binge episodes 
reported in the time period of interest 
Discrete numeric- proportion of those who 
reported any binge episode or more than X 
binge episodes in the time period of interest 
Percentage Days 
Abstinent (PDA) 4
Continuous- mean percentage of days abstinent 
in the time period of interest 
Alcohol status: 
abstinence vs. 
relapse 
4
Continuous- mean time without relapse 
Discrete numeric- proportion of abstinent days 
or relapse days; or proportion of abstinent or 
relapsing patients in a given period 
Self-reported consumption: 
- Questionnaire Form 90 
AQ  
- Time Line Follow Back 
(TLFB) interview 
- Retrospective Drinking 
(RD) diary  
- Quantity-Frequency (QF) 
question  
- Steady Pattern Grid 
Biochemical 
markers 1
Continuous- mean biochemical values 
Discrete numerical- proportion having values 
out of the normal reference range 
- Blood analysis 
N, number of studies. 
Table 18 shows that a wide range of alcohol consumption variables are included in the studies 
reviewed.  Alcohol consumption consequences are directly affected by treatment and explicitly 
reflect the level of consumption.  The most used variables in the studies are binge drinking episodes 
and drinks per drinking day, both used in eight studies.  Abstinence-related measures are also 
widely used.  A challenge faced when reviewing the individual outcomes included in the studies is 
related to the terminology used.  The variables presented in Table 18 meet definitions that vary 
widely between studies and international literature in general.  The World Health Organization 
standardized nomenclature (WHO, 1992) is presented in the previous chapter.  Some of the 
reviewed studies, however, adopt other definitions.  For example, Shakeshaft et al. (2002) define 
binge alcohol consumption as the consumption of more than six (males) or four (females) standard 
drinks on any one occasion.  The authors report the limits of standard units of alcohol according to 
an Australian report (National Health and Medical Research Council, 1992). 
Alcohol consumption is measured in the studies with different questionnaires such as the Form 90 
AQ (Miller WR, 1996) and the Steady Pattern Grid (Sobell and Sobell, 1979).  Studies also report 
83 
the use of the Time Line Follow Back (TLFB) interview, Quantity-Frequency (QF) questions or a 
Retrospective Drinking (RD) diary, to measure alcohol consumption. 
Table 19- Clinical consequences: alcohol-related problems and life expectancy 
Variables 
identified in the 
studies 
N Type of variable (continuous or discrete)  Example of measurement instruments used 
General 
alcohol-related 
problems 
9
Continuous- mean number 
of problems reported; mean 
score on questionnaires 
Self-completed questionnaires: 
- Alcohol Problems Questionnaire (APQ)  
- Alcohol Use Disorders Identification Test 
(AUDIT) 
- Diagnostic and Statistical Manual of Mental 
Disorder (DSM), 4th Edition 
- Health and Daily Living Form 
- Drinking Problems Index 
- Drinker Inventory of Consequences 
Alcohol 
dependence 5
Continuous- mean score on 
questionnaires 
Discrete numeric- 
proportion of patients 
scoring above X score 
Self-completed questionnaires: 
- Severity of Alcohol Dependence Questionnaire 
(SADQ) 
- Diagnostic and Statistical Manual of Mental 
Disorder (DSM), 4th Edition, alcohol 
dependence element 
- Leeds Dependence Questionnaire (LDQ) 
- Alcohol Use Disorders Identification Test 
(AUDIT) 
- Alcohol dependence scale (ADS) 
Relationship 
satisfaction/ 
Marital 
functioning 
1
Continuous- mean score on 
questionnaires, % of days 
separated 
Self-completed questionnaire: 
- Marital Adjustment Test (MAT) 
Social 
satisfaction 
and/ or self 
esteem 
1 Continuous- mean score on questionnaires 
Self-completed questionnaire: 
- Social Satisfaction Scale  
- Self Esteem Questionnaire 
Life expectancy 4
Continuous- mean Life 
Years Gained (LYG) 
Discrete numeric- 
proportion of deaths 
Modelling studies: 
- Complications of alcoholism modelled with 
probabilities for clinical events  
- Life-table method measurement with specific 
mortality retrieved from epidemiological 
literature 
Primary studies: 
- Administrative documents such as patient 
follow-up procedures, family member contact, 
and death registries 
N, number of studies. 
Table 19 gathers the other set of clinical consequences variables: alcohol-related problems and life 
expectancy.  Alcohol-related problems are the outcome of the economic evaluation in many studies 
and are divided in Table 19 into general alcohol-related problems, alcohol dependence, relationship 
satisfaction and social satisfaction.  Nine studies evaluate the effects of treatment by measuring the 
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impact of treatment on general alcohol problems using self-completed questionnaires.  Studies 
identify alcohol-related problems using different questionnaires such as: SADQ (Stockwell et al., 
1983), LDQ (Raistrick et al., 1994), AUDIT (Babor et al., 2001), ADS (Skinner and Allen, 1982), 
APQ (Drummond, 1990), DSM (American Psychiatric Association, 1994), Health and Daily Living 
Form (Moos et al., 1990), amongst others.  Alcohol dependence is also another commonly used 
measure.  Life Years Gained (LYG) is the outcome of the analysis in four studies.  In modelling 
studies it is calculated with the application of epidemiological techniques, whilst in primary studies 
this is informed by patient follow-up procedures, family member contact, and death registries. 
3.5.3.2 Health consequences: HRQoL 
The taxonomy of alcohol-related consequences divides the category of HRQoL into three groups of 
variables, according to the valuation of the effects of alcohol treatment on drinkers’ HRQoL.  When 
the utility approach is used for HRQoL valuation, QALYs and Years Lived with Disability (YLD) 
are presented.  Another study uses the health profile approach for valuing HRQoL.  The monetary 
approach is not used in any of the reviewed studies. The variables identified in the category of 
HRQoL are presented in Table 20 below.  
Table 20- Clinical consequences: HRQoL 
Variables 
identified in the 
studies 
N Type of variable (continuous or discrete)  Example of measurement instruments used 
QALYs 3 Continuous- mean QALYS - EQ-5D, HRQoL gain directly attributed  to behaviour changes  
YLD 1 Continuous- mean YLD averted 
- Conversion of effect sizes to disability 
weights  
Health profile 1 Continuous- mean score - SF 12 
EQ-5D, EuroQol 5 dimensions; HRQoL, Health-Related Quality of Life; YLD, Years Lived with Disability; 
SF 12, Short Form 12. 
The EQ5D (Brooks, 1996; Williams, 1990), a generic preference-based measure, is used in two full 
economic evaluations (Parrott et al., 2006; UKATT Research Team, 2005a) and QALYs are 
estimated using specific UK preferences.  The other study that uses QALYs as an outcome measure 
is the Mortimer and Segal (2005) modelling study.  However, QALYs are computed with disability 
weights taken from Southard et al. (1997), rather than observed data.  Similarly, the YLD computed 
in Corry et al. (2004) uses weight changes taken from a published study (Sanderson et al., 2004).  
The Short Form 12 (SF-12) (Ware et al., 1996), which is a health profile measure that in principle 
can be applied across different patient populations and in different disease areas is used in one study 
(Lock et al., 2006).  As already mentioned, general health profiles are not preference-based 
measures so they cannot be used to calculate QALYs.   
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3.5.3.3 Patients’ Expenditure 
Patient’s expenditure is identified in Lock et al. (2006), where the authors identify the travel and 
time costs and out-of-pocket expenses for other health services.  This is the only economic 
evaluation mentioning the impact of alcohol treatment on the domain of patient’s expenses.  
However, the study does not provide any information regarding measurement and valuation 
methods of these variables. 
3.5.3.4 Summary of Individual-level consequences 
Table 21 depicts the individual outcomes identified in each one of the studies from which the 
methodology used is extracted.   
Table 21- Summary of individual-level consequences variables included in the reviewed studies 
Domains Domain variables Study reference 
Drinks/ drinking day 
(DDD)  
Parrott et al., 2006; Humphreys and Moos, 1996†; Alwyn et 
al., 2004; † Lock et al., 2006††; Pettinati et al., 1999; Sobell et 
al., 2002†; Long et al., 1998††; Shakeshaft et al., 2002 
Total quantity (grams)/ X 
time Doran et al., 2004; Alwyn et al., 2004
†; Bischof et al., 2008†† 
Drinks/ X time 
Barrett et al., 2006; Fleming et al., 2002†; Parrott et al., 2006; 
Shakeshaft et al., 2002; Sobell et al., 2002†; Babor et al., 
2006; Kunz et al., 2004 
Drinking days/ X time Sobell et al., 2002†
Binge drinking episodes/ 
heavy drinking 
Fals-Stewart et al., 2005; Fleming et al., 2002†; Shakeshaft et 
al., 2002; Sobell et al., 2002†; Humphreys and Moos, 1996†;
Kunz et al., 2004; Zarkin et al., 2008; Bischof et al., 2008†† 
Percentage of Days 
Abstinent (PDA) 
Long et al., 1998††; O'Farrell et al., 1996b; Parrott et al., 
2006; Zarkin et al., 2008 
Alcohol status: abstinence 
vs. relapse 
Nalpas et al., 2003; Rychlik et al., 2003; Schadlich and 
Brecht, 1998; Alwyn et al., 2004†
Alcohol 
consumption* 
Biochemical markers Long et al., 1998†† 
General alcohol-related 
problems 
Gentilello et al., 2005†; Long et al., 1998††; Shakeshaft et al., 
2002; Humphreys and Moos, 1996†; Alwyn et al., 2004; Lock 
et al., 2006††; Kunz et al., 2004; Zarkin et al., 2008; Sobell et 
al., 2002†
Alcohol dependence Long et al., 1998
††; Humphreys and Moos, 1996†;
Alwyn et al., 2004; Lock et al., 2006††; Kunz et al., 2004 
Relationship satisfaction/ 
Marital functioning O'Farrell et al., 1996b 
Alcohol-related 
problems* 
Social satisfaction and/or 
self esteem Alwyn et al., 2004
†
Life expectancy* Life years gained (LYG) Lindholm, 1998; Palmer et al., 2000; Wutzke et al., 2001; Fleming et al., 2002†
Utility approach (QALYs) Mortimer and Segal, 2005; Parrott et al., 2006; UKATT Research Team, 2005a 
Utility approach (YLD)  Corry et al., 2004 
HRQoL* 
Monetary approach NA 
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Table 21- Summary of individual-level consequences variables included in the reviewed studies 
Domains Domain variables Study reference 
Health profile approach Lock et al., 2006†† 
Out of pocket health care 
cost Lock et al., 2006
†† 
Travel and time costs due to 
other health care use Lock et al., 2006
†† 
Higher health insurance 
premium NA 
Patients’ 
expenditure 
Criminal justice related 
costs NA 
Note: Shakeshaft et al. (2002) includes all variables identified here in an effectiveness index; HRQoL, Health-
Related Quality of Life; QALYs, Quality Adjusted Life Years; YLD, Years Lived with Disability; NA, Not 
Applicable *categories and variables within the health consequences domain; †Cost consequence analysis 
with no single endpoint specified, ††Cost minimization analysis with no single endpoint defined. 
The individual-level consequences included in each one of the 27 studies reviewed are clearly 
shown in Table 21.  Some judgements can be made about the quality of studies in how they include 
the effects of treatment in the economic analysis, i.e. in how studies define the endpoint of the 
economic evaluation.  This is defined here in three points with the first one having the highest 
quality.  First, high quality economic evaluations are those that have a well defined endpoint for the 
analysis and also present results in terms of a ratio of the incremental costs to the incremental health 
effects between interventions, known as the Incremental Cost Effectiveness Ratio (ICER).  Second, 
studies that have a clear endpoint but only present average ratios of costs to effects or do not present 
any ratio are of middle quality.  Third, studies that do not have a clear endpoint and present a range 
of effects of treatment upon the individual are the lowest quality ones.  Unfortunately, many of the 
economic evaluations of alcohol treatment conducted so far fall in the latter category.  This quality 
issue raises a concern with publication bias.  When a study does not clearly define an endpoint at 
the beginning of the analysis and reports a range of individual measures, there is a possibility that 
only positive outcomes are presented.  Also, many outcomes invite the audience of the study to 
choose the outcomes of their interest, which might lead to different results from the same study.  
Even though studies that select a single endpoint for the economic evaluation are higher quality 
studies, the fact that different endpoints are selected also poses problems related with 
standardization and comparability.  An appraisal of each individual study in terms of the three 
quality points defined is now presented.  The main objective of the economic evaluation is also 
presented. 
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1) Endpoint clearly defined and incremental cost effectiveness ratios presented 
The endpoint of the economic evaluation is clearly presented in seven studies.  These studies also 
present the results in terms of an ICER and are the highest quality economic evaluations of alcohol 
treatment. 
Incremental cost effectiveness ratios are presented in the following seven studies: UKATT Research 
Team (2005a); Barrett et al. (2006); Mortimer and Segal (2005); Wutzke et al. (2001); Lindholm 
(1998); Zarkin et al. (2008); Corry et al. (2004). 
The UKATT Research Team (2005a) study presents the results in terms of an ICER and uses 
QALYs as the outcome measure for the comparison of two psychosocial therapies.  Barrett et al. 
(2006) describe a CEA of referral to an alcohol health worker compared to usual care, presenting 
the ratio of the incremental cost to the reduction in alcohol units consumed per week.  Mortimer and 
Segal (2005) compare the performance of competing and complementary interventions for 
prevention or treatment of problem drinking and alcohol dependence and report incremental costs 
per QALYs.  Wutzke et al. (2001) present the incremental cost per LYG for brief intervention 
training and support strategies.  Lindholm (1998) determines the cost effectiveness of providing 
alcohol advice in primary health care to reduce alcohol intake and uses LYG as the endpoint of the 
economic evaluation.  Zarkin et al. (2008) evaluate the cost effectiveness of nine treatment groups 
and present ICERs for 3 endpoints: percentage of abstinent days, number of patients avoiding heavy 
drinking, and number of patients that achieve a good clinical outcome (abstinent or moderate 
drinking without problems).  Corry et al. (2004) conduct a CUA of “current” and “optimal” 
treatments for alcohol dependency and harmful drinking where the costs and benefits are combined 
in the form of incremental cost per YLD averted. 
2) Endpoint clearly defined and average cost effectiveness ratios presented or no ratio 
presented 
Nine of the studies reviewed select an outcome measure for the economic analysis but present the 
results in the form of average ratios.  Three other studies with a well defined endpoint do not 
present results in the form of a ratio because they represent situations where treatment is more 
effective and less costly or where there is no difference in effects.  For the latter case the study is a 
Cost Minimization Analysis (CMA) where just the costs of the alternatives are compared. 
Average cost effectiveness ratios are presented in the following nine studies: Nalpas et al. (2003); 
O'Farrell et al. (1996b), Rychlik et al. (2003); Kunz et al. (2004); Pettinati et al. (1999); Doran et al. 
(2004); Parrott et al. (2006); Fals-Stewart et al. (2005); and Shakeshaft et al. (2002). 
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Nalpas et al. (2003) analyse and compare the financial cost and effectiveness of alcohol treatment 
programs in four hospital-based centres, presenting the ratio of the cost to the time without relapse 
for each treatment centre.  O'Farrell et al. (1996b) assess the cost benefit and cost effectiveness of 
Behavioural Marital Therapy (BMT) as an addition to outpatient alcoholism treatment with or 
without additional couples’ group therapy.  Cost effectiveness results are computed using cost of 
improvement for percentage of days' abstinence, as well as both husbands' and wives' Marital 
Adjustment Test (MAT) scores, for each treatment condition.  Rychlik et al. (2003) determine 
whether the economic benefit attributable to acamprosate is maintained in the context of standard 
care using a prospective cohort study design and use abstinent rates as the outcome of the analysis.  
Kunz et al. (2004) in their CEA of a brief intervention delivered in an emergency department, 
present three average ratios for three different endpoints: alcohol-related problems and two 
measures of alcohol consumption (number of drinks per week and percentage of patients heavy 
drinking).  Pettinati et al. (1999) assess the cost effectiveness of inpatient versus outpatient 
treatment.  An average cost effectiveness ratio is calculated dividing treatment cost by the 
probability of returning to significant drinking where significant drinking is defined as: three or 
more alcoholic drinks and/or admission to inpatient or detoxification due to alcohol behaviour.  
Doran et al. (2004) present average cost effectiveness ratios of the cost per alcohol consumption 
reduction after at-risk drinkers’ detection and intervention by a GP. 
Parrott et al. (2006) and Fals-Stewart et al. (2005) clearly select the endpoint of the economic 
evaluation but present other outcomes measures that are not summarized with costs. This reflects 
the lack of agreement in a single outcome measure of alcohol treatment.  Parrott et al. (2006) 
describe a range of outcome measures in their economic analysis of two alcohol detoxification 
programmes in the UK.  Four outcomes are presented in the form of a ratio together with costs 
(units consumed, PDA, DDD and QALYs), while another four are not aggregated with costs 
(SADQ, PCS, MCS, GHQ).  Because ratios of costs with effectiveness and utility measures are 
presented, the study is classified as a CEA and also as a CUA.  Fals-Stewart et al. (2005) present 
both the percentage days of heavy drinking and the results for relationship satisfaction (Dyadic 
Adjustment Scale score), but the latter effectiveness estimate is not aggregated with cost estimates.  
Shakeshaft et al. (2002) derive an effectiveness index based on a range of effectiveness measures: 
weekly and binge consumption, drinking intensity, number of alcohol-related problems and AUDIT 
score.  The authors use this index to compute an average cost effectiveness ratio and note that their 
CEA is gross and conservative and that the study is more of an effectiveness one.  
No cost effectiveness ratio is presented in the following three studies: Palmer at al (2000); 
Schadlich and Brecht (1998); Babor et al. (2006). 
89 
Three studies clearly identify an outcome measure but do not present a ratio between costs and 
effects.  The Palmer et al. (2000) study determines the cost effectiveness of alcohol detoxification 
with adjuvant acamprosate therapy.  The main outcome of the analysis is LYG with adjuvant 
acamprosate over standard therapy.  The comparison of the acamprosate group with standard 
therapy reveals lower lifetime costs and higher LYG for the cohort treated with acamprosate.  
Because adjuvant acamprosate therapy leads to cost savings and improved life expectancy an 
incremental cost effectiveness analysis is not required.  Schadlich and Brecht (1998) also determine 
the cost effectiveness of alcohol detoxification with adjuvant acamprosate and show that 
acamprosate is cost saving as it reduces long-term costs and increases the number of abstinent 
patients.  Both Palmer et al. (2000) and Schadlich and Brecht (1998) represent situations of 
dominance, where the treatment evaluated (acamprosate) is more effective and less costly (more 
cost saving).  When dominance occurs a ratio does not need to be computed. 
Babor et al. (2006) define a primary alcohol consumption measure (drinks per week).  They find no 
statistically significant difference between the two interventions compared (brief intervention 
delivered by doctor vs. by nurse) and do not compute a single cost effectiveness ratio.  This study 
also presents secondary outcomes such as the frequency of heavy drinking and SF-12 quality of life 
measures but these are not compared to the costs of the interventions and, therefore, are not an 
endpoint of the economic analysis.  The Babor et al. (2006) study can be classified as a CMA as no 
difference between effects is found and the costs of the two interventions are compared.  
3) No endpoint defined: several outcome measures presented 
Eight studies do not specify an outcome for the economic evaluation and present several individual-
level consequences in their analysis.  When costs and effects are presented desegregated studies can 
be classified as Cost Consequence Analysis (CCA).  If costs and effects are desegregated because 
no difference between effects is found the study is a CMA.  The CMAs described here are the ones 
where several endpoints are presented in the analysis.  The studies that fall in this third group are by 
far the poorest quality economic evaluations of alcohol treatment and exemplify the lack of 
standardization on outcome measures used in the alcohol field.  All the individual-level 
consequences presented in each study are depicted in Table 21. 
Cost consequence analysis are conducted in the following five studies: Fleming et al. (2002); Sobell 
et al. (2002); Humphreys and Moos (1996); Alwyn et al. (2004); Gentilello et al. (2005) 
Fleming et al. (2002) describe the 48-month efficacy and the costs and benefits of Project TrEAT 
(Trial for Early Alcohol Treatment), a randomized controlled trial of brief physician advice for the 
treatment of problem drinking.  When using the health care perspective, the authors present a range 
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of individual effectiveness measures without combining them with costs.  Sobell et al. (2002) 
perform a CCA of two very brief interventions with various effectiveness measures presented.  
Humphreys and Moos (1996) conduct a CCA of AA versus professional outpatient alcoholism 
treatment.  Alwyn et al. (2004) assess the cost effectiveness of home detoxification with brief 
psychological intervention compared to detoxification only.  Gentilello et al. (2005) assess the 
provision of brief alcohol interventions to trauma patients treated in hospitals and emergency 
departments.  The authors do not derive a summary measure of benefit in the economic analysis.   
Cost minimization analyses with no endpoint defined are conducted in the following three studies: 
Lock et al. (2006); Long et al. (1998); Bischof et al. (2008). 
Lock et al. (2006) include many effectiveness measures when comparing screening with brief 
intervention by nurses versus standard advice.  The authors measure alcohol consumption, alcohol-
related problems and also present SF-12 scores of HRQoL.  The study finds no difference between 
all the outcome measures described and the authors conduct a CMA.  Long et al. (1998) compare 
the effectiveness and cost effectiveness of an original 5-week inpatient versus a revised two week 
inpatient (detoxification) and day-patient regime.  The authors find equal efficacy between the two 
regimes and perform a CMA focusing on the lowest cost regime.  Bischof et al. (2008) conduct a 
CMA of stepped care approach for at-risk drinkers. 
3.5.4 Costing the alcohol treatments analysed in the economic evaluation
This section aims at providing a general overview of the methodology for costing the alcohol 
treatments analysed in the 27 selected economic evaluations.  In this section, the level of detail 
when reporting costs, the methods used to determine the volume of resource use (gross-costing or 
micro-costing), and the valuation of these costs, are briefly analysed.  This also informs the 
development of an economic evaluation framework in the following chapter as one of the 
components in an economic evaluation is costing the treatments compared.  Detailed information 
regarding the methods used in the identification, measurement and valuation of input costs, for each 
individual study, is presented in Appendix 4. 
Alcohol intervention costs do not differ from other health care interventions, in terms of 
methodology and challenges.  The level of reporting identification, measurement and valuation of 
treatment costs on the reviewed studies is generally well detailed.  However, some studies only 
present aggregated costs, without detailing unit costs and resource use separately (e.g. Fleming et al. 
(2002)).  Despite this, in general the costing methodology is well described. 
The reviewed studies use both gross and micro-costing techniques for costing alcohol treatments.  
Most of the studies predominantly use the micro-costing approach for input costs while few others 
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appear to only use gross-costing methods.  One study (Nalpas et al., 2003) measures fixed costs in a 
gross way and variable costs in a more detailed way.  In the study conducted by Shakeshaft et al. 
(2002), the authors only measure variable costs that vary between the interventions without 
measuring costs that are identical between the interventions (electricity and rent costs are stated as 
not differing between interventions).  The latter approach might not be the best one as in theory all 
costs related to the intervention and accordingly to the perspective undertaken should be measured 
and valued.  This allows assessing whether transferability of results between settings is applicable 
and also enables a clear presentation of costs and results. 
In general, when a more detailed approach is followed, the health care costs related with the specific 
alcohol intervention identified in the studies include the following items: pharmaceuticals and other 
medical supplies, office supplies, laboratory procedures, health care personnel, facility/ building and 
institutional costs as heating, electricity, maintenance and administration.  In almost all the 
economic evaluations reviewed the volume of resources is collected prospectively thus providing 
reliable estimates.  For example, the cost of the intervention is measured by the average time 
devoted to the intervention, or number of sessions per participant recorded in attendance logs and 
the square foot of space of the building/ facility. 
Unit costs are obtained in different ways and different levels of precision.  For example, the 
UKATT Research Team (2005a) value the time of therapists spent on treatment delivery from 
individual salaries, employers’ costs and overheads (Netten and Curtis, 2002), which is the most 
precise valuation method.  Nalpas et al. (2003) use values derived from French national security 
system for each medical visit, which is a less precise micro-costing method.  Within modelling 
studies, Wutzke et al. (2001) use previously published trials for valuing training and support, and 
Lindholm et al. (1998) use local charges to value nurse and doctor visits.  With respect to the use of 
charges, charges do not always reflect the actual unit cost of the procedure being merely the vehicle 
for transferring money from payers to providers (Finkler, 1982).  Charges can be more appropriate 
in a situation of private health care.  However, in a public health care system they might not reflect 
resource use and a more bottom up approach is a better choice. 
Depending on the perspective of the analysis, patient’s expenditures related to the alcohol treatment 
analysed are or are not included.  These are the costs that patients incur directly related to the 
treatment and can be seen as another component of the intervention cost.  Patients’ costs due to 
treatment uptake, such as the time spent in and getting to and from treatment and the travel costs, 
are estimated in three studies (Fals-Stewart et al., 2005; Fleming et al., 2002; Rychlik et al., 2003).  
These studies use the HCA to value the time of patients as “time out of work” due to treatment 
uptake but with assumptions to overcome the gaps in the HCA given that not all patients are 
92 
employed.  For example, Fleming at al. (2002) assumes that the opportunity costs for subjects out of 
the workforce (students, homemakers, or unemployed) are equal to the average hourly wage rate.  
The Rychlik et al. (2003) study attributes gender-specific average income for unemployed patients 
under the age of 65, whereas no cost is attributed to those over 65. 
3.5.5 Limitations of the methodological review
The review of the methods used for the identification, measurement, and valuation of societal and 
individual-level consequences in previous full economic evaluations has one limitation that is worth 
mentioning.  The main database used in the search, NHS EED, identifies potential economic 
evaluation studies published after 1995.  Therefore, full economic evaluations published before 
1995 are not detected in the review. However, this ensures that the most up-to-date economic 
evaluations of alcohol treatment are identified.  The intention is that the review reflects the best 
quality methods for undertaking economic evaluations in the field.  It can be expected that more 
recent studies provide an improved description and quality of the methods used for the evaluation.   
3.6 Discussion 
Within the reviewed studies, one study particularly highlights the discussion presented in the 
previous chapter regarding the level of consequences that should be included in economic 
evaluations of alcohol treatment and how both the perspective of the analysis and the theory of 
consumer behaviour affect this decision.  This is the Fleming et al. (2002) study where, when a 
societal perspective is adopted, individual consequences are disregarded.  When a health system 
perspective is adopted the authors include individual health consequences.  Apparently, the authors 
adopt the position that, from a societal point of view, the individual drinker does not matter and that 
the intervention’s objective is to improve overall social welfare, which is consistent with the theory 
underlying cost benefit analysis.  As discussed in Chapter 2, the authors assume a rational consumer 
(Becker and Murphy, 1988), with perfect knowledge of the consequences of drinking behaviour.  
The study looks at the harms of excessive alcohol consumption and their reduction through 
treatment as a public health concern, neglecting individual benefits achieved with the treatment of 
alcohol problems.  In contrast, this is not the approach followed in all the other studies.  The other 
full economic evaluations reviewed, even when adopting a societal perspective, value individual 
clinical consequences as the main effect of alcohol treatment.   
Other reviews of substance abuse treatments, including alcohol treatment, have been conducted for 
adolescent programs (Homer et al., 2008), continuing care interventions (Popovici et al., 2008), 
alcohol services (French, 2000), and the economic benefits of addiction interventions (McCollister 
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and French, 2003).  All these reviews provide an important insight into the methodological 
challenges of economic evaluations in this field.  A distinguished feature of the review conducted in 
this thesis is the focus on full economic evaluations of alcohol treatments and on the methods used 
for the identification, measurement and valuation of their consequences.  Previous reviews included 
partial economic evaluations and/ or were not focusing solely on alcohol treatment.   
This review shows that a societal perspective is not taken into full account and almost half of the 
studies totally exclude society-level consequences from their analysis.  The general health care 
utilization domain is the most used within society-level consequences.  This later finding has also 
been reported in the review conducted by McCollister and French (2003).  Although there may be a 
sound reason to exclude an item from further analysis, it is important to indicate its existence in the 
identification phase.  Ease of measurement should not be the initial criteria for identification and 
this is not observed in the majority of the studies reviewed.   
The economic data in the studies are limited whether by a short-term prospective study or by 
retrospective collection methods.  Clinical estimates are derived from studies with short follow-up 
periods (12 months or less), which might not capture the full extent of alcohol treatment impact.  
Only eight economic evaluations use modelling techniques.  Two of the modelling studies evaluate 
acamprosate treatment for the prevention of relapse and the others focus on brief interventions.  An 
insight into the two studies that evaluate the cost effectiveness of acamprosate (Palmer et al., 2000; 
Schadlich and Brecht, 1998) reveals that they focus on a dependent population, previously 
detoxified and with abstinence as an outcome.  Abstinence rates at the end of the trial informing the 
studies are assumed to persist after treatment follow-up and only society-level consequences related 
to health care utilization are included in these studies.  These two studies focus on a limited number 
of alcohol-related diseases and crudely assume that abstinence reduces the probability of these 
diseases which translates into reduced health care costs and also life years gained in the Palmer et al. 
(2000) study.  The efficacy assessment on Palmer et al. (2000) and Schadlich and Brecht (1998) is 
based on abstinence rates and, for this reason, improvement in morbidity and mortality due to lower 
levels of alcohol consumption is not modelled.  No modelling study attempts to model the natural 
flow of patients with alcohol problems after treatment uptake.   
There is a lack of agreement with respect to the best measure of effectiveness and time frame over 
which measurement takes place.  Many studies use abstinence as the only endpoint of the economic 
evaluation.  Some studies use test scores as an outcome measure for measuring various alcohol-
related problems.  The use of scales or test scores as an outcome measure poses comparison 
difficulties as the scores obtained are not inter-convertible.  The studies reviewed identify, measure, 
and value “alcohol consumption” differently, even when assessing similar treatments and do not 
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give an explanation for the variables used.  Different measures of alcohol consumption are 
identified, such as: drinks per drinking day, drinks per week, drinking days per week, drinking 
intensity, binge drinking episodes, etc.  Sometimes studies even report a range of these variables.  
This discrepancy in alcohol consumption measures and, more specifically, in the endpoint of the 
economic evaluation, makes comparisons between treatments in terms of effectiveness rather 
difficult.  Previous reviews have also noted the lack of consistency and standardization in the 
methods used in studies of substance abuse interventions (Popovici et al., 2008; French, 2000). 
Most of the reviewed studies are cost effectiveness analyses (24 out of 27).  Full evaluations 
included in previous reviews were also mainly cost effectiveness analyses (French, 2000; Homer et 
al., 2008; Popovici et al., 2008).  Measures of HRQoL capturing life years and morbidity are not 
extensively used in the alcohol field.  Only two primary studies are CUA and use the standard valid 
questionnaire EQ-5D.  Two modelling studies are cost utility analysis and use YLD and QALYs as 
an outcome measure (Corry et al., 2004; Mortimer and Segal, 2005).  However, HRQoL valuation 
in these two studies is not based on patients’ preferences and is taken from secondary data.   
3.6.1 Recommendations for future full economic evaluations of alcohol treatment
The recommendations provided here are those related to the findings of this particular review.  
More general recommendations in economic evaluations have been described in previous reviews 
(French, 2000; Homer et al., 2008; McCollister and French, 2003; Popovici et al., 2008) and other 
general economic evaluation literature (Drummond and McGuire, 2001; Drummond et al., 2005c; 
Gold et al., 1996b). 
1. The perspective adopted by an economic evaluation determines which costs and 
consequences are considered and should be clearly stated.  With a limited perspective, the study 
may be both more tractable for the evaluator and of direct relevance to the decision maker 
(Godfrey, 2006).  However, due to the range of problems that alcohol consumption causes an 
intervention may yield large overall social benefits if the wider costs and consequences are 
taken into account.  Homer et al. (2008) and French (2000) have also recognized the importance 
of a broad societal perspective and McCollister and French (2003) pointed out the importance 
of including criminal activity in economic evaluations as it represents the greatest economic 
benefit of addiction interventions.  Society-level consequences should be identified early-on in 
studies using the taxonomy of consequences developed in the previous chapter and a societal 
perspective should be adopted.   
2. Alcohol treatment has long-term health and social benefits that should be included in an 
economic evaluation.  Long-term outcomes can be assessed when a long-term follow-up study 
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is conducted, usually combined with modelling techniques.  Previous reviews have also 
mentioned the need for long-term data and modelling techniques (Homer et al., 2008; Popovici 
et al., 2008; French, 2000).  Moving away from short-term outcomes will make it possible to 
know the trend of economic benefits in the long-term and assess whether the immediate effects 
of treatment lead to other long-term outcomes.   
3. Both short and long-term consequences may be difficult to measure in a prospective study 
with patients.  For example, while those continuing to drink hazardously may frequently drink 
and drive, the probability of an accident on each individual occasion is low.  In addition, only 
modelling can capture the potential gain in life years achieved with a treatment for alcohol 
problems.  Therefore, unless studies have very large sample sizes and long follow-up periods 
such effects may be difficult to detect.  Therefore, this thesis argues that a modelling approach 
is paramount to the economic evaluation of alcohol treatment.  In addition, the uncertainty in 
the economic evaluation inputs should be incorporated in the modelling results through the use 
of sensitivity analysis.  Long term modelling techniques that establish a link between drinking 
patterns, health consequences and alcohol treatments effectiveness and cost effectiveness 
should be developed.  The framework presented in the following chapter provides a dynamic 
model that allows for relapse and natural recovery.  
4. All full economic evaluations should include a measure of the impact of treatment on the 
individuals under treatment.  Many earlier economic evaluations of drug and alcohol treatments 
were confined to population level consequences.  However, the omission of individual-level 
consequences could distort the assessment of the relative worth of different interventions, just 
as the exclusion of population level or long term consequences could (Godfrey and Parrott, 
2000). 
5. This thesis argues that a wider population with alcohol problems is eligible for treatment 
and confining treatment effectiveness to abstinence neglects other potential individual and 
social benefits.  A treatment that has the potential to reduce drinking should represent a value to 
society and economic evaluations should be able to reflect this.   
6. Several variables are usually used to measure alcohol consumption.  Even though alcohol 
consumption variables can be compared by making the appropriate conversions with respect to 
standard units, time period and/or measurement unit, this thesis recommends the standard use of 
grams of alcohol per day if a study reports alcohol consumption measures.   
7. The extensive use of natural effectiveness estimates for the economic evaluation of alcohol 
treatment has some fundamental problems.  CEA is based on a single program outcome but 
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alcohol treatment results in a variety of outcomes which poses numerous problems related to 
comparability and standardization (Sindelar et al., 2004).  Therefore, cost benefit analysis and 
cost utility analysis, because they address the issue of outcome valuation, might be preferable as 
they allow an assessment of broader choices than a simple CEA.   
8. Health care providers and policy makers use full economic evaluations to make decisions 
on the allocation of scarce resources between competing programmes.  For such a decision to be 
made treatment outcomes should be comparable and a single outcome measure should be used.  
Preference-based measures such as QALYs are advocated as a comprehensive health measure 
that permits comparison between different health technologies (Drummond and Pang, 2001; 
Drummond et al., 2005b; Gold et al., 1996a; NICE, 2004).  Therefore, outcome scales/tests 
should be replaced by a standardized health measure that facilitates comparison between 
interventions and patient groups and captures quality and quantity of life, such as QALYs.   
9. The methodological review includes two CUA that use the EQ5D to calculate the QALYs 
gained with the intervention (Parrott et al., 2006; UKATT Research Team, 2005a).  These two 
studies show that the HRQoL of individuals with alcohol use disorders is poorer than that of a 
reference population and that QALYs are gained with treatment.  However, this QALY gain is 
not statistically significant.  In contrast, improvements in alcohol consumption variables are 
significant in those two studies.  Some possible explanations for these results can be advanced 
and these are: 1) the EQ-5D used in both those studies, although presenting all the advantages 
of a generic preference-based measure, does not include facets of quality of life related to 
alcohol consumption, 2) both studies have a short follow-up (6 to 12 months) that might not 
capture changes in HRQoL of an alcohol drinking population and, it might be that, although 
there is a large scope for improvement in alcohol consumption measures, the improvement in 
QALYs can only be observed with a lag in time, 3) the nature and severity of problem drinking 
causes a delay in improvement in HRQoL.  In addition, Fayers and Hand (1997) have 
mentioned that the variability in health-related quality of life is often greater than the variability 
in clinical endpoints and the sample size of studies may be insufficient to detect significant 
differences in such economic endpoints.  Investigation into the relationship between QALYs 
and indicators of drinking behaviour, the extent to which improvement in alcohol consumption 
can be linked with QALYs gained and the time period for this to be detected, warrants closer 
scrutiny.  More research should also be done in order to determine whether the small increase in 
QALYs in the short term persists for longer periods and whether generic HRQoL instruments 
are appropriate for a population with alcohol problems.  A longitudinal study, where an alcohol 
drinking population is followed for a long period and where consumption levels and HRQoL 
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are measured, would help in answering some of these questions.  In fact, many countries are 
now using cost per QALYs estimates for reimbursement and adoption decisions.  If alcohol 
treatment programs are to compete with other healthcare interventions for limited resources, the 
relationship between alcohol treatment outcomes and QALYs is of great importance so that 
there is a single, comparable outcome measure. 
10. A previous review strongly recommended the use of CBA (Popovici et al., 2008).  While 
the use of utility measures is currently limited, so is the use of monetary measures of individual 
health benefits or more global measures of the total value of treatment interventions through 
community level global willingness to pay measures.  Most existing so-called CBA studies 
have not included any measure of individual health effects and have been excluded from this 
review.  Alcohol treatments are in general funded through health care mechanisms and CUA 
techniques are increasingly being used to assess other health care interventions so this thesis 
currently recommends the use of a CUA design.  
Many issues are raised above and can be summarized as follows: 
1. Society-level consequences should be identified early-on in studies, using the taxonomy of 
alcohol-related consequences and a societal perspective should be adopted 
2. Long-term health and social benefits should be incorporated in a full economic evaluation 
of alcohol treatments 
3. Modelling techniques should be developed in order to reflect drinking behaviour over time 
and to know the trend of economic benefits over the long-term. 
4. All full economic evaluations should include individual-level health consequences of 
alcohol treatments.  
5. A broader population with alcohol problems not confined to an alcohol dependent 
population should be considered and it should be recognized that abstinence-based measures 
neglect other potential individual and social benefits. 
6. A standard measure of alcohol consumption, such as gram/day, should be used. 
7. Analysts should move away from the use of multiple natural effectiveness measures, if a 
decision on the best allocation of resources is to be made. 
8. Standardized health measures that facilitate comparison between interventions and patient 
groups and capture quality and quantity of life, such as QALYs, should be used. 
9. Studies should try and link alcohol consumption measures to QALYs so that there is a 
single, comparable outcome measure. 
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10. Cost utility analyses should be conducted. 
The main task in the following chapter is to consider as many recommendations generated by this 
review as possible in a decision analytical model for alcohol treatments and also to develop a tool 
that promotes consistency and uniformity in economic evaluations of alcohol treatment.  This thesis 
does not aim at generating all the data for the incorporation of a societal perspective in the 
economic evaluation of alcohol treatments (point 1).  In addition, an empirical study of the 
relationship between QALYs and drinking outcomes is beyond the scope of this thesis (point 9).  
These are issues for future research, the results of which would have direct relevance for the 
extension of the model described and tested in the next chapters of the thesis. 
3.7 Conclusion 
This review extends previous reviews by: 1) depicting all alcohol-related consequences included in 
previous studies; 2) focusing on full economic evaluations of alcohol treatment; 3) providing a clear 
description of the systematic search; 4) not constraining the review to geographical areas, types of 
treatment or treatment populations; and 5) providing several methodological recommendations for 
future full economic evaluations of alcohol treatment.  The literature is still rather scarce in this area 
and it is hoped that the recommendations provided in this chapter will stimulate further work to 
draw harmony between studies.  This chapter calls for an improvement in the quality of studies and 
for the need to construct an approach that can provide useful guidance for decision making.  Only 
rigorous full economic evaluations can inform decisions on the allocation of resources to cost 
effective alcohol treatments.   
 
99 
Chapter 4. Economic model of drinking behaviour 
Reviewing published economic models for the assessment of alcohol treatments, in the previous 
chapter, suggests that the literature is dominated by studies mainly based on premature mortality 
outcomes from those abstinent from drinking after an intervention.  Existing modelling studies, 
when adopting a lifetime horizon, usually assume that the outcomes of the trials remain the same 
for patients’ lifetime and do not attempt to model the natural flow of patients with alcohol problems.  
Mortimer and Segal (2005) present QALYs but these are based on disability weights determined by 
experts rather than empirical data from the relevant population (Stouthard et al., 2000).   
There is evidence both on the individual effectiveness of different alcohol interventions (prevention, 
treatment and enforcement) based on short term drinking and health outcomes (Raistrick et al., 2006) 
and on the epidemiological risks associated with different patterns of drinking over time (Rehm et 
al., 2003b).  However, the variety of alcohol abuse treatment approaches and the complexity and 
multiplicity of treatment outcomes might have created a lag in the advance of economic analysis of 
alcohol treatment.  Alcohol consequences may be difficult to measure in a prospective study due to 
insufficient follow-up time.  Therefore, determining the cost effectiveness and predicting population 
outcomes of different alcohol treatments requires modelling of the long term consequences of 
changing drinking patterns.   
Previous economic evaluation models of alcohol treatment are here extended by: 1) exploring 
patterns of drinking rather than whether people are abstinent or not; 2) providing a dynamic model 
that allows for relapse and natural recovery; 3) including mortality, morbidity, health-related quality 
of life and long term costs savings; 4) considering a wider population with alcohol problems, not 
confined to an alcohol dependent population. 
This chapter develops a decision analytic model to assist decision makers with regard to the cost 
effectiveness of alcohol treatment.  Decision analysis is an established framework to inform 
decision making under conditions of uncertainty (Hunink et al., 2001; Weisntein and Fineberg, 
1980) and such a framework is lacking in the alcohol field.  Costs, effects and cost effectiveness are 
not known with certainty and this uncertainty is embedded in the model.   
Economic analyses are increasingly used to inform health policy decisions and health-care systems 
in many countries are making these decisions using cost effective analysis to determine which 
interventions should be reimbursed from collective funding (Taylor et al., 2004), where both costs 
and effects are taken into account.  For example, in England and Wales NICE makes national policy 
decisions on whether appraised health technologies should be made available through the public 
health care system.  The framework used to achieve “some of the key tasks in reimbursement 
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decisions” is a decision analytical modelling approach (Claxton et al., 2002).  This provides an 
explicit method to integrate the decision to adopt a technology and to demand additional 
information by doing further research (Claxton, 1999).  The basic concepts of decision modelling in 
cost effectiveness analysis have been extensively covered in the literature (Drummond et al., 2005c; 
Hunink et al., 2001; Briggs et al., 2006).   
4.1 Objectives 
The remit of this chapter is to use long term modelling techniques to establish a link between 
drinking patterns, health consequences and alcohol treatment effectiveness and cost effectiveness.  
It describes a method to build a decision analytic model that simulates the drinking patterns of a 
cohort over lifetime.  The model is designed to estimate the overall change in health-related quality 
and quantity of life resulting from changes in drinking behaviour.  It has the potential to provide 
essential information regarding the cost effectiveness of alcohol treatments and which treatments 
represent better value for money, as well as to promote consistency and uniformity on economic 
evaluations of alcohol treatment. 
The following section deals with modelling techniques in economic evaluation.  This is followed by 
several sections describing the methodological development of the model of drinking behaviour 
where decisions regarding specific model structure, type of model inputs and generation of results 
are taken.  This chapter deals with the development of the theoretical model providing a framework 
for the remaining chapters of this thesis and it can be seen as a foundation on which the following 
chapters rest.  The next chapter generates country-specific model inputs and the last two chapters 
illustrate the functionality of the model with two case-studies.   
4.2 Modelling in economic evaluations 
4.2.1 Why use modelling techniques?
Before explaining the model structure a justification of why a modelling approach is being used 
should be provided.  Modelling techniques are used here for two reasons.   
First, the previous chapters show that alcohol has a range of both short and long term consequences 
and that these may be difficult to measure in a prospective study.  This suggests that even in 
prospective studies there is a need for a modelling component for estimating the overall change in 
health-related quality and quantity of life which results from changes in drinking behaviour.  In 
order to make an informed decision of whether to adopt a given alcohol treatment, an assessment of 
the costs and health outcomes must be made over the longer period.   
101 
Second and more general, decisions to adopt, reimburse or issue guidance on the use of health 
technologies are increasingly being informed by an explicit cost effectiveness analysis of the 
alternative interventions (Hjelmgren et al., 2001).  This requires an analytical framework which can 
represent decision problems explicitly, combine evidence from a range of sources and facilitate the 
extrapolation of costs and effects over time and between patient groups and clinical settings 
(Claxton et al., 2002) and decision analytical modelling provides such a framework.  The 
circumstances where a mathematical model should be employed have been described by Buxton et 
al. (1997) as the following: 1) the “temporal extrapolation” of cost and effectiveness parameters 
beyond the data observed in a clinical trial; 2) the linking of intermediate clinical endpoints to final 
health outcomes; 3) the “contextual extrapolation” of the results obtained in one clinical setting to 
other settings; 4) the analysis of head-to-head comparisons of alternative competing interventions 
where such direct comparisons have not been made in clinical trials and; 5) the attempt to inform 
resource allocation policy decisions in the absence of “hard data”.  By using a modelling approach 
trial, observational and epidemiological data can be brought together   
4.2.2 Structure of decision analytic cost effectiveness models
Decision analytic models in cost effectiveness analysis identify optimum treatment decisions in the 
context of uncertainty about future states of the world (Sculpher et al., 2000).  Different types of 
economic evaluation models can be used to combine information from a variety of sources and to 
assess the policy implications for decision making. 
Determining the structure is a key initial stage in the development of a model.  The extent to which 
the availability of data should determine the structure of a model is an area of disagreement in the 
literature (Philips et al., 2006).  Sonnenberg et al. (1994) argued that the model structure should not 
be influenced by the quality, level and availability of data and should reflect the disease process.  
Accordingly, Sculpher et al. (2000) and Philips et al. (2006) recommended model structure to be as 
simple as possible, consistent with the stated decision problem and theory of disease and not 
defined by data availability or health service inputs alone.  Nevertheless, the model should be 
tractable to make it comprehensive to users and some constraints end up being reflected in its 
structure.  Model structure is usually determined by considering the relationship between the inputs 
(natural history of disease, clinical pathways, evidence of the intervention’s effectiveness, utilities 
associated with health states, costs, etc), and the output measures required by the decision maker 
(Brennan et al., 2006).  Therefore, Brennan et al. (2006) suggested that practical considerations such 
as availability of data, the background and skill of the researcher and the type of software available 
also have a considerable weight on the choice of model structure. 
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Model structures can be divided in aggregate or “cohort” models and individual-level models, also 
called Patient-Level Simulation (PLS) models (Brennan et al., 2006).  Aggregate models examine 
the proportions of the population undergoing different events with associated costs and utilities and 
require large population numbers, homogeneous sub-groups and linear interactions.  Individual-
level or PLS models sample individuals with specific attributes and follow their progress over time 
and, despite being more flexible, require replications with different random numbers to estimate 
expected values (Brennan et al., 2006).  PLS accounts for variability in all included parameters 
which cannot be reduced through measurement or further study, but can be characterized with 
empirical distributions.  Variability is related to differences amongst individuals (age, gender, 
comorbidities, body weight, etc.) that will always exist and is also known as “first-order 
uncertainty” or stochastic uncertainty, which is the uncertainty arising from randomness in the data 
studied.  This is different from uncertainty, i.e. the lack of knowledge regarding the true value of a 
quantity for a given patient, which can be characterized with a distribution and reduced with further 
investigation (Brennan et al., 2006; Culyer, 2005).  Both cohort and PLS models can also take into 
account the potential interaction between individuals.  Barton et al. (2004) stated that interaction 
between individuals needs to be taken into account in two main circumstances: “when modelling 
infectious diseases, where the risk of an individual catching the disease depends on how many other 
people already have it; and when constraints on resources mean that the choice of treatment for one 
patient affects what can be given to another” (Barton et al., 2004, pp. 115).  If interaction is 
important and PLS modelling is undertaken the model follows a Discrete Event Simulation (DES) 
structure, whereas if PLS modelling is not undertaken and interaction remains important, the model 
can be a cohort system dynamics one or a Markov chain model.  When interaction is not important 
there are three possible structures: decision tree, Markov model and individual sampling model 
depending on whether pathways can be represented by probability trees, whether a Markov model 
does not require an excessive number of states, and whether many health states would be required to 
build a Markov model and so PLS needs to be undertaken, respectively. 
The analyst should choose the type of model with reference to the time dependence of the disease 
events, selecting the simplest format possible that adequately reflects the disease (Sonnenberg et al., 
1994).  In Markov models discrete health states are clearly defined and the disease process has a 
clear time dimension.  Markov models are state transition models that better represent chronic 
conditions given the time dimension of such diseases process.  Their main benefit is the easy 
representation of recurrent events.  Markov models for cohorts can be deterministic (with expected 
values) or stochastic (using Monte Carlo simulation for model transitions).  Decision trees are 
simpler models where the health states are defined by chance nodes and time is not modelled 
explicitly.  In decision trees, all possible patient pathways are shown explicitly, with associated 
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probabilities and outcome measures and they are appropriate if the time frame is short and if 
patients’ mortality between strategies does not differ.  Decision trees for cohorts can be 
deterministic (with expected values) or stochastic (using Monte Carlo simulation for the mean value 
of each decision option).   
When interaction between individuals needs to be taken into account discrete event simulations can 
be chosen.  However, these models require specialist software or programming skills to construct, 
and running times are much longer than for other types of models.  Patient level models without 
interaction (individual sampling model) track individuals taking into account their heterogeneous 
characteristics but individuals progress through the model independently of each other and of 
environmental constraints.  These models generate a large number of simulated patient histories and 
evaluate results with a sampling algorithm.  The output from a (pseudo) random number generator 
is used to determine which sequence of health states is followed over time by the individual patient 
under consideration.  This can be done by using Monte Carlo simulation.  Individual sampling 
models with no interaction may be untimed, as in PLS decision tree models or timed, as in PLS 
Markov models.  One of the advantages of PLS lies in modelling multiple co-morbiditities which 
depend on multiple attributes/ covariates.  Furthermore, this approach can be modified to simulate 
the “time to next event” rather than using equal time periods, by matching a single random number 
against a probability distribution.  Therefore, the time spent in a state need not be an exact multiple 
of a fixed-length cycle.  So, these models can incorporate time and patient history dependency in 
transitions, as the model can “record” the event history for each individual as he or she progresses 
through the model (Barton et al., 2004; Brennan et al., 2006).   
Usually, health care modelling requires extensive sensitivity analysis to handle the inevitable 
uncertainties if the results are to be used for decision making.  According to NICE (2008) the effect 
of uncertainty should be represented by Probabilistic Sensitivity Analysis (PSA).  In principle, 
decisions on the type of model and the approach to sensitivity analysis are independent of one 
another, although in practice there may be limitations imposed by the available computing power 
and time (Barton et al., 2004).  A limitation of PLS arises when uncertainty in model parameters is 
to be taken into account.  In cohort models, parameters can be defined as random variables, and 
Monte Carlo simulation propagates this parameter uncertainty through the model, providing 
estimates of uncertainty around expected cost effectiveness.  This is distinct from the use of Monte 
Carlo simulation in PLS where the model parameters are fixed and a random number is used to 
determine the path of each individual patient, reflecting 1st order uncertainty (Stinnett and Paltiel, 
1997).  This uncertainty is related to the fact that the results for individual patients entering the 
model will vary, even when the model parameters are defined with certainty.  To reflect parameter 
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uncertainty in PLS requires a two-level simulation, where variability between patients is allowed 
(1st order uncertainty) and uncertainty in model parameters is also allowed (2nd order uncertainty).  
Cohort models do not require the simulation of individual patients and hence require fewer 
simulations than PLS and less time to evaluate as expected values for a cohort of patients are 
estimated during each simulation.  This facilitates the correct estimation of expected costs and 
effects for nonlinear models, the estimation of decision uncertainty arising from parameter 
uncertainty, and the implementation of value of information techniques (Claxton, 1999).  
Furthermore, the issue of variability addressed by PLS can also be addressed within a cohort 
framework by employing a two-level simulation (Griffin et al., 2006). 
4.2.3 Selection of the type of economic model for the economic evaluation of alcohol 
treatments
The first step in the development of a decision analytical model for alcohol treatments is the 
selection of the type of model.  The choice about model structure and complexity is always a trade-
off between descriptive realism and tractability in terms of computational burden and data 
requirements (Claxton et al., 2005).  The chosen structure is one that provides unbiased estimates of 
expected costs and effects and also allows exploring the effects of uncertainty in the model inputs.   
The selection process of the appropriate modelling structure, according to a range of conditions, has 
been described in previous studies (Barton et al., 2004; Brennan et al., 2006; Sculpher et al., 2000), 
and presented in the above section.  Given that the individuals with alcohol problems can be 
regarded as independent, interaction between individuals is not considered.  This leaves us with the 
choice between a cohort model or a PLS with no interaction.  While aggregate cohort models adopt 
assumptions that may produce inadequate solutions, individual-level models may be more time 
consuming to develop and to run. 
The most common type of cohort models that do not involve interaction are decision trees and 
Markov models (Barton et al., 2004).  Despite the simplicity of decision trees structure these would 
not be applicable to what this thesis is concerned with.  In fact, the model of alcohol consequences 
shall have a long time frame and patients’ mortality vary with the strategies analysed throughout 
time.  Therefore, a decision tree would become unmanageable.  The adopted model structure is a 
cohort Markov model.  The decision of a cohort Markov model over a PLS approach becomes clear 
after reviewing the literature that compared the two types of models. 
Karnon (2003) compared cohort Markov model and PLS techniques for the economic evaluation of 
alternative adjuvant therapies for early breast cancer.  The author found close results for both 
techniques which suggested that the use of one model’s results over the other would lead to the 
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same resource allocation decision.  It was concluded that the benefits of PLS, in terms of increased 
flexibility, were outweighed by the far greater time required to develop and evaluate the PLS model.  
Therefore, the author argued that given the substantially increased analytic inputs required by the 
PLS model, a cohort Markov process would have been the optimal technique for the reported 
evaluation.  Similarly, Griffin et al (2007) argued that the parameterization and computational 
burden of PLS compared with cohort models suggests that analysts should carefully access whether 
these additional costs can be justified in terms of their impact on the ultimate decision.  As 
explained in the section above, the potential conflict between PSA and PLS is pertinent in any 
health care system where PSA is considered the appropriate way by which the combined 
uncertainty in decision model parameters can be reflected.  This is the case in the context of the UK 
NHS, where NICE has specified a reference case, within its guidance on the methods of technology 
appraisal, where PSA is explicitly recommended (NICE, 2008).  This guidance has an impact on 
what is required for evaluation of health technologies internationally (Claxton et al., 2005).   
4.3 Modelling lifetime QALYs and health care costs from different drinking 
patterns over time: a Markov model 
In this section, a probabilistic lifetime Markov model using the cohort simulation approach and 
examining the proportion of the population undergoing different events with associated costs and 
outcomes is built (Sonnenberg and Beck, 1993; Briggs and Sculpher, 1998).  The main outcome 
measures are QALYs and health care costs.  This section presents the general Markov structure.  
This is followed by a description of the type of country-specific data required by the model and the 
generation of the long-term model outcomes.  An explanation of how the model deals with 
discounting, uncertainty and heterogeneity is then provided.  The final five sections put the 
developed model into the context of decision making, present the potential use of the model to 
inform the need for conducting further research, discuss the application of the model for different 
settings, present the limitations of the adopted structure and conclude, respectively. 
4.3.1 Markov model structure
A Markov model is adopted (Sonnenberg and Beck, 1993) due to its ability to model recurrent 
events and mortality, which is an ongoing risk over time.  The Markov model of alcohol 
consumption is built in Microsoft Excel® and is presented in Figure 2 below.  
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Figure 2- State transition diagram 
 
The Markov states in Figure 2 are represented by the ovals and possible transitions between these 
sates are shown by the arrows.  Arrows leading from a state to itself indicate that the patient may 
remain in that state in consecutive cycles.  Only certain transitions are allowed.  For example, a 
transition from harmful to ex-hazardous is not allowed.  Transition probabilities are assigned for the 
flow of patients between these drinking states over a discrete time period known as the “Markov 
cycle”.   
A hypothetical cohort of patients is modelled through the cycles according to transition probabilities 
for each drinking category.  The whole cohort starts the model in cycle zero or baseline, in the 
hazardous or harmful drinking states, according to the proportion of patients in each one of these 
states in the setting of the analysis.  Running the analysis over a large number of cycles builds up a 
profile of how many patients are in each state of the model over time.  Then, by attaching estimates 
of resource use and health consequences to the states in the model, the long term costs and 
outcomes are estimated and their contribution to the overall prognosis depends on the length of time 
(number of cycles) spent in each state.   
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In order for the Markov process to terminate, it must have at least one state that the patient cannot 
leave.  This is represented by the “death” state in the model, called an absorbing state because, after 
a sufficient number of cycles have passed, the entire cohort will have been absorbed by that state.  
The transition to the death state is dictated by two transition probabilities, a transition probability 
equal to the all-cause mortality excluding alcohol-related conditions (baseline mortality) and an 
alcohol-specific mortality transition probability.  Both transitions are time-dependent and modelled 
as a function of the patient’s age.  This is explained in a section below.   
The Markov health states are defined in the form of mutually exclusive states of drinking behaviour 
in the form of alcohol consumption.  This structure is consistent with alcohol drinking behaviour as 
a recurrent behaviour with susceptibility for relapse.  The drinking process cannot be modelled as a 
standard chronic disease because patients can move to more serious drinking groups and can also 
move from more serious drinking levels to less serious ones.  The review conducted in the previous 
chapter shows that the majority of economic evaluations of alcohol treatment use individual 
measures of consumption as an outcome of alcohol treatment.  However, there is a general lack of 
consensus regarding which measure of alcohol consumption should be used and how many 
measures are used in a single analysis.  As discussed in the previous chapter, it is clear that there 
should be a standard measure of alcohol consumption in economic evaluations of alcohol treatment.  
The present model suggests the use of grams of alcohol per day (g/day) for the definition of the 
Markov drinking states.  This allows classifying patients according to the amount drank per day and 
also allows following individuals through their lifetime by classifying them into a drinking category.  
Such a measure makes clinical data comparable as different standard units can be taken into account 
when calculating g/day.   
4.3.2 Time horizon 
A lifetime horizon is adopted.  In a decision making context, economic evaluation studies should 
adopt a time horizon that is sufficiently long to reflect all the key differences between options in 
terms of costs and effects  and hence cost effectiveness (Briggs et al., 2006).  The economic model 
adopts a lifetime horizon as alcohol treatments have a potential to improve alcohol-related mortality 
and long-term morbidity by changing drinking behaviour.  Evaluation of alcohol treatments on a 
short-term would seriously underestimate expected health outcomes and overestimate costs and 
uncertainty, since the benefits of alcohol treatment can be expected to accumulate over a much 
longer period of time.   
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4.3.3 Cycle length
A one-year cycle length is adopted.  The choice of cycle length should be driven by what is known 
about the underlying disease process and be the minimum interval over which pathology and/ or 
symptoms in patients is expected to alter (Sculpher et al., 2000).  Technically, the cycle length 
should not be determined by the availability of data with which to populate the model as rates over 
any interval can be translated to model probabilities for a given cycle length (Miller and Homan, 
1994).  Sonnenberg and Beck (1993) suggested that for a model that spans the entire life history of 
a patient and relatively rare events the cycle length can be one year.   
The current model uses one-year cycles for the following reasons: 1) reduction of the complexity of 
the model as a monthly cycle length, for example, would result in a 12-fold increase in evaluation 
time over a yearly cycle length, and 2) it has been shown that the natural course of alcohol 
dependence states does not usually fluctuate on a monthly basis (Dawson et al., 2007).   
4.3.4 Markov states as drinking categories
States should be chosen to represent the underlying biological process of the disease in question 
(Sculpher et al., 2000).  The Markov states are defined by drinking categories which allows 
following the drinking history of individuals.  Only four drinking categories are defined in order to 
keep the number of states as small as possible so the model is kept simple in analytical terms.  The 
main objective of this structure is to follow patients, according to their alcohol consumption defined 
in grams per day, through their lifetime.  The effect of alcohol treatment can then be captured as a 
change in drinking behaviour.  Patients in each state have different morbidity rates and associated 
costs, different utilities and different mortality rates.   
The four drinking categories are: hazardous, harmful, ex-hazardous and, ex-harmful.  Patients start 
the model in two categories according to the proportion in each category at baseline.  The drinking 
categories by gender, defined in grams of alcohol consumed per day, in cycle 0 (or baseline) are the 
following two:  
1) Hazardous drinking (A): X55 g/day (women); X80 g/day (men) 
2) Harmful drinking (B): >55 g/day (women); >80 g/day (men) 
In cycle 1 and following cycles (n+1), patients can be in one of the following five categories: 
1) Hazardous drinking (A): 20-55 g/day (women); 28-80 g/day (men) 
2) Harmful drinking (B): >55 g/day (women); > 80 g/day (men) 
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3) Ex-hazardous drinking (ExA): <20 g/day (women); <28 g/day (men) and hazardous (or ex-
hazardous) drinking in previous cycle 
4) Ex-harmful drinking (ExB): <20 g/day (women); <28 g/day (men) and harmful (or ex-harmful) 
drinking in previous cycle 
5) Death (D): patient is dead 
As women often experience higher risks of disease and injury for less volume of consumption, the 
respective drinking categories for women have lower means (Rehm et al., 2007a).  The definition of 
the harmful drinking category is based on the definition of “drinking category III” presented by the 
WHO (Rehm et al., 2004).  The limits used to define the ex-categories are based on the definition of 
“sensible drinking” presented in the National Alcohol Strategy for England (Department of Health, 
2007) which defines sensible drinking for women as drinking between 2 and 3 units a day, and for 
men as drinking between 3 and 4 units a day.  Units are converted to g/day taking into account that 
one unit corresponds to approximately 8g of alcohol in the UK.  Therefore, in terms of alcohol 
consumption, the ex-categories are defined as drinking below 20 g/day for woman (2.5 units a day) 
and drinking below 28 g/day for men (3.5 units a day).  Hazardous drinking in cycle 0 is solely 
defined by an upper bound which, at first instance, might seem like a mistake.  This is not the case, 
and such an interval is assumed so that patients drinking at what is defined as “sensible drinking” at 
baseline can also undertake alcohol treatment.  It might be the case that those patients drinking at 
lower levels at baseline were actually drinking at higher levels before and are still at risk for 
alcohol-related diseases and, therefore, are eligible for treatment given their past history and 
susceptibility for relapse.  There is no explicit category for starting in a sensible drinking level as 
this model focuses on evaluation of alcohol treatments.  Had the intention been to build a model for 
population level interventions such as prevention, legislation and enforcement, then such a category 
would have a meaning as the benefits of preventing individuals from entering harmful or hazardous 
states would have to be accounted for.  The ex-categories are defined similarly in terms of g/day, i.e. 
both ex-hazardous and ex-harmful states include patients drinking less than 20 g/day (women) or 
less than 28 g/day (men).  They are distinguished by the state where the patient was in the previous 
cycle (hazardous or harmful or any of the two ex-states), for patient history can influence the risk of 
death and morbidity.  This breakdown is further explained below.   
A generic transition matrix presenting the transitions between Markov states and associated 
probabilities is presented in Table 22 below.   
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Table 22- Generic transition matrix for the Markov model of alcohol behaviour 
Cycle n +1 
Hazardous 
(A) 
Harmful 
(B) 
Ex-Hazardous 
(ExA) 
Ex-Harmful 
(ExB) 
Death 
(D) 
Hazardous (A) tpA2A tpA2B tpA2ExA 0 tpA2D1
Harmful (B) tpB2A tpB2B 0 tpB2ExB tpB2D1
Ex-Hazardous 
(ExA) tpExA2A tpExA2B tpExA2ExB 0 tpExA2D
1
Ex-Harmful 
(ExB) tpExB2A tpExB2B 0 tpExB2ExB tpExB2D
1
Cycle 
n
Death (D) 0 0 0 0 1 
1 Time-dependent transition probability. 
Note: tp, transition probability; tpA2A, transition probability from hazardous to hazardous; tpB2A, transition 
probability from harmful to hazardous; tpExA2A, transition probability from ex-hazardous to hazardous; 
tpExB2A, transition probability from ex-harmful to hazardous. Example: a hazardous patient can remain in 
hazardous, transit to harmful, transit to ex-hazardous or transit to death. 
 
The transition matrix in Table 22 specifies the generic transitions between drinking categories for 
any given cycle of the model.  The cohort-based transition matrix uses a transition probability per 
unit time for individuals in the cohort to change to another state, with associated costs and outcomes.  
The rows of the transition matrix must add to one (a conservation of probability mass).  The 
transition matrix presented above shows that transitions between some model states are not allowed.  
Probabilities representing disallowed transitions are zero.  The transition probabilities are constant 
with respect to time, with the exception of the transitions to the death state that are age-dependent.  
When modelling, the probability of remaining in one state will depend on the probability of leaving 
that same state, where the age-dependent transitions to the death state are taken into account, 
making the overall probability of remaining in a particular state time-dependent.  The proportion of 
patients in each drinking category is calculated sequentially for each cycle over the simulated time 
period according to a specific transition probability (tp). 
In the first cycle a Hazardous patient can remain in Hazardous, transit to harmful, transit to ex-
hazardous or transit to death.  Accordingly, in the first cycle a harmful patient can remain in 
harmful, transit to hazardous, transit to ex-harmful or transit to death.  The following cycles have 
the following transition possibilities: 
Hazardous (A): remain in A (tpA2A) or transit to: B (tpA2B), ExA (tpA2ExA), D (tpA2D). 
Harmful (B): remain in B (tpB2B) or transit to: A (tpB2A), ExB (tpB2ExB), D (tpB2D) 
Ex-hazardous (ExA): remain in ExA (tpExA2ExA) or transit to: A (tpExA2A), B (tpExA2B) or D 
(tpExA2D) 
111 
Ex-harmful (ExB): remain in ExB (tpExB2ExB) or transit to: A (tpExB2A), B (tpExB2B) or D 
(tpExB2D) 
Death (D): remains dead (absorbent state) 
Why use Ex-categories? 
A limitation of any Markov model is that the probability of moving out of a state is not dependent 
on the states the patient may have experienced before entering that state (Briggs and Sculpher, 
1998).  This is the “memoryless” feature of Markov models also referred to as the “Markov 
assumption” (Sonnenberg and Beck, 1993).  The Markov assumption does not allow the transition 
probability to depend on the time a patient has spent in a given state nor the full patient’s previous 
history before entering that state.  Thus, Markov models assume that patients in a given state can be 
treated as homogeneous groups.  
One of the methods to model a process where future events depend on past events in a Markov 
model is by adding additional states to the model.  Using “ex-categories” in the Markov model can 
be seen as a way to overcome the Markovian assumption.  The “ex-categories” are distinguished by 
the state where the patient was in the previous cycle.  This breakdown is related to the fact that, 
even if patients reduce their alcohol consumption to a sensible level, the risk of mortality and 
morbidity will depend on the level at which they were drinking before.  Therefore, alcohol-related 
transition probabilities to the death state and morbidity risks depend not only on current drinking 
level, age (time dependency as a function of the time in the model) and gender but also on the state 
where the patient was in the previous cycle.  In this way previous history is included in patients’ 
prognosis.  However, the ex-categories only take into account the previous cycle and not the time 
patients have spent in a given cycle.  The use of time-dependent transition probabilities is another 
way to overcome the Markovian assumption.  Time dependency in the model is incorporated as a 
function of the time elapsed from the start of the model.  When transition probabilities vary over 
time the Markov model can be called as a “time-dependent Markov process” (Sonnenberg and Beck, 
1993).  The way the transition probabilities vary with time in this model is by assuming them to be 
an increasing function of time (i.e. the cycle of the model), they do not, however, depend on the 
time patients have actually spent in each state, which is another form of time dependency that might 
need to be incorporated in a Markov model.   
One way to circumvent the Markov assumption is by adopting a semi-Markov structure (Hawkins et 
al., 2005).  A semi-Markov structure may be implemented in two ways.  One way consists of the 
addition of further tunnel states to the model.  These are states that an individual can only occupy 
for one cycle and represent both the disease state the individual is in and the number of previous 
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cycles spent in this state.  A limitation of this approach is that the transition matrix becomes larger 
as the number of states and total number of cycles increase.  The other way consists of using a 3-
dimensional matrix of transition probabilities, with dimensions for current state, future state, and 
time in current state.  This is logically equivalent to using a series of “tunnel” states.  An alternative 
approach to handling time-dependency is to abandon cohort modelling and to use PLS (Hawkins et 
al., 2005).  A semi-Markov structure and especially PLS make the model computationally complex, 
while it also depends on considerable data availability.  In order to incorporate time dependency as 
a function of time in a state, long-term data from open-label trials or epidemiological data need to 
exist that allow this time dependency to be estimated.   
4.4 Country-specific model inputs 
The model requires a set of country-specific inputs such as transition probabilities between drinking 
states, morbidity and mortality rates, alcohol-related disease costs and utility weights for the 
Markov states.  
4.4.1 Transition probabilities for the first cycle(s)
According to the transition matrix presented in Table 22, yearly transition probabilities for each 
state are used to generate the Markov trace, i.e. the number of patients in each state over lifetime.  
The clinical study of the alcohol treatment which cost effectiveness is analysed should provide 
patient-level data informing drinking behaviour at different time periods.  The transition 
probabilities for the first cycle(s) are calculated by counting the number of patients that transit 
between the states for the clinical study follow-up times.   
The probabilities taken from the clinical effectiveness studies are only used for the number of cycles 
of the model that the data informs.  Most effectiveness studies in the alcohol treatment field have 
not surpassed a one year follow-up (Miller WR and Wilbourne PL, 2002).  Therefore, data from 
these studies should only be used for the first cycle of the model.  The number of patients in each 
Markov state for the first cycle(s) is calculated as presented in Table 23. 
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Table 23- Markov trace for the first Markov cycle 
Hazardous (A):
APat*(1-tp1A2B-tp1A2ExA-mrA2D-mrbas)+BPat*(tp1B2A)+ExAPat*(tp1ExA2A)+ 
ExBPat*(tp1ExB2A) 
Harmful (B):
APat*(tp1A2B)+BPat*(1-tp1B2A-tp1B2ExB-mrB2D-mrbas)+ExAPat*(tp1ExA2B)+ 
ExBPat*(tp1ExB2B) 
Ex-Hazardous (ExA):
APat*(tp1A2ExA)+ ExAPat*(1-tp1ExA2A-tp1ExA2B-mrExA2D-mrbas) 
Ex-Harmful (ExB):
BPat*(tp1B2ExB)+ ExBPat*(1-tp1ExB2A-tp1ExB2B-mrExB2D-mrbas) 
Death (D):
APat*mrA2D+BPat*mrB2D+ExAPat*mrExA2D+ExBPat*mrExB2D+DeadPat+mrbas*(APat + 
BPat + ExAPat + ExBPat) 
APat, number of hazardous patients in the previous cycle; tp1, transition probability for first cycle; tpA2A, 
transition probability from hazardous to hazardous; mr, mortality rate (alcohol specific); mrbas, mortality rate 
for all causes (baseline); see explanation text below. 
Since the probabilities of moving between states in each cycle must sum to one (patients must be in 
one and only in one state at any given time) the probability of staying in a given state is one minus 
the probability of leaving that state.  This allows the inclusion of the age-dependent probabilities to 
the death state in the probability of remaining in a given state.  The probabilities of patients moving 
from other states to a specific state have to be added to the probability of patients remaining in that 
state.  The transition probabilities are multiplied by the number of patients that were in each state in 
the previous cycle, represented by the name of the state with the suffix “Pat” in the table above.   
Age, gender and state specific mortality rates are incorporated in the probability of patients 
remaining in the same state.  These mortality rates have two components: 1) alcohol-specific 
mortality rate (mr) from one drinking category state to the death state and, 2) non-alcohol-related 
mortality rates (mrbas) from any state to the death state.   
The number of patients in the death state is calculated by the number of patients in each state in the 
previous cycle, multiplied by the time-dependent alcohol-specific mortality rates.  The dead patients 
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in the previous cycle are also brought forward, i.e. are also summed to the patients dying in the 
cycle to which the calculation respects.  The time-dependent baseline mortality rate is multiplied by 
the sum of patients alive in each state in the previous cycle.  This rate is the same for all states 
because it is non-alcohol specific (baseline).  The calculation of mortality rates is explained in 
Chapter 5. 
The transition probabilities in this section are applied to the cycles of the Markov model for which 
effectiveness data is available.  This allows calculating the number of patients alive in the first 
cycle(s) and knowing how many patients are in each state at the end of the cycle, for each one of the 
treatments under comparison.  The generation of a transition matrix with the first cycle transition 
probabilities is exemplified in Chapters 6 and 7 where two case-studies are presented. 
In order to build the Markov trace, the same process as the one presented in Table 23 needs to be 
repeated for all the cycles of the model.  In projecting to the lifetime of patients, assumptions need 
to be made concerning the duration of the effect of the alcohol treatment assessed, in terms of 
sustaining health-related benefits.  The model assumes that a cohort of patients transit between 
drinking categories according to the natural history after treatment uptake, i.e. that the effectiveness 
of the treatments evaluated is taken forward by means of other transition probabilities that are not 
the same as the ones calculated with the clinical data.  This is explained below. 
4.4.2 Transition probabilities for the following cycles
It would be a strong assumption to use the transition probabilities taken from the effectiveness data 
for the lifetime of patients, i.e. for the cycles of the model following treatment.  When treatment 
effects are taken from a clinical trial, which does not measure outcomes beyond a limited number of 
years, it is recommended that shorter and longer time horizons are modelled separately when the 
analysis must go beyond the time frame of the primary data (Gold et al., 1996b).   
The review conducted in the previous chapter shows that most previous long-term modelling 
studies assume that the outcomes of the trials remain the same for patients’ lifetime.  They do not 
attempt to actually model drinking behaviour and only focus on few alcohol-related diseases.  
However, patients should transit between drinking categories according to their natural history after 
treatment uptake, where natural remission and relapse are taken into account.   
The transition probabilities for the following cycles of the model are specific to the country where 
the study takes place so that lifetime drinking behaviour of a specific population, after treatment 
uptake, can be reflected.  These transitions should be informed by a long-term follow-up study, 
ideally after treatment uptake.  The generation of a transition matrix with transition probabilities for 
the following cycles is provided in the next chapter (Chapter 5). 
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4.4.3 Epidemiological data: morbidity and mortality 
By attaching estimates of resource use and health consequences to each individual state in the 
model over a large number of cycles, the long term costs and health consequences can be estimated.  
However, in order to do so, the Markov model requires a separate analysis of the lifetime risk of 
mortality and morbidity that is incorporated into the main Markov model to reflect the risk incurred 
by each drinking state and the changing risk of transition into or out of drinking states.   
Alcohol-treatment trials conducted so far do not have a sufficient follow-up that could capture 
mortality and long-term morbidity.  Similarly, no trials with a sample big enough to capture all 
possible alcohol-related injuries are identified.  Epidemiological data at a population level is used in 
order to incorporate life expectancy and morbidity costs into the model, which is achieved by 
specifying the level of risk attached to the levels of drinking as represented by the Markov states.   
The model requires detailed country-specific epidemiological data.  The extent to which a 
consequence can be attributed to the use of alcohol varies according to setting, both for 
epidemiological reasons and due to variations in the institutional arrangements for dealing with 
adverse consequences.  For this reason, the degree of alcohol involvement in mortality and 
morbidity estimates has to be retrieved for the setting in which the cost effectiveness of alcohol 
treatments is analysed.   
The degree of alcohol involvement can be described by Alcohol Attribution Factors (AAFs).  There 
are some conditions that are by definition related to alcohol abuse and so the AAF is 100%.  For 
example, all cases of alcoholic psychosis, alcoholic dependence syndrome and alcohol dependence 
are wholly attributed to the use of alcohol.  For conditions where alcohol consumption is a 
contributory cause, there are two methods for assigning an aetiological fraction (WHO, 2000): 1) a 
direct method and 2) an indirect method.  The direct method directly attributes alcohol use on the 
basis of case series studies in which alcohol’s involvement is systematically investigated.  This 
method can result in over-estimates of alcohol’s contribution to some degree as there is an implicit 
assumption that significant amounts of alcohol are associated with direct causation.  The direct 
method has been used for estimating AAFs for conditions associated with acute alcohol intoxication 
(most forms of injury), as is the case of the AAFs calculated in English et al. (1995).  The indirect 
method uses estimates of Relative Risk (RR) of particular disorders for different levels of alcohol 
use combined with prevalence data on the number of persons consuming at different levels.  The 
RR is the ratio of the chance of experiencing an alcohol-related problem if exposed to alcohol 
divided by the chance of experiencing it if one is not exposed to alcohol (Rothman et al., 2008).  
Estimates of RR for a number of conditions are published in two widely known meta-analyses 
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(Corrao et al., 1999; Corrao et al., 2004), amongst others.  The indirect method is the preferred one 
for conditions partly caused by the effects of long-term consumption, mostly diseases.  
Mortality and morbidity calculation for the model of drinking behaviour 
The model uses country-specific mortality and morbidity rates that vary with age, gender, level of 
consumption, alcohol-related condition and drinking pattern.  Lifetime injury and chronic disease 
mortality and morbidity are modelled through a number of different steps, assumptions and data 
sources, based on methods recently developed in Rehm et al. (2008) and Taylor et al. (2008).  
Briefly, after determination of diseases and injury groups causally related to alcohol consumption 
(Rehm et al., 2004), consumption-specific risks are developed for each age, sex, and disease/injury 
category.  These take into account numbers of drinks and number of drinking occasions (for injury 
risk calculation) or average daily volume of alcohol consumed (for chronic disease risk calculation) 
by drinkers characterized by each drinking state, over the course of one year.  A one-year alcohol-
attributable risk for each disease/injury group by sex, age, and drinker type is calculated.  This risk 
reflects actual consumption patterns of the drinking states being modelled in a population of interest, 
in terms of mortality/morbidity experience, alcohol consumption, and risk per occasion.  An 
example of the calculation of mortality and morbidity rates for the model of drinking behaviour is 
presented in the next chapter. 
4.4.4 Disease-related costs and Markov states utilities
The model also requires country-specific estimates of the costs of diseases affected by alcohol 
consumption.  Average unit costs can be collected for each alcohol-related disease for which 
morbidity rates are calculated.  The other set of country-specific estimates are the health utilities 
associated with each Markov state.  This information should, ideally, reflect the preferences of the 
general population for the setting of the analysis.  Both disease-related costs and states’ utilities, 
together with the epidemiological data and transition probabilities, are used to calculate the model 
outcomes as explained below.  
4.5 Model outcomes 
The outcomes of the Markov model are the lifetime costs, QALYs and life years and these are 
specific to the treatments under evaluation and to the country of the analysis.  QALYs are the 
standard outcome measure used to evaluate whether a health technology represents value for money 
in Scotland and England, and the main effect measure of the model.  When comparing the cost 
effectiveness of two alcohol treatments in the Markov model, the data informing treatment 
effectiveness generate different transition probabilities and so a different number of patients in each 
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drinking category, which will translate into different treatment costs, utilities and life years, over the 
long term.  When two treatments are compared the incremental cost, incremental utilities and 
incremental life years are the outcomes of interest.  Drinking categories with a higher level of 
consumption will accrue higher associated costs, lower utility and an increased probability of dying 
from alcohol-attributable conditions.  The estimation of the model outcomes uses the 
epidemiological data detailed in a section above. 
4.5.1 Life expectancy
Life expectancy for the treatments evaluated is given by the number of model cycles (average 
amount of time) spent in each state, other than the death state, by the patients.  The average life 
expectancy is given in terms of the model cycle length.  Given that the cycle length is 1 year, the 
average life expectancy is already given in years.  After running the model over a large number of 
cycles the patients alive in each cycle are summed and divided by the initial size of the cohort in 
order to get the average life expectancy.  This process is conducted for all treatments under 
evaluation and, when comparing two treatments, incremental life years are calculated by subtracting 
the average life years for one treatment from the average life years for the other treatment.  Alcohol-
specific and general mortality rates are used to calculate the life expectancy of a population with 
alcohol problems.  A lifetable for the model states (alcohol-specific) and baseline (general mortality 
taking out alcohol-attributable reasons) and by gender and age group is linked to each state, with 
rates taking into account both chronic and injury causes.  An example of how to generate a lifetable 
is presented in the following chapter. 
4.5.2 Quality Adjusted Life Years
The incorporation of QALYs into the model follows the same process as the one explained for life 
expectancy.  The QALY scores for patients in each cycle and health state are summed over all 
cycles and divided by the initial cohort size thus providing the average QALYs associated with each 
treatment.  When comparing two treatments the incremental QALY is calculated by subtracting the 
QALYs gained with one treatment from the QALYs gained with the other treatment.  A gain in 
QALYs from one treatment over another can be attributed to differences in utility between the 
drinking categories and differences in life expectancy. 
The construction of QALYs involves weighting the length of time spent in each state of health by a 
value representing quality of life experienced in that state.  Weights representing quality of life on a 
standard 0 to 1 scale are attached to the Markov states.  These weights are called utilities.  An 
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example of the calculation of the utilities attached to each Markov state is presented in the 
following chapter. 
4.5.3 Costs
The economic model has two major categories of costs, the costs of the treatments under evaluation 
and the disease-related costs associated with each Markov state.  The treatment costs are specific to 
the alcohol treatments evaluated in the model.  The disease costs are specific to the country and 
setting where the analysis takes place, preferably average unit costs.  The Markov states’ costs are 
calculated by combining the morbidity rates with the health care costs for the diseases affecting 
alcohol-related morbidity.  Alcohol-related disease morbidity rates by gender, drinking state and for 
each age group are used for the calculation of the health states costs.  The costs of spending one 
cycle in each state of the model are attached to that state.  The lifetime states cost is obtained by 
summing the costs across all cycles of the model for each state and dividing by the initial cohort 
size thus providing an average health care cost of the alcohol-related diseases.  The specific alcohol 
treatment costs are added to the alcohol-related diseases costs.  When comparing two treatments 
with different lifetime costs, the difference between the average costs obtained for each treatment 
under analysis provides the incremental cost of the most expensive treatment.  The calculation of 
the disease-related costs for each Markov state is illustrated in the following chapter.   
4.6 Discounting 
It is standard practice in economic evaluations to adjust costs and outcomes for differential timing 
by applying a rate of discount which allows comparison of costs and outcomes in terms of a Net 
Present Value (NPV).  This is based on the fact that costs and benefits occurring immediately are 
valued more highly than those occurring in the future. 
The discounting formula is given by: 
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Where 0V is the current value (NPV), tV is the value at time t and r is the rate of discount.  The 
discount rate is applied to the number of patients alive, costs and QALYs in each cycle.  Each cycle 
is linked to the discounting formula presented above, allowing discounting costs and outcomes at 
the point in time that they occur in the model.  The model is constructed in such a way that discount 
rates for costs and outcomes are separate, allowing the use of differential discounting rates.  For 
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example, NICE (2008) recommends a discount rate of 3.5% for both costs and outcomes in the 
base-case analysis of a economic evaluation, and different discount rates in the sensitivity analysis. 
4.7 Dealing with uncertainty  
Uncertainty is incorporated in the model parameters.  This uncertainty relates to model parameters 
that have a definitive value, but which cannot be known with certainty.  Sensitivity analysis is a 
method of testing the robustness of the analysis where the deterministic variables for which there is 
uncertainty are varied over a range and the effects in the results are analysed.  Briggs et al. (2006) 
presented many reasons for the importance of considering uncertainty in cost effectiveness 
modelling for decision making.  Very briefly, the reasons the authors presented for considering 
uncertainty include: 1) the nonlinearity in model inputs parameters, 2) the possibility of incorrect 
decisions which impose a cost in terms of the benefits forgone and, 3) the possible value associated 
with delaying an irreversible decision.   
Two types of sensitivity analyses are incorporated in the Markov model of drinking behaviour to 
estimate the impact that parameters uncertainty has on the cost effectiveness results, and these are 1) 
probabilistic sensitivity analysis and 2) univariate sensitivity analysis.  PSA quantifies the 
uncertainty in mean outputs as in the measures of costs, effects and cost effectiveness, due to input 
parameters uncertainty.  Guidance on the use of decision models emphasizes the use of PSA (Gold 
et al., 1996b).  PSA is conducted in the model for the input parameters of the model that the results 
are uncertain about and a Cost Effectiveness Acceptability Curve (CEAC) is produced for each 
treatment.  The CEAC shows the probability that a given treatment is cost effective for different 
values of the willingness to pay thresholds for that treatment.  The model also incorporates 
univariate sensitivity analysis for a set of input parameters.  One way sensitivity analysis varies 
each parameter individually in order to isolate the consequences of each parameter in the results of 
the study.   
The following two subsections explain the incorporation of sensitivity analyses in the long-term 
Markov model of alcohol consequences.   
4.7.1 Probabilistic sensitivity analysis
Probabilistic sensitivity analysis is conducted in the model by assigning distributions to all input 
parameters of the model that the results are uncertain about, under the assumption of a 
homogeneous sample of patients informing parameter estimation.  The input parameters that the 
model is most uncertain about are the transition probabilities between drinking states and the 
utilities attached to each Markov state.  The distributions chosen to represent each set of parameters 
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depend on the volume and quality of the information available in which little or poor information is 
represented by assigning a diffuse distribution.  After assigning a distribution, the resulting output 
of the model represents a single trial.  Monte Carlo simulation randomly selects values of the 
parameters from the assigned distributions and propagates these distributions through the model 
(Doubilet et al., 1985).  This process is repeated for a large number of trials and a distribution of the 
output from the model is estimated.  The Markov model of drinking behaviour is set to run 1000 
simulations.  This means that, when considering uncertainty through PSA, it is the expectation over 
the distribution of the output parameters that represents the point estimate for the decision model 
(Claxton et al., 2002).  An example of the application of the appropriate distributions for the model 
inputs is given in Chapters 5 and 6. 
4.7.2 Univariate sensitivity analysis
One-way sensitivity analysis is conducted for the initial distribution of patients, where the effect of 
different proportions of a cohort starting in hazardous (A) and harmful (B) states (cycle 0) is 
analysed.  This one-way sensitivity analysis assesses whether a range of different drinking 
behaviours at the starting cycle has an impact on the cost effectiveness of the treatments under 
evaluation.  In addition, the impact of applying alternative discount rates can be analysed.  This is 
exemplified in the case-studies presented in Chapters 6 and 7. 
4.8 Heterogeneity 
A standard Markov model assumes that all patients in a given state are homogenous.  Therefore, the 
model structure allows subgroup analyses on patients’ age and sex to be conducted, so that 
heterogeneity can be taken into account.  Heterogeneity relates to differences that can, in part, be 
explained, therefore it is not a source of uncertainty (Briggs et al., 2006).  Modelling heterogeneity 
assesses the extent to which patient characteristics affect the outcomes.  Patient characteristics can 
affect the potential outcomes of the model, such that treatment choices may be different for patients 
with different characteristics.  Age and sex affect both alcohol-specific and other-cause mortality 
rates.  Alcohol-related morbidity rates are also both gender and age-specific.  The model is built in 
such a way that changing the gender and age of the cohort is relatively straightforward.  Subgroup 
analyses can be run for different age (20, 40 and 60 years old) and gender cohorts (male or female).  
The deterministic and probabilistic cost effectiveness results are assessed for these cohorts and 
multiple CEACs produced, where the probability of an alcohol treatment being cost effective is 
plotted against the willingness to pay threshold, for each subgroup.  Subgroup analyses are 
exemplified in Chapters 6 and 7 where two model applications are presented. 
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4.9 Decision making 
The results of the model are used for decision making.  Within a decision making framework, under 
conditions of certainty, the more effective and less costly alcohol treatment is the one that should be 
adopted.  In this case the treatment is said to dominate the alternative and the decision of which 
treatment to adopt is straightforward.  However, this situation is not common for new treatments 
and multiple options.  It is common that an intervention is both more effective and more costly or 
less effective and less costly than the comparator.  In this case a decision has to be made as to 
whether the additional benefits of the more expensive alcohol treatment are worth the additional 
cost, for the country of interest in the analysis.  Similarly, a decision needs to be made as to whether 
a less costly alcohol treatment justifies the reduced benefits.  A measure used in order to determine 
whether an intervention represents good value for money is the expected incremental cost per 
QALY (ICER, Incremental Cost Effectiveness Ratio) between technologies against a threshold 
willingness to pay ([) or equivalently, the expected monetary Net Benefit (NB= [*QALY-Cost) 
(Briggs et al., 2006).  The ICER compares the additional costs that one strategy incurs over another 
with the additional benefits and represents the additional cost required to achieve one additional unit 
of outcome (QALY).  Hence, where one therapy does not dominate (i.e. is not both more effective 
and less costly) an incremental cost effectiveness ratio (ICER) can be calculated using the following 
formula: 
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where C represents the mean lifetime costs for treatment groups A and B and E represents the 
lifetime effects (life years or QALYs) for each treatment group.   
As a reference point, NICE uses a threshold cost per QALY of around £20,000-£30,000 to 
determine whether an intervention represents good value for money in the NHS (NICE, 2008).  The 
preferred option is determined by comparing the ICER with this notional threshold value which 
decision makers are assumed to be willing to pay for an additional unit of effect.  Consequently, if 
the ICER for the evaluated treatment is below £20,000 then this treatment should be considered 
potentially cost effective.  ICERs within the range itself (i.e. £20,000-£30,000) are considered 
borderline and an ICER above £30,000 is not typically considered cost effective. 
4.10 Value of information: the decision to acquire more evidence 
Given the paucity of published evidence for the cost effectiveness of alcohol treatment, the potential 
value of future research for the alcohol treatments considered is assessed.  The model results, in 
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terms of expected cost effectiveness, are based on the existing evidence available.  However, often 
the information on a number of model parameters such as the effectiveness of a particular alcohol 
treatment or the transition probabilities between states after treatment uptake is scarce.  Therefore, 
another component of the model of alcohol behaviour is the examination of the value of information.  
This helps in making the decision whether a specific treatment under evaluation should be adopted 
on the basis of existing evidence or whether further evidence is required to support this decision in 
the future taking into account the objective and constraints on health care provision (Briggs et al., 
2006).   
In case decision uncertainty or the consequences of making the wrong decision are large, the 
decision-maker may require further evidence on which to base the adoption decision (Claxton et al., 
2004).  The decision to adopt a specific alcohol treatment based on expected values is uncertain, 
and there is a chance that the wrong decision will be made.  If the wrong decision is made, there 
will be opportunity costs in terms of health benefits and resources forgone.  The expected cost of 
uncertainty is determined jointly by the probability that a decision based on existing information 
will be wrong and the consequences of an incorrect decision.  Information reduces the expected 
costs of uncertainty surrounding the decision (Claxton et al., 2002).   
The expected costs of uncertainty associated with a decision based on current information can be 
interpreted as the Expected Value of Perfect Information (EVPI), as perfect information can 
eliminate the possibility of making the wrong decision.  The EVPI places an upper limit to the value 
of additional research that could be undertaken to reduce the uncertainty associated with a decision 
regarding the adoption of a particular alcohol treatment in a health care system.  If the EVPI for the 
population of current and future patients exceed the expected costs of further research, then it is 
potentially cost effective to acquire more information.   
EVPI incorporation in the model 
The implications of uncertainty associated with the cost effectiveness of the alcohol treatments 
analysed are explored in the model by incorporating analysis of the expected value of information, 
as described by Claxton (1999).  The use of Monte Carlo simulation allows the expected costs of 
uncertainty associated with the initial adoption decision to be expressed as the proportion of 
iterations in which the uncertainty within the model results in an adoption decision other than that 
arising from maximising expected cost effectiveness (i.e. expected net benefits).  The benefits 
forgone are the difference in costs and outcomes (net benefit) between the optimal strategy for a 
given iteration and those of the strategy identified as optimal in the adoption decision (i.e. based on 
the expected cost effectiveness estimates) (Sculpher and Claxton, 2005).  The expectation of 
benefits forgone over the 1000 iterations in the model represents the EVPI for an individual patient.  
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More formally, this implies that for a decision involving j treatments where NB is dependent upon a 
set of unknown parameters \, the EVPI is the difference between the value of the decision made 
with perfect information averaged over all possible realisations of uncertainty and the expected 
value of the decision made on the basis of existing information: 
EVPI = E\ [maxj (NB(j, \))] - maxj [E\ (NB(j, \))]. 
The overall value of information for a population of patients who could benefit from alcohol 
treatment is determined by applying the EVPI per individual to the number of patients who would 
be eligible for alcohol treatment over the anticipated lifetime of the modelled alcohol treatment: 
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Where It is the eligible population in period t, T is the total number of periods for which information 
from research would be useful, and r is the discount rate. 
An application of the methods described for EVPI is illustrated in Chapter 7. 
4.11 Application of the model to different countries 
The developed framework helps in assessing the cost effectiveness of alcohol treatments.  However, 
it should be noted that the results from the model might not be transferrable between settings.  The 
cost effectiveness of alcohol treatments will depend on a range of setting-specific conditions and 
this is reflected in model inputs that vary according to the population and/or setting modelled.  The 
model requires a range of country-specific data that needs to be collected in order to inform the 
following model parameters:  
1) Alcohol treatments effectiveness data 
2) Transition probabilities for the transitions not informed by the effectiveness study or studies 
of the treatments being compared 
3) Morbidity and mortality rates, for injury and chronic diseases, by age, gender and drinking 
category 
4) Cost data for alcohol-related diseases and for the specific treatments evaluated 
5) Utility weights for the Markov states 
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4.12 Discussion 
The model developed in this chapter provides an innovative framework to assess the cost 
effectiveness of alcohol treatments.  However, it is based on a number of assumptions which should 
be mentioned here.  The main assumption in a simple Markov model is that it is essentially without 
memory.  That is, it does not enable one to follow patients’ history.  The Markov assumption does 
not allow the transition probabilities to depend on neither the time a patient has spent in a given 
state (time in state dependency), nor the full patient’s previous history before entering that state, 
meaning that the future is conditionally independent of the past, given the present.  Time-
dependency in the transition probabilities are accounted for only by increasing age but they do not 
depend on the time patients have actually spent in each state.  The use of “ex-categories” can be 
seen as a way to overcome the lack of memory of a standard Markov model, but not to a full extent 
as they only consider the state where the patient was in the previous cycle and not patient’s full 
history or pathway.  Establishing transition probabilities that depend on the time the individuals 
spent in each state would require a PLS.  However, the computational burden of PLS models 
compared with cohort models makes PLS less attractive.  
The choices of cut-offs for the definition of “hazardous” and “harmful” categories are arbitrary even 
if defined in previous literature.  The cut-offs obviously influence the proportion of subjects in a 
given state and this has an impact on the results.  Defining different cut-offs requires a totally new 
model, not just in terms of drinking category definitions but also in terms of all epidemiological 
data that is calculated for specific drinking levels.  However, a way to mimic the impact of changing 
cut-offs is to allocate higher or lower proportions of patients to each category, by doing a one-way 
sensitivity analysis.  This one-way sensitivity analysis is embedded in the model by simply 
changing the proportion of the cohort starting in each drinking category. 
The model is built for a health care system perspective.  Economic evaluations in other fields also 
adopt the narrow perspective of the health care system which is also in line with current NICE 
guidelines.  The public health impact of alcohol, however, is not only experienced by individual 
drinkers but also by the rest of society and treatment may also affect consequences that reduce costs 
to the rest of society.  With a narrow perspective there is an incentive to “cost-shift” from one sector 
of society to another.  A health care perspective could lead to the adoption of a intervention that 
increases overall costs to society and reduces utility, because within the health care sector, the costs 
are lowered and the utility is increased, which would lead to societal inefficiencies (Torgerson and 
Torgerson, 2008).  Adopting a broader perspective where the consequences identified in Chapter 2 
of the thesis are included, should be part of further extensions of the economic model developed 
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here.  It would also be interesting to analyse the impact of a societal perspective on the ranking of 
alcohol treatments.   
The decision analytical model is a tool that can be used to assess the value for money of a range of 
alcohol treatments.  However, the innovative structure of the model, where alcohol drinking 
behaviour is of primordial interest, may present some difficulties with respect to the incorporation 
of treatment effects from previous studies.  The ideal alcohol treatment effectiveness data are 
clinical trials where drinking behaviour at baseline and follow-up are recorded, so the transition 
matrices for the treatments under analysis can be determined.  However, many published studies 
only present odd ratios (with effects derived from meta-analyses) and relative risks.  Therefore, if 
the model is used for assessing the cost effectiveness of alcohol treatments for which effectiveness 
data is already published, the means by which effect measures are incorporated in the model to 
inform the transition probabilities needs to be analysed.   
This thesis is concerned with alcohol treatments which involve individuals voluntarily changing 
behaviour.  While much of the content of this thesis refers to alcohol treatment, it is possible to 
adapt the model for other alcohol interventions.  Population-level interventions, for example, 
prevention, legislation and enforcement, should have a range of individual and social impacts.  An 
adaptation of the model to incorporate different alcohol interventions warrants further research.  An 
important contribution models the population-level impact of a range of interventions (Chisholm et 
al., 2004) and can serve as an umbrella for such types of model extensions.   
4.13 Conclusion 
Despite some of the limitations, which naturally arise when a modelling approach is adopted, the 
model is a contribution for the link between drinking patterns, health consequences and alcohol 
treatments effectiveness and cost effectiveness.  This chapter provides a framework by which 
policymakers can evaluate alcohol treatments taking into account longer term health outcomes and 
costs.  It enables the estimation of benefits from alcohol treatment related to a change in alcohol 
consumption which is not necessarily confined to abstinence.  This represents a major development 
in the techniques traditionally used in the field of alcohol treatment, in which short-term costs and 
outcomes are assessed, omitting potential longer term cost savings and improvements in health-
related quality of life.  
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Chapter 5. Economic model: country-specific model inputs, an 
example for the UK 
This chapter presents the calculation of UK-specific model inputs which can be used to populate the 
Markov model for any alcohol treatment assessment in the UK.  Model inputs such as treatment 
costs and the effects of treatment in drinking behaviour are specific to the treatments under 
evaluation and are presented in the next two chapters where the model is applied.   
First, transitions between states after treatment uptake, epidemiological data (mortality rates and 
morbidity rates), lifetables and alcohol-related diseases costs and utilities for the health states are 
calculated.  Second, the distributions used in the probability sensitivity analysis, for the transition 
probabilities and utilities, are described.  The last sections discuss the limitations of the methods 
applied and conclude. 
5.1 Following cycles transition probabilities for a UK population 
The transition probabilities of the effects of treatment should not be used for the remaining cycles of 
the model, i.e. for lifetime.  Ideally, the population treated with the specific alcohol treatments is 
followed for a long period of time after treatment delivery.  However, most alcohol treatment trials 
conducted so far have a follow-up of one to two years.   
As an application to the UK population, a UK long-term drinking behaviour follow-up study, 
conducted by Taylor et al. (1985), is used as the best information for the following cycles 
transitions available until present date.  This study reported patterns of drinking over 10 years, using 
68 patients who were admitted into a controlled study of treatment versus advice with 1 and 2 years 
follow-up.   
Taylor et al. (1985) reported the proportion of patients who remain in a certain drinking status for 
the following year.  The authors defined three drinking categories: abstinence, social drinking and 
troubled drinking.  These categories are matched to the model categories: ex-categories (ex-
hazardous and ex-harmful), hazardous drinking, and harmful drinking, respectively.  There is no 
possible distinction between the ex-categories as the study did not report the effect of present 
consumption on following year consumption.  The proportions reported in Taylor et al. (1985) are 
used in the model to describe the probability of remaining in the same state.  The probability of 
transiting to any of the two other allowed states is assumed to be one minus the probability of 
remaining in the same state, divided by two.  This is rather crude and assumes that the probability of 
transiting to the two other states is the same.  The Taylor et al. (1985) study reported a yearly 
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stability of 81% for the abstinence category, 86% for the social drinking category and 83% for the 
troubled drinking category.  Based on these estimates, a transition matrix for the following cycles is 
derived in Table 24 below. 
Table 24- Transition matrix for the following cycles, for a UK population 
Cycle n +1 
Hazardous Harmful Ex-Hazardous Ex-Harmful Death (D) 
Hazardous (A) 0.862 0.07 0.07 0 tpA2D1
Harmful (B) 0.085 0.832 0 0.085 tpB2D1
Ex-Hazardous 
(ExA) 0.095 0.095 0.81
2 0 tpExA2D1
Cycle 
n
Ex-Harmful 
(ExB) 0.095 0.095 0 0.81
2 tpExB2D1
1Time-dependent transition probability; 2Yearly stability reported in Taylor et al. (1985);tp, transition 
probability; tpA2D, transition probability from hazardous to death; tpB2D, transition probability from 
harmful to death; tpExA2D, transition probability from ex-hazardous to death; tpExB2D, transition 
probability from ex-harmful to death. 
5.2 Mortality and morbidity calculation for a UK population 
The model requires data on the mortality and morbidity of the population modelled.  This informs 
the estimation of model outcomes, such as life expectancy and lifetime costs.  The general steps for 
the calculation of mortality risk from alcohol-attributable injury and chronic disease are discussed 
below, followed by a brief discussion of where the morbidity calculations differ.   
Step 1: Identifying causal conditions 
Step 1 is common to both injury and chronic disease mortality and morbidity risk.  This step is a 
general step whilst the following ones produce estimates specific to the country where the analysis 
is done.  The injury and chronic disease categories causally related to alcohol are identified using 
the approach of the WHO Comparative Risk Assessment (CRA) Study (Ezzati et al., 2002; WHO, 
2002c; Ezzati et al., 2004; Rehm et al., 2003d; Rehm et al., 2004a).  The injury and chronic disease 
categories used for the calculation of mortality and morbidity risks for the model are presented in 
Table 25 below. 
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Table 25- Injury and chronic disease categories causally related to alcohol and alcohol-attributable 
fraction/ relative risk sources 
Disease 
category 
WHO 
GBD 
code 
ICD-10 code(s) Source 
Unintentional injuries 
Road traffic 
accidents W150 
V01-V04, V06, V09-V80, V87, 
V89, V99 (WHO, 2002) 
Poisoning W151 X40-X49 (WHO, 2002) 
Falls W152 W00-W19 (WHO, 2002) 
Fire W153 X00-X09 (WHO, 2002) 
Drowning W154 W65-W74 (WHO, 2002) 
Other 
unintentional 
injuries 
W155 
Rest of V-series not codified above 
and W20-W64,W75-W99, X10-
X39, X50-X59,Y40-Y86,Y88,and 
Y89  
(WHO, 2002) 
Intentional injuries 
Self-inflicted 
injuries W157 X60-X84, and Y870 (WHO, 2002) 
Homicides W158 X85-Y09, and Y871 (WHO, 2002) 
Other 
intentional 
injuries 
W160 Y35 (WHO, 2002) 
Chronic Diseases 
Lip, oral and 
pharyngeal 
cancer 
W061 C00-C14 (Corrao et al., 1999) 
Esophageal 
cancer W062 C15 (Corrao et al., 1999) 
Liver cancer W065 C22 (Corrao et al., 1999) 
Breast cancer W069 C50 (Corrao et al., 1999) 
Alcohol use 
disorders W086 F10 
Own calculations based on the US 
National Epidemiologic Survey on 
Alcohol and Related Conditions 
(NESARC) (http://niaaa.census.gov/)
Hypertensive 
diseases W106 I10-I13 (Corrao et al., 1999) 
Ischemic 
heart disease W107 I20-I25 (Corrao et al., 2004) 
Ischemic 
stroke* W108 I60-I69 (Corrao et al., 1999) 
Haemmorhae
gic stroke* W108 I60-I69 (Corrao et al., 1999) 
Cirrhosis of 
liver W117 K70-K74 (Corrao et al., 1999) 
WHO GBD, World Health Organization Global Burden of Disease; ICD-10, International Classification of 
Diseases Tenth Revision (WHO, 1992);*Cerebrovascular disease; conversion between GBD and ICD-10 
codes from:  http://www.dcp2.org/pubs/GBD/3/Table/3.A2. 
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Mortality 
5.2.1 Injury mortality risks 
This chapter uses a recently developed approach for the calculation of injury mortality risks 
presented in Taylor et al. (2008).  The method used for the quantification of injury mortality risk 
takes into account different levels of consumption per occasion and different frequencies of 
drinking such amounts for the UK population. 
Estimation of alcohol-attributable injury mortality in the UK requires combining the absolute yearly 
risk of injury mortality with gender and consumption-specific relative risks, while taking into 
account the number of drinking occasions at a particular level per year, and then calculating the risk 
per occasion and the yearly alcohol-attributable risk.  This requires step 1 already presented above 
and the following three steps. 
Step 2: Dividing the risk into baseline and alcohol-attributable risk. 
The estimation of the one-year absolute risk of alcohol-attributable injury death first requires the 
knowledge of the risk of injury mortality that is not alcohol-attributable, i.e. the baseline risk.  The 
baseline risk is calculated for each injury category identified in Step 1, differentiated by gender, and 
the following age groups: 15-29, 30-44, 45-59, 60-69, 70-79 and +80.  For this calculation, the total 
number of deaths by gender and age, for a UK population and for each injury obtained from the 
WHO Global Burden of Disease (GBD) project for the year 2005 (unpublished data, kindly given 
by Juergen Rehm, consists of the latest available data from WHO), with the underlying cause coded 
according to the GBD, is used.  By dividing the number of deaths from each injury category for 
each age group and sex by the total population at risk, for the respective age groups and sex in the 
UK, for the year 2005 (unpublished data, kindly given by Juergen Rehm, consists of the latest 
available data from WHO), the total risk of injury death for one year per 1000 population in each 
age and sex group is calculated (i.e. the population-level absolute risk of mortality by injury type).  
The baseline risk (not including the risk due to alcohol) is obtained by multiplying the total risk by 
the age, gender and injury-specific AAF and subtracting the resulting number (alcohol-attributable 
risk) from the total risk.  The baseline risk is the risk of injury mortality that would have been 
present in the UK in the year 2005 without any involvement of alcohol.  The AAF for each injury 
category is derived from the WHO CRA Study for Europe A Region, which includes the UK (Rehm 
et al., 2004; WHO, 2002), and is defined as that fraction of injury that would disappear if alcohol 
were completely absent.  The calculation of one year injury mortality uses the baseline risk in the 
following steps.  It should be noted that Taylor et al. (2008) calculated lifetime alcohol attributable 
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risks.  However, the calculations referred to here are for one year as the Markov model itself 
propagates the risk for a lifetime period.  
Step 3: Risk function for injury: determination of relative risk for different alcohol quantities 
Step 3 requires estimating the impact of different patterns of alcohol consumption on the baseline 
risk.  It has been shown that alcohol-related injuries are the result of both the volume of alcohol 
consumed and the drinking pattern, i.e. the frequency and setting of drinking (Rehm et al., 2003a; 
Rehm et al., 2004; Rehm et al., 2007a).  The RRs corresponding to consumption of standard drinks 
are taken from a case-crossover 10-country Emergency Room (ER) study (N = 4,320, 91% response 
rate) (Borges et al., 2006), in which patients presenting with an injury were asked about their 
alcohol consumption prior to the injury.  The ER study used volume-specific RRs corresponding to 
a specific number of international standard drinks where one standard drink corresponded to 12.5g 
or 16ml of pure alcohol.  This data is modelled on the basis of a quadratic equation and the RRs are 
converted to UK standard drinks for consumption up to 6.5 international drinks (10.27 UK drinks).  
Beyond 6.5 standard drinks, the ER study RR is used.  A quadratic function shows the non-linear 
effect of alcohol on risk of injury death, indicating that risk increases at a rate that is more than 
proportional to the number of drinks consumed.  The table below presents the risk data in 16ml 
standard drinks and the corresponding relative risks after conversion to UK standard drinks (Table 
26). 
Table 26- Conversion of alcohol intake and RR from Borges et al. (2006) 
No. of 
International 
drinks a
RR b Quadratic Regression c No. of UK drinks d
UK 
RR e
0 1.0 0 1.0 
1 3.3 1 1.6 
2.5 3.9 3 3.3 
4.5 6.5 5 5.6 
>6 10.1 
2ln 0.0656 0.758RR D D= +
RR- Relative Risk 
D- number of international drinks 
7 7.9 
9 8.9 
11 10.1 
aNumber of international drinks, taken from the Borges et al. (2006) study, where an average drink contains 
12.5 g of alcohol; bRR, Relative Risk, taken from the Borges at al. (2006) study; cRegression of the number of 
international drinks on the RR as reported in the Borges et al. (2006) study; dOne UK standard drink contains 
7.9 g of alcohol; eRelative Risk for UK standard drinks calculated using the equation obtained through the 
regression. 
Next, the RR associated with each Markov state drinking category is developed using the equation 
that modelled the ER data.  For this calculation, the four drinking categories are modelled for men 
and women separately: harmful drinkers, hazardous drinkers, ex-harmful drinkers, and ex-
hazardous drinkers, as shown in Table 27 below.  The middle column for each gender in the table 
131 
shows the number of drinks per occasion by drinking category used to estimate the RR associated 
with each drinking pattern. 
Table 27- Consumption levels for UK drinking patterns, by drinking category and gender 
 Men Women 
Grams/
day Drinks/occ. 
Occ. 
/week 
Grams 
/day Drinks/occ. Occ./week 
Hazardous 54 9.45 5 38 6.65 5
Harmful 110 13.75 7 80 10 7
Ex-Hazardous 18 3.15 5 13 2.275 5
Ex-Harmful 37 6.475 5 27 4.725 5
Occ., occasion. 
In Table 27 the definition of grams/day is the arithmetic mean of the levels of consumption that 
characterize each Markov state, as presented in Chapter 4.  For ex-drinkers, the definition of the 
grams/day used for the calculation of the number of drinks per occasion is more complex.  This is 
because the ex-categories have a lower bound of zero grams per day and so both abstinent and 
sensible drinkers are captured within these categories.  For most injuries when no alcohol is 
consumed the risk becomes zero.  In trying to determine a quantification which fulfils all of these 
assumptions, a risk which corresponds to about 1/3 of the previous level of drinking, is modelled.  
The number of occasions per week is estimated based on the definition of the drinking category, 
where a harmful drinker is assumed to drink every day and the hazardous and ex-drinker is assumed 
to drink five times a week.  Such numbers of occasions per week are based on the CRA of the GBD 
attributable to alcohol study (Murray and Lopez, 1997), for the WHO region Europe A (Rehm et al., 
2003c; Rehm et al., 2006c).  The number of drinks per occasion is calculated based on the grams 
per day and occasions per week.  Thus, to give an example: a hazardous drinker drinks 5 times a 
week 54 g/day which corresponds to 6.75 UK standard drinks per day (54/8).  The 6.75 drinks per 
day correspond to 9.45 drinks per occasion ((6.75*7)/5).  The RRs obtained for each drinking 
category by gender are presented in Table 28 below. 
Table 28- Injury relative risks for UK drinking patterns, by drinking category and gender 
Males Females 
No. of Drinks Relative risk No. of Drinks Relative risk 
Hazardous 9.45 8.1 6.65 7.5 
Harmful 13.75 10.1 10 8.8 
Ex-Hazardous 3.15 3.4 2.275 2.6 
Ex-Harmful 6.475 7.3 4.725 5.3 
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The next step involves combining the alcohol RR obtained for each drinking category by gender 
with the baseline risk in order to obtain an estimate of alcohol-attributable risks for different 
consumption patterns. 
Step 4: Combination of baseline risk and alcohol-based RR 
For this last step, the baseline risk from Step 2 is combined with the consumption-based relative 
risks of Step 3 to estimate the absolute alcohol-attributable risk of injury death for each drinking 
category in a way to reflect real-time and cumulative risk based on drinking habits, i.e. the 
probability of dying given the baseline risk and being a (ex-) hazardous (ex-) harmful drinker.  The 
yearly injury mortality risk is calculated using a probability scenario that incorporates Steps 2 and 3 
in the following way, using the same approach applied to Canadian and Australian data by Taylor et 
al. (2008) and Rehm et al. (2008), respectively: 
Pr (death | N) = 1 – (1- (Pr(death)d/id))N
Where:  
N = the number of drinking occasions per year.  See Table 27 for a breakdown of the number of 
occasions in each drinking category for men and women.  Seven occasions in a week corresponds to 
365 drinking occasions a year and 5 occasions a week correspond to 260 drinking occasions a year, 
for harmful and the other drinking categories, respectively. 
d = the number of drinks consumed per occasion.  See Table 27 for a breakdown of the number 
drinks consumed per occasion for each drinking category for men and women. 
Pr (death | N) = the risk of injury death (per 1000) given N one-year drinking occasions 
Pr (death)d = the risk of injury death for one drinking occasion per year, depending on the number 
of drinks per occasion.  This is the baseline risk (from Step 2) multiplied by the consumption-
specific RRs (from Step 3). 
id = the “risk period”.  This is the time period in which the person is at risk of an alcohol-attributable 
injury death.  When a person drinks one drink, for example, he or she is not at risk for an entire day 
(24 hours).  Rather, risk should be based on the average time it takes for the liver to metabolize a 
certain number of drinks and this is modelled based on work from the National Institute for Alcohol 
Abuse and Alcoholism (NIAAA, 1997).  The relative risk associated with each drinking event 
changes as the amount consumed increases for each drinking occasion.  Rapid consumption of 
multiple drinks results in a higher BAC during the period following ingestion, because the liver has 
a relatively fixed rate of metabolism (Wilkinson et al., 1977).  Generally, for 1, 3, 5, and 7 drinks 
per occasion, the per-occasion risk equates to periods of 30 minutes, two hours, three hours and 4.8 
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hours.  Thus, for example, for three drinks per occasion a risk period of two hours during the 24-
hour period of that day is assumed.  So, id becomes 365*(24/2), as it is based on the probability of 
one year (Rehm et al., 2008).   
Probabilities of injury death are added up across injuries to get final estimates by consumption 
group, age group and gender, as presented in Table 29 below. 
Table 29- Risk of injury death for each Markov drinking category, by gender and age group, per 
1000 UK population 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
Age Males Females Males Females Males Females Males Females 
15-29 0.38 0.07 0.89 0.17 0.04 0.01 0.21 0.03 
30-44 0.44 0.07 1.01 0.19 0.05 0.01 0.24 0.04 
45-59 0.37 0.09 0.85 0.24 0.04 0.01 0.20 0.04 
60-69 0.38 0.10 0.89 0.27 0.04 0.01 0.20 0.05 
70-79 0.68 0.26 1.49 0.64 0.08 0.03 0.37 0.12 
> 80 1.51 0.93 2.53 1.60 0.25 0.14 0.96 0.54 
5.2.2 Chronic disease mortality risks
Estimation of alcohol-attributable chronic disease mortality in the UK requires similar steps to the 
injury mortality risks. 
Step 2: Dividing the risk into baseline and alcohol-attributable risk. 
The estimation of the one-year absolute risk of alcohol-attributable chronic disease death first 
requires the knowledge of the risk of disease mortality that is not alcohol-attributable.  The baseline 
risk is calculated for each chronic disease category identified in Step 1, differentiated by gender, 
and the following age groups: 15-29, 30-44, 45-59, 60-69, 70-79 and +80.  For this calculation, the 
total number of deaths by gender and age, for a UK population and for each chronic disease 
obtained from the WHO GBD project for the year 2005 (unpublished data, kindly given by Juergen 
Rehm, consists of the latest available data from WHO), with the underlying cause coded according 
to the GBD, is used.  By dividing the number of deaths from each disease category for each age 
group and sex by the total population at risk for the respective age groups and sex in the UK for the 
year 2005 (unpublished data, kindly given by Juergen Rehm, consists of the latest available data 
from WHO), the total risk of chronic disease death for one year per 1000 population in each age and 
sex group is calculated (i.e. the population-level absolute risk of mortality by chronic disease type).  
The baseline risk (not including the risk due to alcohol) is obtained by multiplying the total risk by 
the age, gender and disease-specific AAF and subtracting the resulting number (alcohol-attributable 
risk) from the total risk.  The baseline risk is the risk of specific chronic diseases mortality that 
would have been present in the UK in the year 2005 without any involvement of alcohol.  The AAF 
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for each chronic disease category is derived from the WHO CRA Study for Europe A Region 
(Rehm et al., 2004; WHO, 2002).  The approach used for the calculation of one year chronic disease 
mortality uses the baseline risk in the following steps.   
Step 3: Determination of relative risk for different alcohol quantities 
Relative risks are calculated for different average daily consumption levels and adjusted for age.  As 
for injuries, the definition of grams per day used to calculate the relative risks is based on the 
arithmetic mean of the levels of consumption that define the four Markov states.  The definition of 
the ex-categories grams per day for chronic diseases risk is also complex as chronic diseases 
develop many years after the onset of alcohol drinking.  Clearly, risk is reduced if people reduce 
drinking, but it is also substantially higher when compared to lifetime abstainers (Shaper, 1990; 
Wannamethee and Shaper, 1997), and it depends on the amount consumed before such reduction.  
For most chronic diseases, risk goes down slowly, but the exact amount is hard to quantify (for an 
example of head and neck cancer see Rehm et al., 2007b), and there are differences between disease 
categories (e.g. liver cirrhosis vs. cancer).  Therefore, since prior drinking may be involved in the 
aetiology of chronic disease, or vice versa (e.g. “sick quitter” effect) (Shaper, 1990), for ex-drinkers, 
an underlying level of consumption of one third of the previous level of drinking is assumed (see 
Table 27), resulting in a risk estimation for ex-drinkers based on their previous consumption level 
(“harmful” or “hazardous”), as used previously for injury risk.  Most diseases relative risks are 
modelled using data from Corrao et al. (1999), except for ischemic heart disease, which is based on 
another publication by Corrao et al. (2004).  Male harmful drinkers, who are assumed to be 
consuming an average of 110 g/day, are at risk for ischemic heart disease because their level of 
consumption is outside of a protective effect, as reflected in the J-shaped relationship between 
alcohol consumption and risk for ischemic heart disease (Corrao et al., 2004).   
Age specificity of relative risks  
Consumption-specific chronic disease relative risks are not age-specific.  Relative risks tend to 
converge to one with age and not taking this into account leads to an overestimation of deaths 
caused and prevented by alcohol in older age groups (Rehm et al., 2006b).  For this reason, the 
model incorporates decreasing functions of RR with age.  
The RR for alcohol-attributable chronic disease mortality, for the age groups above 45 years-old, is 
modelled using the following equations, based on the work of Klatsky and Udaltsova (2007): 
135 
 
Age group 45-59  0.0955145 59 30 44 30 44RR RR RR   = ×  
Age group 60-69  0.5704960 69 45 59 45 59RR RR RR   = ×  
Age group 70-79  0.5798470 79 60 69 60 69RR RR RR   = ×  
Age group 80+    0.634780 70 79 70 79RR RR RR +  = ×  
The special case of Alcohol Use Disorders 
Alcohol Use Disorder (AUD) is 100% attributable to alcohol, i.e. it would not exist if alcohol was 
not present.  Therefore, the issue here is not determining the portion of risk that is alcohol 
attributable, but rather to estimate the risk of developing AUD at a given level of drinking (Rehm et 
al., 2008).  For this, survey data (confidential data provided by Juergen Rehm) from the US-based 
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) data is used 
(sample size = 43, 093 persons 18 years and older, response rate = 81%) (Grant et al., 2003).  The 
risk of AUD for males and females observed with the NESARC data, for different levels of alcohol 
consumption, is modelled using a quadratic regression (Rehm et al., 2008).  This same regression is 
used for calculating the risk of AUD for the four drinking categories  
Step 4: Combination of baseline risk and consumption-based RR 
For this last step, the baseline risk from Step 2 is combined with the consumption-based relative 
risks of Step 3 for each age, sex, and disease category to estimate the absolute alcohol-attributable 
risk of chronic disease death for each drinking category.  Finally, the risks are added up across 
disease categories in order to get final estimates by drinking category, age group and gender, as 
presented in Table 30 below. 
Table 30- Risk of chronic disease death for each Markov drinking category, by gender and age 
group, per 1000 UK population 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
Age Males Females Males Females Males Females Males Females 
15-29 0.06 0.04 0.12 0.08 0.03 0.03 0.04 0.04 
30-44 0.48 0.35 0.93 0.59 0.34 0.27 0.39 0.31 
45-59 2.58 1.65 4.19 2.52 2.11 1.36 2.30 1.51 
60-69 7.95 4.86 9.57 5.64 7.40 4.57 7.62 4.72 
70-79 23.24 17.02 25.16 18.13 22.51 16.63 22.79 16.82 
> 80 61.44 66.87 63.42 68.63 60.61 66.28 60.90 66.56 
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Morbidity 
The calculation of alcohol-attributable risk for injury and chronic disease morbidity involves an 
identical series of steps as the ones presented above for mortality.  Only the differences between the 
two methods are presented in this section.  It can be anticipated that key differences relate to the use 
of morbidity total risks instead of mortality risks.  Another difference is the use of AAFs for injury 
morbidity instead of mortality, as detailed below. 
5.2.3 Injury morbidity risks
The calculation of yearly alcohol-attributable injuries morbidity risk requires the use of total 
morbidity risk by age group, gender and injury category.  The calculation of this risk uses hospital 
morbidity data from the Hospital Episode Statistics (HES) 2006-07 (for inpatient data, primary 
diagnosis coded with three characters) for England (The NHS Information Centre, 2007b).  In the 
NHS episode statistics, the injury categories indentified in Table 25 are coded according to the ICD-
10.  However, the HES are not available for the same age and gender groups previously defined.  
The age groups presented in the HES are 0-14, 15-59, 60-74 and +75 years old.  When gender 
separation is presented in the HES, the number of cases is aggregated for all ages.  Given that the 
total morbidity risk is required for the age groups15-29, 30-44, 45-59, 60-69, 70-79 and +80 and by 
gender, the following steps are taken: 
1) Computation of all hospitalizations for each alcohol-related injury for two age groups: 15-
59 and +60. 
2) Determination of age and gender distributions for each injury group based on UK injury 
number of deaths data (the same data previously used for mortality). 
3) Assumption of the same gender and age distributions for morbidity data and computation of 
raw numbers of injury hospitalizations for males and females separately in the following 
age groups: 15-29, 30-44, 45-59, 60-69, 70-79, and 80+. 
4) Computation of rates of total injury morbidity for each age/ gender category by dividing the 
raw number of hospitalizations by the total at-risk population.  At risk population is the 
2006 population estimates for England by gender and age (Office for National Statistics, 
2006).   
The other difference, with respect to mortality rates, is that the AAFs for injuries are adjusted from 
the AAFs reported for injury mortality, obtained from the CRA (Rehm et al., 2004; WHO, 2002).  
In general, more severe outcomes are more related to alcohol than less severe outcomes (Rehm et 
137 
al., 2003b).  Consequently, the AAFs for mortality should be higher than the AAFs for morbidity.  
The AAFs for morbidity from injuries are derived by multiplying the mortality AAFs by two thirds 
for motor vehicle accidents and by four ninths for all other types of injury (Cherpitel, 1993, 1996; 
Rehm et al., 2004; Cherpitel, 1994).  Table 31 below presents the risks of injury morbidity, by 
gender and age group for each drinking category of the model. 
Table 31- Risk of injury morbidity for each Markov drinking category by gender and age group 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
Age Males Females Males Females Males Females Males Females 
15-29 0.0053 0.0024 0.0060 0.0041 0.0019 0.0003 0.0045 0.0013 
30-44 0.0057 0.0029 0.0062 0.0047 0.0023 0.0005 0.0049 0.0017 
45-59 0.0048 0.0033 0.0057 0.0046 0.0021 0.0007 0.0042 0.0023 
60-69 0.0038 0.0025 0.0050 0.0035 0.0015 0.0005 0.0031 0.0017 
70-79 0.0041 0.0030 0.0053 0.0040 0.0022 0.0013 0.0033 0.0025 
> 80 0.0043 0.0031 0.0052 0.0043 0.0025 0.0021 0.0036 0.0026 
5.2.4 Chronic disease morbidity risks
As for injury morbidity risks, a total risk must be computed for chronic diseases morbidity.  The 
calculation of this risk follows exactly the same procedure as presented above for injuries, i.e.: 
1) Computation of all chronic disease hospitalizations for two age groups: 15-59 and +60 from 
the HES 2006-07 (The NHS Information Centre, 2007b). 
2) Determination of age and gender distributions for each disease category based on UK 
chronic disease number of deaths data (the same data previously used for mortality). 
3) Assumption of the same gender and age distributions for morbidity data and computation of 
raw numbers of chronic disease hospitalizations for males and females separately in the 
following age groups: 15-29, 30-44, 45-59, 60-69, 70-79, and 80+. 
4) Computation of rates of total chronic disease morbidity for each age/ gender category by 
dividing the raw number of hospitalizations by the total at-risk population.  At risk 
population is the 2006 population estimates for England by gender and age (Office for 
National Statistics, 2006).   
The sources for RR and AAF are the same as for mortality and there is no further difference 
regarding the methods for chronic disease alcohol-attributable morbidity risk, when compared with 
the methods for mortality.  The table below presents the risks of chronic disease morbidity, by 
gender and age group for each drinking category of the model. 
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Table 32- Risk of chronic disease morbidity for each Markov drinking category, by gender and age 
group 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
Age Males Females Males Females Males Females Males Females 
15-29 0.0010 0.0005 0.0025 0.0009 0.0004 0.0003 0.0007 0.0004 
30-44 0.0088 0.0066 0.0188 0.0108 0.0048 0.0050 0.0066 0.0058 
45-59 0.0357 0.0275 0.0616 0.0407 0.0265 0.0224 0.0306 0.0250 
60-69 0.0259 0.0166 0.0344 0.0198 0.0226 0.0153 0.0241 0.0160 
70-79 0.0685 0.0523 0.0759 0.0557 0.0657 0.0512 0.0668 0.0517 
> 80 0.1464 0.1618 0.1515 0.1654 0.1445 0.1610 0.1451 0.1613 
5.3 Life expectancy: generation of a UK lifetable for the economic model 
In the model the transition probabilities from each state to the death state consist of two components.  
The first component is the probability of dying from non-alcohol-related causes, i.e. the baseline 
mortality, which is the same for all states and different for women and men.  This probability 
changes over time because, as the patient gets older, the probability of dying from unrelated causes 
will increase continuously.  The baseline mortality rate is simply the total mortality risk discounting 
the risk for alcohol-related injuries and diseases.  The second component is the probability of dying 
from alcohol-related causes, taking both alcohol-related injuries and chronic diseases into account.  
This one is state specific and also varies with time and gender, as presented in the above section for 
a UK population.   
Therefore, each drinking category has its own gender and age-dependent mortality transition 
probabilities.  The way this is implemented in the model is by using a country-specific table of 
gender and age-specific mortality rates (lifetable) for each drinking state.  The following table 
(Table 33) presents the age-dependent transition probabilities to death for a UK population.  With a 
yearly cycle length, the patient’s age at the end of cycle n is: Age cycle n=Start age + n and this is 
introduced in an excel VLOOKUP function.  For each Markov state, a VLOOKUP function looks 
up the index age in a lifetable in order to retrieve the transition probability from each state to the 
death state.  For each cycle, mortality from other causes (baseline mortality in Table 33) is added to 
the alcohol-specific mortality rates to produce a total compound mortality for each drinking 
category.   
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Table 33- Lifetable: age-dependent transition probabilities to death by gender, for each drinking 
state and baseline, per 1000 UK population 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
Baseline 
mortality 
Age A’ M F M F M F M F M F 
15-29 15 0.44 0.11 1.01 0.25 0.08 0.04 0.25 0.07 0.27 0.16 
30-44 30 0.92 0.42 1.94 0.79 0.39 0.28 0.63 0.35 0.55 0.39 
45-59 45 2.95 1.74 5.04 2.76 2.15 1.37 2.50 1.55 2.47 1.78 
60-69 60 8.33 4.96 10.46 5.92 7.44 4.58 7.82 4.77 9.21 5.99 
70-79 70 23.92 17.28 26.65 18.76 22.59 16.66 23.16 16.94 25.72 15.66 
> 80 80 62.95 67.81 65.95 70.24 60.86 66.42 61.86 67.10 68.70 48.40 
M, males; F, females; A’, Age Index. 
The text that follows provides a more detailed analysis of the UK mortality rates by gender and age 
groups.  This is important for the interpretation of subgroup analyses that study the impact of 
population characteristics on the effectiveness and cost effectiveness of alcohol treatments.  Table 
34 below shows the mortality rates by gender (averaged by age group) for chronic diseases and 
injuries together and for injuries and chronic diseases separately.  The proportion of male mortality 
rates compared to female rates is presented.  It can be seen that overall mortality rates for males are 
only slightly higher than female rates for all drinking categories.  The proportion of males dying 
from injury-related causes is more than double that of females for all drinking groups.  The 
proportion of males and females dying from alcohol-related chronic disease is similar between the 
drinking groups.   
Table 34- Proportion of males/females alcohol specific mortality rates by gender and drinking 
category 
 Injuries and Chronic Injuries Chronic 
Drinking group M/ F M/ F M/F 
Hazardous 1.08 2.46 1.05 
Harmful 1.13 2.46 1.08 
Ex-Hazardous 1.05 2.54 1.04 
Ex-Harmful 1.06 2.65 1.05 
M, males; F, females. 
Mortality rates for males of all age groups less than 80 years old through the four drinking 
categories are on average higher than female rates, with the biggest difference for the lower age 
groups, where the rates for males are two to four times higher than those for females (Table 35).  
The high proportion of male vs. female mortality rates for the lower age groups is explained by the 
higher alcohol-attributable injury mortality risks for males in lower age groups.  The proportions of 
the rates decrease with an increase in age, where the gender difference in mortality starts to be less 
pronounced.  The proportion of males dying from injuries, when compared to females, is higher 
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than the proportion for chronic diseases.  After 80 years old more females than males die from 
chronic diseases, which can be explained by females’ higher life expectancy 
Table 35- Proportion of males/ females alcohol specific mortality rates by gender and age group 
 Injuries and Chronic Injuries Chronic 
Age group M/ F M/ F M/F 
15-29 3.80 5.53 1.32 
30-44 2.11 5.60 1.40 
45-59 1.70 3.80 1.59 
60-69 1.68 3.46 1.64 
70-79 1.38 2.51 1.37 
> 80 0.93 1.63 0.92 
M, males; F, females 
Table 36 shows that alcohol specific rates are higher for more serious drinking levels, with the ex-
hazardous category presenting the lower mortality rates, for both males and females.  Table 37 
shows that alcohol specific mortality rates, for males and females, increase with age. 
Table 36- Alcohol specific mortality rates by gender and drinking category, 
per 1000 UK population 
Drinking group Males Females 
Hazardous 16.58 15.39 
Harmful 18.51 16.45 
Ex-Hazardous 15.59 14.89 
Ex-Harmful 16.04 15.13 
Table 37- Alcohol specific mortality rates by gender and age group, per 
1000 UK population 
Age group Males Females 
15-29 0.45 0.12 
30-44 0.97 0.46 
45-59 3.16 1.85 
60-69 8.51 5.06 
70-79 24.08 17.41 
> 80 62.90 67.89 
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5.4 Calculation of disease costs for the Markov states 
This section is concerned with the calculation of the alcohol-related diseases costs for a UK 
population.  These costs are specific to each drinking category and represent the hospital alcohol-
related diseases costs of the health states.  The alcohol-related morbidity rates for the alcohol-
related diseases identified in Table 25, by gender, drinking state and for each age group, are used 
for the calculation of state costs.  The calculation of the morbidity rates is presented in section 5.2.4 
above.  WHO ICD-10, GBD and HRG codes for the diseases used for costing the Markov states are 
presented in Table 38 below.   
Table 38- Diseases used to cost the Markov states 
GBD code and description ICD-10 code HRG code 
W061 Oral cavity, pharynx C00-C14 C17,C27,C37 
W062 Oesophageal cancers C15 F08 
W065 Liver cancer C22 P07 
W069 Breast cancer C50 J10 
W086 Alcohol use disorders F10 Not coded in HRG* 
W106 Hypertensive disease I10-I13 E25,L53 
W 107 Ischaemic heart disease I20-I25 E23,E12 
W 108 Ischaemic stroke I60-I69 P09,A19,A23 
W 108 Haemorrhagic stroke I60-I69 P09,A19,A23 
W117 Cirrhosis of the liver K70-K74 P12,G06 
GBD, Global Burden of disease (Murray and Lopez, 1997); ICD-10, International Classification of Diseases 
10th revision (WHO, 1992); HRG, Health Care Resource Group;*Alcohol use disorders (W086) is not costed 
in elective inpatient HRG data. 
Average unit costs for each one of the diseases identified as being alcohol-related are retrieved as 
follows.  First, the GBD codes are converted to ICD-10 codes using an online conversion table 
available in the Disease Control Priorities Project website (The World Bank Group, 2006).  Second, 
the ICD-10 codes of the diseases as provided in the Hospital Episode Statistics (The NHS 
Information Centre, 2007b) are converted to Heath Care Resource Group (The NHS Information 
Centre, 2007a) (see Table 38 above).  The conversion from ICD-10 codes to HRG uses a casemix 
converter available online in the NHS website (The NHS Information Centre, 2007c).  Finally, 
national average unit costs are retrieved from the National Schedule of Reference Costs available 
online, using elective inpatient HRG data (Department of Health, 2006; Appendix NSRC1 Aa) and 
up-rated to 2006/07 prices, using the Hospital and Community Health Services (HCHS) pay and 
prices index from the PSSRU Unit Costs of Health and Social Care 2007 (Curtis, 2007).  Alcohol 
use disorders (W086) is not costed in elective inpatient HRG data.  Therefore, the average cost is 
calculated based on the unit cost reported by the PSSRU (Curtis, 2007) and on the mean length of 
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stay reported in the Hospital Episode Statistics (The NHS Information Centre, 2007b).  The mean 
cost used is £1,469.70 (£213 per inpatient day taken from PSSRU 2006/07, combined with a mean 
length of stay of 6.9 days, as reported in the HES 2006/07).  The average unit costs for each disease 
are presented in Table 39. 
Table 39- Unit average costs for the alcohol-related diseases 
GBD GBD description Average unit cost 
W061 Oral cavity, pharynx £1,989.68 
W062 Oesophageal cancers £1,275.63 
W065 Liver cancer  £2,138.80 
W069 Breast cancer £1,091.27 
W086 Alcohol use disorders £1,469.70 
W106 Hypertensive disease £1,329.48 
W107 Ischaemic heart disease £1,515.50 
W108 Ischaemic and Haemorrhagic stroke £2,345.72 
W117 Cirrhosis of the liver  £1,961.69 
GBD- Global Burden of disease (Murray and Lopez, 1997); 2006/07 prices. 
The average unit costs of each disease are then weighted by the disease-specific morbidity risk, by 
gender, age and drinking group.  The weighted costs for all alcohol-related diseases, by age and 
gender, are linked to each drinking state.  Given that the morbidity risks are disease, age, gender and 
consumption specific, it would be exhaustive to present all the calculations.  An example of the 
computation of disease-related costs is presented in Table 40 for males of the 30-44 year old group.  
The table presents the morbidity rates for each disease, the weighted costs (average unit costs 
presented in Table 39 multiplied by the morbidity rate) and the overall state cost (last line of the 
table), for a males with 30 to 44 years old.   
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Table 40- States costs computation for males with 30 to 44 years old, UK population 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
GBD mr* Cost £ mr* Cost £ mr* Cost £ mr* Cost £ 
W061 0.18 0.36 0.34 0.67 0.09 0.18 0.13 0.26 
W062 0.11 0.14 0.25 0.31 0.06 0.08 0.09 0.11 
W065 0.03 0.06 0.04 0.08 0.02 0.05 0.03 0.06 
W069 0.02 0.03 0.04 0.04 0.02 0.02 0.02 0.02 
W086 4.50 6.62 11.52 16.93 1.26 1.85 2.85 4.19 
W106 0.50 0.66 1.10 1.46 0.30 0.39 0.39 0.52 
W107 2.33 3.53 2.78 4.21 2.33 3.53 2.33 3.53 
W108 0.79 1.85 2.14 5.01 0.52 1.21 0.55 1.28 
W117 0.32 0.62 0.61 1.20 0.18 0.35 0.25 0.48 
SUM 8.78 13.87 18.80 29.91 4.77 7.66 6.62 10.45 
GBD, Global Burden of disease (Murray and Lopez, 1997); mr, morbidity rate; 2006/07 prices; * per 1000. 
A table with each drinking category cost by age and sex per year is then constructed with the sum of 
the weighted costs of the alcohol-related diseases.  The expected state costs are presented in Table 
41 below.  The economic model is linked to the table of state costs in a similar way as it is linked to 
the lifetable explained above.  For each Markov state, a VLOOKUP function looks up the index age 
in the state cost table in order to retrieve the average cost of that state and cycle.  Costs are 
accumulated according to the number of patients in a given category in each cycle and an estimate 
of the average disease-related costs over lifetime is obtained. 
Table 41- Yearly state cost by age and sex for each drinking category, UK population 
 Hazardous Harmful Ex-Hazardous Ex-Harmful 
Age Age index Males Females Males Females Males Females Males Females 
15-29 15 1.65 0.74 3.99 1.47 0.72 0.54 1.13 0.64 
30-44 30 13.87 8.76 29.91 15.02 7.66 6.54 10.45 10.45 
45-59 45 56.65 36.89 99.16 56.63 41.96 30.03 48.26 33.48 
60-69 60 41.82 25.00 55.55 30.26 36.46 23.13 38.73 24.06 
70-79 70 113.87 85.93 126.75 92.22 109.00 84.22 110.73 84.96 
> 80 80 253.03 288.24 262.64 295.73 249.45 286.90 250.42 287.29 
*2006/07 prices, pound sterling (£, GBP). 
Comparing health care costs by gender and age subgroup reveals that costs are higher for males of 
all age groups below 80 years old.  For an older cohort (more than 80 years old), females’ costs are 
higher which can be explained by females higher life expectancy.  For both men and women, state 
costs increase with age (Table 42).  Therefore, if alcohol treatments have the potential to reduce 
alcohol-related costs, more health care savings can be achieved for older age cohorts and a bigger 
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difference in health care savings by gender should be observed for younger age groups.  The biggest 
gender difference is observed for the younger age cohort (15-29 years old) and this can be explained 
by the higher morbidity rates for younger males. 
Table 42- Health care costs by gender and age group, averaged for all drinking groups 
Age group Males (M) Females (F) Proportion M/ F 
15-29 £1.87 £0.85 2.21 
30-44 £15.47 £10.19 1.52 
45-59 £61.51 £39.26 1.57 
60-69 £43.14 £25.61 1.68 
70-79 £115.09 £86.83 1.33 
> 80 £253.89 £289.54 0.88 
When comparing the same drinking category and with no age differentiation, health care costs are 
slightly higher for men than for women (Table 43).  The drinking state with higher associated health 
care costs is the harmful state, followed by the hazardous, ex-harmful and ex-hazardous states.  
Therefore, it is shown that a higher level of alcohol consumption is associated with increased 
hospital alcohol-related diseases costs. 
Table 43- Health care costs by gender and drinking group, averaged for all age groups 
Drinking group Males (M) Females (F) Proportion M/ F 
Hazardous £80.15 £74.26 1.08 
Harmful £96.33 £81.89 1.18 
Ex-Hazardous £74.21 £71.89 1.03 
Ex-harmful £76.62 £73.48 1.04 
5.5 Calculation of utility weights for the Markov states 
The estimation of utilities associated with each Markov state for the UK uses the UKATT trial data 
(UKATT Research Team, 2005a).  This is the only economic evaluation of alcohol treatments 
conducted alongside a clinical trial that used a standardised preference-based measure of health 
status, the EQ-5D questionnaire (Williams, 1990), in a population with alcohol problems.  Patients 
in the study classified their own health state using the multiattribute instrument EuroQol and UK 
population norms were used to value patients’ health states (Kind et al., 1999).  This trial used the 
EQ5D at baseline, 3 months and 12 months to measure each patient’s utility.  Similarly, drinking 
variables were reported at baseline, 3 months and 12 months.  The calculation of utility weights for 
the Markov states involves three steps. 
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1) Calculation of variables in terms of grams per day 
The UKATT trial did not present individual-level outcomes in terms of grams per day but drinking 
categories are defined in these terms.  The estimation of grams per day per patient for each follow-
up period involves the following steps (using SPSS 15).  The variable “drinks per drinking day” is 
multiplied by the variable “number of drinking days” for each patient to derive the total number of 
drinks per patient.  As alcohol consumption was assessed using Form 90 (Miller WR, 1996), the 
total number of drinks was consumed over a period of 90 days.  The number of drinks per patient is 
divided by 90 in order to get the number of drinks per patient per day.  Given that in the UK a 
standard drink has 8 g of Ethanol the number of drinks per patient per day is multiplied by 8 to get 
the total grams of alcohol consumed per patient per day.   
In order to get utility weights for the model states, all UKATT sample (n=742) is used and patients 
are divided into drinking categories according to g/day at 6 months.  The 6-month drinking in 
grams/day for the UKATT is obtained by using linear interpolation between 3 and 12-month 
follow-up data.  First, 3 and 12-month g/day are obtained for each patient.  Then an “incremental 
variable” computed as the difference between 3 and 12-month g/day divided per 3 gives an estimate 
of the 3-month decrement in g/day between 3 months and 12 months.  Finally, the computed 
increment is deducted from the 3-month g/day for each patient.  This method of calculating 6-month 
g/day for each patient in the trial assumes a linear negative relation between consumption at 3 and 
12 months. 
Patients are allocated according to their level of drinking at 6 months and utilities are retrieved for 
12 months due to the possibility that participants’ utility at time t can just be captured at time t+1.
The trial data provides 414 patients with EQ-5D values at 12 months that can be allocated to a 
drinking category according to the level of drinking, in g/day, at 6 months.   
2) Drinking categories definition for calculation of utilities 
No gender differentiation is possible with the data due to the low number of female patients with 
utility values at 12 months.  Therefore, the grams per day that define each Markov state are 
collapsed in order to estimate the drinking level for each category with no gender differentiation.   
The drinking categories for estimating utilities with no gender differentiation at baseline are the 
following two:  
1) Hazardous drinking (M): X 67.5 g/day (67.5 g/day is the mean of 55 g/day and 80 g/day) 
2) Harmful drinking (H): >67.5 g/day  
At 6 months patients can be in one of the following drinking categories: 
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1) Hazardous drinking (M): 24-67.5 g/day (24 g/day is the mean of 20 g/day and 28 g/day) 
2) Harmful drinking (H): >67.5 g/day  
3) Ex- Hazardous drinking (ExM): <24 g/day and hazardous drinking in previous cycle 
4) Ex-Harmful drinking (ExH): <24 g/day and harmful drinking in previous cycle 
3) Utility estimates for the Markov states 
After dividing the patients according to the above drinking categories, the utility estimates at 12- 
month follow-up are retrieved for each Markov state.  These estimates are presented in Table 44, 
along with the standard error and number of patients informing the values. 
Table 44- Utilities for the Markov States per cycle 
States’ utilities Hazardous Harmful Ex-Hazardous Ex-Harmful 
Utility/ weight 0.6597 0.6349 0.7001 0.6459 
Standard error 0.02582 0.0245 0.07591 0.0436 
n 160 180 15 59 
The utilities estimates reflect a decrease in HRQoL for higher consumption levels.  The harmful 
state has the lowest utility, followed by the ex-harmful, hazardous and ex-hazardous, respectively.  
The ex-states have a higher utility than the states where they derive from which is related with a 
sensible level of drinking.  The high standard errors observed in the ex-categories are related to the 
small number of patients in those states.  However, this uncertainty can be taken into account in the 
probabilistic sensitivity analysis that is incorporated in the Markov model, as explained below. 
5.6 Probabilistic sensitivity analysis: application of specific distributions 
This chapter focus on the model inputs that are country-specific and independent of the treatments 
under evaluation.  Chapter 4 explains how probabilistic sensitivity analysis deals with uncertainty in 
the model inputs (see section 4.7 in the previous chapter).  The model inputs that the results are 
most uncertain about are the transition probabilities and the utilities associated with each Markov 
state.  Therefore, it is appropriate to explain the probabilistic distributions used for the transition 
probabilities of the following cycles and the utility weights, given that the two inputs are calculated 
in this chapter. The distributions applied depend on the type of data that generates model inputs.  
Even though the inputs considered are UK-specific, it can be expected that an adaptation of the 
model for other countries will need the same type of data and therefore, the same distributions 
should apply. 
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5.6.1.1 Distribution for the following cycles transition probabilities 
The following cycle probabilities are based on the study conducted by Taylor et al. (1985).  This 
study reported the proportion of patients remaining in a given category (p) and used a sample of 68 
patients (n) (Taylor et al., 1985).  The probabilities of transiting to any one of the two other allowed 
states are derived from the reported probability of remaining in a given state.  Therefore, two 
categories can be considered.  One category is remaining in the state and the other category is 
leaving that state, where the probability of the latter is half of one minus the probability of 
remaining in the state.  When two categories are considered, where one category is remaining in a 
state and the other category is leaving that state, the transitions probabilities between the two 
categories are estimated from a binomial proportion.   
In Bayesian inference, a prior distribution is a probability distribution representing a belief about an 
unknown quantity and a posterior distribution is a conditional distribution of the uncertain quantity 
given the data.  The beta distribution is a conjugate of binomial data, which means that specifying a 
beta prior distribution on binomial data results in a beta posterior distribution (Briggs et al., 2006).  
The beta distribution allows the probability rules to be maintained, i.e. probabilities keep taking 
values between the range of zero and one, and probabilities of mutually exclusive events keep 
summing to one.  Therefore, the chosen distribution for representing uncertainty in the following 
cycles transition probabilities is a beta distribution.   
Fitting the beta distribution in the Markov model of drinking behaviour for the following 
cycle transition probabilities 
The beta distribution is constrained on the interval 0-1 and is characterized by two shape parameters, 
a and b. The beta distribution is fitted in the model by the method of moments (Briggs et al., 2006).  
The moments of the beta distribution, for \ ~ beta (a, b), are given by: 
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The sample moment proportion (p) and the sample size (n) are used to calculate the standard error 
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(1 ) /se p p n=  ,
where 2s is the error variance, n= 68 and p= yearly stability reported in Taylor et al. (1985) as in 
Table 24. 
Rearranging the above equations allows the calculation of the unknown parameters a and b as a 
function of the known sample proportion and standard error (se) of the proportion.  The model is 
developed in Microsoft® Excel and in this software a beta distribution is fitted as: 
BETAINV(RAND(),a, b), where RAND() is the command for drawing a random value from the 
beta distribution in Excel.  The reason why BETAINV is specified in Excel is because it is the 
inverse of the cumulative distribution function that gives the expected value when an integrated 
probability is specified (Briggs et al., 2006). 
5.6.1.2 Distributions for utilities
Utility parameters are constrained between infinity at the lower end (representing the worse possible 
health state) and 1 at the upper end (representing perfect health).  Given that the utilities used in the 
model are far from zero (see Table 44 above), a beta distribution is used in order to reflect 
uncertainty in these parameters.  
Fitting the beta distribution in the Markov model of drinking behaviour for utility weights 
The same approach as explained above for fitting the beta distribution is used for utilities.  The 
sample moments µ (sample mean) and 2s (error variance) are taken from the utility data presented 
in Table 44 for the corresponding drinking states and are equated to the distribution moments as 
follows: 
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Rearranging the above equations allows the calculation of the unknown parameters a and b as a 
function of the known sample mean utility and standard error.  As described above for the transition 
probabilities, the BETAINV function is used to generate random draws from the distributions 
specified for each utility parameter. 
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5.7 Discussion 
Epidemiological approach
Some limitations of the epidemiological approach should be pointed out.  The definition of the ex-
categories grams per day for injury and chronic diseases risk calculation is complex.  For most 
injuries when no alcohol is consumed the risk becomes zero while chronic diseases develop many 
years after the onset of alcohol drinking.  The definition of ex-categories, for risk calculation, is 
based on the assumption that the consumption for these categories corresponds to about 1/3 of the 
previous level of drinking.  The ex-categories have a lower bound of zero grams per day and so, 
both abstinent and sensible drinkers are captured within these categories.  If the midpoint between 
0g and the upper bound of these categories had been used, no distinction between the risk for ex-
harmful and ex-hazardous drinkers would have been possible. 
Injury consumption-specific mortality risks are calculated with a regression equation based on an 
emergency rooms study, Borges et al. (2006), which focused on non-fatal injury.  Although the 
focus of the study was on non-fatal injuries, the reasons for the use of this study not presenting a 
major limitation, when the reported RRs are used for alcohol-related injury mortality, are twofold.  
On the one hand, the relevant literature indicates that injuries tend to be more severe when alcohol 
is involved, and thus the RR and AAF are larger for mortality when compared to morbidity (Rehm 
et al., 2003a; Rehm et al., 2004; Cherpitel, 1993; Rootman et al., 2007; Cherpitel, 1996; Li et al., 
1997; Fuller, 1995; Humphrey et al., 2003).  Therefore, it can be assumed that the RR for the 
number of drinks would underestimate the AAF, since Borges et al. (2006) is based on morbidity 
data, not mortality as for WHO (2002).  On the other hand, ER studies may lead to an overestimate 
of the effects.  Clearly, the attendees of ERs are not representative of the general population.  They 
may be characterized as higher risk-taking, and thus the RR for alcohol in this population may be 
higher than in the general population.  The two aforementioned effects have opposite directions and 
it could be assumed that they cancel each other out.  However, Rehm et al. (2008) pointed out that 
the impact of these potential biases on the estimates for risk injury is not clear and more research is 
needed.   
Most research to determine AAFs for injury did not explicitly separate morbidity and mortality 
(English et al., 1995; Single et al., 1996; Stinson et al., 1993).  Nevertheless, the meta-analysis 
conducted by Ridolfo and Stevenson (2001), in Australia, separated the AAFs for motor vehicle 
accidents for males.  It was based on this work and that of Cherpitel (1994, 1996), that Rhem et al. 
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(2004) derived the ratio of AAF for morbidity as two thirds for motor vehicle accidents and as four 
ninths for all other injuries.  However, these weights are only a best estimate. 
Total morbidity risk for each chronic disease and injury is based on hospital data (NHS episode 
statistics), which presents some limitations such as: 1) hospital admissions can be selective in terms 
of personal characteristics, severity of the disease, associated conditions and admission policies; 2) 
hospital records are not designed for research and they may be incomplete, illegible or missing and 
variable in quality; and 3) population at risk is generally not defined (Gordis, 2009).  Also, as the 
data from the HES is not disaggregated for the age and gender groups required in the model, it is 
assumed that the same age and gender distribution as that of mortality rates can be used.  In addition, 
the HES are reported for England and not the whole of the UK.  For this reason, for a matter of 
consistency, the population at risk for morbidity is the population for England for the same year as 
the HES data (2006).  Nevertheless, it can be expected that the morbidity rates calculated for 
England are very close to the ones for the whole UK population. 
Limitations of the model for UK-specific input parameters 
There are some limitations concerning the specific UK data used to populate the theoretical model.  
In particular, drinking behaviour after treatment uptake is taken from a longitudinal study with a 
small sample size.  The transition matrix for the following cycles’ transition probabilities is derived 
from Taylor et al (1985).  These estimates are based on strong assumptions, namely: 1) drinking 
groups as defined in the Taylor et al. (1985) study can be matched to the model categories; 2) 
transitions remain constant over time; 3) transition to the two other states, not informed by the 
Taylor et al. (1985) study are the same; 4) transitions reported in the study are observed right after 
the cycles for which clinical effectiveness data is available; 5) transitions do not differ by gender; 6) 
once treatment stops transition rates are assumed to be the same between the compared arms of the 
model.  One of the biggest assumptions related to using long-term follow-up data that does not 
follow the specific treatments evaluated is that the model assumes that exposure to other alcohol 
interventions (enforcement and prevention) is the same for the alternative groups in the long run.  
Therefore, the outcomes after treatment are the same for a group of patients in the same drinking 
category and with the same age and sex.  Further information regarding the rate of relapse after 
treatment and transitions between drinking categories over the lifetime of individuals is highly 
required for a UK alcohol treated population.  Moreover, in order to take into account the effect of 
different exposures on drinking behaviour a long-term follow-up study for the specific intervention 
groups is needed.  In addition, possible interactions between exposures would need to be taken into 
account.  Nevertheless, the use of transition probabilities taken from a peer reviewed study 
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overcomes the assumption that treatment effects remain after the end of a trial, over patients’ 
lifetime, which would be an even stronger assumption as there is no evidence for such. 
Markov states’ utilities are calculated with data from the UKATT trial.  However, using utilities 
taken from the UKATT trial for the computation of the utilities for each drinking state in the model 
might present some limitations.  For example, the trial was UK-based and utility valuations were 
that of a UK population which might hamper utilities transferability to other settings.  Nevertheless, 
it is common practice that economic evaluations conducted worldwide use UK preferences for 
QALY calculations and, more importantly, the data obtained in this chapter intends to be UK-
specific.  Health-related quality of life should be dependent on age and sex and this is shown in the 
published HRQoL norms for the UK (Kind et al., 1999).  For this reason, state utilities should be 
age and gender-dependent.  This is not the case for the valuation of the model states as the sample 
size informing the utilities would not allow gender and age differentiation.  Also, these utilities 
were generated from the EQ-5D questionnaire which may not include facets of HRQoL related to 
alcohol consumption.  Nevertheless, for comparison between health technologies, NICE 
recommends the use of utilities taken from the general population and not disease-specific 
valuations.  Therefore, the Markov state utilities are in line with the published UK guidelines (NICE, 
2008).  
The economic model only considers two major categories of costs: the costs of the specific 
treatments analysed (not covered in this chapter) and the chronic disease hospital costs.  Regarding 
the latter, disease related costs are the hospital costs related with a sustained intake over 80 years, 
i.e. the long-term disease hospital costs.  Injury costs are not included in the costs of the four health 
states.  Even with the narrow health services perspective taken, injury morbidity costs should be 
included in future developments.  However, in order to do so methods for costing alcohol-related 
injuries also need to be developed.  More broadly, the social consequences of alcohol consumption 
are not considered, which is in accordance with the health system perspective adopted.  Social 
outcomes including family problems, criminal activity, or productivity losses need to be considered 
if a societal perspective is advocated.  Given the wider social and economic benefits of alcohol 
treatments the economic analysis should aim at being more complete.  Further extensions of the 
model should consider these wider social costs associated with each drinking category.  Data 
regarding alcohol-related UK criminal activity and productivity losses needs to be collected.  This 
represents a challenge, especially in the field of criminal activity given the different definitions and 
measurement techniques associated with the different types of crime. 
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5.8 Conclusion 
This chapter presents the calculation of country-specific inputs that feed into the economic model of 
drinking behaviour developed in the previous chapter.  This data is UK- specific and can be used for 
the economic evaluation of alcohol treatments in the UK.  Despite the acknowledged limitations, 
the methods presented allow the incorporation of patterns of drinking and levels of drinking on 
morbidity and mortality risks.  This helps in achieving more accurate estimates of the cost 
effectiveness of alcohol because health and economic consequences can be estimated based on 
lifetime drinking behaviour and associated risks. 
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Chapter 6. Model application to the UKATT trial 
This chapter consists of an application of the Markov model of drinking behaviour to a UK setting.  
It brings together the results of Chapter 4, where the model is developed, and of Chapter 5, where 
UK-specific model inputs are generated, for the cost effectiveness analysis of two psychosocial 
therapies delivered in the UKATT trial (UKATT Research Team, 2001, 2005b, a).  The published 
cost effectiveness analysis did not find any significant differences in terms of costs and effects 
between the two treatments and this might be related to the short time horizon of the analysis. 
This case-study aims at applying the Markov model of drinking behaviour to the UKATT trial data 
in order to assess the incremental costs, survival and QALYs of Motivational Enhancement Therapy 
(MET) vs. Social Behaviour and Network Therapy (SBNT) in the long term.  This is achieved by 
augmenting the trial patient-level data with evidence from other sources, thereby extending the trial-
based economic evaluation with synthesis and modelling.  The model application also deals with 
heterogeneity and so it helps in assessing whether any of the therapies represents better value for 
money for a specific subgroup of patients, based on age and gender characteristics.   
This is not an attempt to validate the model as clinical trials can provide inputs for decision 
analytical models but cannot provide a valid test of their predictions (Sculpher et al., 2000).  
Sculpher et al. (2000, pp 463) argue that clinical trials and decision analytical models are not 
directly comparable because “their objectives are fundamentally different: a model combines 
information already available in an explicit and formal framework, a clinical trial generates new 
information about one or more parameters of interest”.  Therefore, the purpose of applying the 
model to the UKATT trial is to inform decision making based on long-term costs and outcomes.  
See Appendix 5- Markov model features, for a summary table of the model characteristics. 
6.1 The UKATT trial and why modelling UKATT data? 
The UKATT trial was designed to compare the effectiveness and cost effectiveness of SBNT, a new 
treatment for alcohol problems, with that of the proved MET (UKATT Research Team, 2001, 
2005b, a).  The trial aimed at testing the following two main null hypotheses: 1) less intensive 
motivationally based treatment- MET, is as effective as more intensive socially based treatment- 
SBNT; 2) more intensive socially based treatment- SBNT, is as cost effective as less intensive 
motivationally based treatment- MET, particularly in improving patients’ quality of life (UKATT 
Research Team, 2001). 
The UKATT trial was a pragmatic multicentre randomized controlled trial with open follow-up at 
three months after entry and blind follow-up at 12 months.  The design and methods are fully 
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detailed in the UKATT trial protocol (UKATT Research Team, 2001). The trial was conducted in 
five treatment centres, comprising seven UK treatment sites, including NHS, social services and 
joint NHS/ non-statutory facilities. 
In the UKATT trial, MET combined the principles of ‘motivational interviewing’ (Miller WR and 
Rollnick S, 2002) with objective feedback to the client of the results of assessments carried out prior 
to the first session of MET (Miller WR et al., 1992).  A large and growing body of research has 
confirmed the effectiveness of motivational interviewing principles (Lundahl and Burke, 2009; 
Burke et al., 2003).  Motivational interviewing has become extremely popular in the alcohol field in 
Britain and is now widely used throughout the country, either as a form of treatment in its own right 
for clients with relatively less severe problems, or as a component of treatment for those with more 
severe difficulties (UKATT Research Team, 2001).  In the UKATT trial MET was viewed as a 
usual form of treatment that any other treatment must surpass in effectiveness or cost effectiveness 
to be considered for routine application in service provision.  MET in the UKATT trial 
compromised three 50 minute sessions over eight to 12 weeks.   
SBNT was a treatment modality developed for UKATT, it had a strong theoretical and empirical 
basis using a range of cognitive and behavioural strategies to build social networks supportive of 
change involving the client and other network members (family and friends) (Copello et al., 2002).  
It has been shown that within intensive treatments better outcomes are obtained for interventions 
with a strong social component (Holder et al., 1991; Miller WR and Wilbourne PL, 2002; Project 
MATCH Research Group, 1997) and for family and friends involvement (Orford, 1994).  In the 
UKATT trial, SBNT was carried out over eight 50 minute sessions for eight to 12 weeks. 
The UKATT cost effectiveness results concluded that there was no strong evidence about the 
effectiveness and cost effectiveness of the two treatments compared.  The study showed that, in the 
short term, SBNT was more cost-saving and less effective than MET but these differences were not 
statistically significant.  The trial supported evidence that treatment for alcohol problems leads to 
net savings (Holder et al., 2000; Parthasarathy et al., 2001; UKATT Research Team, 2001).   
Why modelling UKATT data?
The UKATT trial was a multicentre pragmatic trial and such design confers both the internal 
validity (freedom from bias) associated with RCTs and the external validity (generalisability to 
practical clinical settings) typically associated with models.  A pragmatic trial mimics reality 
(Torgerson and Torgerson, 2001) and is directly applicable to decision making in clinical practice 
(UKATT Research Team, 2001).  Pragmatic clinical trials represent a major improvement in the 
availability of data for economic evaluation (Buxton et al., 1997).  A pragmatic assessment provides 
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the actual costs and benefits, including patient’s utilities, that will apply to future patients (Fayers 
and Hand, 1997).   
Nevertheless, the UKATT trial had a one-year follow-up after treatment initiation which might be 
too short to capture any differences between the two therapies.  The trial could not distinguish the 
two treatments compared in terms of both effectiveness and cost effectiveness. By using a 
modelling approach in this chapter, intermediate outcomes, such as alcohol consumption, can be 
linked with UK epidemiological data in such a way that lifetime costs and QALYs can be estimated.  
The long-term analysis might help to determine which treatment has a higher probability of being 
cost effective and whether the same decision is reached for different patient subgroups. 
6.2 Modelling the UKATT trial results 
6.2.1 Objective
The objective of this case-study is to conduct a long-term cost effectiveness and cost utility analysis 
using patient-level data collected in the UKATT trial and the cohort model of drinking behaviour 
populated with UK-specific data, as developed in the previous two chapters, to inform decision 
making in the UK NHS.  The results of the model aim to extend the results of the published cost 
effectiveness analysis of the analysed trial (UKATT Research Team, 2005a).  The probability that 
one therapy is more cost effective than the other is assessed over the long term.  Another important 
objective of this case study is to explore possible variations in the cost effectiveness results based 
on the age and gender of the cohort analysed to inform whether these characteristics change the 
decision of which therapy is more cost effective.  
6.2.2 Comparators
Just as in the UKATT trial, MET is compared to SBNT.  The UKATT trial recruited 742 patients, 
617 (83.2%) were interviewed at 12 months and 608 of these patients yielded data for economic 
analysis (98.5% of 617).  From the patients with complete economic data, 347 patients received 
MET and 261 received SBNT.  The UKATT study used the 608 patients with complete data for the 
economic analysis (UKATT Research Team, 2005a).  Costs and effects were analysed for patients 
according to the group to which they were originally randomized, also know as “intention to treat 
strategy”.  An Intention to Treat (ITT) analysis means that all patients are analysed in the group to 
which they were initially randomized, even if they “cross over” to the other intervention arm, 
discontinue the intervention, are lost to follow-up or did not start the allocated intervention (Estellat 
et al., 2009; Hollis and Campbell, 1999).  However, a full ITT would only be possible if all patients 
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had been followed up for 12 months and had provided all the data required for the analysis , which 
was not the case in the UKATT trial as there were 134 (742-608) patients that did not meet those 
requirements.   
Similarly to the UKATT study, the model uses all patients that were followed up with economic 
data (n=608) and also for whom there is data on drinking behaviour at baseline and 12 months, 
which gives a total of 495 patients (81.4% of 608).  Missing data is dealt with by using complete 
case analysis, in which patients with a missing response for grams per day at baseline or 12 months 
follow-up are excluded from the analysis.  For this reason, it is important to analyse whether there is 
any attrition bias, where randomization would be lost if the characteristics of people lost to follow-
up or with missing data differ between the randomized groups (Dumville et al., 2006).  Comparing 
the sample used for the model (n=495) to the 608 patients used in the UKATT cost effectiveness 
published study, 64 are lost from the MET group (18.4 % of 347) and 49 are lost from the SBNT 
group (18.7 % of 261).  If there are different numbers of participants leaving the trial arms, the 
likelihood that participants in one group are not balanced with similar participants in the other trial 
arm is increased.  However, the rates of lost to follow-up are similar between the two arms, which is 
a first prognostic that there is no attrition bias.   
The baseline characteristics of the patients used in the model (n=495), of the group used in the 
published cost effectiveness analysis (n=608) and of those not included in the case-study (n=113) 
are presented in Table 45. A comparison of the baseline characteristics for the 113 patients not used 
in the case-study (due to missing data), between each arm, reveals that there is no statistically 
significant difference between baseline characteristics (Table 45).  This shows that there is some 
confidence that the analysed sample reflects the groups compared in the published cost 
effectiveness analysis.  Furthermore, the baseline characteristics of those patients used in the model 
are well balanced as there are no significant differences between the SBNT and MET arms (Table 
45).  In addition, a comparison between the two arms of the trial for the 247 (742-495) patients lost 
to follow-up or with missing data also showed no statistically significant difference in terms of 
baseline variables.  Therefore, the internal validity of the UKATT design is maintained for the 
sample used in the economic model. 
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Table 45- Baseline characteristics in the UKATT trial: patients with economic data, patients with 
missing data not used in the model and patients used in the model  
All patients (n=608) Patients with missing data (n=113) 
Patients used in model 
(n=495) Baseline 
variables MET 
(n=347) 
SBNT 
(n=261) 
MET 
(n=64) 
SBNT 
(n=49) 
MET 
(n=283) 
SBNT 
(n=212) 
Mean (SD) age 
(years) 42 (10) 42 (10) 43 (10) 41 (9) 42 (10) 42 (10) 
Mean (SD) PDA 
(days) 29 (26) 27 (26) 36 (28) 27 (27) 28 (25) 27 (26) 
Mean (SD) 
g/day  139 (92) 142 (98) 137 (90) 155 (121) 140 (93) 139 (92) 
Males 74 (256) 74 (194) 77 (49) 69 (34) 73 (207) 75 (160) 
Females 26 (91) 26 (67) 23 (15) 31 (15) 27 (76) 25 (52) 
Employed 34 (119) 31 (80) 43 (27)* 22 (11)* 33 (92) 33 (69) 
Detoxification** 26 (90) 32 (83) 19 (12) 31 (15) 28 (78) 32 (68) 
*Difference not significant at 99% confidence level (p-value=0.024), all other values are not statistically 
different at 95% and, hence, at 99% confidence levels (p-values higher than 0.05); **Detoxification done 
between screening and recruitment; PDA, Percentage Days Abstinent; SD, Standard Deviation; n, number of 
patients. Note: values are percentages (numbers) unless stated otherwise. 
6.2.3 Base case
The base-case cohort is a UK male cohort with an average starting age of 40 years old.  The cohort 
of patients is modelled for an 80 year time horizon by which time all patients will have been 
predicted to die (WHO, 2008).  The distribution of the patients in the two initial Markov states, 
modelled in the base-case, is 25% hazardous and 75% harmful.  This is based on the UKATT trial 
where 26% of the male cohort is drinking hazardously at baseline and 74% is drinking harmfully 
(the respective percentages for females are 21% and 79%).  Therefore, the base-case considers a 
severe population with the majority of patients drinking harmfully at baseline.   
6.2.4 Discounting and price year
The long term simulation evaluates costs from the perspective of the NHS, expressed in pound 
sterling (GBP, £) at a 2007 price base.  Both costs and outcomes are discounted using a 3.5% 
annual discount rate, in line with current NICE guidelines (NICE, 2008). 
6.3 Model Inputs 
The model inputs that are UK-specific and independent of the treatments under analysis are the 
transition between states after treatment uptake, mortality rates, morbidity rates, state utilities and 
disease costs, as presented in Chapter 5.  Only the model inputs that are specific to the treatments 
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under evaluation, which are the effects of treatment in drinking behaviour and the treatment costs, 
are presented here. 
6.3.1 Transition probabilities for the first cycle
The first cycle transition probabilities, for the cohort delivered MET and SBNT, are derived from 
the UKATT trial (UKATT Research Team, 2005b) and represent the effectiveness of the treatments 
compared.  These transition probabilities are calculated by counting the individuals that moved 
between the drinking categories from baseline to follow-up.  The drinking categories are defined in 
terms of grams per day.  However, the trial did not present individual-level outcomes in terms of 
grams per day.  The calculation of grams of alcohol consumed per day is explained in Chapter 5 
(see section 5.5).  The number of patients in each drinking category, by gender, at baseline and 12 
months is calculated for each treatment.   
The number of patients, by gender, in each state for each treatment is presented in the following 
four tables.  The corresponding transition matrices are presented in the bottom part of each one of 
these tables.  In order to obtain point estimates of the transition probabilities for the model, each 
transition probability in the matrix corresponds to the observed cell count divided by the row total.  
A value of 1 (vague prior) is added to each observed count from the data.  This overcomes the 
possibility of observing zero counts and is explained further in the probabilistic sensitivity analysis 
section presented below. 
Table 46- Counts of transition between model states and transition matrix for SBNT (males) 
SBNT- Counts of transitions between the five states for the 12 months period for males* 
MALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 12 13 17 NA 0 42 
Harmful 29 52 NA 43 0 124 Baseline 
N 41 65 17 43 0 166 
Transition matrix 
MALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.285714 0.309524 0.404762 0 TD 1 Baseline Harmful 0.233871 0.419355 0 0.346774 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
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Table 47- Counts of transition between model states and transition matrix for SBNT (females) 
SBNT- Counts of transitions between the five states for the 12 months period for females* 
FEMALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 4 5 7 NA 0 16 
Harmful 6 17 NA 19 0 42 Baseline 
N 10 22 7 19 0 58 
Transition matrix 
FEMALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.25 0.3125 0.4375 NA TD 1 Baseline Harmful 0.142857 0.404762 NA 0.452381 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
Table 48- Counts of transition between model states and transition matrix for MET (males) 
MET- Counts of transitions between the five states for the 12 months period for males* 
MALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 13 20 25 NA 0 58 
Harmful 38 52 NA 65 0 155 Baseline 
N 51 72 25 65 0 213 
Transition matrix 
MALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.224138 0.344828 0.431034 NA TD 1 Baseline Harmful 0.245161 0.335484 NA 0.419355 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
Table 49- Counts of transition between model states and transition matrix for MET (females) 
MET- Counts of transitions between the five states for the 12 months period for females* 
FEMALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 3 6 5 NA 0 14 
Harmful 11 39 NA 18 0 68 Baseline 
N 14 45 5 18 0 82 
Transition matrix 
FEMALES  12 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.214286 0.428571 0.357143 NA TD 1 Baseline Harmful 0.161765 0.573529 NA 0.264706 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
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6.3.2 UKATT costs
The UKATT cost effectiveness study used a mean net public sector savings for MET and SBNT of 
£593 (SD 4,114) and £798 (SD 3,817), respectively (net reduction in public sector resource costs 
minus costs of trial treatments) (UKATT Research Team, 2005a).  The costs of SBNT and MET are 
taken from the UKATT study and are up-rated from the original data (2000/01 prices) to 2006/7 
prices, using the HCHS pay and prices index from the PSSRU Unit Costs of Health and Social Care 
2007 (Curtis, 2007).  The UKATT costs are only applied to the first cycle of the model, given that 
follow-up after trial entry did not surpass 12 months.  The model uses a mean net public sector 
savings for MET of £760 and for SBNT of £1,023 (2006/07 prices).  Full details of the treatments 
and public sector resource use measurement and unit costs used for valuation are presented in the 
UKATT cost effectiveness paper (UKATT Research Team, 2005a).  The UKATT study is included 
in methodological review conducted in Chapter 3.  A summary of the methods used in the trial for 
the identification, measurement and valuation of treatment costs and economic consequences is 
presented in Appendix 4- Methods for identification, measurement and valuation of individual 
consequences, societal consequences and treatment under evaluation costs. 
6.4 Sensitivity analysis and heterogeneity 
6.4.1 Probabilistic Sensitivity Analysis
Probabilistic sensitivity analysis is conducted in the model by assigning distributions to the input 
parameters of the model that the results are uncertain about.  As explained in the previous chapter, 
uncertainty in the following cycle’s transition probabilities and on the utility weights attached to 
each drinking state is represented by a beta distribution.  The distribution explained in this section is 
the one used for the first cycle transition probabilities, which is an input parameter specific to the 
intervention under evaluation (i.e. the first cycle transition probability values are informed by the 
UKATT trial in this case-study). 
The data used to estimate the first cycle transition probabilities are multinomial as the total sample 
is split not between 2 categories, as in the binomial case, but between 5 categories (the four 
drinking states and the death state).  Multinomial data favours an unconditional probability structure 
to the model with multiple branches from each chance node representing the probability of moving 
to other states of the model.  For this case, the Dirichlet distribution, a continuous multivariate 
probability distribution, is used (Briggs et al., 2003).   
The Dirichlet is the multivariate generalization of the beta distribution (explained in the previous 
chapter), with parameters equal to the number of categories in the multinomial distribution.  In 
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Bayesian inference, the Dirichlet distribution is conjugate to the multinomial distribution, which 
means that specifying a Dirichlet prior distribution (i.e. a probability distribution representing a 
belief about an unknown quantity) on multinomial data results in a Dirichlet posterior distribution 
(i.e. a conditional distribution of the uncertain quantity given the data) (Briggs et al., 2003).  The 
posterior distribution parameters are simply the prior distribution parameters plus the respective 
observed cell counts. 
While assigning the Dirichlet distribution to these transition probabilities a problem can be raised 
because there might be cases of zero counts in one of the transition cells and then a zero transition 
would be assigned to such a cell.  When using counts to estimate a transition matrix for the Markov 
Model, it is important that 1) no potential transitions are excluded simply because they were not 
observed in the study that informs the data, and 2) uncertainty in the possible values of the 
estimated transitions is adequately reflected (Briggs et al., 2003).  A Bayesian approach overcomes 
the possibility of observing zero counts as the intuition that a probability is nonzero can be formally 
expressed through the prior distribution (Briggs et al., 2003).  The approach used in the model is 
that of employing a “vague” or minimally informative prior distribution.  The prior distribution 
specified is an uniform distribution expressing the believe that each outcome is equally likely which 
is given by a Dirichlet (1,1,1,1), where the transitions for not allowed states are kept as zero (for 
example, the transition from harmful to ex-hazardous is null).  This effectively assigns a 0.25 
probability to all transitions, but with a high level of uncertainty (Briggs et al., 2003).  The posterior 
distribution for each transition matrix is obtained by summing 1 (vague prior) to each observed 
count from the data.  Thereby, the expected values of the transition probabilities for any row are the 
posterior Dirichlet means divided by their row totals (this is illustrated in section 6.3.1 above where 
the transition probabilities for the first cycle of the model are presented).   
After generating uncertainty in the transition probabilities, this uncertainty needs to be propagated 
through the decision model.  A detailed description of fitting the Dirichlet distribution in the 
economic model is given in Appendix 6- Transition probabilities from multinomial data: fitting a 
Dirichlet distribution.  Monte Carlo simulation is then conducted to select values of the parameters 
at random from the selected distribution, where RAND() is the command for drawing a random 
value from a distribution in Excel.  The simulation is introduced in the Markov model as part of a 
program know as “macro” in Excel using the record function, the looping command and relative 
cell referencing as explained in Briggs et al. (2006).  The model is run for 1000 simulations.   
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6.4.2 Univariate sensitivity analysis
Sensitivity analyses are undertaken to assess the robustness of the base-case results to variations in 
alternative assumptions related to key parameters in the model.  One-way sensitivity analysis is 
conducted for the initial distribution of patients, where the effect of the same proportion of patients 
starting in hazardous (A) and harmful (B) states is analysed (50% A-50% B).  The effect of a less 
severe drinking population at baseline is also analysed (75% A-25% B).  According to NICE 
guidelines for sensitivity analysis on the discount rate, the impact of an alternative discount rate of 
6% for costs and 1.5% for outcomes is investigated (NICE, 2008). 
6.4.3 Heterogeneity
The analysis is run for cohorts of males and females of 20, 40 and 60 years old in order to deal with 
heterogeneity.  This subgroup analysis is also conducted for the three different distributions in the 
first cycle.  Multiple CEACs are produced, where the probability of MET being cost effective is 
plotted against the willingness to pay threshold for each age and gender group. 
Table 50 below depicts the base-case used in the model and the variations in the base-case for 
which results are presented in the results section below.  Four alternative scenarios are considered 
and for each element the position in the base-case analysis is outlined alongside the alternative 
assumption applied.  
Table 50- Key elements of the base-case analysis and alternative scenarios, case-study 1 
Scenario Element Position in base-case analysis Alternative scenario 
1 Discount rate 3.5% applied to both costs and outcomes (NICE, 2008) 
6% costs, 1.5% outcomes  
(NICE, 2008) 
2 Cohort distribution 
25% hazardous, 75% harmful 
(UKATT Research Team, 
2005a) 
50% hazardous, 50% harmful 
75% hazardous, 25% harmful 
3 Population 
All males, average age=40 
years (UKATT Research 
Team, 2005a) 
Separate analysis for males and 
females 
Alternative starting ages 
assumed: 20, 40 and 60 years 
4
Cohort distribution+ 
population (scenarios 
2+3) 
All males, average age=40; 
25% hazardous, 75% harmful 
Males or females, 20, 40 or 60 
years old AND 50% harzadous, 
50% harmful or 75% 
hazardous, 25% harmful 
6.5 Case-study results 
Firstly, the cost effectiveness results are presented for the deterministic and probabilistic base-case 
analyses.  Secondly, the results of one-way sensitivity and subgroup analyses are considered.  
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Thirdly, a conclusion regarding decision making and policy implications for the results of the study 
is given.  The last section discusses the limitations of the study and topics for future research. 
6.5.1 Deterministic cost effectiveness results
For the base case analysis (male cohort of 40 years old with 75% of the patients drinking harmfully 
at baseline), on average MET is more costly (less cost saving) and more effective than SBNT.  
Therefore, the additional costs and benefits that MET incurs over SBNT can be compared in the 
form of a ratio (i.e. the ICER) in order to estimate the additional cost required to achieve one 
additional unit of outcome.  The deterministic ICER is £37,439/ QALY, which falls above the upper 
bound of the £20,000 to £30,000 per additional QALY benchmark used in England and Wales 
(NICE, 2008), suggesting MET is not a cost effective treatment compared to SBNT in this patient 
population.  A breakdown of the costs and QALYs associated with MET and SBNT is presented in 
Table 51.   
Table 51- Base-case analysis, deterministic results for the cost effectiveness of MET compared to 
SBNT 
Males, 40 years old MET SBNT MET vs. SBNT 
Deterministic results  
Costs (£, 2006/07 prices) £499 £241 £259 
QALYs  12.989 12.982 0.007 
Life Years 19.853 19.847 0.006 
ICER (Lcost/ LQALY)  £37,439 
ICER (Lcost/ LLYG)  £43,459 
ICER, Incremental Cost Effectiveness Ratio; QALY, Quality Adjusted Life Years; LYG, Life Years Gained; 
MET, Motivational Enhancement Therapy; SBNT, Social Behaviour Network Therapy; 3.5% discount rate 
for costs and outcomes. Estimates rounded for presentation. 
In an attempt to illustrate the importance of a long-term model in the cost effectiveness analysis of 
alcohol treatments the ICER for each model cycle is obtained.  The reduction in the ICER as the 
short-term analysis progresses to a long-term one is depicted in Figure 3.  The innovative figure 
represents the ICER, computed as the cumulative difference in costs and QALYs for each cycle 
year.  It is shown that the ICER is never below £30,000/ QALY for the base-case, reassuring the 
idea that MET is not cost effective in the base-case, even when the long term benefits and costs are 
taken into account. 
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Figure 3- Incremental cost effectiveness ratio of MET vs. SBNT per cycle year 
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6.5.2 Probabilistic cost effectiveness results
The outputs of the probabilistic sensitivity analysis, using Monte Carlo simulation, provide the 
distribution over the incremental cost, incremental effect and the joint cost-effect distribution.  The 
mean cost effectiveness ratio of MET vs. SBNT estimated from 1000 random draws is £34,080 per 
QALY.   
Briggs et al. (2006; pp 78) state that the “difference between the expectation over the output of a 
probabilistic model and that model evaluated at the mean values of the input parameters is likely to 
be modest” and this is the case for the probabilistic results, which are very close to the deterministic 
ones.  Therefore, when accounting for the effect of uncertainty of model inputs in the outputs, the 
ICER keeps falling within £30,000 to £40,000 per additional QALY, for the base-case. 
The simulation results of the overall uncertainty in the model are presented in a cost effectiveness 
plane (Briggs and Tambour, 2001) and in a cost effectiveness acceptability curve (Briggs et al., 
2006).  Figure 4 below shows the results of 1000 Monte Carlo simulations in a cost effectiveness 
plane.  The cost effectiveness plane shows the difference (MET minus SBNT) in effectiveness per 
patient against the difference in cost per patient.  The plane shows that the simulations fall on the 
northeast area, where MET is more costly and effective than SBNT, and on the northwest area, 
where MET is more costly and less effective than SBNT. 
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Figure 4- Incremental cost effectiveness plane of MET vs. SBNT 
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The overall high level of uncertainty associated with economic models means that some of the 
simulation results cross the vertical axis and/ or the horizontal axis.  For this case-study, many 
simulations cross the vertical axis and given the high density on both northern quadrants the relative 
effectiveness of MET appears to be very uncertain.  The standard ICER figure does not differentiate 
situations where ratios have the same sign but not the same interpretation.  If there were situations 
where MET is less effective and more costly and situations where it is more effective and less 
costly both would produce negative ICERs where the interpretation from the point of view of the 
intervention under evaluation is not possible.  The former situation would lead to the rejection of 
MET while the latter would lead to the opposite.  The same happens with positive ICERs, where 
positive ratios can have the opposite interpretation.  This is overcome by presenting a CEAC as a 
result of the simulation to represent uncertainty instead of using the frequentist confidence intervals 
(Briggs et al., 2006).   
The CEAC derived from the model is presented in Figure 5 where the resulting probability that one 
therapy is better than the other is plotted against the maximum that decision makers might pay for 
an additional QALY.  The CEAC shows that the probability that MET is cost effective cuts the 
horizontal axis for threshold values below £3,000 per QALY, where SBNT is more cost effective 
than MET (when thresholds are small, SBNT seems preferable to MET).  Therefore, when the 
decision maker is only interested in the cheaper option, SBNT has a probability of 100 percent to be 
cost-saving.  As the threshold increases and therefore, health gains are more highly valued, the 
probability that MET is cost effective increases, being 0.5 at the value of the ICER where both 
treatments have the same probability of being cost effective.  If decision makers were willing to pay 
more than around £34,080 per QALY gained, then MET would be adopted for it has a higher 
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probability of being cost effective after the value of the ICER.  However, the probability that MET 
is the most cost effective therapy is only 0.3 and 0.4 for threshold values of £20,000 and £30,000, 
respectively.   
Figure 5- Cost effectiveness acceptability curve for MET vs. SBNT 
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6.5.3 Univariate sensitivity analysis
Modelling a cohort equally distributed between the hazardous and harmful categories makes MET 
treatment less cost effective, with an ICER of £82,113/ QALY which is well above the upper bound 
£30,000/ QALY.  This can be explained by the fact that with a lower proportion of male patients in 
the harmful drinking state there is a higher potential to benefit from SBNT and, therefore, the 
incremental QALYs of MET vs. SBNT are less pronounced.  Accordingly, when modelling a 40 
years-old male population with only 25% of harmful drinkers at baseline MET is even less cost 
effective (Table 52).  For these two situations, the level of uncertainty is close to the base-case and 
the probability that MET is more cost effective is around 0.3 and 0.4 for thresholds WTP between 
£20,000 and £30,000 per QALY, respectively. 
The base-case results are robust when the model is tested via sensitivity analysis on the discount 
rate, where the alternative discount rates slightly improve the cost effectiveness (ICER= £30,446/ 
QALY) (Table 52).  For a discount rate of 6% on costs and 1.5% on health outcomes, the 
probability that MET is the most cost effective therapy is slightly higher than for the base-case: 0.4 
and 0.5 for threshold values of £20,000 and £30,000, respectively. 
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Table 52- Probabilistic results for one-way sensitivity analysis (MET vs. SBNT) 
MET vs. SBNT Incremental costs Incremental QALYs ICER 
Initial cohort distribution  
75% hazardous; 25% harmful £263 0.0002 £1,452,277 
50% hazardous; 50% harmful £261 0.0032 £82,114 
25% hazardous; 75% harmful* £258 0.0076 £34,080 
Discount rate  
3.5% cost and outcomes* £258 0.0076 £34,080 
6% costs; 1.5% outcomes £259 0.0085 £30,446 
*Base-case conditions; ICER, Incremental Cost Effectiveness Ratio; QALY, Quality Adjusted Life Years; 
Costs in GBP (£); price year 2006/07; MET, Motivational Enhancement Therapy; SBNT, Social Behaviour 
Network Therapy. Estimates rounded for presentation. 
6.5.4 Modelling heterogeneity
The analysis of the effect of heterogeneity in the results shows that SBNT dominates MET for the 
three simulated age cohorts of females and for all the simulated initial distributions in hazardous 
and harmful drinking (see Table 53).  Therefore, for a female cohort SBNT is always more cost 
saving and more effective than MET.  An ICER is not computed for dominant cases as the decision 
on which treatment is more cost effective is straightforward.  There is a clear improvement in 
female drinking behaviour with SBNT when compared to MET, as can also be seen in the 
transitions probabilities presented in Table 47 and Table 49.  In fact, a considerable percentage of 
females delivered MET therapies got worse (43% drinking hazardously at baseline were drinking 
harmfully at follow up) or did not get better (57% drinking harmfully at baseline kept drinking 
harmfully at follow-up). 
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Table 53- Probabilistic results for the subgroup analysis with variations in the cohort distribution at 
baseline (MET vs. SBNT) 
 Incremental Cost Incremental QALY ICER 
Probabilistic results for subgroup analysis (75% Harmful-25% Hazardous) 
Males, 20 years old £262 0.0058 £45,093 
Males, 40 years old* £258 0.0076 £34,080 
Males, 60 years old £256 0.0062 £41,055 
Females, 20 years old £263 -0.0131 NA 
Females, 40 years old £267 -0.0157 NA 
Females, 60 years old £261 -0.0156 NA 
Probabilistic results for subgroup analysis (50% Harmful-50% Hazardous) 
Males, 20 years old £262 0.0026 £101,243 
Males, 40 years old £261 0.0032 £82,114 
Males, 60 years old £257 0.0031 £82,413 
Females, 20 years old £263 -0.0190 NA 
Females, 40 years old £267 -0.0246 NA 
Females, 60 years old £261 -0.0212 NA 
Probabilistic results for subgroup analysis (25% Harmful-75% Hazardous) 
Males, 20 years old £263 -0.0008 NA 
Males, 40 years old £263 0.0002 £1,452,277 
Males, 60 years old £258 -0.0001 NA 
Females, 20 years old £263 -0.0241 NA 
Females, 40 years old £267 -0.0276 NA 
Females, 60 years old £261 -0.0253 NA 
*Base-case conditions; ICER, Incremental Cost Effectiveness Ratio; QALY, Quality Adjusted Life Years; 
NA, Not Applicable; Costs in GBP (£); price year 2006/07; discount rate, r= 3.5%; MET, Motivational 
Enhancement Therapy; SBNT, Social Behaviour Network Therapy. Estimates rounded for presentation. 
The subgroup analysis shows that, for males, the lowest ICER is observed for 40-years-old for all 
initial cohort distributions.  For the base-case distribution (75% harmful, 25% hazardous) and for an 
equal distribution (50% harmful, 50% hazardous) the ICER of a 20-year old cohort is higher than of 
a 60-year old cohort.  The age variation in the ICER can be explained by two factors: 1) impact on 
the numerator of the ICER and therefore on the incremental costs and, 2) impact on the denominator 
of the ICER and therefore on the incremental effects.  Mortality rates, morbidity rates and drinking 
behaviour affect the two aforementioned factors.  The smallest ICER of a 40-year old male cohort 
can be explained by the higher potential for gaining QALYs without other competing factors such 
as the high chronic disease mortality rates of an older cohort or the high injury rates, coupled with 
more years for discounting health benefits, of a younger cohort.   
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Each subgroup of patients is represented by a different CEAC in Figure 6 below and for an initial 
distribution of 75% harmful and 25% hazardous.  This allows the assessment of the extent to which 
the results vary across different subgroups and whether different treatment decisions should be 
made for different categories of patients, according to the decision maker’s threshold for treatment 
adoption. 
Figure 6- Multiple CEAC for different age and sex cohorts for MET vs. SBNT 
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The CEACs for each group of patients encourage the decision maker to make different treatment 
decisions across the different categories of patients, based on the expected cost effectiveness for the 
set of patient characteristics and associated uncertainty.  It is clearly shown that MET is dominated 
by SBNT for females and the decision maker can be very confident about these results as the 
CEACs show that SBNT is the most cost effective option in about 70% of the situations at 
conventional WTP thresholds.  For males, MET can be more effective than SBNT but at very high 
costs and this is associated with a high level of uncertainty.  Also, the probability that MET is more 
cost effective than SBNT for males is never above 60%, no matter how much the decision maker 
would be willing to pay. 
6.5.5 Summary of the cost effectiveness results
Table 54 details the results of each of the alternative scenarios considered for the cost effectiveness 
analysis of MET vs. SBNT.  The table reports the ICER and the probability that MET is cost 
effective at thresholds of £20,000 and £30,000 per additional QALY.  The base-case ICER of 
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£34,080/ QALY provides the benchmark for assessing whether the cost effectiveness results appear 
robust to particular assumptions made in the base-case analysis.  
The base-case scenario suggests that MET is slightly more effective and costs much more than 
SBNT.  The results show that the ICER of MET vs. SBNT, £34,080/ QALY, is over the range of 
conventional thresholds used to identify whether a particular treatment is considered to be cost 
effective in the NHS, and this is associated with high levels of uncertainty.   
When simulating a 40-year-old male population with a higher percentage of hazardous drinkers than 
in the base-case the ICER increases considerably.  Applying an alternative discount rate of 6% for 
costs and 1.5% for health outcomes (compared to 3.5% for both in the base-case analysis) improves 
the cost effectiveness by a minor amount.   
Heterogeneity in patient characteristics (age and gender) is explored using a series of separate 
scenarios.  These scenarios are explored by varying the mortality and morbidity rates according to 
the particular age and sex characteristics considered.  The results are presented for different 
assumptions regarding the initial distribution of patients in harmful and hazardous drinking states.  
The cost effectiveness estimates in these scenarios are affected by the number of patients who can 
potentially stand to gain from HRQoL improvements associated with MET and SBNT over time.  
The results demonstrate that SBNT dominates MET for females.  SBNT is the most cost effective 
strategy for females and this is associated with very low levels of uncertainty.  The cost 
effectiveness results for a male cohort suggest that MET is associated with very high costs which 
might not justify the situations where MET is more effective than SBNT and this is associated with 
a high levels of uncertainty. 
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Table 54- Summary of cost effectiveness results (MET vs. SBNT) 
 ICER Probability cost effective for max WTP 
£20,000 £30,000 
Initial cohort distribution  
75% hazardous; 25% 
harmful £1,452,277 0.305 0.370 
50% hazardous; 50% 
harmful £82,114 0.314 0.383 
25% hazardous; 75% 
harmful* £34,080 0.348 0.443 
Discount rate  
3.5% cost and outcomes* £34,080 0.348 0.443 
6% costs; 1.5% outcomes £30,446 0.405 0.504 
Subgroup analysis (75% Harmful-25% Hazardous)  
Males, 20 years old £45,093 0.294 0.394 
Males, 40 years old* £34,080 0.348 0.443 
Males, 60 years old £41,055 0.319 0.434 
Females, 20 years old NA 0.225 0.267 
Females, 40 years old NA 0.185 0.226 
Females, 60 years old NA 0.199 0.236 
Subgroup analysis (50% Harmful-50% Hazardous)  
Males, 20 years old £101,243 0.305 0.382 
Males, 40 years old £82,114 0.314 0.383 
Males, 60 years old £82,413 0.264 0.345 
Females, 20 years old NA 0.210 0.246 
Females, 40 years old NA 0.182 0.217 
Females, 60 years old NA 0.188 0.226 
Subgroup analysis (25% Harmful-75% Hazardous)  
Males, 20 years old NA 0.264 0.326 
Males, 40 years old £1,452,277 0.305 0.370 
Males, 60 years old NA 0.288 0.336 
Females, 20 years old NA 0.231 0.262 
Females, 40 years old NA 0.227 0.257 
Females, 60 years old NA 0.222 0.254 
*Base-case conditions; ICER, Incremental Cost Effectiveness Ratio; WTP, Willingness to Pay; Costs in GBP 
(£); price year 2006/07; NA, Not Applicable. Estimates rounded for presentation. 
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6.6 Decision making 
The case-study shows that, even when comparing low intensive treatments with very similar 
effectiveness and costs, the model provides information highly valuable for decision making.  The 
long-term analysis shows that there is considerable uncertainty about the most cost effective 
treatment for a male cohort and that different decisions should be adopted according to the gender 
of the patients and the decision maker threshold for treatment adoption.   
The ICER for a male cohort of 40 years old is around £34,000/QALY, which is over the upper limit 
of the current benchmark of £20,000 to £30,000 adopted in England and Wales.  Looking at the 
base-case point estimate of the probabilistic results suggests that MET may be a more effective 
approach for the treatment of alcohol problems, but at a very high cost which might not represent 
good value for money according to the benchmark.  Furthermore, the cost effectiveness of MET is 
associated with a very high level of uncertainty and even if the decision maker is willing to pay 
much more than £34,000 for additional QALY, the probability of MET being more cost effective is 
never higher than 60%.  At a threshold of £30,000 per QALY, the probability that MET is more 
cost effective than SBNT is only 0.4 and hence there is a 60% chance that adopting MET is the 
wrong decision.   
Current evidence suggests that the decision on whether MET is more cost effective than SBNT for a 
male cohort is very uncertain and further research should be done before supporting any decision.  
Decision makers might be more confident on adopting SBNT for a less severe male cohort, given 
that the QALYs gained are more or less the same as MET and SBNT is more cost saving.  The most 
interesting outcome of this analysis is that SBNT clearly represents better value for money than 
MET when delivered to females.  
6.7 Policy implications 
When allocating health care resources from a limited budget, as in the NHS, the decision maker 
aims to maximize health outcomes given available resources.  Therefore, the policy maker needs to 
decide whether she or he is willing to invest additional health care resources funding MET and pay 
an average of £34,000 in order to acquire an additional unit of health outcome in a 40-year old male 
population drinking mainly harmfully.  This is based on current evidence and modelling techniques, 
however the estimates are associated with high uncertainty and more research needs to be done in 
order to support this decision.   
When a higher percentage of males are drinking less heavily at baseline it appears that SBNT 
delivers more QALYs.  Perhaps a less severe male population is more receptive to socially based 
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interventions than a more severe one.  Surely, this difference amongst males needs further 
assessment.   
SBNT dominates MET for all female age-groups.  The reasons for such difference should be further 
analysed.  It might be that the more intense social component of SBNT is the reason for the more 
effective and cost effective results for females.  The findings suggest that there may not be a 
“single” optimal treatment for all patients with alcohol problems and it is important to take into 
account patient’s gender when reporting the results in economic evaluations of alcohol treatments. 
6.8 Discussion 
The case-study presents the long-term cost effectiveness results of a brief intervention versus a new 
more socially based approach for the treatment of alcohol problems.  The long-term analysis applies 
the economic model developed in previous chapters to the results of a UK multicentre trial-based 
cost effectiveness analysis, the UKATT trial.  Patient-level data from the UKATT trial is used and 
combined with epidemiological risks for a UK population and with the NHS costs of alcohol-related 
diseases. 
The limitations of the study regarding the UK-specific model inputs and general model features are 
detailed in the two previous chapters.  Regarding this specific case-study, it should be recognized 
that the treatments compared are very similar in terms of costs and effects making the application 
less favourable to the potentialities of the model.   
In this case-study MET is compared to SBNT and this is in line with the published cost 
effectiveness analysis on which the case-study is based (UKATT Research Team, 2005a).  The 
costs used are the net costs which take into account the treatment costs (SBNT is significantly more 
expensive than MET) and the public sector resource savings (SBNT is not significantly more cost 
saving than MET).  The UKATT effectiveness study (UKATT Research Team, 2005b) showed that 
SBNT was less effective than MET, but this difference was not significant.  Therefore, if cost-
savings were not being used MET would probably have dominated SBNT (MET would be cheaper 
and equally effective when compared to SBNT) and no deterministic point estimate of the ICER 
would be computed.  However, SBNT appears to be more effective for a female cohort, but the 
UKATT trial did not report results for males and females separately.  In this last case, MET would 
not dominate SBNT and an incremental analysis would make sense even without using cost-savings 
(SBNT would be more effective and more costly).  The choice of using cost-savings is based on the 
UKATT Research Team (2005a) published paper.  If only the costs of treatment were used in the 
model, it can be expected that, in most simulations, MET would dominate SBNT for a male cohort 
and SBNT would be both more costly and more effective for a female cohort.  
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A full application of the intention to treat approach is only possible when complete outcome data 
are available for all randomized patients.  However, there is no follow-up data for some participants 
and missing data is dealt with by using complete case-analysis, as in the published cost 
effectiveness study of the UKATT trial.  Different approaches can be used to deal with missing data 
and there appears to be no consensus on the best approach to use.  However, this is out of the scope 
of this thesis as the main objective here is to apply the novel economic model to patient level data 
taken from the UKATT trial.  In addition, a review has shown that most studies deal with missing 
data through complete case-analyses albeit classifying their analysis as intention to treat (Hollis and 
Campbell, 1999).  Furthermore, the baseline comparisons for the patients not included in the case-
study do not show any significant differences between the two arms, suggesting that attrition bias is 
not a problem. 
The application of the model to the UKATT data enables determination of costs and effects, by 
gender and age, over the long term and makes important contributions to the published study in 
terms of subgroup analyses and certainty of the results.  However, the long term simulation model 
used in the case-study analysis employs a NHS perspective.  A wider societal impact of alcohol is 
not modelled.  The application of a wider societal perspective might have an important impact on 
the results and should be part of future extension of the model and the case-study in particular. 
Patient preferences were not assessed in the UKATT trial.  In a randomized controlled trial, patients 
may have a preference for one of the therapies or be indifferent to both treatments.  If patients with 
preferences consent to be randomised then some patients will get their preferred treatment and 
others will not (Preference Collaborative Review Group, 2008).  Patients who do not receive their 
preferred treatment may experience “resentful demoralisation” (Torgerson et al., 1996).  They may 
be less motivated and not report accurately during follow-up or even drop out of the trial (King et 
al., 2005).  It is possible that patients had a preference for one of the treatments and it might be that, 
had the trial been a randomized patient preferences trial, where preferences are assessed before 
randomization, the effectiveness and cost effectiveness of the therapies would have been different 
for different preferences (Manca et al., 2006; Preference Collaborative Review Group, 2008).  Had 
the information on patient preferences been available from the UKATT trial, the long-term impact 
of preferences on the relative effectiveness and cost effectiveness for different subgroups could be 
assessed with the economic model, which would be an interesting exercise. 
The UKATT trial was a RCT with blinded assessment at 12-months follow up and due to its good 
internal validity produces trustworthy results to be inputted into the model (Estellat et al., 2009; 
Hollis and Campbell, 1999).  The external validity of the results is related to their generalisability to 
practical clinical situations (UKATT Research Team, 2001).  Pragmatic trials are the best design for 
175 
an economic evaluation as this design more closely resembles routine clinical practice which is 
what needs to be costed and evaluated (Torgerson and Torgerson, 2008).  The pragmatic approach 
of UKATT together with modelling of the UKATT results should ensure external validity.  
However, the application of these particular results will depend on the setting and patients to which 
treatments are delivered.  Specific considerations should be made before applying the results 
generated in this case-study to other patients.  The trial used in the case-study was conducted in the 
UK in seven treatment sites, including NHS, social services and joint NHS/ non-statutory facilities.  
Patients were selected in a way to avoid excluding those who would normally be offered treatment 
at UK alcohol specialist treatment centres.  The UKATT patients were drinking high levels of 
alcohol and presented more alcohol-related problems and dependence levels than average 
problematic drinkers (Drummond, 1990; UKATT Research Team, 2005b).  These characteristics of 
the UKATT population are modelled through lifetime and for this lifetime propagation, the 
epidemiological risks of a UK-based population are used.  The characteristics of the population 
modelled should, therefore, be adapted for another setting.  The model provides the potential to 
conduct subgroup analysis.  However, the results of the interventions are still the ones observed in 
the specific population modelled, even when a specific age and gender is specified.  The model 
compares SBNT, a new more socially based psychosocial approach, with MET.  In the UKATT 
study MET was considered to reflect standard practice in the UK which might or might not be the 
situation in another country.  The clinical effects for both treatments are taken from the UKATT 
trial where therapists were highly trained and experienced, and this might not be possible to 
reproduce in different settings.  The perspective on costs is that of the NHS and thus represents 
therapists working in the UK public sector, which needs to be adapted if the analysis is conducted in 
another country.  In conclusion, if SBNT and MET are to be compared in another setting and/or for 
a different population, model inputs such as transition probabilities, epidemiological risks and costs 
data might need to be adapted accordingly.  
This chapter shows that modelling a cost effectiveness analysis of alcohol treatments conducted 
alongside a clinical trial offers the potential to explore the results over the long term while 
incorporating evidence on drinking behaviour and associated health risks and costs.  The model 
application provides a means to increase the relevance for the decision context based on subgroup 
analyses and to quantify decision uncertainty. 
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Chapter 7. Model application for a new treatment compared to 
standard care in the UK 
The aim of this chapter is to model the cost effectiveness of a new pharmacological treatment for 
alcohol problems in a UK setting.  The second application of the model uses patient-level data from 
two randomized controlled trials conducted in different countries and with different populations. 
The new alcohol treatment “Treatment A” (the names of the treatment and trial are confidential 
information) is compared to “usual” care in a UK setting.  The evidence for the new treatment is 
taken from a US-based trial, whereas current practice is informed by a UK-based trial.   
This case-study provides an example of how the model can be used to aid decision making when 
there is limited evidence for new treatments.  There is just one clinical trial for the new alcohol 
treatment assessed and this was an efficacy trial with a short time horizon conducted in a different 
setting.  Cost effectiveness varies by country and context and the second model application suggests 
a useful example of how to deal with this while using the limited information available for a new 
treatment. 
There are numerous challenges that do not have to be dealt with in the first case study.  Several 
analyses are carried out before conducting the economic evaluation.  The trials compared were 
conducted in different countries, with different populations and different follow-up periods.  
Therefore, the comparators for the economic evaluation have to be defined as to find the best match 
in terms of patient characteristics.  In addition, the effects of the treatments should be compared at 
similar follow-up points.   
The perspective of the analysis is that from the health system, in this case the NHS, which is in line 
with NICE recommendations for the UK (NICE, 2008).  The cost effectiveness of Treatment A in 
the NHS is determined by a number of potential factors.  These factors relate to the clinical 
evidence base that is available and the generalisability of this evidence to the NHS.  For the new 
treatment to be cost effective it is important to demonstrate that the additional costs result in 
potential long-term gains in HRQoL, in the UK.  This represents the common situation where a cost 
effectiveness analysis helps decision making regarding a new more costly and potentially more 
effective treatment.  The results of the model can inform the decision about adoption, rejection or 
requirement of more information for the new alcohol treatment.   
Before going into the case-study cost effectiveness modelling, a description of the two treatments 
compared is presented followed by the procedure for matching the populations. 
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7.1 The compared trials 
Treatment A trial 
The new treatment trial was conducted in the US and consisted of a 6-month, double-blind, 
randomized, placebo controlled, efficacy, multicentre trial of Treatment A.  Exclusion criteria and 
randomization procedures were well detailed.  The trial randomized 627 treatment-seeking alcohol-
dependent adults actively drinking to one of three treatment groups: a group receiving Treatment A 
(208 patients); a group receiving a different dose of Treatment A (210 patients) and a group 
receiving placebo (209 patients), each group also received a psychosocial intervention.  The trial 
showed significant results in the reduction of alcohol consumption for Treatment A and that these 
results were greater amongst men.  Whilst more information about the US trial cannot be detailed 
here, it can be assumed that the new treatment is an effective treatment but also highly costly. 
Treatment A is designed to help problematic drinkers reduce their consumption of alcohol and can 
be delivered in non specialist medical settings.  For this case-study, the treatment population for 
Treatment A is potentially the significant number of problematic drinkers in the UK seeking 
community-based treatments, only excluding those very dependent drinkers who may require more 
intensive psychological and medical care.  Given the current limited identification of alcohol 
problems and the limited supply of alcohol treatments in the UK, it is difficult to determine the 
proportion of these drinkers who may, once identified, be motivated to seek treatment. 
In accordance with NICE guidelines (NICE, 2008), the appropriate comparator in economic 
evaluation should be the treatment that will most likely be replaced, and should reflect current UK 
practice rather than “best” practice.  For this reason it is not appropriate to use the US clinical trial 
comparator (placebo) as the comparator for the economic evaluation. 
UK usual care trial 
Set in the context of alcohol treatment, usual care is assumed to be the current standard of care for 
the management of problematic drinkers who seek community-based treatment in the UK.  There 
are currently only limited studies of the range of problematic drinkers seeking community-based 
treatment in the UK setting.  The UK Alcohol Treatment Trial (UKATT Research Team, 2005a, b) 
was a pragmatic trial of alcohol dependent individuals drawn from a wide range of alcohol 
treatment agencies, with open follow-up at 3 months after entry and blind follow-up at 12 months.  
The participants were drawn from all those attending the alcohol agencies with exclusions kept to a 
minimum.  This trial provides the cost and effectiveness data for a low-intensity manual based 
psychosocial therapy based on SBNT and MET.  The UKATT trial design, interventions and results 
are described with more detail in the previous chapter.  The UKATT clinical study showed evidence 
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of a statistically non-significant difference in effectiveness between MET and SBNT (UKATT 
Research Team, 2005b).  In addition, despite the protocol defining a higher number of sessions for 
the SBNT group than the MET group, patients randomized to both treatment groups ended up 
taking a similar number of sessions.  For those two reasons, the data from both groups is pooled and 
forms the comparator to the US therapy.  The UKATT trial is taken as providing the current 
standard of care in the UK and is used as the comparator to Treatment A for modelling purposes.   
7.1.1 Why modelling the two trials?
The two trials from which effectiveness and treatment cost data come from had a short follow-up 
period.  One trial had 6 months follow-up (Treatment A trial) and the other had 12 months follow-
up (UKATT).  The model estimates the effects of changes in drinking behaviour over the long term 
costs, morbidity and mortality.  It allows the projection of effects and also costs beyond the short 
follow-up periods, as explained throughout the model development chapter (Chapter 4).  This is 
achieved by augmenting the trials’ patient-level data with evidence from other sources, namely UK 
epidemiological data and NHS costs.  The model allows comparing the two treatments over lifetime, 
even though their effectiveness has not been studied in a head to head randomized controlled trial.  
Furthermore, it deals with heterogeneity and so it helps in assessing whether any of the therapies 
represent better value for money for a specific subgroup of patients, based on age and gender.   
7.2 Can the two trials be compared? 
There is no evidence from a direct comparison between Treatment A and current UK practice which 
makes it difficult for the decision maker to choose the alternative that is most cost effective for UK 
patients and/ or to make a decision on whether treatment A should be implemented in the UK. 
The comparison drawn for this study departs from an indirect comparison in which two 
interventions are compared through their relative effect versus a common comparator (Song et al., 
2003).  The UK and US trials do not have a common comparator.  Nevertheless, the validity of 
indirect comparisons depends on the internal validity and similarity of the included trials and it 
might be reasonable to assume that these two factors are also of importance for the two trials 
compared here.  The internal validity of the trials is important because any biases in the two trials 
will affect the validity of the comparison of costs and effects.  The similarity of the trials is also 
important so the effects of the interventions compared can be consistent across patients from the 
two trials.   
The UKATT trial, as previously mentioned, was a multicentre pragmatic trial and such design 
confers both the internal validity (freedom from bias) associated with RCTs and the external 
179 
validity (generalisability to practical clinical settings) typically associated with models.  The design 
of the US trial also confers internal validity but this was an efficacy trial conducted under highly 
controlled conditions and, hence, with lower external validity.   
Regarding the similarity of the two trials, both the UK and the US trial were multicentre trials.  
However, the UK patients were much more severe than the US patients and the results from the US 
trial might not be directly applicable to a UK population.  In fact, the UKATT patients had a 
slightly above-average level of alcohol-related problems for a British treatment sample (Drummond, 
1990; UKATT Research Team, 2005b) which may also not accurately reflect the general UK 
population seeking for alcohol treatment.  There might be a range of different prognostic 
characteristics between study participants among the trials and these different patient characteristics 
may interact with the effect of treatments.  It is important to assess how comparable the populations 
are and whether Treatment A can be delivered to a UK population, i.e. if the UKATT population or 
a subgroup of it has some similarities with the US population so the effects of Treatment A can be 
extrapolated to UK patients.  This is dealt with in the next section, where the UK and US population 
trials are matched according to baseline characteristics. 
7.3 Comparators: matching patients characteristics 
In a randomized design treatment groups are randomly selected from a population.  With 
randomization treatment status does not depend on potential health outcomes, and it may be 
assumed that, on average, those individuals exposed to an intervention are not different from those 
not exposed to it either regarding observable characteristics or unobservable ones.  Thereby, any 
statistically significant difference in health outcomes between both groups can be attributed solely 
to the intervention’s impact (Moreno-Serra, 2007).  When using non-experimental data, the bias 
caused by omitted variables is extremely important for the reliability of the estimates of an 
intervention’s impact.   
Although the data used in the model comes from two randomized controlled trials, the power of 
randomization is lost when comparing treatments from each trial.  The population used in the model 
has not been randomized between the two treatments compared, Treatment A and UKATT 
treatment.  The comparison in this case-study suffers from the same biases as observational data, in 
which patients are drawn from separate populations, with the likelihood that differences in 
prognosis unrelated to treatment will bias the comparison of effectiveness (Dehejia and Wahba, 
1999).  Using the whole sample of US and UK patients can be a source of selection bias if the two 
groups are not comparable at baseline and it might not be appropriate to directly compare the two 
trials.  Using matching methods is one alternative for explicitly addressing and eliminating selection 
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bias, while assuming that selection on unobservables that are correlated with heath outcomes is not 
a problem in the relevant data. 
Estellat et al. (2009) stated that for a comparison to be valid and to avoid bias, the groups must be 
similar at baseline, undergo the same care apart from the treatment under study and be assessed in 
the same way at the end of the study.  The first condition is dealt with in the section below. The last 
two conditions are assumed to be valid for this case-study. 
7.3.1 Baseline comparison
When comparing the US Treatment A trial with the UKATT trial it is important to minimise any 
potential bias, and in particular to ensure that Treatment A results are not biased in favour of the US 
trial as a consequence of differences in patient characteristics at baseline.   
The UKATT trial data used for the case study encompasses all observations that were followed up 
with economic data (608 patients), with information on grams of alcohol per day at baseline, 3 and 
12 months follow-up and on baseline covariates (a total of 437 patients out of the 608 patients with 
economic data).  The US trial data for the case-study comprises the data from patients in the active 
arm of the trial- Treatment A arm (208 patients), and with information on grams of alcohol per day 
at baseline and 6 months and on baseline covariates (a total of 201 patients).  Therefore, missing 
data is dealt with by using complete case analysis in which patients with a missing response are 
excluded from the analysis. 
An analysis of the baseline characteristics for the two groups compared (437 UK patients and 201 
US patients) is shown in the following table. 
Table 55- Sociodemographic, mental and physical scores and alcohol use characteristics of the US 
and UK groups at baseline 
Variable UK (n = 437) US (n = 201) P
Age (SD) 41.7 (9.6) 45.2 (10.0) 0.000** 
Number of males (%) 326 (74.6) 134 (66.7) 0.038*** 
Number employed (%) 146 (33.4) 175 (87.1) 0.000*** 
Mental Score* (SD) 31.9 (12.8) 38.7 (12.5) 0.000** 
Physical Score* (SD) 46.9 (10.1) 53.6 (8.0) 0.000** 
Percentage of days 
abstinent (SD) 27.6 (25.5) 24.0 (23.4) 0.094** 
Alcohol (g/day) (SD) 138.2 (89.0) 84.5 (44.1) 0.000** 
*From SF-36 questionnaire; **P-value from two-sample t-test with equal variance; ***P-value for chi-
squared test of homogeneity; SD, Standard Deviation. Note: values are means, unless stated otherwise. 
The results of the tests for the difference in the mean values of the baseline characteristics show that 
there are statistically significant differences (at a 95% confidence level) between the two 
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populations in terms of baseline characteristics, for all the variables studied but the percentage of 
days abstinent at baseline (Table 55).  The UKATT sample has a slightly higher proportion of males 
than the US group (p-value= 0.038).  In terms of age, the US group is older than the UK group 
(mean age 45.2 vs. 41.7, p-value = 0.000).  The UK group shows considerable lower employment 
levels than the US group (33.4% vs. 87.1%, p-value = 0.000).  A higher proportion of baseline 
abstinent days is observed for the UK group but this is not statistically significant different from the 
US group (p-value = 0.094).  The UK group drinks considerably more alcohol at baseline than the 
US group (138 g/day vs. 85g/day; p-value = 0.000).  A comparison using health status scores based 
on the SF-36 questionnaire (Ware and Sherbourne, 1992), emphasizes the difference between the 
two samples.  The UKATT sample is in both poorer physical and mental health than the Treatment 
A sample (p-value = 0.000). 
The sample drawn from that proportion of the UK problem drinking population receiving 
psychosocial therapies is more severe than the Treatment A population.  The comparison of data 
from the UKATT sample to those from the US trial would seem therefore to be inappropriate, as it 
would risk biasing the comparison in favour of Treatment A, and reinforcing the perception that 
alcohol treatments achieve better results in the US than in the UK or Europe.  Hence, it seems 
inappropriate to compare the 437 patients of the UK trial to the 201 patients from the US trial as the 
groups are not comparable at baseline.  The two trial groups need to be matched in terms of those 
characteristics so selection bias can be eliminated and the differences in drinking behaviour can be 
solely attributed to differences in treatments (assuming any unobservable factors to be balanced 
between the two groups).  Comparing the two full samples is likely to mask considerable 
confounders that affect treatment effects.  Consequently, the next step in this case-study is to find 
the best match for comparison from which the transition probabilities and treatment costs can be 
derived. 
One method widely used in observational studies consists of the use of propensity scores for 
matching baseline characteristics.  This thesis explores the use of the propensity score for obtaining 
populations that are comparable at baseline and so a direct comparison between treatment A and 
UKATT therapies can be more meaningful.  The application of propensity score for this case study 
falls somehow outside of its general use.  Propensity scores have been widely used for obtaining 
average treatment effects of a treated population in observational studies (Moreno-Serra, 2007).  
Recently, they have also been used as an approach to estimating the cost effectiveness of medical 
therapies from observational data (Mitra and Indurkhya, 2005).  However, the application of the 
propensity score here is not for obtaining an average effect as the lifetime effect from each 
treatment is calculated by means of the Markov model.  The aim of propensity score matching for 
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this specific case is to select the patients from each trial that are comparable in terms of baseline 
characteristics, i.e. to select the patients that should be used for the economic analysis.  Patients 
with similar distribution of baseline characteristics will have a similar propensity to be delivered the 
new treatment and will therefore be more comparable.   
7.3.2 General principles of propensity score matching
The propensity score is the conditional probability of assignment to a particular treatment given a 
vector of observed covariates.  Matching sampling has been described by Rosenbaum and Rubin 
(1983) as a method for selecting units from a large reservoir of potential controls to produce a 
control group of modest size that is similar to a treated group with respect to the distribution of 
observed covariates. 
Rosenbaum and Rubin (1983) proposed propensity score matching as a method to reduce bias in the 
estimation of treatment effects with observational datasets.  In observational studies subjects’ 
assignment to the treatment and control groups is not random and the estimation of the effect of 
treatment may be biased by the existence of confounding factors (variables related to both exposure 
and outcome).  Propensity score matching is a way to “correct” the estimation of treatment effects 
controlling for the existence of these confounding factors based on the idea that the bias is reduced 
when the comparison of outcomes is performed using subjects who are as similar as possible.   
It has been shown that adjustment for the scalar propensity score is sufficient to remove bias due to 
all observed covariates (Rosenbaum and Rubin, 1983).  Matching on the propensity score balances 
the observed covariates but, unlike randomization, it does not balance unobserved confounding 
factors.  This means that matching will not remove selection bias if individuals that uptake 
Treatment A or the standard therapy differ in terms of unobserved characteristics which are 
themselves correlated with their potential outcomes.  For example, cultural differences such as 
different lifestyles might have an impact on the type of patients randomized.  Unfortunately, there is 
no way to empirically validate this assumption from the data.  Therefore, as much information as 
possible about potential confounders should be captured. 
The methods of propensity score matching assume that “treatment assignment is strongly ignorable”, 
meaning that any other factors jointly affecting treatment effects and exposure to treatment, whether 
unobservable or unknown, are controlled for in the analyses.  A second assumption is that 
observations with the same propensity score must have the same distribution of observable (and 
unobservable) characteristics independently of treatment status (balancing hypothesis) (Rosenbaum 
and Rubin, 1983).  Based on the two assumptions, for a given propensity score, exposure to 
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treatment is random and therefore the matched groups should be on average observationally 
identical (Becker and Ichino, 2002)  
The matching method is a non-parametric approach that tries to re-establish conditions of an 
experiment when only non-experimental data is available.  The propensity score calculation is done 
parametrically and matching on the propensity score results in a semi-parametric method. The 
general idea is to construct a matched comparison group based on individual observable 
characteristics and compare individuals who are similar in terms of these observable factors. 
The propensity score matching method evaluates pre-treatment characteristics of each treatment 
group computing a single propensity score which, for this case-study, is the conditional probability 
of being assigned to Treatment A, given pre-intervention characteristics.  The idea is to mimic the 
properties of the US group in the properly designed experimental context from a statistically strong 
match between the US and UK groups based on their observable characteristics (Becker and Ichino, 
2002; D'Agostino, 1998). 
There are different types of propensity score matching techniques and the most widely used are 
Nearest-Neighbour Matching (one to one or k-nearest neighbours), Radius Matching, Kernel 
Matching, and Stratification Matching (Becker and Ichino, 2002). The practical advantages of each 
matching estimator are still inconclusive (Imbens, 2004).  The full details of the theory 
underpinning these methods are accessible in the existing statistical literature (Becker and Ichino, 
2002; D'Agostino, 1998; Imbens, 2004; Rosenbaum and Rubin, 1985; Rosenbaum and Rubin, 1983).  
The theory is not covered in depth in this thesis, but a brief summary of the method used is provided. 
When choosing covariates for propensity score matching four points should be taken into 
consideration (Moreno-Serra, 2007).  Matching variables should include pre-treatment variables 
(baseline measurements), time invariant characteristics (such as gender) and variables deterministic 
with regards to time (such as age).  Also, covariates that are only weakly correlated with the 
treatment variable and health outcome may decrease the precision (increase expected mean squared 
error).  In addition, covariates affected by the health programme (such as intermediate outcomes) 
should not be included.  Finally, factors which affect only treatment status or the potential health 
outcome do not need to be controlled for.   
The simplest form of applying propensity score matching is by using Nearest-Neighbour Matching 
(NNM) without replacement, where each comparison observation (UK patient) can serve as a match 
for at most one treated person (US patient).  The minimum distance between the propensity scores 
defines the comparators matched to the treated patients.  However, the simplest form of NNM can 
lead to considerable bias if it results in many bad matches, due to treated individuals being matched 
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to comparison counterparts with very different propensity scores (despite being the “closest” 
neighbours).  Some flexibility can be introduced by allowing the matching procedure to be 
performed with replacement.  Matching with replacement allows extreme observations within the 
comparison group to be used more than once.  If re-use occurs, matching with replacement will use 
better matches for each treated individuals thus reducing bias.  However, the variance of the 
estimates will probably be higher than in the no-replacement case due to the smaller number of 
different comparison observations used to construct the counterfactual (Moreno-Serra, 2007). 
The quality of matching may be improved by imposing the common support restriction.  However, 
with this approach there is a possibility that high quality matches are lost at the boundaries of the 
common support and the sample may be considerably reduced (Lechner, 2000).  Nevertheless, 
matching without common support can introduce severe bias by relying on the matching of treated 
individuals to substantially different comparison individuals (Moreno-Serra, 2007). 
7.3.3 Propensity score matching for the US and UK trials
The matching method used for this case-study is the NNM method which basically takes each 
treated unit (US patient) and searches for the control (UK patient) with the closest propensity score 
to use as a match.  The method is applied here with replacement meaning that after a UK patient is 
used as a match it is put back into the sample and can be used more than once if it is the closest 
match for many different US patients.  The weight accruing to each individual of the UK group, 
when constructing the comparator for the US treatment, depends on the distance between the 
propensity scores of the UK and US patients and it reflects the number of times an individual is 
used as a match (frequency weight).  The matched sample consists of all the original US patients, 
along with all the UK patients used as matches and this is the sample used for the economic 
evaluation.  All analyses are conducted in STATA v 10.1 (Stata  Corp, 2009). 
Before matching the correct specification for the propensity score needs to be defined.  This is done 
using the command pscore in STATA, which tests for the balancing property.  The correct 
specification is also tested using the psmatch2 command followed by the pstest command to inspect 
the extent of covariate balancing (Leuven and Sianesi, 2003).  Overall, taking out the variable 
“percentage of abstinent days at baseline” (which is the only variable not statistically different 
between the two groups at baseline) does not produce better results in terms of the balancing 
property in the pscore and pstest results.  The covariates used for estimating the propensity score 
are the following seven baseline variables: age, sex, employment, Mental Component Score (MCS) 
from the SF-36 questionnaire, Physical Component Score (PCS) from the SF-36 questionnaire, 
Percentage of Days Abstinent (PDA), and grams of alcohol consumed per day (g/day).  All 
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covariates are highly correlated with treatment and the amount of alcohol consumed at follow-up 
(p-values of pairwise correlations less than .05 at a 95% confidence level).  A linear regression 
between treatment and all the selected covariates shows that there is no collinearity between 
baseline variables (the variance inflation factor calculated with command “estatvif” in STATA is 1; 
when estatvif is smaller than 10 there is no collinearity). 
A logit specification is used for estimating the individual probability of being exposed to the US 
treatment conditional on the seven baseline covariates defined above, using the psmatch2 STATA 
command.  The results of the one-to-one Nearest-Neighbour propensity score matching method in 
STATA, with replacement, are presented in Appendix 7- Matching the UK and US group   
The region of common support should be analyzed to see if there is enough overlap between the 
two groups to make reasonable comparisons.  Figure 7 below graphs the propensity score histogram 
by treatment status.  It can be seen that there are more UK patients with low propensity scores and 
more US patients with high propensity scores.  If there is a common support problem it might 
happen that for some treated units the nearest neighbour has a very different propensity score.  
However, a second analysis plotting a histogram of the UK patients with a propensity score greater 
than 0.1 shows, more clearly, that the UK group spans the full range of propensity scores (Figure 8).  
When there are relatively few UK cases that are similar to high propensity score US cases, as 
matching is done with replacement, the few control cases with high propensity score must be used 
over and over again as matches to the US cases. 
Figure 7- Propensity score histogram by treatment status 
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Figure 8- Propensity score >0.1 histogram, UK patients 
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Overall, 95 UK patients are used to match the 201 US patients and some of these 95 patients are 
used several times (see Appendix 7- Matching the UK and US group, to check the weights assigned 
in the matching process).  The characteristics of the 201 UK patients matched to the 201 US 
patients are analysed in Table 56 below.  The quality of the matching is tested using the STATA 10 
pstest command.  The output of the pstest command shows two rows for each variable, unmatched 
and matched.  In each row, it shows the mean of the variable for the US group and the mean for the 
UK group.  The pstest calculates several measures of the balancing of the variables before and after 
matching.  In particular, for each variable it calculates (a) t-tests for equality of means in the UK 
and US groups, both before and after matching, (b) the standardised bias before and after matching, 
together with the achieved percentage reduction in absolute bias.  The standardised bias is the 
difference of the sample means in the US and UK (full or matched) sub-samples as a percentage of 
the square root of the average of the sample variances in the US and UK groups (Rosenbaum and 
Rubin, 1985).  The percentage reduction in bias is how much of this bias is eliminated by matching.  
Table 56 shows that, after NNM on the propensity score, there is no statistically significant 
difference between the two groups in all covariates analysed and there is a considerable reduction in 
absolute bias.  The matched samples are similar regarding their baseline characteristics and, 
therefore are used for the economic evaluation.   
187 
Table 56- Baseline variables balance before and after matching (results from the pstest command in 
STATA 10) 
Mean t-test Variable Sample US UK % bias 
% reduct 
|bias| t p>|t| 
U 45.244 41.694 36.2  4.28 0.000 Age  M 45.244 44.579 6.8 81.3 0.75 0.456 
U 0.667 0.746 -17.5  -2.08   0.038 Proportion 
of males M 0.667 0.751 -18.6 -6.6 -1.87 0.062 
U 0.871 .334 130.9  14.50 0.000 Proportion 
employed M 0.871 .871 0.0 100.0 0.00 1.000 
U 38.694 31.938 53.4  6.24 0.000 Mental Score M 38.694 38.28 3.3 93.9 0.33 0.742 
U 53.603 46.883 73.9  8.33 0.000 Physical 
Score M 53.603 52.837 8.4 88.6 0.99 0.325 
U 24.017 27.574 -14.5  -1.68   0.094 Percentage 
of abstinent 
days M 24.017  24.914 -3.7 74.8 -0.34 0.738 
U 84.469 138.18 -76.5  -8.11 0.000 Alcohol 
(g/day) M 84.469 75.986 12.1 84.2 1.72 0.087 
U, Unmatched; M, Matched; *Negative values for the percentage reduction in bias mean that bias increases as 
a result of matching. However, taking out the sex variable gives a worse balance in all other covariates. 
7.4 Modelling the UK and US trials 
7.4.1 Objectives
The objective of this case-study is to conduct a long-term cost effectiveness and cost utility analysis 
of a new pharmacological treatment for a UK population with alcohol problems when compared to 
what can be considered as standard therapy in the UK, using patient-level data collected in two 
trials and the model of drinking behaviour, to inform decision making in the UK NHS. 
7.4.2 Comparators
The new Treatment A is compared to standard UK therapies.  The comparators for the economic 
analysis are based on the results of the matching procedures presented in the previous section, 
where 201 UK patients are matched to 201 US patients.   
7.4.3 Base case
The base-case cohort for the present model is a male cohort with an average starting age of 40 years 
old.  The cohort of individuals with alcohol problems is modelled through 80 cycles, as it is 
expected that on the 80th cycle all patients are in the death state (WHO, 2008).  The distribution of 
patients in the two initial Markov states (hazardous and harmful) is the one observed in both trials 
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distribution.  Approximately 50% of the population modelled is drinking hazardously and another 
50% is drinking harmfully.  Therefore, the base-case considers a cohort equally distributed between 
the two initial drinking states. 
7.4.4 Discounting and price year
In accordance with NICE (2008) guidance a discount rate of 3.5% is applied to both costs and 
outcomes.  The price year of the economic analysis is 2006/07.  The currency used in the economic 
evaluation is pound sterling (GBP, £). 
7.5 Model Inputs 
The model inputs that are UK-specific and independent of the treatments under analysis are 
presented in Chapter 5.  The model inputs presented here are the effects of treatment in drinking 
behaviour (the first cycle transition probabilities) and treatment costs. 
7.5.1 Transition probabilities for the first cycle
Transition probabilities for the first cycle of each treatment are derived from the 201 patients of the 
US trial (confidential data) and the matched 201 patients of the UKATT trial (UKATT Research 
Team, 2005b, a).  Transition probabilities for each trial are calculated through counting the 
individuals that moved between the drinking categories from baseline to follow-up.   
The UK and US trials have different follow-up periods, the former was a 12-month trial while the 
latter was a 6-month trial.  The studies ought to be comparable in terms of the time of assessment as 
this can have an impact on the corresponding drinking level.  Therefore, baseline and 6 month 
drinking categories are defined for both trials, according to the grams of alcohol consumed per day.  
However, none of the trials presented individual-level outcomes in terms of grams per day.  For the 
UK trial, the calculation of grams of alcohol consumed per day is presented in Chapter 5 (see 
section 5.5).  The US trial provided similar data to the UK data but for 30 days instead of 90 days.  
The same general procedure as the one used for the UKATT study is applied, for both baseline and 
6 month follow-up, but the grams of alcohol consumed per patient is obtained by multiplying the 
number of drinks per day by a factor of 13.6, as in the US one drink has 13.6g of absolute EtOH.  
The calculation of grams per day at 6 months for the UKATT trial uses linear interpolation between 
3 and 12 months grams per day, in the same way as explained in section 5.5. 
The number of patients in each drinking category, by gender, at baseline and 6 months, is presented 
in the following four tables for each trial.  The corresponding transition matrices are presented on 
the bottom part of each table. 
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Table 57- Counts of transition between model states and transition matrix for the US trial (males) 
US trial- Counts of transitions between the five states for the 6 months period for males* 
MALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 20 1 43 NA 0 64 
Harmful 26 14 NA 36 0 76 Baseline 
N 46 15 43 36 0 140 
Transition matrix 
MALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.3125 0.0156 0.6719 NA TD 1 Baseline Harmful 0.3421 0.1842 NA 0.4737 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
Table 58- Counts of transition between model states and transition matrix for the US trial (females) 
US trial- Counts of transitions between the five states for the 6 months period for females* 
FEMALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 14 2 19 NA 0 35 
Harmful 16 11 NA 11 0 38 Baseline 
N 30 13 19 11 0 73 
Transition matrix 
FEMALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.4000 0.0571 0.5429 NA TD 1 Baseline Harmful 0.4211 0.2894 NA 0.2895 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
Table 59- Counts of transition between model states and transition matrix for the UK trial (males) 
UK trial- Counts of transitions between the five states for the 6 months period for males* 
MALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 27 31 20 NA 0 78 
Harmful 36 21 NA 22 0 79 Baseline 
N 63 52 20 22 0 157 
Transition matrix 
MALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death  
Hazardous 0.3462 0.3974 0.2564 NA TD 1 Baseline Harmful 0.4557 0.2658 NA 0.2785 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
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Table 60- Counts of transition between model states and transition matrix for the UK trial (females) 
UK trial- Counts of transitions between the five states for the 6 months period for females* 
FEMALES  6 months 
Hazardous Harmful Ex-Haz Ex-Harm Death N 
Hazardous 4 20 6 NA 0 30 
Harmful 7 10 NA 9 0 26 Baseline 
N 11 30 6 9 0 56 
Transition matrix 
FEMALES  6 months 
Mod HE Ex-Haz Ex-Harm Death  
Hazardous 0.1333 0.6667 0.2 NA TD 1 Baseline Harmful 0.2692 0.3846 NA 0.3462 TD 1 
Ex-Haz, Ex-Hazardous; Ex-Harm, Ex-Harmful; NA, Not Applicable; TD, Time Dependent; N, total number; 
*A value of 1 was added to each cell count assuming an uniform Dirichlet prior distribution. 
7.5.2 Cost of the treatments
The costs of each treatment are calculated with the trials’ data and are based on the actual treatment 
received by the individuals matched according to the propensity score for each trial.  These costs are 
only applicable to the first cycle of the model, given that treatment is only given in the first cycle.   
The economic model compares a time-limited psychosocial treatment with a new pharmacological 
treatment.  The new pharmacological treatment, Treatment A, is delivered monthly, as in the US 
randomized controlled trial.  The standard care treatment is based on the therapies delivered in the 
UKATT pragmatic trial.  The costs of screening and identifying problematic drinkers or referring 
such drinkers to those delivering the treatments are assumed to be the same between the groups and 
therefore these costs are excluded from the analysis.   
Treatment A  
The costs of Treatment A are made up of the active drug and an accompanying psychosocial 
treatment.  The psychosocial treatment sessions are assumed to last for 20 minutes per patient.  The 
average number of psychosocial sessions taken per patient was 10.1 (SD. 2.68, n=201). 
The cost per minute derived from the UKATT trial is used to estimate an approximate cost of 
psychosocial sessions per patient. The mean UKATT session length was 50.8 minutes, with a cost 
of £1.62/ min (£82.12/ 50.8min).  The cost per psychosocial session (20min) is then £32.4 
(£1.62*20min).  The mean cost of psychosocial therapy per patient used is £326.74 (SD 86.86, 
n=201). 
The cost of the pharmacological treatment of the 201 patients who received the active drug takes 
into account the mean number of doses received by this sample which was 4.80 (SD 1.80, n=201). 
The cost per dose used in the base-case is £350.  The total cost of the pharmacological component 
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of treatment per patient is estimated at £1,679 (4.80*£350).  In addition, one GP contact per 
treatment per patient is included.  The estimate of this cost is £30 (Curtis, 2007), for a 2006/07 price 
year.  It is assumed that Treatment A was administered on the first visit by the GP and on the 
subsequent visits by the nurse as part of the psychosocial sessions.  Therefore no additional costs 
for administration of the pharmacological component are included.  The total cost of the new 
pharmacological treatment putting all these components together is presented in Table 61 below. 
Table 61- Treatment A costs 
Resource Unit Cost (£) unit Units consumed Total cost (£) 
Pharmacological 
component 1 dose £350 
1/ month total of 
4.80 £1,679 
Psychosocial treatment 20 minute contact  £32.4 
Mean 10.1 sessions 
per patient (202 
minutes per patient) 
£327 
GP contacts Contact £30 1 contact for referral  £30 
Total Treatment Costs £2,035 
UKATT treatment 
UKATT therapies are costed as delivered in the trial.  These therapies were time limited over a 12 
week period.  One treatment type had a maximum of 3 sessions – 50 minutes in length and the other 
treatment type had a maximum of 8 sessions – 50 minutes in length.  Such time limited treatments 
are not necessarily the norm in the UK and therefore the costs of these therapies may be lower than 
average treatment costs.  Also no attempt was made to cost adjunct pharmacological treatments 
which some patients were offered, e.g. acamprosate or disulfiram.  This and other UK alcohol 
treatment trials indicate that patients will take up a range of other alcohol treatment services.  The 
take-up of such other alcohol services was measured at the 12 months follow-up period for the 
previous 6 months and at the 3 months follow-up in the UKATT trial.  Such costs may be seen as an 
overestimation of treatment costs within the treatment period but UKATT treatment costs alone 
may be seen as an underestimate of the true costs.  It is important to note that UKATT clients 
showed a “saving” of total alcohol treatment costs after their UKATT therapy. 
The costs used for the economic evaluation are up-rated from the original data (2000/01 prices), 
using the HCHS pay and prices index from the PSSRU Unit Costs of Health and Social Care 2007 
(Curtis, 2007) to 2006/7 prices.  The total treatment cost of UKATT therapies, for the sample 
matched to the US trials, is £336.60 (SD 122.19) and the alcohol service cost at 3 months is £43.15 
(SD 311.03).  The matched UKATT sample took up an average of 178 min of psychosocial 
therapies per patient.  The costs used in the model are the total treatment costs plus the other alcohol 
services, which adds to £379.5. 
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It can be seen that even with other alcohol services included, the cost of UKATT therapies are only 
equivalent to the psychosocial and GP input for the treatment arm of the US trial.  The new 
treatment is almost 6 times more expensive than standard therapy.  It may be that the new drug 
delivered in the UK is accompanied by a lower psychosocial component.  This may reflect different 
overall patient and health service practice between the US and UK.  However, the major component 
is the cost of the new pharmacological treatment. 
7.6 Sensitivity analysis and heterogeneity 
7.6.1 Probabilistic Sensitivity Analysis
Two different distributions are chosen in order to conduct the probabilistic sensitivity analysis.  
Transition probabilities for the first cycle are estimated from multinomial data and, therefore, 
assigned the Dirichlet distribution.  Transition probabilities for the following cycles and utilities are 
both derived from binomial data and, therefore, assigned a beta distribution (see section 6.4.1 in the 
previous chapter). 
7.6.2 Univariate sensitivity analysis
Sensitivity analyses are undertaken to assess the robustness of the base-case model results to 
variations in alternative assumptions related to key parameters in the model.  One way sensitivity 
analysis is conducted for the initial distribution of patients, where the effect of a different proportion 
of patients starting in hazardous (A) and harmful (B) states is analysed (25% A-75% B and 75% A -
25% B).  The impact of an alternative discount rate of 6% for costs and 1.5% for outcomes is 
analysed.  One-way sensitivity analysis is also conducted for the market price of the 
pharmacological component of Treatment A.   
7.6.3 Heterogeneity
The analysis is run for cohorts of males and females of 20, 40 and 60 years old in order to deal with 
heterogeneity.  Multiple CEACs are produced, where the probability of Treatment A being cost 
effective is plotted against the willingness to pay threshold, for each subgroup.   
Table 62 below depicts the base-case used in the model and the variations in the base-case for 
which results are presented in section 7.7 below.  Four alternative scenarios are considered and for 
each element, the position in the base-case analysis is outlined, alongside the alternative assumption 
applied.  
Table 62- Key elements of the base-case analysis and alternative scenarios, case-study 2 
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Scenario Element Position in base-case analysis Alternative scenario 
1 Population Male cohort with starting age of 40 years old 
Separate analysis for males and 
females 
Alternative starting ages 
assumed: 20, 40 and 60 years 
2 Discount rate 3.5% applied to both costs and outcomes (NICE, 2008) 
6% costs, 1.5% outcomes 
(NICE, 2008) 
3 Cohort distribution 50% hazardous, 50% harmful  75% hazardous, 25% harmful 25% hazardous, 75% harmful 
4 Treatment A drug price £350 £300, £350, £400, £450, £500 
7.7 Case-study results 
The model results are first presented according to a particular set of assumptions employed as part 
of the base-case analysis.  The impact of employing alternative assumptions to those presented in 
the base-case analysis is then explored.  This is followed by a section taking into account the value 
of information analysis.  The last sections present the implications and limitations of the study. 
7.7.1 Deterministic cost effectiveness results
The summary deterministic results of the model are the incremental costs and incremental 
effectiveness of Treatment A compared with standard UK therapy.  For the base case analysis (male 
cohort of 40 years old, drug price of £350, discount rate of 3.5% for costs and outcomes, and initial 
distribution of 50% in hazardous and 50% in harmful drinking states), Treatment A is more costly 
and more effective than the standard treatment approach.  The ICER is £22,772/ QALY, which is 
within the £20,000 to £30,000 per additional QALY benchmark used in England and Wales (NICE, 
2008) suggesting that Treatment A may be a cost effective treatment compared to standard UK 
therapy in the population studied.  A breakdown of the costs and QALYs for the base case is 
presented in Table 63 below.  
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Table 63- Base-case analysis, deterministic results for the cost effectiveness of Treatment A 
compared to UKATT therapies 
Males, 40 years old 
Deterministic results Treatment A UKATT treatment 
Difference (Treatment 
A vs. UKATT) 
Costs (£, 2006/07 
prices) 
QALYs  
Life Years 
£3,283 
 
13.09 
 
19.89 
£1,654 
 
13.02 
 
19.86 
£1,629 
 
0.072 
 
0.030 
ICER (Lcost/ 
LQALY) £22,773/ QALY 
ICER (Lcost/ LLYG) 
 
£54,292/ LYG 
QALY, Quality Adjusted Life Year; LYG, Life Years Gained; costs and effect discount rate=3.5%; drug price 
£350; initial distribution of 50% in hazardous and 50% in harmful drinking states. Estimates rounded for 
presentation. 
Clearly, the new treatment is more expensive than standard UK therapy, being two times more 
expensive if a long term analysis is conducted and almost 6 times more expensive on the short term.  
However, Treatment A is more effective in terms of life years gained and especially in terms of 
QALYs gained as presented in Table 63. 
The importance of a long-term model in the analysis of the cost effectiveness of the new alcohol 
treatment is reflected in the ICER obtained for each model cycle.  The reduction in the ICER as the 
short-term analysis progresses to a long-term one is depicted in Figure 9.  The chart represents the 
ICER, computed as the cumulative difference in costs and QALYs, for each cycle year.  It is shown 
that after the tenth cycle the new treatment for alcohol problems is cost effective, achieving an 
ICER below £30,000/ QALY. 
Figure 9- Incremental cost effectiveness ratio of Treatment A vs. UKATT therapies 
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7.7.2 Probabilistic cost effectiveness results
The results of the PSA for the base case analysis are presented in Table 64.  Even when accounting 
for the effect of uncertainty in model inputs on the outputs, Treatment A is cost effective.  The 
mean cost effectiveness ratio of Treatment A vs. standard UK therapy estimated from 1000 random 
draws is £21,722 per QALY.   
Table 64- Base-case analysis, probabilistic results for the cost effectiveness of Treatment A 
compared to UKATT therapies 
Males, 40 years old 
Probabilistic results Treatment A UKATT treatment 
Difference (Treatment 
A vs. UKATT) 
Costs (£, 2006/07 
prices) 
QALYs  
Life Years 
£3,280 
 
13.10 
 
19.89 
£1,651 
 
13.03 
 
19.86 
£1,628 
 
0.075 
 
0.031 
ICER (Lcost/ 
LQALY) £21,722/ QALY 
ICER (Lcost/ LLYG) 
 
£52,514/ LYG 
QALY, Quality Adjusted Life Year; LYG, Life Years Gained; costs and effect discount rate=3.5%; drug price 
£350; initial distribution of 50% in hazardous and 50% in harmful drinking states. Estimates rounded for 
presentation. 
The simulation results of the overall uncertainty in the model are presented in a cost effectiveness 
plane and cost effectiveness acceptability curve (Briggs et al., 2006; Briggs and Tambour, 2001).  
Figure 10 below shows the results of 1000 Monte Carlo simulations in a cost effectiveness plane.  
The cost effectiveness plane shows the difference (Treatment A minus UKATT) in effectiveness per 
patient against the difference in cost per patient.  
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Figure 10- Incremental cost effectiveness plane of Treatment A vs. UKATT therapies 
 
Figure 10 shows that the new drug is more costly than the UKATT treatment for all simulations as 
all simulation fall above the horizontal line of the cost effectiveness plane.  Some of the simulation 
results cross the vertical axis (the new treatment is less effective than UKATT based therapies).  
However, for the biggest part of the simulations, Treatment A is more effective than UKATT 
therapies, as more dots fall on the right quadrant of the plane.   
The standard ICER figure does not differentiate situations where ratios have the same sign but not 
the same interpretation.  This problem can be solved by drawing a line in the cost effectiveness 
plane that goes through the origin and represents the maximum that decision makers are willing to 
invest to achieve a unit of effectiveness.  In this case, if the computed ICER lies below the threshold 
ratio the intervention should be adopted.  Usually, a decision analytical framework uses CEAC to 
represent uncertainty.  The CEAC presented below, in Figure 11, shows the probability that 
Treatment A is cost effective for a range of cost effectiveness thresholds, i.e. it shows how many of 
the 1000 simulations fall below and to the right of a line representing the threshold cost per QALY.  
The CEAC for UKATT treatment is the perfect complement of the Treatment A curve. 
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Figure 11- Cost effectiveness acceptability curve for Treatment A vs. UKATT therapies 
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The CEAC in Figure 11 shows that the probability that Treatment A is cost effective cuts the 
horizontal axis (probability is zero) for threshold values below £6,000/ QALY and increases 
thereafter.  Therefore, when the decision maker is only interested in the cheaper option, standard 
UK therapy has a probability of 100 percent to be cost effective.  Both treatments have the same 
probability of being cost effective when the decision maker is willing to pay around £21,722 per 
QALY, which is the value of the ICER.  At this threshold the decision maker is indifferent between 
the two options.  If the decision maker is willing to pay more than £21,722/ QALY then Treatment 
A should be adopted for it has a higher probability of being cost effective.  The probability that 
Treatment A is the most cost effective therapy is 0.45 and 0.60 for threshold values of £20,000 and 
£30,000, respectively.   
7.7.3 Univariate sensitivity analysis
One way sensitivity analysis is conducted for the initial distribution of patients, where the effect of 
different proportion of patients starting in hazardous (A) and harmful (B) states is analysed (75% A- 
25% B; 25% A-75% B).  This sensitivity analysis reflects the impact of delivering the treatments 
compared to a population drinking at levels different from the base-case.  Table 65 shows that if 
Treatment A is delivered to a mainly hazardously drinking population (75% hazardous) it is even 
more cost effective mainly because of a higher scope for QALYs gained (ICER= £14,773/ QALY).  
In contrast, it appears that the new treatment is not so cost effective if given to a population mainly 
represented by harmful drinkers (ICER= £45,397/ QALY).  This shows that the new treatment 
might represent a very cost effective option to a 40-year-old UK male population with moderate 
drinking problems but not drinking too heavily. 
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One way sensitivity analysis is also conducted for a discount rate of 6% for costs and 1.5% for 
health outcomes.  The results are presented in Table 65, where it can be seen that the alternative 
discount rates improve the cost effectiveness by a minor amount.  This is mainly because a lower 
discount rate on the outcomes values them higher which is reflected in a higher QALY gain and 
therefore, in a higher denominator of the cost effectiveness ratio reducing the overall ICER. 
As would be expected, a reduction in the price of the pharmacological component of Treatment A 
reduces the ICER significantly due to a reduction in the incremental cost of Treatment A versus 
UKATT therapies.  A reduction in the base-case price of the new treatment supports the decision of 
adopting it from a NHS/ payer perspective.  A price higher than £500 results in an ICER above the 
upper accepted limit of £30,000/ QALY. 
Table 65-Probabilistic results for one-way sensitivity analysis (Treatment A vs. UKATT therapies) 
 Incremental costs Incremental QALYs 
ICER 
£/ QALY 
Initial cohort distribution  
75% hazardous; 25% harmful £1,620 0.1096 £14,773 
50% hazardous; 50% 
harmful* £1,628 0.0750 £21,722 
25% hazardous; 75% harmful £1,636 0.0360 £45,397 
Discount rate  
3.5% cost and outcomes* £1,628 0.0750 £21,722 
6% costs; 1.5% outcomes £1,629 0.0823 £19,782 
Treatment A price  
£350* £1,628 0.0750 £21,722 
£300 £1,388 0.0774 £17,944 
£400 £1,867 0.0755 £24,730 
£450 £2,106 0.0746 £28,244 
£500 £2,346 0.0789 £29,724 
*Base-case conditions; QALYs, Quality Adjusted Life Years; ICER, Incremental Cost Effectiveness Ratio; 
price year 2006/07. Estimates rounded for presentation. 
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7.7.4 Modelling heterogeneity
The incremental probabilistic results of Treatment A when compared to UKATT therapies, for the 
six patient groups analysed, are presented in Table 66 below.   
Table 66- Probabilistic results for the subgroup analysis (Treatment A vs. UKATT therapies) 
 Incremental Cost Incremental QALY 
ICER 
£/ QALY 
Males, 20 years old £1,651 0.0694 £23,775 
Males, 40 years old* £1,628 0.0750 £21,722 
Males, 60 years old £1,613 0.0695 £23,189 
Females, 20 years old £1,653 0.0893 £18,499 
Females, 40 years old £1,638 0.0979 £16,724 
Females, 60 years old £1,631 0.0970 £16,805 
*Base-case conditions; ICER, Incremental Cost Effectiveness Ratio; QALY, Quality Adjusted Life Year; 
price year 2006/07; discount rate r= 3.5%; drug price £350; initial distribution of 50% in hazardous and 50% 
in harmful drinking states. Estimates rounded for presentation. 
The gender and age variation in the ICER can be explained by two factors.  One factor is the 
variation in costs by subgroup, which can be explained by gender variation in the first cycle 
transition probabilities (treatment effect) and variations in morbidity rates by gender and age.  The 
second factor is the variation in effects by subgroup, which can be explained by gender variation in 
the first cycle transition probabilities (treatment effect) and variations in mortality rates by gender 
and age.   
The subgroup analysis presented in Table 66 shows that the lowest ICER is observed for 40-year-
old females and the highest for 20-year-old males.  Comparing females and males of the same age 
shows that the ICER is always slightly lower for the female cohort and, therefore, Treatment A is 
more cost effective for females than males, in the UK.  This is a very interesting result also because 
the US trial showed that Treatment A was more cost effective for males.  However, the results from 
the model cannot be directly compared to the trial results.  The model conducts a lifetime analysis 
while the trial had a 6-month time horizon.  Also, the model uses a range of data to generate results 
and models a specific cohort.   
Within the same age groups, the biggest difference between males and females is in terms of 
QALYs gained.  It appears that females gain more QALYs with the new treatment than males.  The 
states’ utilities are the same for men and women and actually by looking at the first cycle transition 
probabilities (Table 46-Table 49) it appears that males improved more than females for each 
treatment individually.  Even though there is a higher absolute improvement for males, when 
comparing the incremental utility for males with that for females, between treatments, there is a 
higher gain for a female cohort.  This might be related to the rather intense psychosocial therapy 
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that is part of Treatment A.  This psychosocial treatment has a strong network component, to which 
women are said to be more responsive than men (Schneider et al., 1995).  However, UKATT 
therapies also had a strong network component (as delivered in SBNT) and it might be that the 
better improvement for females is related to a higher response to the pharmacological drug.  
Nevertheless, it should be noted that the psychosocial component of Treatment A was more intense, 
in terms of average duration per patient, than the UKATT therapies (202 min vs. 178 min, 
respectively).  This gender difference is also explained by the lower mortality rates for females than 
males and therefore, a higher scope for QALYs gained throughout lifetime.  With respect to the 
incremental costs, Table 66 shows that these are very similar for males and females of the same age 
group.  This is because the lower cost of female’s drinking categories is balanced with their higher 
life expectancy and therefore, lifetime incremental costs are similar between males and females (as 
shown in Table 41, Chapter 5).  In summary, the lower ICERs for a female cohort are explained by 
the QALYs gained and not so much by differences in costs. 
The model results presented in Table 66 show that the ICER for males increases for a 40, 60 and 
20-year old cohort, respectively.  The QALY gain for men is higher for 40-year old men than 60-
year old men due to the competing effect of a higher mortality rate.  The ICERS for 60 and 20 years 
old cohorts are very similar for males.  For females, similarly to males, the ICER increases for a 40, 
60 and 20-year old cohort, respectively.  Both female and male young cohorts (20 years old) have 
higher costs and lower utility gains.  The higher costs might be related with the fact that there are 
more potential years in the model for accruing health care costs.  The lower utility gains might be 
related to the fact that the benefits of treatment fade with time (which is enhanced with more years 
of discounting). 
Nevertheless, for all the analysed cohorts the ICER is below or around £24,000/ QALY and the 
ICERs are very similar for the different age groups of the same gender.  Each subgroup of patients 
is represented by a different CEAC in Figure 12 below.  This allows the assessment of the extent to 
which the results vary across different subgroups and whether different treatment decisions should 
be made for different categories of patients, according to the decision maker’s threshold for the new 
treatment adoption.  The CEACs are very close to each other and treatment is potentially cost 
effective for all age and gender cohorts and more cost effective for a female cohort.  The CEACs for 
each group of patients encourage the decision maker to make similar treatment decisions across the 
different categories of patients, based on the expected cost effectiveness for the set of patient 
characteristics and associated uncertainty.  However, if the decision maker is not willing to pay 
more than £20,000/ QALY he or she might be more confident in adopting Treatment A for a female 
cohort. 
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Figure 12- Multiple CEAC for different age and sex cohorts for Treatment A vs. UKATT 
therapies 
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7.7.5 Summary of the cost effectiveness results
Table 67 details the results of each of the alternative scenarios considered for the cost effectiveness 
analysis of Treatment A.  The table reports the ICER and the probability that Treatment A is cost 
effective at thresholds of £20,000 and £30,000 per additional QALY.  The base-case ICER of 
£21,722/ QALY provides the benchmark for assessing whether the cost effectiveness results appear 
robust to particular assumptions made in the base-case analysis.  
The base-case scenario suggests that the new treatment is likely to be considered cost effective.  The 
ICER of Treatment A vs. UKATT (£21,722/ QALY) is within the range of conventional thresholds 
used to identify whether a particular treatment is considered to be cost effective in the NHS.  For 
thresholds between £20,000 and £30,000 per QALY, the probability that Treatment A is more cost 
effective than UK standard treatment is 0.45 and 0.60.   
Some deviations from the base-case assumptions improve the ICER and make the new treatment 
more cost effective, such as: delivering the treatment to less severe patients, to females, or 
decreasing the price of the pharmacological component.  Theses options should be considered in 
case the decision maker is willing to pay less than £20,000/ QALY.  If the price of the drug is set at 
£300 per dose, the new treatment has a 52% chance of being a more cost effective option than 
UKATT therapies, for a threshold value of £20,000/ QALY.  If Treatment A is delivered to a 
population where drinkers are mainly hazardous, the chance of cost effectiveness increases to 60% 
and 70%, for a £20,000 to £30,000 threshold, respectively.  Applying an alternative discount rate of 
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6% to costs and 1.5% to health outcomes (compared to 3.5% for both in the base-case analysis) 
improves the cost effectiveness by a minor amount.  The ICER is then below the lower bound of the 
£20,000 threshold. 
Heterogeneity in patient characteristics is explored using a series of separate scenarios.  The results 
demonstrate that cost effectiveness is improved in female subgroups.  However, differences within 
the subgroups are relatively minor. 
Table 67- Summary of cost effectiveness results (Treatment A vs. UKATT therapies) 
 Probability cost effective for max WTP ICER 
£20,000 £30,000  
Initial cohort distribution  
75% hazardous; 25% harmful 0.596 0.694 £14,773 
50% hazardous; 50% harmful* 0.449 0.604 £21,722 
25% hazardous; 75% harmful 0.136 0.308 £45,397 
Discount rate  
3.5% cost and outcomes* 0.449 0.604 £21,722 
6% costs; 1.5% outcomes 0.507 0.638 £19,782 
Injection price  
£350* 0.449 0.604 £21,722 
£300 0.520 0.673 £17,944 
£400 0.393 0.572 £24,730 
£450 0.343 0.520 £28,244 
£500 0.328 0.503 £29,724 
Subgroup analysis  
Males, 20 years old 0.421 0.565 £23,775 
Males, 40 years old* 0.449 0.604 £21,722 
Males, 60 years old 0.434 0.596 £23,189 
Females, 20 years old 0.511 0.621 £18,499 
Females, 40 years old 0.547 0.676 £16,724 
Females, 60 years old 0.555 0.669 £16,805 
*Base case conditions; ICER, Incremental Cost Effectiveness Ratio; WTP, Willingness to Pay; price year 
2006/07. Estimates rounded for presentation. 
7.7.6 Value of information
Value of information is related to the value of reducing uncertainty such that a decision may include 
the option to acquire more information (see Chapter 4, section 4.10).  This involves balancing the 
costs of acquiring more information with its value (Briggs et al., 2006).  The effective population 
for alcohol treatment in England each year is taken from the report of Alcohol Needs Assessment 
Research Project (Drummond et al., 2005a).  The report estimated that approximately 8.2 million 
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people in England have an alcohol use disorder and that around 1,125 million per annum are 
alcohol dependent drinkers eligible for treatment.  The population EVPI is estimated using the latter 
value and assumes that the information would be valuable for a 10-year lifetime of the alcohol 
treatments.  A 3.5% annual discount rate is applied.  Individual patient and population EVPI are 
calculated for the base-case model.  Figure 13 below illustrates the population EVPI for Treatment 
A when compared to UKATT therapies for the base-case analysis.   
Figure 13- Population expected value of perfect information for Treatment A vs. UKATT therapies 
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Figure 13 shows that when the decision maker is not willing to spend much on alcohol treatments 
(cost effectiveness thresholds below £6,000) the EVPI is low.  This is because additional 
information is unlikely to change the decision about adopting UKATT therapies for low thresholds.  
In this case, there is minimal decision uncertainty that Treatment A is not optimal, and current 
evidence can be regarded as sufficient to support the decision to adopt UKATT therapies.  Between 
threshold values of around £6,000 and £21,722 (the base-case ICER) the value of information on 
whether treatment A is better value for money, increases.  This means that, as the decision maker is 
willing to pay more for alcohol treatments, he or she is also willing to finance the more expensive 
treatment (Treatment A) or research that reduces the uncertainty regarding which treatment is more 
cost effective.  The population EVPI reaches a peak at the point where the threshold for cost 
effectiveness is equal to the expected ICER.  This peak occurs when there is uncertainty on whether 
to adopt or reject Treatment A based on current evidence (i.e. at £21,722 per QALY) because the 
probability of each treatment being cost effective is 50%.  The decision to require more information 
is based on the cost of further research, the threshold and the cost of uncertainty or value of 
information.  Therefore, if further research were expected to cost, say £300m then, further research 
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would be requested in order to accept Treatment A for thresholds above £9,000.  This is because for 
thresholds above £9,000 the value of information is always higher than the hypothetical value of 
£300m and so further research would be considered cost effective.   
After the threshold value of the ICER the cost of uncertainty decreases slightly with a steep increase 
for thresholds higher than £30,000.  When the threshold is higher than the ICER, the new 
intervention is expected to be cost effective and this decision is slightly less likely to be changed by 
further research until the threshold reaches £30,000.  The small EVPI decrease is justified by a 
slight reduction in decision uncertainty which offsets the increased value of the consequences of an 
error.  As the threshold increases the cost of uncertainty increases and further research becomes 
highly important because the increased value of the consequences of an error is not offset by a 
reduction in uncertainty.  The decision that Treatment A is the most cost effective option, for 
threshold values between £22,000 and £30,000, needs more research in case the cost of further 
research is lower than the cost of uncertainty.  The value of information is very high and it can be 
expected that the costs of further research would be lower than the costs of uncertainty for the 
conventional range of threshold willingness to pay (£20,000-£30,000).  Therefore, the EVPI curve 
shows that further research should be conducted before accepting Treatment A in the UK.   
The population EVPI can be scaled back to provide results for the individual per patient EVPI.  This 
allows decision makers to apply the results to the potential size of their own population of interest.  
Table 68 provides a summary of the population and individual EVPI estimates for selected 
threshold values. 
Table 68- Individual patient and population EVPI for selected values of the threshold for the base-
case (Treatment A vs. UKATT therapies) 
 Individual EVPI for maximum WTP Population EVPI for maximum WTP 
£20,000 £30,000 £20,000 £30,000 
Base-case £537 £614 £5 billions £6 billions 
EVPI, Expected Value of Perfect Information; WTP, Willingness to Pay; price year 2006/07. 
7.8 Decision making 
The new treatment for alcohol problems, Treatment A, analysed in the Markov model of drinking 
behaviour appears to be both more effective and more costly than UKATT-based therapies.  The 
probabilistic results of the economic analysis show that the additional benefits of Treatment A 
appear to be worth the additional cost in the UK for all age and gender cohorts analysed under base-
case conditions.  The delivery to a population where half is drinking heavily (harmful drinkers) and 
another half is drinking high amounts (hazardous drinkers) is very close to the £20,000 lower bound 
of the threshold willingness to pay.  The cost effectiveness of the new treatment is greatly improved 
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if it is delivered to a population that consists mainly of hazardous drinkers.  In addition, a lower 
price of the pharmacological component of Treatment A increases its cost effectiveness.  The 
subgroup analysis shows that Treatment A is even more cost effective for a female cohort and the 
ICER for this cohort is below £20,000/ QALY for all age groups. 
The ICER for a male cohort of 40 years old is £21,722/ QALY, which is just slightly above the 
lower bond of the benchmark of £20,000 to £30,000 adopted in England and Wales.  If the decision 
maker is willing to pay more than £21,722 per QALY, then the new treatment might be adopted for 
it has a higher probability of being cost effective.  However, the value of additional evidence for 
Treatment A is very high.  Perhaps a randomized controlled trial of Treatment A in the UK would 
reduce some of the uncertainty.  Furthermore, some of the model inputs such as the states utilities 
and the transition probabilities for the following cycles are associated with high uncertainty and 
more research to produce more certain estimates would be very important. 
7.9 Policy implications 
The cost effectiveness of the new treatment is greatly improved if it is delivered to a population that 
consists mainly of hazardous drinkers.  Therefore, the decision maker might prefer the adoption of 
this treatment in settings where a less severe population can be found, such as in the workplace if 
employers are willing to invest in controlled alcohol drinking, or first points of contact with patients 
where a screening programme is established (primary care in England).   
When compared to psychosocial therapies, as delivered in the pragmatic UKATT trial, the major 
addition with the new treatment is the requirement for specialist staff to deliver the pharmacological 
drug.  The setting where the treatment will be delivered needs to be defined.  If the treatment is to 
be delivered at the workplace then special arrangements with employers need to be done.  If the 
treatment is to be delivered at a primary care setting some specific points need to be addressed such 
as: 1) more training in generalist staff and medical schools, 2) more specialist staff, 3) more 
screening of problematic alcohol drinkers, etc. 
7.10 Discussion 
The case-study presents the long-term cost effectiveness results of a new alcohol treatment versus 
standard UK therapies.  The long-term analysis applies the economic model developed in previous 
chapters to the results of two randomized controlled trials.  Patient-level data from both trials is 
used and combined with epidemiological risks for a UK population and with the NHS costs of 
alcohol-related diseases. 
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The limitations of the study regarding the general model features and UK-specific model inputs are 
presented in Chapters 4 and 5, respectively.  There are four specific limitations worth mentioning 
here.  First, the economic model directly compares two treatments with costs and effects taken from 
two randomized controlled trials conducted in different countries.  This might be considered a naïve 
comparison, in which results from individual arms between different trials are compared as if they 
were from a single trial.  However, before assessing the costs and effects of the two trials, in the 
model of drinking behaviour, several analyses are carried out such as: matching patients on baseline 
covariates and adjusting outcomes for the same follow-up time.  One of the main limitations of 
propensity score matching is the impossibility to control for unobserved confounding factors.  Such 
problem is present in all observational studies and the comparison drawn here suffers from the same 
type of biases as those studies.   
Second, there is no current definition of standard care for problem drinking in the UK.  The 
appropriate comparator for the purpose of economic evaluation should be the treatment that will 
most likely be replaced, and should reflect current UK practice.  The therapies delivered in the 
UKATT trial are used as the comparator to Treatment A.  In the UKATT study these therapies were 
delivered in a specialist setting and to a very severe population which may not represent current UK 
problem drinkers (UKATT Research Team, 2005b).  The ideal comparator for Treatment A in the 
UK would include a broader range of problematic drinkers and therapies delivered in a community 
setting, by a GP, nurse or psychologist.  To date there is little data on the costs and effects of 
therapies delivered in a community setting.  Cost effectiveness data on standard alcohol treatment 
delivered in the community setting is highly required for the UK.  Such information would provide 
a benchmark to which treatments, such as Treatment A, would need to surpass in order to be 
deemed cost effective.   
Third, the appropriateness of the assumption related to using long-term follow-up data that did not 
follow the specific treatments evaluated in the long run is explored in the conclusion of Chapter 5.  
Regarding this case-study one specific limitation is that any other interventions are assumed to be 
the same across UKATT therapies and the US treatment.  For this reason, it is valid to assume that 
other possible interventions received in each trial are not relevant for the incremental analysis 
(Drummond et al., 2005c).   
Finally, it must be emphasized that the perspective of the study is narrow and many economic 
benefits might have been left out of the analysis.  The costs and benefits of alcohol treatment are 
realized in multiple sectors such as criminal justice, workplace, transport and so on.  For this 
specific case-study, workplace productivity costs have been overlooked and its inclusion in the 
analysis would have probably provided stronger evidence for the cost effectiveness of Treatment A 
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for a less severe population.  Also, the inclusion of family and friends costs, such as care giving 
activities, would have been an important contribution to the cost effectiveness analysis.  A broader 
societal perspective should be part of future extensions of the case-study as the impacts of alcohol 
are beyond those confined to the health services. 
The clinical trial of Treatment A showed that this treatment was more effective amongst men, when 
comparing Treatment A to placebo (the psychosocial component).  It is possible that the study did 
not have enough power to detect effects amongst females because the number of females recruited 
was well below the number of males recruited.  Even though this is consistent with prevalence 
patterns in Europe and North America, the women who participated in that study may not be 
representative of women in general.  Another possibility is that the intensive psychosocial 
component of the placebo did not enable the detection of an added effect of Treatment A in women.  
The model of drinking behaviour shows that the new Treatment is more cost effective when 
delivered to a female population.  Even though the results from the model cannot be directly 
compared to the trial results, an explanation for the better long-term cost effectiveness results of 
Treatment A amongst a female cohort needs to be explored.  The results of the subgroup analysis 
show that when comparing the benefits of Treatment A to UKATT therapies between females and 
males, the relative gain in utility is higher for females.  Perhaps one justification for the better 
results amongst females is that by modelling the effects of alcohol treatments these effects can be 
more extensively captured and in fact alcohol treatments can be highly cost effective for females.  
However, the new treatment was accompanied by an intensive psychosocial component and, when 
compared to the less intensive UKATT therapies, females might improve more than men because 
they tend to respond better to a variety of psychosocial interventions (Sanchez-Craig et al., 1989; 
Schneider et al., 1995).  Women are more likely than men to have a history of psychological 
problems or to perceive alcohol-related problems such as depressed mood as psychological in 
nature rather than a consequence of substance use (Weisner and Schmidt, 1992).  It would be 
interesting to disentangle the effects of the intensive psychosocial treatment and the 
pharmacological treatment, Treatment A, when comparing to UKATT therapies.  This would enable 
an understanding of the real reason why females have better results than males in the long term 
model.  
The external validity of the case-study results is related to their generalisability to practical clinical 
situations.  As mentioned, the UKATT trial had a pragmatic design and the Treatment A trial was 
an efficacy trial.  Nevertheless, the UKATT trial population is more severe than the UK problem 
drinking population.  Therefore, the results might not be generalisable to the UK population eligible 
for Treatment A.  In addition, the generalisability of the results might be hampered by the fact that 
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the UKATT population is matched to the US population and a US-like population is modelled.  The 
application of these particular results will depend on the setting and patients to which treatment A 
will be delivered.  The characteristics of the population modelled should be adapted for another 
setting.  UKATT therapies are used as the comparator to Treatment A, which may or may not be the 
situation in another country.  The clinical effects for both treatments are taken from two randomized 
trials where therapists were highly trained and experienced and this might not be possible to 
reproduce in different settings.  The perspective on costs is that of the NHS and needs to be adapted 
if the analysis is conducted in another country.   
Overall, this case-study provides an example of how the model of drinking behaviour can be 
applied to a situation where there is only efficacy data derived from a single trial for a new 
treatment and where this data comes from a setting that does not correspond to the setting of the 
analysis.  It demonstrates that a cost effectiveness analysis of two alcohol therapies delivered in two 
clinical trials to different populations and in different jurisdictions can be conducted.  The model of 
drinking behaviour explores cost effectiveness results over the long term, provides useful 
information for decision makers and deals with the imperfections of the data by incorporating 
decision uncertainty and value of further research. 
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Chapter 8. Discussion 
Alcohol drinking is associated with various health and social negative problems worldwide.  For such 
an important area of health, it is striking that only 27 full economic evaluations were identified as being 
published since 1995.  Far more economic studies in the field have focused on issues such as the total 
cost of alcohol misuse.  The main aim of this thesis was to explore how future economic evaluations of 
alcohol treatment could be rigorously conducted in order to provide better information to decision 
makers. 
This thesis identified many issues that make economic evaluations of alcohol treatments particularly 
challenging: alcohol drinking imposes societal as well as individual costs, alcohol treatment effects are 
not fully captured in a short term period, there are many alcohol abuse treatment approaches and, there 
are multiple treatment outcomes with different definitions, interpretations and impact at the societal and 
individual-level.  Therefore, the ability of economic evaluations of alcohol treatment to frame cost 
effective decisions is currently restrained for two reasons: first, the lack of accumulated evidence that 
can aid on decision making; second, the lack of rigour in individual studies due to differences in the 
inclusion of society-level consequences, inconsistencies in measurement and valuation of alcohol-
related consequences, lack of agreement on the individual health measure of alcohol treatment, inability 
to capture long-term effects, and particular technicalities related to economic evaluation studies.   
8.1 Summary of the main findings and limitations 
Chapter 2 identified all consequences that could be included in an economic evaluation of alcohol 
treatments.  The methods used for identification, measurement and valuation of individual and 
society-level consequences were given full consideration.  The consequences were stratified in a 
taxonomy with special attention to prevent double counting.  The taxonomy was designed to help 
appraising existing studies and also for guiding in the identification of consequences for economic 
evaluations of alcohol treatment.   
Chapter 3 reviewed the methods for identification, measurement and valuation of costs and 
outcomes used in previous cost effectiveness analyses of alcohol treatments.  The review showed 
that a societal perspective has never been taken into full account and almost half of the studies 
totally excluded society-level consequences from their analysis.  Previous economic evaluations 
used short-term data to derive clinical effects and constrained their economic data either by a short-
term prospective study or by retrospective collection methods.  Many studies have confined 
treatment effectiveness to abstinence-based measures and alcohol dependent patients.  Most of the 
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full economic evaluations conducted in the past were cost effectiveness analyses where individual-
level consequences were not consistently identified, measured and valued.  Few studies used a cost 
utility design and measures of HRQoL capturing life years and morbidity have not been extensively 
used in the alcohol field.  All these drawbacks formed the foundation for the set of 
recommendations drawn in Chapter 3.  Most of these recommendations were pursued throughout 
the remaining thesis and more specifically through the development of an economic model for the 
economic evaluation of alcohol treatments. 
Chapter 4 presented a framework where long term modelling techniques establish a link between 
drinking patterns, health consequences and alcohol treatments effectiveness and cost effectiveness.  
A probabilistic lifetime Markov model using the cohort simulation approach, with QALYs and 
lifetime costs as the main outcome measures was constructed.  The decision analytical model 
moved away from abstinence-based measures by taking into account the benefits of reduced 
drinking and change in drinking patterns.  The Markov model included mortality, morbidity, and 
long term costs savings and considered a wider population with alcohol problems, not confined to 
an alcohol dependent population.  The grams of alcohol consumed per day were used as a common 
natural effectiveness measure.  Such consumption-based measure classified the different drinking 
categories that define the four health states in the Markov model.  Defining the Markov states in 
terms of grams of alcohol consumed per day facilitated modelling alcohol drinking behaviour as a 
recurrent behaviour with susceptibility for relapse.   
The economic model of drinking behaviour is extremely data demanding and needs country-specific 
data such as: mortality and morbidity rates that vary with age, gender, level of consumption, 
alcohol-related condition and drinking patterns; alcohol treatment effectiveness data; transition 
probabilities after treatment; cost data for alcohol-related problems and for the specific treatments 
evaluated; and utility weights for the Markov states.   
UK-specific model inputs have been generated in Chapter 5 and can be used to populate the Markov 
model for any alcohol treatment assessed in the UK.  If the economic evaluation is conducted in 
another country then the same level of data needs to be drawn for that country.   
The Markov model of drinking behaviour requires a separate epidemiological model of lifetime 
injury and chronic disease mortality and morbidity which in itself is based on numerous 
assumptions and data requirements.  Despite the acknowledged limitations, the approach presented 
in Chapter 5 allowed the incorporation of patterns of drinking and levels of drinking on mortality 
and morbidity risks.  This allows for more accurate estimates of the cost effectiveness of alcohol 
because health and economic consequences are estimated based on lifetime drinking behaviour and 
associated risks. 
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Previous economic evaluations assumed that treatment effect remains the same over patients’ 
lifetime, which is a strong assumption that this thesis overcame with the calculation of transition 
probabilities informed by a UK long-term drinking behaviour follow-up study (Taylor et al., 1985).  
One of the limitations associated with the use of this study is that exposure to other alcohol 
interventions is assumed to be the same for the compared treated groups in the long run.   
UK-specific utilities for the drinking states were generated.  The utilities assigned to the Markov 
states were calculated based on individual patient level data from the UKATT trial.  The trial used 
the EQ-5D instrument with scores valued using a sample of the UK general public.  Given that the 
relationship between Health-Related Quality of Life instruments, such as the EQ-5D, and 
effectiveness measures have not as yet been studied, attaching utilities to health states defined by 
consumption levels circumvents making assumptions about this relationship for which there is not 
yet evidence.  However, the utilities estimates were associated with some limitations.  It was 
assumed that utilities could be propagated though lifetime based on the drinking categories on 
which patients were classified.  In addition, the number of patients used for collecting preference 
values for each Markov state was small and estimates had associated high standard errors.  The 
utilities associated with the Markov states were used in the case-studies to generate a generic 
outcome measure of health, the QALY.  This is considered the appropriate methodology for current 
decision makers (NICE, 2008) but is not universally accepted (Dolan, 1999).  There is a concern 
that the QALY does not capture all outcomes of interest for a population with alcohol problems.   
The economic model of drinking behaviour and the UK-specific data were used in two case-studies 
presented in Chapters 6 and 7.  While both case-studies were cost effectiveness and cost utility 
analyses that compared two different alcohol treatments in a UK setting, they differed in a number 
of aspects.  The first case-study analysed two treatments that had presented similar costs and effects 
in a short-term UK multicentre pragmatic randomized controlled trial (UKATT Research Team, 
2005a).  The long-term analyses enabled drawing more directions in terms of the level of certainty 
around the cost effectiveness of the two treatments, by gender and age.  It also showed that the 
therapy with a slightly higher probability of being cost effective for a male cohort (MET) had a very 
low probability of being cost effective for females and was dominated by the more socially-based 
therapy (SBNT), for all female age groups.  The discrepancy of MET and SBNT cost effectiveness 
according to gender was an extremely interesting result.  While it was not clear that MET was the 
most cost effective strategy for males (high level of uncertainty), it was definitely clear that SBNT 
was cost effective for females (high level of certainty).   
The first case-study used the model to extrapolate the results of the UKATT trial.  However, the use 
of a single RCT as a vehicle for economic analysis and a basis for decision making has been 
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criticized by some authors (Sculpher et al., 2006).  The arguments given for such criticism are the 
following: 1) failure to compare all relevant options producing a partial analysis; 2) a truncated time 
horizon, where QALYs gained would only allow for differences in survival duration until the end of 
the trial; 3) possible lack of relevance to the decision context; 4) failure to incorporate all evidence; 
and 5) inadequate quantification of decision uncertainty.  The application of the model to the 
UKATT case-study solved many of the arguments against the use of a single RCT for economic 
evaluations.  More specifically, arguments two, three, and five above were solved.  It was 
demonstrated that there is potential for using modelling techniques in a single randomized 
controlled trial to guide on the decision regarding the choice of the interventions compared in a trial.   
However, arguments one and four above were not solved.  According to arguments one and four 
given by Sculpher et al. (2006), a comprehensive evidence synthesis of all psychosocial treatments 
would seem more appropriate for the model.  Some reviews and meta-analyses have been conducted 
for alcohol treatments (Heather et al., 2006; Ludbrook, 2004; Raistrick et al., 2006) and more 
specifically for psychosocial treatments of alcohol problems (Burke et al., 2003; Kaner et al., 2007; 
Lundahl and Burke, 2009; McQueen et al., 2009).  However, previous systematic reviews and meta-
analysis have pooled data from a very heterogeneous sample of studies regarding the population of 
interest (e.g., with higher or lower degree of alcohol problems), the setting of the study (e.g., 
general practice, hospital wards, specialist clinics), the type of intervention (e.g., within 
psychosocial treatments there is not yet a standard definition of brief intervention), and the health 
systems organization (e.g., a National Health Service in the UK and private insurance in the US).  
This thesis did not focus on evidence synthesis of all psychosocial treatments, but it can be foreseen 
that due to the factors presented above this is particularly challenging in the alcohol field. 
The second case-study differed from the first in that it compared two treatments with clinical effects 
taken from two randomized controlled trials, with short follow-up periods conducted in different 
countries and with populations with significantly different characteristics at baseline.  The cost 
effectiveness comparison was made possible by first matching the patients in terms of baseline 
characteristics with the use of propensity score matching techniques.  An adjustment for the 
different follow-up times was done.  The model of drinking behaviour compared the matched 
populations and explored the results over the long term, incorporating decision uncertainty.  The 
model results showed that the new treatment would be a cost effective alternative to standard UK 
therapies, represented by UKATT therapies, especially when delivered to a less severe cohort of 
patients and to females.  The lower the price of the new treatment the more cost effective it was, 
achieving ICERs well below the lower bound of the decision maker threshold.  In this case-study 
UKATT therapies were assumed to represent standard UK therapy.  However, even if these 
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therapies are accepted to be the standard approach, it should be recognized that their effectiveness 
was drawn from a RCT where the population was more severe than what would be expected from 
UK problem drinkers.   
Whilst this thesis dealt with almost all the challenges identified in full economic evaluations of 
alcohol treatment, there is still one point that could not meet the recommendations set up in Chapter 
3.  The application of a full societal perspective was not possible due to data limitations on the costs 
and epidemiological risks associated with the social consequences of alcohol.  The model was built 
from a health care system perspective which does aid decisions where the decision maker does not 
have any benefit from changes on the levels of consequences borne by others than the person in 
treatment.  However, as explained in this thesis, the extent of externalities, that is the un-
compensated consequences to third parties, generates strong normative arguments for the adoption 
of a broad societal perspective in the economic evaluation of alcohol treatment.  A health care 
perspective could lead to the adoption of a treatment with lower health care costs but higher costs 
and lower utility to society, which for a wider perspective would lead to an inefficient allocation of 
resources.  With a broader perspective, where social consequences are also taken into account, 
alcohol treatments may be more cost effective due to the large scope for society-level improvements.  
It might also be the case that a societal perspective changes the ranking of treatments.  
8.2 Recommendations for future research 
The limitations to the analyses presented above form the basis of the recommendations for future 
research. 
A keystone of any economic evaluation is the perspective the analyst employs.  The perspective of 
the analysis dictates the range of costs and consequences included in an economic evaluation.  
Different perspectives foster different outcomes which can result in different resource allocation 
decisions.  This thesis recommends the used of a broader perspective in economic evaluations of 
alcohol treatment.  With a broader perspective, where all consequences, no matter on whom or 
where they fall are identified, the analyst can also explore the impact of taking a narrower 
perspective which may be required by a decision maker, for example NICE in England or other 
health care financing regulators.  The taxonomy of alcohol consequences presented in Chapter 2 can 
help in the identification of the types of consequences that could be measured and valued.  The 
development of consistent methods for the measurement and valuation of the broader consequences 
of alcohol treatment is a topic for further research.  Once these methods are developed and data is 
generated a societal perspective can then be part of future extensions of the model and of the case-
studies.   
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The follow-up of most clinical studies of alcohol treatments have not surpassed one to two years.  
Alcohol problems differ from many other health problems for the psychological and social 
dimensions that characterize them.  These special characteristics make the need of long-term 
analysis even more important, so drinking behaviour can be captured and better understood.  Also, 
in order to take into account the effect of different exposures on drinking behaviour, long-term 
follow-up studies of the treatments evaluated are required.   
An area of research that needs to be investigated is the relationship between QALYs and measures 
of alcohol consumption.  The extent to which improvement in alcohol consumption can be linked 
with QALYs gained and the time period for this to be detected warrants closer scrutiny.  More 
research should also be done in order to determine whether a small increase in QALYs in the short 
term persists for longer periods.  A longitudinal study, where an alcohol drinking population is 
followed for a long period and where consumption levels and HRQoL are measured, would help to 
answer some of these questions.   
The results of the first case-study showed clear differences on the cost effectiveness of MET and 
SBNT by gender.  Based on these results, it is recommended that future effectiveness and cost 
effectiveness analyses of alcohol treatments take into account patient’s gender when reporting the 
results.  The heterogeneity on cost effectiveness results by gender is a topic for further research.   
For the second case-study, it would have been important to also compare the new treatment with 
other alcohol treatment alternatives in a community setting.  This would inform not only whether 
the new treatment is cost effective compared with standard therapy, but also which intervention is 
most cost effective compared with each other.  Even though creating a network of evidence 
comparing several alternatives was out of the scope of this thesis, the economic framework 
developed in Chapter 4 has the potential to incorporate such analyses.   
So far, the model has been developed to use patient-level data as the source of effectiveness.  
Developing other methods using results already published in meta-analysis is a matter for future 
research.  Whilst further research is required, the results produced in the case-studies can, in the 
future, be used with a comprehensive synthesis of evidence in this area and so other strategies could 
be compared to the treatments considered in the model applications.   
8.3 Future applications of the model 
The model has been applied to a UK setting.  The potential for demonstrating the cost effectiveness 
of alcohol treatments that reduce alcohol consumption will probably be greatly extended if the 
model is applied to a setting with higher alcohol-related mortality and morbidity rates, i.e. a setting 
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where alcohol problems have a higher impact compared to other health conditions.  Within the 
WHO European region, the number of deaths and DALYs attributable to alcohol are the highest in 
Europe C region (Rehm et al., 2009).  Europe C is also believed to be the one with the most 
detrimental patterns of drinking (Rehm et al., 2004).  This region encompasses countries such as 
Belarus, Estonia, Hungary, Latvia, Lithuania, Republic of Moldova, Russian Federation, and 
Ukraine.  These countries have an extremely high prevalence of alcohol dependence and average 
volume of drinking (Rehm et al., 2006c).  Therefore, applying the model of drinking behaviour to 
these populations will fully depict the effect of treatments that aim at a reduction in alcohol 
consumption.  An application of the model of drinking behaviour to former Soviet Union countries 
would be of great interest if treatments that aim at reducing consumption are compared to 
treatments that focus on abstinence or to other health care interventions that compete for the same 
source of funding. 
Current discussions are assessing the use of the model in an ongoing European project.  The 
Alcohol Measures for Public Health Research Alliance (AMPHORA) project, work package 6, is 
concerned with the public health impact of individually directed alcohol interventions in European 
countries.  The research in this work package is divided into 4 elements and one of them is the 
secondary analysis of the impact and cost effectiveness of alcohol interventions in Europe.  This 
study aims to conduct a meta-analysis to compare treatment outcomes from brief interventions and 
specialist interventions between Europe and the rest of the world.  This information will be used to 
assess the cost effectiveness of alcohol interventions in Europe, using the model developed in this 
thesis. 
8.4 Conclusion 
This thesis explored the methods used in previous studies, developed and implemented a framework 
that links drinking patterns, health consequences and the effectiveness and cost effectiveness of alcohol 
treatments over patients’ lifetime.  It is hoped that the research conducted throughout this thesis will 
stimulate further work to bridge the gap between studies and will provide guidance on the conduct of 
more and better economic evaluations of alcohol treatments.   
This thesis contributed to the development of an innovative methodology that deals with many of the 
difficulties identified in previous studies.  It is proved, both theoretically and empirically, that rigorous 
full economic evaluations can be conducted for the analysis of alcohol treatments.   
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Appendices 
Appendix 1- Scoping strategy 
For primary studies, this search is undertaken in a range of relevant databases, such as MEDLINE, 
EMBASE, CINAHL, PsycLINT, NHS Economic Evaluation Database (NHS EED) and Health 
Technology Assessment (HTA) Database.   
Appendix 2- Search terms for the methodological review 
Search terms used in NHS EED (search conducted on the 20th February 2009): 
MeSH Alcohol-Related Disorders EXPLODE 1 2 
MeSH Alcohol Drinking EXPLODE 1 
MeSH Temperance EXPLODE 1 
MeSH Alcohol Deterrents EXPLODE 1 
"alcohol drinking" 
alcoholism 
dispomania 
"alcohol consumption" 
drink* NEAR excess* 
drink* NEAR binge 
drink* NEAR heavy 
drink* NEAR hazard* 
drink* NEAR problem* 
drink* NEAR abuse 
drink* NEAR misus* 
drink* NEAR dependen* 
drink* NEAR harm* 
alcohol* NEAR excess* 
alcohol* NEAR binge 
alcohol* NEAR heavy 
alcohol* NEAR hazard* 
alcohol* NEAR problem* 
alcohol* NEAR abuse 
alcohol* NEAR misus* 
alcohol* NEAR dependen* 
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alcohol* NEAR harm* 
"alcohol intake" 
#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 
or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 
Search term used in Ovid MEDLINE(R) <1996 to June Week 3 2009> 
1 exp "Costs and Cost Analysis"/ (82400) 
2 "Value of Life"/ (1918) 
3 Economics/ (4946) 
4 Economics, Nursing/ or Economics, Medical/ or exp Economics, Hospital/ or Economics, 
Pharmaceutical/ (10206) 
5 or/1-4 (92049) 
6 (econom$ or cost$ or pric$ or pharmacoeconomic$).ti,ab. (211115) 
7 (expenditure$ not energy).ti,ab. (7686) 
8 (value adj1 money).ti,ab. (5) 
9 budget$.ti,ab. (7551) 
10     or/6-9 (218522) 
11     5 or 10 (256051) 
12     letter.pt. (345003) 
13     editorial.pt. (157702) 
14     historical article.pt. (87278) 
15     12 or 13 or 14 (582776) 
16     11 not 15 (242581) 
17     Animals/ (1855341) 
18     Humans/ (5020366) 
19     17 not (17 and 18) (1233871) 
20     16 not 19 (222896) 
21     (metabolic adj cost).ti,ab. (324) 
22     ((energy or oxygen) adj cost).ti,ab. (1055) 
23     20 not (21 or 22) (221855) 
24     *Alcohol Drinking/ (12245) 
25     exp Alcohol-Related Disorders/ (26846) 
26     *Temperance/ (477) 
27     Alcohol Deterrents/ (671) 
28     exp Self-Help Groups/ (3755) 
29     "alcohol drinking".mp. (20904) 
30     Alcoholism.mp. (20011) 
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31     dipsomania.mp. (7) 
32     "alcohol consumption".mp. (11894) 
33     (drink$ adj excess$).tw. (59) 
34     (drink$ adj binge).tw. (48) 
35     (drink$ adj heavy).tw. (61) 
36     (drink$ adj hazard$).tw. (31) 
37     (drink$ adj problem$).tw. (319) 
38     (drink$ adj abuse).tw. (10) 
39     (drink$ adj misus$).tw. (1) 
40     (drink$ adj dependen$).tw. (7) 
41     (drink$ adj harm$).tw. (9) 
42     (alcohol$ adj excess$).tw. (61) 
43     (alcohol$ adj binge).tw. (45) 
44     (alcohol$ adj heavy).tw. (20) 
45     (alcohol$ adj hazard$).tw. (4) 
46     (alcohol$ adj problem$).tw. (1451) 
47     (alcohol$ adj abuse).tw. (4908) 
48     (alcohol$ adj misus$).tw. (686) 
49     (alcohol$ adj dependen$).tw. (4500) 
50     (alcohol$ adj harm$).tw. (41) 
51     "alcohol intake".tw. (4549) 
52     or/24-51 (56921) 
53     23 and 52 (2454) 
54     Rehabilitation Centers/ (2426) 
55     Health Behavior/ (16257) 
56     Health Education/ (17506) 
57     Preventive Health Services/ (4364) 
58     Preventive Psychiatry/ (25) 
59     Directive Counseling/ (403) 
60     exp Behavior Therapy/ (18354) 
61     exp Cognitive Therapy/ (7964) 
62     exp Evidence-Based Medicine/ (33317) 
63     Hospitalization/ (26490) 
64     (Referral and Consultation).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] (21707) 
65     Health Promotion/ (24792) 
219
66     Health Maintenance Organizations/ (7158) 
67     "relapse prevention".mp. (976) 
68     "harm reduction".mp. [mp=title, original title, abstract, name of substance word, subject 
heading word] (1410) 
69     (naltrexone or acamprosate or disulfiram or opioid-antagonist).tw. (3630) 
70     campral.mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
(12) 
71     anti?craving.tw. (52) 
72     dis?lfiram.tw. (506) 
73     disulfiram.tw. (506) 
74     dissulfiram.tw. (1) 
75     disulfuram.mp. [mp=title, original title, abstract, name of substance word, subject heading 
word] (2) 
76     "brief intervention".tw. (616) 
77     "motivational interviewing".tw. (582) 
78     "motivational enhancement therapy".tw. (96) 
79     "social behavio?r".tw. (2120) 
80     "cognitive behavio?ral therapy".tw. (2355) 
81     "aversion therapy".tw. (28) 
82     "relapse prevention".tw. (976) 
83     "skills training".tw. (1531) 
84     treatment.mp. (1322331) 
85     or/54-84 (1448580) 
86     53 and 85 (1076) 
87     limit 86 to yr="2008-2009" (110) 
.
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Appendix 3- Characteristics of the studies reviewed
General characteristics of the 27 economic evaluations: Primary studies
Study ID Objectives Population/ Setting Intervention Perspective Ec. Ev./ endpoint*
Alwyn et
al., 2004
To assess the cost effectiveness of a
psychosocial intervention for use as an
adjunct to a home detoxification
programme, in comparison to
detoxification only.
Patients suitable for home
detoxification: delivered in 4
centres.
UK.
Home detoxification with brief
psychological intervention vs.
detoxification only, delivered by
Community Psychiatric Nurses
(CPNs).
Health care
system.
CEA, CCA.
Effectiveness included
alcohol consumption and
alcohol-related problems. No
endpoint specified.
Babor et
al., 2006
To evaluate the effectiveness and costs
of Brief Intervention (BI) for patients
screening positive for at risk drinking
in Managed Care Organizations
(MCOs).
Patients 18 years of age or older.
15 clinic sites within 5 MCO
settings.
USA.
BI delivered by licensed
practioners compared to BI
delivered by nurses.
Health service
provider
perspective.
CEA, CMA.
Number of drinks per week.
Barrett et
al., 2006
To assess the cost effectiveness of
referral to an Alcohol Health Worker
(AHW) for alcohol misusing patients
attending an Accident and Emergency
Department (AED).
Adults drinking hazardously
attending an AED in a general
hospital in London.
UK.
AHWs brief intervention lasting
20 and 50 min versus usual care
(an information leaflet “Think
About Drink”).
Societal
perspective.
CEA.
Unit reduction in the amount
of alcohol consumed per
week.
ICER presented.
Bischof et
al., 2008
To compare a Stepped Care (SC)
approach for at-risk consumers and
individuals with alcohol use disorders
in primary health care settings
compared to a Full Care (FC)
intervention and a Control Group
(CG).
Patients between 18 and 64 years
old screening positive were
separated into: Alcohol
Dependence (AD), Alcohol
ABuse (AAB), At Risk (AR) and
Heavy Episodic Drinking (HED).
German general practices.
GERMANY.
SC: a computerized intervention
plus up to three 40 min telephone-
based interventions depending on
the success of the previous
intervention; FC: a computerized
intervention plus a fixed number
of four 30 min telephone-based
interventions; CG: untreated.
German health
system.
CEA, CMA.
Effectiveness included
alcohol consumption
measures. No endpoint
defined.
Fals-
Stewart et
al., 2005
To examine the clinical efficacy and
cost effectiveness of the new Brief
Relationship Therapy (BRT). This was
a shortened version of Standard
Behavioural Couple Therapy (S-BCT).
Heterosexual couples with males
seeking treatment for alcohol
problems. Male was alcohol
dependent (DSM-IV). Female
was no substance-abusing. USA.
BRT compared to S-BCT,
Individual-Based Treatment (IBT)
and Psychoeducational Attention
Control Treatment (PACT).
Health service
and patient’s
perspective.
CEA.
Percentage Days of Heavy
Drinking (PDHD).
Average effectiveness/ cost
ratios presented.
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Study ID Objectives Population/ Setting Intervention Perspective Ec. Ev./ endpoint*
Fleming et
al., 2002
To describe the 48-month efficacy and
benefit cost analysis of Project TrEAT
(Trial for Early Alcohol Treatment), a
randomized controlled trial of brief
physician advice for the treatment of
problem drinking.
Men and women ages 18-65.
Community-based primary care
practices in 10 southern
Wisconsin counties.
USA.
Two physician visits (15 min
sessions 1 month apart) and two
nurse follow-up calls (5 min, 2
weeks after each physician
session). Subjects in the control
group received a general health
booklet; as well as those in the
experimental group.
Health care and
patient’s
perspective
(CEA).
Societal
perspective
(CBA).
CEA, CCA.
Effectiveness included
consumption. No endpoint
defined.
CBA: monetary benefits of
avoided suffering, pain and
reduction in quality of life of
victims.
Humphrey
s and
Moos,
1996
To assess the cost effectiveness of
using Alcoholics Anonymous (AA)
versus professional outpatient
treatment.
Patients seeking help for
alcoholism, with no previous
treatment history.
USA.
AA, a self-help and mutual aid
programme versus professional
outpatient alcoholism treatment.
Health care
sector.
CEA, CCA.
Four indicators of alcohol
problems. No endpoint
specified.
Kunz et
al., 2004
To examine the cost and cost
effectiveness of an alcohol Screening
and Brief Intervention (SBI) delivered
in an inner city hospital Emergency
Department (ED) to an underserved
population.
Patients 18 years of age or older
present in the ED to receive
medical care and screened
positively for alcohol problems.
USA.
Brief counselling session and a
health information packet
delivered by Health Promotion
Advocates (HPAs) vs. only the
packet.
Health service
provider
perspective.
CEA.
Three average
cost/effectiveness ratios for
three endpoints AUDIT
score, number of drinks and
percentage of patients heavy
drinking.
Lock et
al., 2006
To evaluate the effectiveness and cost
effectiveness of nurse-led screening
and brief intervention in reducing
excessive alcohol consumption.
Patients 16 years of age or older,
screened with the AUDIT test.
40 general practices.
UK.
Screening and brief intervention
(5-10 min using the “Drink-Less
protocol”) by nurses versus
standard advice with the leaflet
“Think about Drink”.
NHS perspective
and patients’
costs.
CEA, CMA.
Alcohol problems and
HRQoL measures. No
endpoint specified.
Long et
al., 1998
To compare effectiveness and cost
effectiveness of a 5-week inpatient
versus a revised two week
detoxification and day-patient regime.
The revised programme had a
cognitive behavioural orientation.
Males and females with an ICD-
10 diagnosis of Alcohol
Dependence Syndrome. UK.
A 5-week residential programme
(current treatment) was compared
with a 2 week in and day- patient
programme.
NHS perspective
CEA, CMA
Alcohol consumption and
related problems.
No endpoint specified.
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Study ID Objectives Population/ Setting Intervention Perspective Ec. Ev./ endpoint*
Nalpas et
al., 2003
To analyse and compare the financial
cost and effectiveness of alcohol
treatment programs in four hospital-
based centres, from inpatient stay to
follow-up 1 year later.
Alcohol dependent (DSM-IV)
patients, 18 years of age or older,
admitted for alcohol
detoxification.
FRANCE.
Four specialized alcohol treatment
centres. Each consisted of a
protocol that started with an
alcohol detoxification period-
inpatient or outpatient- and
continued with a follow-up period.
French national
health insurance
service.
CEA.
Time without relapse.
Average cost/ effectiveness
ratios presented.
O'Farrell
et al.,
1996b
To assess the cost benefit and cost
effectiveness of Behavioural Marital
Therapy (BMT) as an addition to
outpatient alcoholism treatment with or
without additional couples group
therapy.
Newly abstinent married male
alcoholics under outpatient
alcoholism counselling. Spouses
are non-alcoholic. USA.
BMT with individual counselling
compared to individual
counselling alone and compared to
individual counselling with
Interactional Couples Therapy
(ICT).
Veterans Affairs
Medical Centre
perspective
(VAMC) (CEA)
CEA.
PDA and improved marital
functioning.
Average cost/effectiveness
ratios presented
Parrott et
al., 2006
To examine the relationship between
service use and outcomes using an
economic analysis of two alcohol
detoxification programmes in the
Smithfield Centre and the Plummer
Court. Each programme was compared
with no intervention (baseline
compared to 6 months after
intervention).
Alcohol dependents.
Smithfield Centre: direct-access
admissions for alcohol
detoxification.
Plummer Court: all admissions
for alcohol detoxification. UK.
Smithfield Centre- 10-day
detoxification service staffed by
mental health nurses with 24 hour
support from a GP and social care
interventions.
Plummer Court- partial
hospitalisation, 3-day inpatient
detoxification with counselling,
followed by day programme.
Health service
and public sector
perspective.
CEA and CUA.
CEA- PDA, mean DDD and
units consumed over 60 days.
CUA- QALYs gained.
Average cost/effectiveness
ratios presented.
Pettinati et
al., 1999
To assess the cost effectiveness of
inpatient versus outpatient treatment of
selected subjects with alcohol
dependence.
Subjects with alcohol
dependence (DSM-III-R).
Non-profit hospital.
USA.
Inpatient vs. outpatient treatment.
Both treatments were based on the
12-step programme of Alcoholics
Anonymous, but inpatient received
more treatment hours and
attendance at support groups.
Payer
perspective.
CEA.
Rates of “significant
drinking”.
Average cost/ effectiveness
ratio presented.
Rychlik et
al., 2003
To determine whether the economic
benefit attributable to acamprosate is
maintained in the context of standard
care using a prospective cohort study
design.
Alcohol dependent patients
(DSM-IV) prescribed acute
detoxification, followed by
rehabilitation.
GERMANY.
Cohort of patients delivered
adjuvant acamprosate treatment
(1,998 mg/ day), compared to
cohort with no acamprosate
treatment.
German health
insurance and
patient’s
perspectives.
CEA.
Abstinence rate.
Average cost/ effectiveness
ratio presented.
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Study ID Objectives Population/ Setting Intervention Perspective Ec. Ev./ endpoint*
Shakeshaf
t et al.,
2002
To examine the effectiveness and cost
effectiveness of a Brief Intervention
(BI) and Cognitive Behaviour Therapy
(CBT) for alcohol abuse in an
outpatient, community-based setting.
Clients attending a free,
community-based, substance
abuse counselling service.
AUSTRALIA.
BI (one or multiple sessions of
varying length not exceeding 90
min, maximum of six weeks)
versus CBT (six 45-minute weekly
sessions).
Agency
perspective.
CEA.
Effectiveness Index (weekly
and binge consumption,
drinking intensity, number of
alcohol-related problems and
AUDIT score). Average
cost/effectiveness ratios
presented.
Sobell et
al., 2002
To compare the effectiveness and costs
of Motivational Enhancement
Personalized Feedback (MEPF) and
BDG Bibliotherapy Drinking
Guideline (BDG).
Problem drinkers (more than 12
drinks per week or 5 or more
drinks on 5 or more days in the
past week). CANADA.
MEPF consisted of advice and
personalized feedback by post to
help reduce consumption. BDG
consisted of two informative
pamphlets.
Payer
perspective.
CEA, CCA.
Effectiveness included
alcohol consumption. No
endpoint specified.
UKATT
Research
Team,
2005a
To compare the cost effectiveness of
Social Behaviour and Network
Therapy (SBNT), a new treatment for
alcohol problems, with Motivational
Enhancement Therapy (MET).
Patients seeking treatment for
alcohol problems of all ages
above 16. Seven treatment sites.
UK.
SBNT (up to eight 50 min
sessions) versus MET (three 50
min sessions).
Health service
and public sector
perspective.
CUA.
QALYs gained.
ICER presented.
Zarkin et
al., 2008
To evaluate the costs and cost
effectiveness of the COMBINE
(Combined Pharmacotherapies and
Behavioural Intervention) study
interventions after 16 weeks of
treatment.
Alcohol dependent participants
(DSM-IV) abstinent for 4 to 21
days. Eleven US clinical sites.
USA.
Nine treatment groups: 4 received
Medical Management (MM) for 16
weeks with naltrexone,
acamprosate or both, and/or
placebo; 4 received the same but
with Combined Behavioural
Intervention (CBI), and 1 received
CBI only.
Treatment
provider
perspective.
CEA.
Three ICERs for 3 endpoints:
percentage of abstinent days,
number of patients avoiding
heavy drinking, and number
of patients achieving a good
clinical outcome.
*The endpoint used in the economic analysis is the one presented; ID, Identification; Ec. Ev., Economic Evaluation; CEA, Cost Effectiveness Analysis; CUA, Cost
Utility analysis; CBA, Cost Benefit Analysis; CCA, Cost Consequence Analysis; CMA, Cost Minimization Analysis; ICER, Incremental Cost Effectiveness Ratio
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Study ID Objectives/ Modelstructure Population/ Setting Intervention Perspective
Ec. Ev./
endpoint*
Corry et
al., 2004
To compare the cost
effectiveness of “current”
and “optimal” treatments
of alcohol dependency
and harmful use, each one
in comparison with “no
treatment”.
Hypothetical cohort of the Australian
population who met the criteria for an
alcohol-use disorder (ICD-10) and who
identified it as their main principal
complaint.
AUSTRALIA.
For current care, harmful use had two or more
contacts with the same health professional and
treatment either with CBT or counselling,
while alcohol dependency additionally
required medication. Optimal care was a
hypothetical treatment informed by evidence-
based practice.
Australian
National
Health
Service.
CUA.
Years Lived with
Disability (YLD)
averted.
ICER presented.
Doran et
al., 2004
To evaluate the
effectiveness and the
costs of GPs detecting at-
risk drinkers and offering
an intervention to modify
drinking behaviour.
Decision tree.
Hypothetical cohort of patients presenting
at a GP for any reason. Patients were at
least 14 years of age. At-risk alcohol
consumption was defined as a score of 5+
(males) and 4+ (females) to the first three
items of the AUDIT questionnaire.
AUSTRALIA.
The current level of detection and intervention
was compared with four different scenarios:
1) increased rate of detection by 5, 10 or
100%; 2) increased rate of intervention by 5,
10 or 100%; 3) increased rate of effectiveness
of the intervention by 5, 10 or 100%; 4)
increases in rates of detection and intervention
by 5%, rates of intervention and effectiveness
by 5%, and rates of detection and
effectiveness by 5%.
Australian
National
Health
Service.
CEA.
Consumption
reduction.
Average cost/
effectiveness ratio
presented.
Gentilello
et al., 2005
To estimate the cost
savings resulting from
routine provision of BIs
to patients in general
wards or EDs. Markov
model.
Injured patients treated in an ED or
admitted to a hospital. Patients were 18
years of age or older, and had either a blood
alcohol level h 100mg/dl or a positive result
on a standard brief alcohol disorder
screening questionnaire.
USA.
Patients who screened positive and offered a
brief intervention compared to injured patients
not screened and not offered the intervention.
Health service
perspective.
CEA, CCA No
endpoint defined.
Lindholm,
1998
To determine the cost
effectiveness of providing
alcohol advice in primary
health care to reduce
alcohol intake from a
“high” to a “moderate”
level.
Two hypothetical cohorts of 100 men who
were 40 years old. One cohort consisted of
“heavy drinkers” while the other consisted
of “moderate drinkers”.
SWEDEN.
5 GP visits during 1 year compared to “do
nothing” (no advice to reduce alcohol
consumption).
25 GP visits during 5 years compared to “do
nothing”.
Swedish health
care system.
CEA.
Life years gained.
ICER presented.
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Study ID Objectives/ Modelstructure Population/ Setting Intervention Perspective
Ec. Ev./
endpoint*
Mortimer
and Segal,
2005
To compare the
performance of
competing and
complementary
interventions for
prevention or treatment of
problem drinking and
alcohol dependence.
Separate Markov models
for each intervention.
Brief intervention for problem drinking:
heavy drinkers h 19 years old and
hazardous drinkers not physically
dependent 17-70 years old.
Psychotherapy for mild to moderate
dependence: patients seeking help for
alcohol problems and drinkers 15-59 years
old.
Drug therapy for detoxified patients with a
history of severe dependence: no significant
psychological disorder and no coexisting
drug use.
AUSTRALIA.
Interventions were divided into three clusters
of mutually exclusive programs: 1) brief
interventions for problem drinking, 2)
psychotherapy for mild to moderate
dependence and 3) drug therapy adjuvant to
counselling for detoxified patients with a
history of severe physical dependence.
Payer
perspective.
CUA.
QALYs. gained.
ICER presented.
Palmer et
al., 2000
To determine the cost
effectiveness of alcohol
detoxification with
adjuvant acamprosate
therapy. Separate Markov
models for each disease.
Detoxified alcoholic male cohort with
average age of 41 years, 80% with fatty
liver, 15% with cirrhosis, 22% with chronic
pancreatitis, and 1% with cardiomyopathy
at baseline.
GERMANY.
Standard counselling therapy versus standard
therapy plus 48 weeks of adjuvant
acamprosate in detoxified alcoholic patients.
German third-
party payer
(health
insurance).
CEA
Life years gained
from abstinence.
No ratio:
acamprosate is
dominant.
Schadlich
and
Brecht,
1998
To determine the cost
effectiveness of alcohol
detoxification with
adjuvant acamprosate
therapy. Decision tree
with Monte Carlo
simulation.
Patients included in the Prevention of
Relapse with Acamprosate in the
Management of Alcoholism (PRAMA)
study (Sass et al. 1996): alcohol-dependent
patients, recruited from 12 psychiatric
outpatient clinics.
GERMANY.
Standard therapy versus standard therapy plus
48 weeks of adjuvant acamprosate in
detoxified alcoholic patients. Standard care
consisted on counselling or psychotherapy
according to routine practices.
German
healthcare
system.
CEA.
Proportion of
abstinent
alcoholics.
No ratio:
acamprosate is
dominant.
Wutzke et
al., 2001
To determine the cost
effectiveness of a BI.
Decision tree.
Hazardous and harmful drinkers from a BI
trial (Gomel et al., 1994): h 16 years of age.
AUSTRALIA.
Four training and support strategies compared:
control, no-support, minimal support and
maximal support.
Health service
perspective.
CEA.
Life years gained.
ICER presented.
*The endpoint used in the economic analysis is the one presented; ID, Identification; Ec. Ev., Economic Evaluation; CEA, Cost Effectiveness Analysis; CUA, Cost
Utility analysis; CBA, Cost Benefit Analysis; CMA, Cost Minimization Analysis; CCA, Cost Consequence Analysis; ICER, Incremental Cost Effectiveness Ratio
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treatment under evaluation costs
Methods for identification, measurement and valuation of individual outcomes, economic consequences and input costs
Individual outcomes Primary studies
Study ID Identification Measurement Valuation
Alwyn et al.,
2004
1) Alcohol consumption; 2) Dependence;
3) General alcohol-related problems; 4)
Social satisfaction; 5) Self esteem.
1) Number of days abstinent in the previous 90
days, drinks per drinking day (1 unit=8g ethanol),
total consumption during the 90 previous days (all
measured with Form 90), and time to first drink
following treatment; measured at baseline, 3
months and 12 months after treatment; 2) SADQ,
at baseline and 12 months; 3) APQ, baseline and
12 months; 4) Social Satisfaction Scale, baseline,
3 months and 12 months after treatment;
5) Self Esteem Questionnaire.
Comparison between intervention and control groups.
1) Differences in changes from baseline to 3 months and to
12 months. Number of participants abstinent or moderate
drinking (X 3 units a day); 2, 3) Differences in changes in
score from baseline to 12 months; 4) Differences in
changes in score from baseline to 3 and 12 months; 5)
Differences in changes in score.
Babor et al.,
2006
Primary alcohol consumption: number of
drinks per week
Secondary alcohol consumption:
frequency of heavy drinking (4 or more
drinks); “Drinkers Index”
Other secondary: Health-Related Quality
of life (HRQoL)
Interviews at 3 and 12 months.
Alcohol consumption: measured using the AUDIT
questionnaire. The primary outcome used the first
two AUDIT questions (quantity and frequency),
and the secondary used the third AUDIT question.
“Drinkers Index” consisted of a summary score of
the first three AUDIT items.
HRQoL- used the SF-12 for physical and mental
functioning.
Changes between baseline and 3 and 12-month follow-up,
between the two interventions and between interventions
together and comparison group. SF12 was not
administered at baseline.
Primary: reduction in number of drinks per week.
Secondary: decrease in heavy drinking, improvement in
the index’s score and change in SF 12 (not explicitly
showed in the study).
Barrett et al.,
2006
Alcohol consumption- alcohol consumed
per week.
Number of units of alcohol consumed per week-
self-reported using Form 90AQ and the Steady
Pattern Grid, at 6 and 12 months follow-up.
Reduction in the number of units of alcohol consumed per
week.
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Individual outcomes Primary studies
Study ID Identification Measurement Valuation
Bischof et al.,
2008
Alcohol consumption for: all patients,
AD, AAB/AR or HED patients, for SC
and FC separately, for SC+FC together,
and for CG.
Measured at baseline and 12 months follow-up QF
estimation.
1) Gram alcohol per day follow-up; 2) Mean
difference in gram of alcohol per day baseline to
follow-up; 3) Percentage binge criteria at follow-
up. Also, regression to compare effectiveness of
SC +FC with CG.
AR defined according to British Medical Association; AD,
AA defined according to DSM-IV; HD defined according
to authors’ own criteria.
Differences in 1, 2 and 3 between intervention (SC+FC)
and CG and between SC and FC. Percentage reduction in
alcohol consumption at follow-up with intervention vs.
CG.
Fals-Stewart
et al., 2005
1) Alcohol-related problems: global
relationship satisfaction to female
partner; 2) Alcohol consumption.
Measurements at baseline, completion at discharge
and every 3 months thereafter for 1 year.
1) Dyadic Adjustment Scale (DAS); 2) Days of
heavy drinking- TLFB.
1) DAS score; 2) Percentage days of heavy drinking.
Heavy drinking defined as drinking six or more standard
drinks.
Fleming et
al., 2002
1) Alcohol consumption: mean number of
drinks during the past 7 days, number of
binge drinking episodes in the past 30
days, any binge drinking in the past
month, and excessive drinking in the past
week; 2) Health status included:
depression, medication use, tobacco use,
and illicit drug use; 3) Mortality.
1) Follow-up at 6, 12, 24, 36, and 48 months post
intervention, using TLFB methods; 2) Assessed at
the follow-up interviews; 3) Obtained through
patient follow-up procedures, family members
contact, the Social Security Death Index, and the
Wisconsin Department of Administration Records
Management Section.
1) Reductions in alcohol use by comparing intervention
and control groups: differences in 7-day alcohol use and
30-day binge drinking episodes during the last 30 days,
changes in the proportions of heavy drinkers and binge
drinkers; 2) Change from baseline- not presented; 3)
Number of deaths in each group (control vs. intervention).
Humphreys
and Moos,
1996
Four indicators of alcohol problems: 1)
Alcohol consumption; 2) Alcohol
dependence symptoms in the past six
months; 3) Adverse consequences of
drinking in the past six months; 4)
Depression.
Follow-up at one and three years after study entry.
1) Number of days intoxicated in the past month
and number of ounces of ethanol consumed on a
typical drinking day on the past month (1 US
unit=14g=0.5oz); 2) Modified 11-item version of
the ADS; 3) Nine-item scale and also from
collaterals; 4) Nine-item depression scale from the
Health and Daily Living Form.
1) Difference in improvement in alcohol consumption
between the two treatments at follow-up; 2, 3, 4)
Difference in improvement in scores between the two
treatments at follow-up.
Kunz et al.,
2004
1) Alcohol-related problems; 2) Alcohol
consumption: weekly drinks and heavy
drinking.
Measured at baseline and 3 months.
1) AUDIT; 2) Average number of drinks per week
and percentage patients heavy drinking in the past
month: quantity and frequency questions
pertaining to the past 3 months.
1) Drop in AUDIT score; 2) Mean differences in average
reduction in weekly number of drinks and in reduction in
percentage of heavy episodic drinker, at follow-up
between the two groups.
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Lock et al.,
2006
1) Alcohol-related problems; 2) Alcohol
consumption: drinks per drinking day; 3)
Drinking problems in older adults; 4)
HRQoL for mental and physical health.
Measured at baseline, 6 and 12 months.
1) AUDIT score; 2) TLFB; 3) Drinking Problems
Index (DPI) score; 4) SF-12 questionnaire score.
Difference in mean scores between intervention and
control (for baseline, 6 and 12 months) and differences in
change from baseline to 6 and 12 months and from 6 to 12
months, between intervention and control.
Long et al.,
1998
1) Alcohol consumption: days abstinent,
intensity of drinking; 2) Alcohol-related
problems: alcohol-related life problems,
SADQ score; 3) Global Measure of
Drinking Outcome and Relapse: alcohol-
related consequences and problems-
patients were categorized into abstinent,
non-problem drinkers, drinking but
improved and unimproved groups.
Patients were followed-up at 6 and 12 months
after discharge:
1) Percentage of days abstinent, Intensity of
drinking (total units consumed-1unit=8g alcohol-
during the follow-up period divided by the number
of actual drinking days); 2) Alcohol-related life
problems (range 0-18), Self-reported SADQ score
(range 0-60); 3) Categorization of patients based
on: a) Drinkers profile, b) Collateral report, c)
Blood test, on intake and at 12-months.
1, 2) Mean values at baseline and follow-up and
differences between the groups at 1 year; 3) Differences in
the percentages of categorized patients between groups.
Blood test: MCV and GGT.
Nalpas et al.,
2003 Alcohol status: abstinence or relapse.
Relapse: any alcohol consumption.
Evaluations were scheduled at months 3, 6, 9, and
12.
Mean time without relapse.
O'Farrell et
al., 1996b
1) Alcohol-related problems: marital
satisfaction and marital stability; 2)
Alcohol consumption: abstinence.
Measurements 12 months before and 24 months
after.
1) Marital Adjustment Test (MAT) was used to
assess marital satisfaction, and the number of days
separated to assess marital stability; 2) TLFB
method.
1) Comparisons between husbands’ and wives’ MAT
scores and percentage of days separated; 2) Comparison
between percentages of days abstinent.
Parrott et al.,
2006
1) Alcohol consumption variables:
percent days abstinent, mean number of
drinks per drinking day, total quantity of
alcohol consumed by a patient; 2)
Alcohol-related problems; 3) Health-
related quality of life measures: QALYs
and health profiles.
Assessments at baseline and at follow-up 6 months
after discharge.
1) Form 90 (covering the previous 60 days); 2)
SADQ; 3) Questionnaires SF-12 (PCS and MCS),
EQ5D and GHQ.
Mean changes per patient for the questionnaires’ scores
assessed with a set of regressions.
QALYs were calculated using the area under the curve
between the EQ-5D score at baseline and 6 month follow-
up assuming a linear change over the time period.
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Pettinati et
al., 1999
Alcohol consumption: significant
drinking defined as three or more
alcoholic drinks in a sitting and/ or
admission to inpatient or detoxification.
TLFB: number of drinking days and whether there
was significant drinking on drinking days, during
treatment and at 3, 6 and 12 months after
treatment.
Differences between the outpatient and inpatient groups in
the rate of return to significant drinking following
treatment up to 12 months after treatment (survival
analysis), intention to treat and treatment completers.
Differences between the outpatient and inpatient groups in
the rate of return to significant drinking at all 3 follow-up
points while covarying subjects for the number of lifetime
drinking consequences (hierarchical logistic regression
analysis).
Rychlik et
al., 2003 Alcohol consumption- Abstinence rates. Abstinence was assessed by the treating physician.
Abstinent/ not abstinent/ unknown.
The patient was assessed as abstinent only if both the
patient and the doctor confirmed this.
Shakeshaft
et al., 2002
1) Weekly alcohol consumption, National
Health and Medical Research Council
(1992) criteria, low risk: 28 (males) or 14
(females) standard drinks or less per
week, hazardous: 29-42 (males) or 15-28
(females) standard drinks per week,
harmful: more than 42 (males) or 28
(females); 2) Binge alcohol consumption:
more than six (males) or four (females)
standard drinks on any one occasion; 3)
Alcohol-related problems; 4)
Effectiveness Index.
Baseline and 6 months after intervention
measurements.
1) Assessed using a 1-week RD diary; 2) Assessed
using the QF index; 3) Assessed using the APQ
and a composite measure, the AUDIT
questionnaire; 4) Based on 5 drinking outcomes:
weekly consumption, number of binge drinking
episodes, drinking intensity (number of drinks
consumed per week divided by number of
drinking days), number of alcohol-related
problems and AUDIT score
1) Change in mean weekly consumption and proportion of
clients at-risk at pre versus post-test (at risk is hazardous
or harmful consumption); 2) Change in mean number of
binge episodes reported and proportion of those who
reported any binge episode, and the proportion of those
who reported 12 or more binge episodes; 3) Change in
mean number of problems reported. AUDIT- Proportion
of clients scoring 8 or more at post-test, relative to pre-
test; 4) A self-reported increase in each drinking outcome:
score of 1, no change in outcome: score of 2 and decrease:
score of 3. Scores for each treatment outcome were
summed.
Sobell et al.,
2002
1) Alcohol consumption: drinking days
per week, drinks per drinking day, drinks
per week, days drinking five or more
drinks; 2) Alcohol-related problems.
TLFB questionnaire covering the period of time
from initial screening through to 12-month follow-
up.
1) Percentage change on mean alcohol consumption
measures (1 drink= 13.6g); 2) Percentage change on mean
alcohol problems (the number of consequences ranged
from 0 to 8).
UKATT
Research
Team, 2005a
Health-related measure: QALYs. Participants completed the EQ5D questionnaire atbaseline and at 3 and 12 months.
UK population norms for the valuation of health states and
linear interpolation to identify the areas under the QALY
curve.
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Zarkin et al.,
2008
Alcohol consumption: 1) Abstinence; 2)
Heavy drinking; 3) Good clinical
outcome (abstinent or moderate drinking
without problems).
1) Percentage of days abstinent; 2) Proportion of
patients who did not return to heavy drinking; 3)
Proportion of patients who maintained a good
clinical outcome.
Differences in: 1) Mean percentage of days abstinent; 2)
Proportion of patients who did not return to heavy
drinking; 3) Proportion of patients who maintained a good
clinical outcome.
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Corry et al.,
2004
Years Lived with Disability
(YLD) averted.
The effectiveness of optimal care was
derived from two meta-analyses. For
current care, the Australian survey of
residents was reviewed.
YLD were calculated as the product of prevalence and disability. The
conversion of changes in symptoms severity, expressed as effect sizes,
into disability weights used a linear function. The YLD averted for “no
treatment” were assumed to be null.
Doran et al.,
2004 Alcohol consumption.
Number of at risk drinkers reducing their
alcohol consumption after detection and
intervention by a GP.
Several published sources were used to populate the model.
It was assumed that the rate at which at-risk drinkers consult a GP was
similar to that of the general population.
Gentilello et
al., 2005
Intoxication or alcohol problems,
with injuries requiring ED visits or
hospitalization.
Number of patients with subsequent
injuries and having to repeat an ED visit or
having to repeat hospitalization.
Reduced probability of a patient having to repeat an ED visit or having
to repeat hospitalization due to subsequent injuries. A literature review
was conducted. Authors’ assumptions were applied. The reduced
probability was directly calculated by the model, however values were
not presented. The authors only considered cost-savings from this
reduction.
Lindholm,
1998 Life years gained.
Survival curves were presented to calculate
the number of years of life gained in
average if heavy drinkers reduce their
consumption of alcohol before the age of
40.
Moderate drinkers were assumed to have the same annual age-specific
mortality risk as the average figures for Swedish men.
Heavy drinkers were assumed to have a doubled mortality risk during
the ages 40-70. After the age of 70 years, the two cohorts were
assumed to have the same risk. Discount rate 5%.
Mortimer
and Segal,
2005
HRQoL: QALYs.
HRQoL gain: proportion of patients
drinking either side of a specified threshold
at 6 or 12- month follow-up and relapse
rates in the base-case.
HRQoL gain directly attributable to behaviour change depends on the
severity of alcohol problems as per disability weights from Southard et
al. (1997) such that returning problem and dependent drinkers to a
“safe” consumption pattern is assumed to imply annual QALY-gains of
0.110 and 0.330, respectively. Discount rate 5%.
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Palmer et al.,
2000 Life years gained.
Complications of alcoholism modelled:
relapse, alcohol-related hepatic disease,
acute and chronic pancreatitis, acute and
chronic gastritis, oropharyngeal carcinoma,
oesophageal carcinoma, alcoholic
cardiomyopathy, alcohol-related peripheral
neuropathy, alcoholic psychosis, accidental
death and suicide.
Probabilities for clinical events were retrieved from published
literature, mostly German studies. For each of these complications
different events were attributed probabilities which were different if the
individual relapsed or abstained.
Abstinence rates for the acamprosate-treated cohort were taken from a
single long-term study, the PRAMA study (Sass et al., 1996) and
projected for 5 years.
Life years gained with adjuvant acamprosate over standard therapy
calculated from the lifetime model. Discount rate 5%.
Schadlich
and Brecht,
1998
Abstinence.
Proportion of abstinent alcoholic at 48
weeks follow-up after a 48-week
intervention.
Percentage of patients remaining abstinent at the end of the medication
taken from the follow-up period in the PRAMA study (Sass et al.,
1996). Discount rate 5%.
Wutzke et
al., 2001 Life years gained.
Life years gained was derived by
combining the estimates of the impact of
the programme if it were implemented
nationally with available evidence on the
health effects of excess alcohol
consumption.
The results of the drink-less trial (Gomel et al., 1994) were used to
estimate the number of people who would be screened in GP practice,
the proportion of those screened who would be “at-risk” drinkers, and
the proportion of “at-risk” drinkers who would be subsequently
counselled.
Number of lives saved: pre and post-intervention aetiological fractions
of alcohol-caused mortality taken from epidemiological sources.
Discount rate 3%.
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Alwyn et al., 2004 Not taken into account.
Babor et al., 2006 Not taken into account.
Barrett et al., 2006
1) Other alcohol services; 2)
Hospital services; 3) Primary
care services; 4) Other social
and non statutory services; 5)
Criminal justice; 6)
Productivity losses.
Mentioned that childcare and
travel costs were not included
because they were likely to
be negligible.
Measurements at 6 and 12 month follow up, based on
Parrott (2001) questionnaire.
1) Inpatient days, attendance at outpatient and day
patient, contacts with other alcohol support; 2)
Attendance at AED, outpatient and day patient, call
outs to emergency ambulance and inpatient days; 3)
Contacts with GP, practice nurse, district nurse,
community psychiatric nurse, psychiatrist,
psychologist, occupational therapist, and counsellor;
4) Contacts with social worker, social worker
assistant, home help, advice service, solicitor, fire
service, and other community service; 5) Contacts
with police and probation officer, night in Prison and
days in court; 6) Number of days out of work due to
alcohol misuse.
1, 2, 3, 4) Average costs: taken from Trust Financial
Returns and NHS reference cost from the Department of
Health; National unit costs: Netten and Curtis (2002),
British Medical Association & Royal Pharmaceutical
Society of Great Britain; 5) Government sources: contacts
with police- costed using the Metropolitan Police Ready
Reckoner; Time spent in prison- costed using the Prison
Service Annual Report; 6) Human capital approach
(number days taken off work*individual gross daily salary).
Unit costs not presented, but quantities of resources
presented. Price year 2001/02, inflated using HCHS (Netten
and Curtis, 2002).
Discounting NA.UK pound sterling.
Bischof et al., 2008
Utilization of formal help:
professional advice, alcohol
detoxification, rehabilitation
treatment or visits to self-
help groups.
1) Percentage of patients seeking help at follow-up for
SC+FC and CG by AD and AA/ AR subgroups.
2) Percentage of patients seeking help at follow-up for
SC and FC by AD and AA/ AR
1) Statistically significance of the difference between
SC+FC and CG reported
2) Statistically significance of the difference between SC
and FC reported
Monetary valuations not reported.
Fals-Stewart et al.,
2005 Not taken into account.
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Fleming et al., 2002
1) Motor vehicle events; 2)
Legal events; 3) Medical use;
4) Victims’ work loss.
1,2) Motor vehicle and legal events, during the 48-
month follow-up period, numbers for treatment and
control groups- records from the Wisconsin
Department of Justice, Crime Information Bureau
(1994, 1999) and the Wisconsin Department of
Transportation (1994, 1999); 3) Patients were asked to
recall, since last interview.
1) Motor vehicle crash with fatalities, with non-fatal
injuries or with property damage only, operating while
intoxicated or other moving violations; 2) Assault/
Battery/ Child abuse, Resist/ Obstruct officer/
Disorderly conduct, Controlled substance/ Liquor
violation, Criminal damage/ Property damage, Theft/
Robbery, other arrests; 3) days of hospitalization,
number of emergency department visits.
Health care utilization/ benefits of avoided health services
utilization: Average Medicare reimbursement rates for per
day hospitalizations and per emergency department visit-
used in the medical care system perspective and societal
perspective.
Reductions in legal events and motor vehicle accidents-
derived from estimates reported in Miller et al. (1996):
include direct expenses such as medical care, mental health
services, property damage, victim work loss, public service
costs, and other monetary losses. Costs of crime and motor
vehicle crashes include victims’ pain and suffering and
reduction in quality of life- used in the societal perspective.
Medical care expenses for legal events pertain to health care
for victims of crimes. Miller et al (1996) estimated the costs
of reduced quality of life caused by crimes or accidents
from jury awards of pain, suffering, and morbidity resulting
from physical injuries and fear.
To avoid the possibility of double counting hospitalizations
and emergency room visits resulting from accidents, the
estimated medical costs provided by Miller et al. (1996)
were excluded from the total cost of accidents.
Unit costs not reported separately from quantities of
resources. Price year 1993. Discounting was not conducted.
US dollars.
Humphreys and
Moos, 1996
Additional care:
detoxification, inpatient and
residential treatment.
Measured at one and three years after study entry.
Detoxification- number of days; inpatient and
residential treatment- number of days.
Costs for the different services were computed based on
published information (Holder et al., 1991).
Quantity of resources reported. Unit costs not presented.
Price year 1994 dollars. Discount rate 5%. USA dollars.
Kunz et al., 2004 Not taken into account
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Lock et al., 2006
1) NHS resources;
2) Individuals’ costs: travel
and time costs, absences
from work, property damage
or accidents.
Resources use by individual patients reported by self-
completion questionnaire, at 12 months follow-up for
the previous 12 months.
1) Number of visits: GP and nurse, AED, hospital
inpatient, and hospital outpatient; 2) Time travelling,
waiting at surgeries and hospitals, and spent in
appointments, transport costs, number and length of
absences from work, out-of-pocket expenses related to
property damage or accidents.
Resource use and mean cost per patient described for health
care costs, but not for the individual costs identified.
Average patient costs reported but a breakdown of these
costs was not given. Unit costs taken from Netten and
Curtis (2002).
Price year 2001/2002. Discounting NA. UK pound sterling.
Long et al., 1998 Not taken into account.
Nalpas et al., 2003 Work interruptions related toalcohol problems. Number of days lost at work due to alcohol problems.
Costs of work interruptions- calculated according to the
socioprofessional category and the corresponding salary of
governmental employees.
Average costs presented. Price year 2000. Discounting NA.
Francs, converted to Euros.
O'Farrell et al.,
1996b
1) Inpatient hospitalizations
(for alcohol detoxification or
rehabilitation programs) and
alcohol halfway houses; 2)
Legal Costs: jail for alcohol-
related reasons.
Measurements 24 months after as compared to 12
months before:
1) Days spent in inpatient hospitalizations and in
alcohol halfway houses- TLFB drinking interview; 2)
Days in jail for alcohol-related reasons (simple arrest-
1 day).
1) Per diem rate for hospitalization was taken from the VA
Cost Distribution Report; per diem rate for halfway house
stays was based on the cost paid on a contract basis by the
VA to local halfway houses for VA patients placed there; 2)
Per diem rate in jail- reported by the Massachusetts
Department of Corrections.
Unit and average costs presented. Price year 1992.
Discounting NA. US dollars.
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Parrott et al., 2006
1) Statutory and non-
statutory services; 2) Other
health care service; 3)
Criminal justice.
Quantities of resource used were recorded from
patient questionnaires (baseline and 6 month follow-
up, for 6 month pre-baseline and 6 months after the
start of treatment).
1) Visits to: social worker, state benefit advisor,
housing benefit advisor and other social advisors, and
citizens advice; 2) GP surgery visits, GP home visits,
Accident and Emergency (no stay), outpatient visits,
and inpatient stays; 3) Arrest, Magistrates court/
appearance, County court/ plea.
1,2) National source of unit costs:
Netten et al. (1999); 3) Government source of unit costs:
Field (1997), HM Treasury (2000), Home Office (1998),
Harries (1999)
Unit costs presented. Price year 2003/4, inflated using
HCHS (Hospital and Community Health Services) index
(Netten and Curtis, 2002). Discounting NA. UK pound
sterling.
Pettinati et al., 1999 Not taken into account
Rychlik et al., 2003 Hospitalisations andrehabilitation.
Hospitalisations and rehabilitation were documented
retrospectively, over one year, by the physician:
number of patients hospitalised, number of
hospitalisations and number of hospitalisations/
patient.
Total average costs presented for hospitalisation and
rehabilitation, for each cohort, taken from the medical
departments. No unit costs presented.
Price year 1998/99. Discounting NA. Euros.
Shakeshaft et al.,
2002 Not taken into account.
Sobell et al., 2002 Not taken into account.
UKATT Research
Team, 2005a
1) Health care and alcohol
treatment outside the trial; 2)
Social services; 3) Criminal
justice.
Questionnaire at baseline and 12 months of clients’
use over the previous six months.
1) Hospital inpatient/ night, Hospital day patient/ visit,
Hospital outpatient/ appointment, Hospital accident
and emergency department/ visit, GP at home/ home
visit, GP surgery/ consultation, Prescriptions,
Community psychiatric nurse/ home visits,
Detoxification in primary care/ episode, Alcohol
agency- rehabilitation/ night, Alcohol agency-
consultation/ appointment, 2) Social services/ contact;
3) Court attendance- Crown court/ appearance, Court
attendance- Magistrates court attendance/ appearance
1,2) National source of unit costs: Netten and Curtis.
(2002), alcohol treatment: literature (Slattery et al., 2003;
UKATT Research Team, 2005b); 3) Government sources of
unit costs: HM Treasury (2000), Home Office (1998),
Harries (1999)
Unit costs and quantities fully presented. Price year 2000/1.
Discounting NA. UK pound sterling.
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Zarkin et al., 2008 Not taken into account
Note: This is a summary of the methods used in each individual study. For more detailed information of specific procedures and of the references used see the original
source. NA, Not Applicable
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Corry et al., 2004 Not taken into account.
Doran et al., 2004 Not taken into account.
Gentilello et al.,
2005
Health care use: annual ED injury
recidivism (hazard ratio) and annual
injury recidivism requiring
hospitalization (hazard ratio).
Reduction of subsequent health care use taken from
another study by the same authors
Costs of ED visit and of hospitalization- MarketScan
database.
Unit costs and quantities of resources reported
separately. Price year 1998, adjusted with CPI.
Discount rate 3%, US dollars. 3 years time horizon.
Lindholm, 1998 Health care costs.
It was assumed that moderate drinkers have the same
health care costs per person as the average costs for
the Swedish population, while the costs for heavy
drinkers were twice as high.
Annual health care costs per age group from The
Swedish Council on Technology Assessment in
health care.
Unit costs and quantities of resources presented
separately. Price year 1997. Discount rate 5%.
European Currency Units.
Mortimer and
Segal, 2005 Not taken into account
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Palmer et al.,
2000
Alcohol-related interventions and
complications:
Relapse, Liver disease, Gastrointestinal
disease, Cardiomyopathy, Alcohol
psychosis, Peripheral neuropathy.
Cost items used in the model (broken down by event
+first 12 month costs following event and annual
follow up after first 12 months): Alcohol dependence
syndrome, Fatty liver, Cirrhosis, Ascites (non-
infected), Ascites (infected), Hepatic
encephalopathy, Oesophageal varices (no bleeding),
Primary hepatic carcinoma, Liver transplant,
Bleeding oesophageal varices (treated by beta-
blockers or endoscopic sclerotherapy), Bleeding
oesophageal varices (treated by distal spleno-renal
shunt), Alcoholic cardiomyopathy, Heart
transplantation, Acute gastritis, Chronic gastritis,
Acute pancreatitis, Chronic pancreatitis,
Oropharyngeal carcinoma, Oesophageal carcinoma,
Peripheral neuropathy, Alcoholic psychosis.
Costs for each of the alternative intervention
strategies and complications were calculated from
published German sources.
The mean total lifetime costs by relapse, liver
disease, gastrointestinal disease, cardiomyopathy,
alcohol psychosis, and peripheral neuropathy were
valued for standard therapy alone or with adjuvant
acamprosate.
Unit costs and quantities of resources not reported
separately. Price year 1996. Discount rate 5%.
Lifetime model. German Deutschmarks.
Schadlich and
Brecht, 1998
Avoided target events, were coded with
ICD 9: alcohol dependence syndrome,
chronic alcoholic liver diseases, and
alcoholic psychoses.
The costs for these events were: 1)
Case-related hospital treatment costs:
hospital and treatment costs; 2) Case-
related rehabilitation treatment costs:
rehabilitation units and treatment costs.
Number of target events for the acamprosate and
standard-care group (1000 hypothetical patients in
each group): taken from secondary analysis of
epidemiological information, from official and
administrative statistics and expert knowledge.
1) Average hospitalisation per ICD position given by
the disease statistics of the National Association of
Local Sickness Funds; 2) Average duration of
rehabilitation according to ICD position.
Follow up was assumed to remain constant over
time.
1) Costs per treatment day in hospital given by the
Federal Statistical Office (1993 values); 2) Costs per
treatment day in rehabilitation units given by the
Federal Association of Pension Funds (1992 values).
No unit costs presented.
Price year 1995. Discount rate 5%. Lifetime model.
German Deutschmarks.
Wutzke et al.,
2001 Not taken into account
Note: This is a summary of the methods used in each individual study. For more detailed information of specific procedures and of the references used see the original
source. NA, Not Applicable
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Alwyn et al.,
2004
Home, inpatient and outpatient
detoxification, programmes.
In patient: number of days and follow-ups.
Out-patient: number of attendances and follow-ups.
Home-based: number of visits and time (minutes)
spent on visits and follow-ups.
Unit local costs (Cardiff and Vale Community NHS Trust
Finance Department) and unit national costs used (Netten et al.,
2001). Pharmacological treatment costs not reported. Unit costs
and resources reported. Price year 2001. Discounting NA. UK
pound sterling.
Babor et al.,
2006
1) Labour costs; 2) Space costs;
3) Media cost.
1) Average number of minutes spent by MCO staff
per patient; 2) Square footage occupied by each
patient; 3) Number of screening and patient education
materials.
1) Weighted average wage per minute; 2) Dollar value of the
space. More costs information in another study. Unit costs and
quantities of resources not presented. Price year not reported.
Discounting NA. US dollars.
Barrett et al.,
2006
Treatment costs: AHW and
overhead costs (capital,
administration, managerial etc.).
Number of interventions and session time plus
paperwork and onward referral.
Mid-point of the relevant AHW salary scales including all
employer costs and overhead costs (Netten et al., 1998). Unit
costs not presented, but resource use presented. Price year
2001/02, inflated using HCHS (Netten and Curtis, 2002).
Discounting NA. UK pound sterling.
Bischof et al.,
2008
Costs savings of SC vs. FC in an
average medical practice.
Average duration of counselling sessions for SC and
FC, for all patients and, AD, AA/AR or HED patients
separately.
Time spent counselling multiplied by hourly wages. Costs
saved per counselled patient with SC reported. Unit costs and
average costs not reported. Price year not reported. Discounting
NA. Euro.
Fals-Stewart
et al., 2005
1) Treatment costs: equipment
and overheads, staff
(counsellor), space used for
treatment and administration,
urine tests; 2) Time costs for
patient and female partners’; 3)
Travel costs for patient and
female partners’.
1) Time spent by counsellor and space used for
treatment and administration - square footage cost per
patient/month. Overheads- divided equally amongst
patients at the facility; 2) Measured by session time in
attendance logs and self reported time in transit; 3)
Miles travelled.
1) Staff time valued with the pay rate (salary+ fringe benefits).
Space - square footage cost obtained from a local realtor
divided by number of patients; 2) Time costs-pay rate shown on
patient pay stubs brought to sessions; 3) Travel costs- mileage
reimbursement rate used by the university ($0.35 per mile) or
self-reported cost of public transportation used. Resources and
unit costs not presented. Price year not stated. Discounting NA.
US dollars.
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Fleming et
al., 2002
1) Clinic costs- supplies
(booklets, pencils, etc),
overhead-benefit, rent,
screening, assessment,
interventions, follow-up calls
and training sessions for
physicians and staff; 2) Patient
costs- travel cost and waiting
times.
1) Obtained by surveying the manager at each clinic.
Average hourly wage for each category of medical
personnel (provided by the clinic manager)*per-
patient time necessary for the screening, assessment
and intervention. Medical personnel included medical
records clerks, receptionists, registered nurses, and
physicians; 2) Average travel to and from the clinic
(travel cost) and waiting times (lost work time)
(minutes) assessed through surveys.
1) Clinic costs (used in the medical care system and societal
perspectives) - Overheads- assessed at 25% of staff salaries; 2)
Patient costs (used in the societal perspective) were determined
by occupation data from the Wisconsin Career Information
System (1994). The opportunity cost for subjects who were
students, homemakers, or unemployed was assumed equal to
the average hourly wage rate for all occupations in Wisconsin.
Unit costs not reported separately from quantities of resources.
Price year 1993. Discounting was not conducted. US dollars
Humphreys
and Moos,
1996
Outpatient treatment and AA.
Measured at one and three years after study entry.
Outpatient treatment- number of visits; AA- number
of visits.
Costs were computed based on published information (Holder
et al., 1991). AA free of charge but assigned a specific cost per
meeting. Quantity of resources reported but aggregated with
other alcohol services. Unit costs not presented.
Price year 1994. Discount rate 5%. US dollars.
Kunz et al.,
2004
Interventions resources:
personnel, supplies and
materials, contracted services,
buildings and facilities,
equipment, patient incentives
and “miscellaneous items”.
Measurement at follow up and at 3 months.
The Drug Abuse Treatment Cost analysis Program
(DATCAP) (French et al., 2002) was used to collect
resource utilization and cost data. Patient incentives-
money given at baseline and follow-up for survey
completion.
Total SBI costs, average costs of screening per patient and of
brief intervention session per patient were reported. Percentage
spent on personal salaries and benefits, on overheads and
patient incentives and on “miscellaneous supplies” and
equipment were reported. Patient monetary incentive was
reported. Unit costs and quantity of resources were not given.
Control group costs were assumed to be zero. Price year not
reported. Discounting NA. US dollars.
Lock et al.,
2006
Treatment costs: 1) Programme
materials; 2) Intervention
delivery.
1) Allocated to intervention patients using the
equivalent annual cost method (materials were
assumed to last for 10 years); 2) Nurse time (minutes)
per patient.
Programme materials: 6% rate of interest applied. Unit costs
and resources reported. Price year 2001/2002. Discounting NA.
UK pound sterling.
Long et al.,
1998
1) Treatment costs: length of
time in treatment; 2) Use of
aftercare.
1) Mean period of treatment- days and hours; 2) Use
of aftercare- hours of follow-up sessions.
1, 2) Cost per patient= number of hours of inpatient and/ or
outpatient days and follow-up sessions, multiplied by the
standard rate per day for each type of care. Percentage changes
were given, but not unit costs.
Price year not reported. Discounting NA. UK pound sterling.
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Nalpas et al.,
2003
1) Hospitalization for alcohol
withdrawal: type of medical
visits, drugs, tests,
administration, hospital ward
and employees and no medical
support services;
2) Follow-up after alcohol
discharge: stays in the Post
Withdrawal Unit (PWU), type of
medical visits, biological and
medical evaluations, drugs, use
of ambulance transportation,
social interventions.
1) Fixed costs: hospital ward, no medical support
services (nurses, food), and administration expenses.
Variable costs: number and type of medical visits,
drugs and tests performed during this period; 2)
Number and length of stay in PWU (days), sanitary
transportation, paramedical acts, laboratory
investigations, social interventions (hour), drugs,
medical visits (psychiatrist/ psychologist, emergency
units, gastroenterologist, general practitioner, other
specialist, specialist in alcohol treatment).
1) Fixed costs evaluated by using the lower official refund price
from the French national social security service for a 1-day
stay, multiplied by the number of days in the unit. Variable
costs taken from the French general professional act
nomenclature (the price of each medical act was calculated
according to its medical code and its financial value). Costs of
drugs- public sale prices; 2) PWU- highest cost of a 1-day stay
for such a centre*number of days stayed. Ambulance costs
calculated according to the official rate. Social interventions-
cost of a 1-hr intervention with a social worker.
Average and total costs presented. Price year 2000. Discounting
NA. Francs, converted to Euros.
O'Farrell et
al., 1996b Treatment costs.
Number of sessions/ participant=Determined from
research project attendance logs and progress notes in
VA medical records.
Session cost- VA cost accounting information.
Unit and average costs presented. Price year: 1992. Discounting
not reported. US dollars.
Parrott et al.,
2006
Treatment costs: Staff, building,
drugs, overheads, non-staff costs
and 24 hour GP cover and daily
site visits.
Treatment resource use (daily) taken from the centres.
Staff included: nursing, management, catering,
nursing assistants, relief workers, and administration.
Local costs from the two services: all costs valued at centre
prices. Unit costs presented. Price year 2003/04, inflated using
HCHS. Discounting NA. UK poundssterling.
Pettinati et
al., 1999
1) Treatment costs; 2) Patient
costs: transportation to
outpatient sessions and wage
loss due to treatment uptake.
1) Number of treatment service hours and support
groups hours attended each week via interviews with
the subject.
2) Transportation costs and wage loss- no details.
Weighted cost-to-charge ratio applied to the billing charges for
services to adjust for geographic- or institution-specific charges.
Average costs of treatments reported. Some quantities reported
separately from costs. Unit costs not reported. Price year not
reported. Discounting NA. US dollars.
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Rychlik et
al., 2003
1) Treatment costs; 2) Patient
costs- time off work; 3) Patient
costs- travel expenses.
1) Use of treatment resources documented by the
treating physicians and presented for each cohort:
number of physician visits and days of treatment; 2)
Evaluated using the human capital approach; 3)
Kilometre travelled.
1) Costs calculated according to a standardized evaluation scale
in Germany, where all medical interventions are coded; 2) Time
off work- for employed patients the salary was used for the
calculation of the cost per day off work. Unemployed patients
under the age of 65 were attributed gender-specific average
income, whereas no cost was attributed to those over 65; 3)
Each patient visit was attributed a fixed rate per travel. Unit
costs not presented. Price year 1998/99. Discounting NA.
Euros.
Shakeshaft
et al., 2002
1) Treatment costs: CBT and BI;
2) Training costs: CBT and BI;
3) Resource.
1) Time spent by counsellor; 2) CBT: two half-day
training workshops, BI: half-day in house workshop;
3) Number of treatment manuals printed.
1, 2) Treatment and training costs- salary.
Average costs presented. Price year not stated. Discounting NA.
Australian dollars.
Sobell et al.,
2002
Research assistant costs,
materials and advertisement
costs.
Cost per participant: one year’s salary and fringe
benefits for a research assistant, one year’s charge for
a telephone line, and number of: mailed-out feedback
material.
The costs and quantities were not presented separately. Prices
were taken from the authors’ setting. Price year not reported.
Discounting NA. US dollars.
UKATT
Research
Team, 2005a
Treatment costs:
1) Training and supervision; 2)
Treatment delivery.
1) Time trainers and therapist spent, use of space and
materials; 2) Time therapist spent, space and other
resources used at individual sites.
1) Time valued from individual salaries: national source (Netten
and Curtis, 2002); 2) Time valued in the same way as training
costs. Space and other resources- local costs.
Session length and number of sessions were provided. Average
cost presented. Price year 2000/01. Discounting NA. UK pound
sterling.
Zarkin et al.,
2008
Each COMBINE intervention:
space, labour, medication, non
laboratory (medical history,
physical examination, and other
assessments) and laboratory
costs.
Labour: number of times staff conducted each activity
and time spent on each activity (MM, CBI, physical
examinations and so on); Medication: number of
tablets per day of treatment; Space- not reported;
Laboratory- number of tests.
Acamprosate and naltrexone costs: Federal Supply Schedule,
unit daily costs presented. Labour cost: median weighted hourly
wage. Mean cost of each intervention separated into
medication, labour costs of MM and CBI, and costs of
laboratory and non-laboratory. Cost methodology detailed in
another study. Price year 2007 (updated from the cost study
using the CPI). Discounting NA. US dollars.
Note: This is a summary of the methods used in each individual study. For more detailed information of specific procedures and of the references used see the original
source. NA, Not Applicable
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Input costs Modelling studies
Study ID Identification Measurement Valuation
Corry et al.,
2004
Health services use: alcohol detoxification,
relapse prevention and health consultation
with a health professional. Identified:
Inpatient care, psychiatric care, psychology
care, mental health team care, general
practitioner care, medical specialist care
and pharmaceuticals.
Quantities of resources under the current care option
were derived from National Survey of Mental Health
and Wellbeing.
Quantities of resources used under optimal care were
derived from recommendations in the literature.
It was assumed that the medication was acamprosate.
Unit costs- derived from national sources:
Commonwealth Department of Health and Aged
Care (1999) and Medical Benefits Schedule; and a
published study. “No treatment” was assumed to
have no cost.
Unit costs presented. Price year 1997/98, adjusted
with CPI. Discounting NA. Australian dollars.
Doran et al.,
2004
The only cost included in the analysis was
the cost of the GP visit.
GP fees for consultation of less than 20 min and GP
consultation lasting at least 20 min but less than 40 min
were used.
Unit costs- derived from national sources:
Commonwealth Department of Health and Aged
Care (2001) and Medical benefits Schedule. Unit
costs of the two types of GP consultation were
presented. Price year 2000. Discounting NA.
Australian dollars.
Gentilello et
al., 2005
1) Screening costs: BAC (blood alcohol
concentration) test, Brief alcohol-disorder
screening questionnaire; 2) Cost of Brief
Alcohol Intervention.
1) Number of BAC for all eligible patients and number
of brief alcohol-disorder screening questionnaires; 2)
Professional expenses and materials. Professional
costs- work time per intervention including
administrative time, taken from the HMC (Harboview
Medical Center, Seattle) brief intervention programme.
1) BAC test- Medicare fee schedule in 2000,
Screening questionnaire: cost of paper; 2) Hourly
salary range- Bureau of Labour Statistics. Unit costs
and quantities of resources presented. Price year
2000, adjusted with CPI. Discount rate 3%. US
dollars.
Lindholm,
1998
Intervention costs: 1) Screening; 2) Visit to
a GP; 3) Visit to a nurse; 4) GT-test.
1) One screening per person; 2, 3) Number of visits; 4)
Number of tests.
1) Value assumed per person; 2, 3, 4) Costs taken
from the district of Umea University hospital. Unit
costs presented. Price year 1997. Discount rate 5%.
European Currency Units.
Mortimer
and Segal,
2005
Cost analysis available from the authors
upon request.
It was noted that patient costs as waiting
time and transport costs were excluded.
Incremental programme costs were based on a
description of resource use in intervention and control
groups obtained from the study reports.
Unit costs and resource use not reported. Price year
2003. Discount rate 5%. Australian dollars.
Palmer et
al., 2000 Acamprosate treatment. Acamprosate treatment for 48 weeks.
Unit cost of acamprosate presented.
Price year 1996. Discount rate 5%.
German Deutschmarks.
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Input costs Modelling studies
Study ID Identification Measurement Valuation
Schadlich
and Brecht,
1998
Acamprosate treatment. Acamprosate treatment for 48 weeks.
Unit cost of acamprosate presented.
Price year 1995. Discount rate 5%. German
Deutschmarks.
Wutzke et
al., 2001
1) Marketing / recruitment strategy; 2)
Providing training and support; 3) Costs of
screening and counselling Services; 4)
Costs of the intervention.
1,2) Published study; 3) Costs of screening and
counselling (no more than 5 min of GP’s time per
patient); 4) Costs of the intervention- level C
consultation by GP (lasting at least 20 min).
1, 2) Published study; 3) Medicare Fee Schedule 4)
Costs of the intervention- difference between costs
for consultation level C and B. Average costs for
each intervention presented. Price year 1996.
Discount rate 3%. Australian dollars.
Note: This is a summary of the methods used in each individual study. For more detailed information of specific procedures and of the references used see the original
source. NA, Not Applicable
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Appendix 5- Markov model features 
Model Structure 
Type of model Markov model 
Markov states 5 Markov states: Hazardous drinking (A), Harmful drinking (B), Ex-Hazardous drinking (ExA), Ex-Harmful drinking (ExB) and Death (D) 
Time horizon Lifetime 
Cycle length One year 
Model inputs 
Population The model uses the cohort simulation approach. A base-case population should be specified (age and gender). 
Treatment effect 
Treatment effect is the change in drinking behaviour, reflected in the flow of 
patients between the Markov states. This is incorporated with the tp for the first 
cycle(s). This parameter is specific to the treatments under evaluation 
Transition 
probabilities (tp) 
informed by 
clinical study 
These transitions are informed by the clinical data by counting the number of 
patients in each drinking category at baseline and follow-up. The number of model 
cycles informed by the clinical data depends on the duration of the clinical study.  
Transition 
probabilities for 
the following 
cycles 
These transitions are informed by country-specific data on the drinking behaviour 
of patients after treatment uptake. The ideal source of data is a longitudinal study 
that assesses drinking behaviour after treatment uptake.  
Mortality rates 
This is country-specific. Mortality rates have two components: alcohol-specific 
mortality rates and baseline mortality rates. Alcohol-related mortality rates for both 
injury and chronic diseases causes, by gender, age and drinking category. Baseline 
mortality rates are age and gender-specific. 
Morbidity rates This is country-specific. Morbidity rates should be calculated for both injury and chronic alcohol-related events. These vary by gender, age and drinking category. 
Markov state 
utilities 
Utilities attached to each Markov state are country-specific. Ideally, the utility 
associated with each drinking category is estimated using general population 
valuations and a generic preference-based measure. 
Discount rate The model applies an annual discount rate for costs, LYG and QALYs 
Model Outcomes 
Years of life 
These are calculated by total number of cycles spent in each state, other than the 
death state. The years of life with each treatment under analysis can be compared 
and the incremental LYG computed. 
Quality adjusted 
life years 
These are calculated by multiplying the time in each state by the utility weights 
and summing over all cycles. The QALYs associated with each treatment under 
analysis can be compared and an incremental QALY gain is computed. 
Lifetime costs 
There are two categories of costs: the treatment costs and Markov state costs. The 
treatment costs are specific to the treatment under evaluation and the Markov state 
costs are country and setting-specific. The total costs for each treatment can be 
compared and an incremental cost computed. 
Sensitivity analysis and Heterogeneity 
Probabilistic 
sensitivity 
analysis (PSA) 
PSA, using Monte Carlo simulation, is incorporated in the model for the input 
parameters of the model that the results are uncertain about: transition probabilities 
and utilities.  
One-way Sensitivity analysis on different discount rates and changes in the proportion starting in hazardous or harmful states. 
Heterogeneity The model can assess the impact on the results of modelling different age and gender cohorts (subgroup analysis). 
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Appendix 6- Transition probabilities from multinomial data: fitting a Dirichlet 
distribution 
Simulation of the Dirichlet distribution can be done in WinBUGS (Bayesian Inference Using Gibbs 
Sampling for Windows) software, Microsoft Excel, TreeAge DATA and SAS (Briggs et al., 2003).  
The last three software packages do not include direct representations of the Dirichlet distribution 
and two approaches can be used to generate a Dirichlet distribution: 1) normalized sum of 
independent gamma variables and 2) series of conditional beta distributions.  The normalized sum 
of independent gamma variables approach is chosen for sampling from the Dirichlet distribution in 
Microsoft® Excel.  The gamma distribution is constrained on the interval 0 to positive infinity.  The 
gamma distribution is parameterized as gamma (a, b) in Excel, where a is the shape parameter and 
b is the rate parameter.  The expectation and variance of the distribution are expressed as functions 
of these parameters as:  
\ ~ gamma (a, b)
E[\] = ab 
var [\] = ab2
In order to construct the Dirichlet distribution for generating a probabilistic transition matrix in the 
model the following two steps are followed: 
1) Assigning independent single parameter gamma distributions for each possible transition, where 
the single parameter (alpha) is the count number, as observed in the data, and the second parameter 
(beta) is set to 1.  In Microsoft® Excel this is defined as: GAMMAINV(RAND(),a, 1), where 
RAND() is the command for drawing a random value from the gamma distribution in Excel.  The 
reason why GAMMAINV is specified in Excel is because it is the inverse of the cumulative 
distribution function that gives the expected value when an integrated probability is specified 
(Briggs et al., 2006). 
2) Assigning probabilities for each possible transition by dividing the correspondent random draw 
by the sum of the random draws within each category. 
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Appendix 7- Matching the UK and US group 
STATA results using “psmatch2” command: Nearest-Neighbour propensity score Matching 
 
Total  638 638
Treated  201 201
Untreated  437 437
assignment  On suppor  Total
 Treatment  support
 psmatch2:  Common
 psmatch2:
> ated.
Note: S.E. for ATT does not take into account that the propensity score is estim
>
> -4.37
ATT  32.5383041 73.5276359 -40.9893318 9.38653434
> -9.23
follow_up_gram~y  Unmatched  32.5383041 79.9196678 -47.3813636 5.13234474
>
> T-stat
 Variable     Sample  Treated     Controls   Difference         S.E.
>
_cons  -6.029533 .9850511 -6.12 0.000 -7.960198 -4.098869
baseline_g~y  -.0126934 .0020668 -6.14 0.000 -.0167441 -.0086426
perAbsBas  -.0054985 .0046057 -1.19 0.233 -.0145256 .0035286
pcs_Bas  .0591141 .0133523 4.43 0.000 .0329441 .0852841
mcs_Bas  .018433 .008925 2.07 0.039 .0009403 .0359256
employ  2.260808 .2594842 8.71 0.000 1.752228 2.769387
sex  -.2602159 .2443577 -1.06 0.287 -.7391481 .2187164
age  .0425534 .0117074 3.63 0.000 .0196074 .0654994
treatm  Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
 
Log likelihood = -257.21928 Pseudo R2       =  0.3529
Prob > chi2     =  0.0000
LR chi2(7)      =  280.61
Logistic regression                               Number of obs   =  638
> utcome(follow_up_gramsday) logit
. psmatch2 treatm  age sex employ mcs_Bas pcs_Bas perAbsBas baseline_gramsday, o
. *One-to-one, nearest-neighbor propensity score matching, with replacement.
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Balancing test: pstest 
 
Matched  84.469 75.986 12.1 84.2 1.72 0.087
baseline_g~y  Unmatched  84.469 138.18 -76.5 -8.11 0.000
Matched  24.017 24.914 -3.7 74.8 -0.34 0.738
perAbsBas  Unmatched  24.017 27.574 -14.5 -1.68 0.094
Matched  53.603 52.837 8.4 88.6 0.99 0.325
pcs_Bas  Unmatched  53.603 46.883 73.9 8.33 0.000
Matched  38.694 38.28 3.3 93.9 0.33 0.742
mcs_Bas  Unmatched  38.694 31.938 53.4 6.24 0.000
Matched  .87065 .87065 0.0 100.0 0.00 1.000
employ  Unmatched  .87065 .3341 130.9 14.50 0.000
Matched  .66667 .75124 -18.6 -6.6 -1.87 0.062
sex  Unmatched  .66667 .746 -17.5 -2.08 0.038
Matched  45.244 44.579 6.8 81.3 0.75 0.456
age  Unmatched  45.244 41.694 36.2 4.28 0.000
Variable     Sample  Treated Control    %bias  |bias|  t p>|t|
 Mean               %reduct  t-test
 
. pstest  age sex employ mcs_Bas pcs_Bas perAbsBas baseline_gramsday
 
Weights assigned in the matching process 
 
> matched sample will have 201 observations from each group
> 01, so each US observation is matched to one and just one UK observation- the
. *95 controls are used, one of them is used 14 times!!! and sum(freq*weight)= 2
Total  95 100.00
14  1 1.05 100.00
12  1 1.05 98.95
8 3 3.16 97.89
7 1 1.05 94.74
6 1 1.05 93.68
5 2 2.11 92.63
4 4 4.21 90.53
3 6 6.32 86.32
2 18 18.95 80.00
1 58 61.05 61.05
controls  Freq.     Percent        Cum.
 matched  
weight of  
psmatch2:  
. tab _weight if treatm==0
. *How many controls are used and what is the weight ?
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List of abbreviations 
AA Alcoholics Anonymous 
AAB Alcohol ABuse 
AAF Alcohol Attribution Factor 
AD Alcohol Dependence 
ADS Alcohol Dependence Scale 
AED Accident and Emergency Department 
AHW Alcohol Health Worker 
APQ Alcohol Problems Questionnaire 
AQoL Assessment of Quality of Life 
AR At Risk 
AUD Alcohol Use Disorders 
AUDIT Alcohol Use Disorders Identification Test 
BAC Blood Alcohol Concentration 
BDG Bibliotherapy Drinking Guideline  
BI Brief Intervention 
BMT Behavioural Marital Therapy 
BRT Brief Relationship Therapy 
CBA  Cost Benefit Analysis 
CBI Combined Behavioural Intervention 
CBT Cognitive Behaviour Therapy 
CCA  Cost Consequences Analysis 
CCTV Closed-Circuit Television 
CEA  Cost Effectiveness Analysis 
CEAC Cost Effectiveness Acceptability Curve 
CG Control Group 
CHD Coronary Heart Disease 
CMA Cost Minimization Analysis 
COMBINE Combined Pharmacotherapies and Behavioural Intervention 
CPI Consumer Price Index 
CPN Community Psychiatric Nurse 
CRA Comparative Risk Assessment 
CRD Centre for Reviews and Dissemination 
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List of abbreviations 
CUA Cost Utility Analysis 
DALY Disability Adjusted Life Year 
DAS Dyadic Adjustment Scale 
DDD Drinks per Drinking Day 
DES Discrete Event Simulation 
DSM-III-R 
Diagnostic and Statistical Manual of Mental Disorders 3rd 
edition revised 
DSM-IV 
Diagnostic and Statistical Manual of Mental Disorders 4th 
edition 
ED Emergency Department 
EVPI Expected Value of Perfect Information 
EQ-5D EuroQol 5 Dimensions 
ER Emergency Room 
FC Full Care 
FEE Full Economic Evaluation 
GBD Global Burden of Disease 
GGT Gamma-Glutamyl Transferase 
GHQ General Health Questionnaire 
GP General Practioner 
HCA Human Capital Approach 
HCHS Hospital and Community Health Services 
HED Heavy Episodic Drinking 
HES Hospital Episode Statistics 
HPA Health Promotion Advocate 
HRG Health Care Resource Group 
HRQoL Health-Related Quality of Life 
HUI Health Utility Index 
IBT Individual-Based treatment 
ICD-10 WHO 10th revision codes International Classification Disease 
ICD-9 WHO 9th revision codes International Classification Disease 
ICER Incremental Cost Effectiveness Ratio 
ICT Interactional Couples Therapy 
ITT Intention to Treat 
LDQ Leeds Dependence Questionnaire 
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List of abbreviations 
LYG Life Years Gained 
MAT Marital Adjustment Test 
MCO Managed Care Organization 
MCS Mental Component Score 
MCV Mean Cell Volume 
MEPF Motivational Enhancement Personalized Feedback 
MET Motivational Enhancement Therapy 
MI Motivational Interviewing 
NB Net Benefit 
NESARC 
National Epidemiologic Survey on Alcohol and Related 
Conditions 
NHS National Health Service 
NHS EED National Health Service Economic Evaluation Database 
NIAAA National Institute for Alcohol Abuse and Alcoholism 
NICE National Institute for Health and Clinical Excellence 
NNM Nearest-Neighbour Matching 
NPV Net Present Value 
PACT Psychoeducational Attention Control Treatment 
PCS Physical Component Score 
PDA Percentage of Days Abstinent 
PDHD Percentage Days of Heavy Drinking 
PLS Patient-Level Simulation 
PRAMA 
Prevention of Relapse with Acamprosate in the Management of 
Alcoholism 
PSA Probabilistic Sensitivity Analysis 
PSSRU Personal Social Services Research Unit 
PTO Person Trade-Off 
PWU Post Withdrawal Unit 
QALY Quality Adjusted Life Year 
QF Quantity Frequency 
QWB Questionnaire of Wellbeing 
RCT Randomized Controlled Trial 
RD Retrospective Drinking 
RR Relative Risk 
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List of abbreviations 
SADQ Standard Alcohol Dependence Questionnaire 
SBI Screening and Brief Intervention  
SBNT Social Behaviour and Network Therapy 
S-BCT Standard Behavioural Couple Therapy 
SC Stepped Care 
SF-12 Medical Outcomes Study 12- Item Short Form Health Survey 
SF-36 Medical Outcomes Study 36- Item Short Form Health Survey 
SF-6D Short Form 6 Dimensions 
TLFB Timeline Followback 
tp transition probability 
TrEAT Trial for Early Alcohol Treatment 
TTO Time Trade-Off 
UK  United Kingdom  
UKATT United Kingdom Alcohol Treatment Trial 
USA  United States of America  
VA Veterans Affairs 
VAMC Veterans Affairs Medical Centre 
WHO World Health Organization 
WTP Willingness to Pay 
YLD Years Lived with Disability 
YLL Years of Life Lost 
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